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Abstract 
 
Inappropriate and un-regulated inflammation is the hallmark of a variety of inflammatory diseases 
including Rheumatoid Arthritis (RA). Central to the pathogenesis of this disease is the cytokine 
Tumour Necrosis Factor α (TNF), a product of activated macrophages. Macrophages are activated 
by numerous exogenous and endogenous ligands through Toll like receptors (TLR) leading to the 
activation of numerous protein tyrosine kinases (PTK). These studies have mainly described the 
LPS pathway and have not focused on endosomal TLRs, which are being increasingly implicated 
in the pathology of RA.  
The work presented in this thesis describes the role of Bruton‟s Tyrosine Kinase (Btk) in TLR8 
signalling in human primary macrophages.  Using an adenovirus overexpression system and RNAi 
technology, Btk has been shown to control the production of TNF in R848-stimulated cells. This 
regulation occurred on a transcriptional level as Btk downregulation decreased the level of the 
primary TNF transcript at 2h as well as the recruitment of RNA Polymerase II to the promoter of 
the TNF gene at 1h.  This rapid effect of Btk depletion on gene transcription resulted in 
significantly less TNF protein production at 2h following R848 stimulation.  
Subsequent analysis of transcription factors potentially involved in the Btk-dependent regulation 
of TNF transcription revealed that Btk affects both NFκB and AP-1 in TLR8 signalling.  In 
particular, Btk downregulation decreased the binding of NFκB to its consensus site as shown by 
EMSA as well as the recruitment of p65 to the TNF promoter or 3‟ enhancer region as shown by 
ChIP. The regulation of p65 by Btk occurred at the level of p65 phosphorylation on Serine 536 
and did not affect the degradation of IκBα. AP-1 activity in EMSA was also decreased under the 
Btk knockdown conditions, with cJun and ATF-2 but not cFos being involved in Btk signalling. 
At the same time, Btk did not alter p38, ERK and JNK MAPK activity ruling out their 
involvement in the Btk-dependent control of AP-1 in R848-challenged macrophages. These data 
extend current knowledge regarding the involvement of Tec kinases in the regulation of cytokine 
production under inflammatory conditions by providing a potential mechanism of transcriptional 
control. 
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1.1 Inflammation  
 
Inflammation, the defensive response of immune system to pathogens, irritants and damaged cells, 
is an extremely complex, multistep process. The biological aim of inflammation is to remove the 
causative agent and start the healing process of injured tissue. There are two types of 
inflammation; acute and chronic. The onset of acute inflammation is rapid, taking only a few days, 
and is predominantly mediated by cells of innate immune system and results in the resolution or 
chronic inflammation. Chronic inflammation, on the contrary, can last for years, engages cells 
from the innate and adaptive immune response and is characterised by severe tissue destruction. 
Therefore, chronic inflammation is a pathological condition and poses a serious threat to the 
organism (Janeway 2005). 
Classic characteristics of inflammation are swelling, redness, pain, heat, and loss of function. 
Redness and increased heat are caused by widening of blood vessels (vasodilation) and elevated 
blood flow at the site of inflammation, swelling that results from the leakage of plasma fluid into 
the tissue (extravasation), increased sensitivity to pain that is believed to be caused by the release 
of pain mediators and is accompanied by a loss of function. Following physical injury (trauma) 
and infection, destruction (necrosis) of surrounding cells occurs. Necrotic cells release so called 
'danger signals' such as the transcription factor high mobility group box 1 (HMGB1), heat shock 
proteins, hyaluronan oligosaccharides, fibronectin fragments and antibody-DNA complexes which 
together with pathogenic antigens stimulate neutrophils, mast cells and antigen presenting cells 
(APCs) (Matzinger 2002; Piccinini and Midwood 2010). Simultaneously, in response to pain, 
neurons secrete neuropeptides that activate mast cells, residents of the connective tissue in the 
mucus membranes. Mast cells in turn secrete histamine, eicosanoids and tryptases which facilitate 
vasodilation and movement of leukocytes out of circulatory system. The main function of APCs is 
the presentation of antigen to lymphocytes, recruitment of lymphocytes to the site of infection, 
secretion of inflammatory mediators as well as phagocythosis. Lymphocytes in turn sustain 
inflammation by secreting cytokines which together with the antigen activate macrophages to 
secrete molecules responsible for pathogen and cellular debris elimination such as proteases, 
reactive oxygen species (ROS), cytokines and nitrogen intermediates. Furthermore, lymphocytes 
are responsible for the regulation of inflammation and formation of memory cells (Nathan 2002).  
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1.1.1 The interplay between Innate and Adaptive Immunity 
 
Innate immunity responds predominantly to microbes such as bacteria, fungi and viruses. It is an 
initial defence mechanism able to fully eradicate the pathogen preventing the activation of an 
adaptive response. Innate immunity is specific as it recognises pathogen-associated molecular 
patterns (PAMPs); highly conserved structures of microbes not produced by mammalian cells. 
The host cells recognise these structures through pattern recognition receptors (PRRs) such as 
Toll-like receptors (TLRs) or mannose receptors which are encoded in the germ line and are 
characterised by limited diversity. Innate immunity allows a rapid and effective response against 
repeated or persistent infections (Janeway and Medzhitov 2002).  If, however, this initial response 
fails to protect the host, the cells of innate immunity remain crucial for the secondary immunity as 
they drive the adaptive response.  
The first line of defence against invading pathogens is the epidermis and mucosal membranes. 
Apart from forming a physical barrier to infections, epithelium also eliminates microbes by locally 
producing peptide antibiotics. In addition, mucosal linings of gastrointestinal and reproductive 
tracts contain a subset of T lymphocyte, called intraepithelial lymphocyte (IEL). IEL express 
antigen receptors of limited diversity recognising microbial lipids and other elements which are 
conserved among microbes of the same type. Upon antigen challenge, IEL release cytokines and 
cause killing of infected target cell (Montufar-Solis et al. 2007). Neutrophils are recruited to the 
site of pathogen invasion in the blood or extravascular tissue where they rapidly eliminate the 
microbe coated with antibodies and complement. The granule content is crucial for neutrophil 
function as neutrophil-specific granule deficiency causes impaired chemotaxis,
 
receptor up-
regulation and bactericidal activity,
 
resulting in frequent and severe bacterial infections (Shiohara 
et al. 2004). Neutrophils do not return to circulation as they die within a few hours. Monocytes 
fulfil a similar to neutrophils function in rapidly fighting the infectious agent.  Unlike neutrophils, 
circulating monocytes differentiate into macrophages which ensconce themselves in extravascular 
tissue where they survive for many days (Butterfield et al. 2006). 
Natural killer (NK) cells are destined to recognise and kill infected and stressed cells and to 
secrete macrophage-activation cytokine interefor-γ (IFN-γ). NK cells are a class of lymphocytes 
but in contrast to T cells and B cells, they do not express T cell receptors or immunoglobulins. 
Instead, they produce abundant cytoplasmic granules which are full of molecules able to initiate 
apoptotic death of the infected cell upon discharge. The cells are activated by the NKG2D receptor 
and deactivated by self class I MHC proteins. They are crucial in recognition of virus infected 
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cells which have lost the ability to present an antigen on class I MHC molecules to T cells. 
Alternatively, NK cells bind to antibody-coated cells through an Fc receptor called FcγRIII 
(CD16) and cause their death in a process called antibody-dependent cellular cytotoxicity. 
Furthermore, NK cells are involved in the clearance of irreparably injured and tumor cells as they 
carry receptors recognising DNA damage or malignant transformation. Activated macrophages 
and DCs produce IL-12 which additionally enhances the effector function of NK cells (Bottino et 
al. 2005).  
The adaptive immune system is activated when microbes or pathogenic agents break the barrier of 
the innate system. It is able to respond to a large variety of antigens with high specificity. The 
components of adaptive immunity strongly rely on and cooperate with the cells of innate 
immunity in antigen presentation and microbial clearance. In contrast to PRRs which recognise 
highly conserved microbe-derived peptides, the cells of adaptive immunity operate with an 
extremely diverse range of receptors designed for the immune recognition of proteins (T cells) or 
proteins, lipids, carbohydrates and nucleic acids (B cells). T cell and B cell receptors are produced 
in the somatic line during lymphocyte development and are generated randomly during the course 
of gene segment recombination. When the receptor encounters the target antigen, the lymphocyte 
undergoes clonal expansion to produce an army of cells reactive to the same antigen. These 
specific receptors are not inherited by the next generation of cells as opposed to PRRs which are 
encoded in the germline.  The adaptive immune system comprises of humoral and cell-mediated 
immunity. The first one involves B lymphocytes and their products, antibodies, also known as 
immunoglobulins (Ig). Antibodies are secreted into the circulation and mucosal fluids. They 
specifically bind to antigens present on a microbe surface or to microbial toxins, to neutralise and 
eliminate them. When the antigen invades a host cell or becomes ingested by a phagocyte, then it 
can no longer be detected by antibodies. Cell-mediated immunity is then recruited to recognise 
antigens produced by intracellular microbes (Janeway 2005).  
T-cell mediated immunity 
Cell-mediated immunity provides a secondary defence mechanism against microbes such as 
intracellular bacteria, fungi and protozoa which are resistant to lysosomal degradation as well as 
against viruses that infect and replicate in the cytoplasm of a host cell. T lymphocytes are key cell 
types involved in cell-mediated immunity able to recognise host and foreign peptides presented on 
MHC molecules from every cell type in the body. Naive T cells constantly recirculate through 
lymph nodes where they scan for foreign peptides presented on dendritic cells (DCs). Upon 
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antigen recognition, naive T cells undergo activation accompanied by the secretion of cytokines, 
clonal expansion and ultimately differentiation into effector cells. Effector T cells can remain in 
the peripheral lymph node where they eliminate infected cells and activate B lymphocytes or they 
can circulate to the site of infection (Abbas 2009). 
T cells themselves are not able to distinguish between extracellular and intracellular microbes. 
Professional APCs such as DCs, macrophages and B lymphocytes present protein antigens on 
class II MHC molecules as well as provididing co-stimulatory signals to CD4+ T cells (also 
known as helper T cells or Th cells). Microbes internalised by professional APCs undergo 
digestion in intracellular vesicles facilitated by lysosomal enzymes. The CD8+ subset of T cells, 
on the other hand, responds to peptides presented on class I MHC molecules which are expressed 
on all nucleated cells.  Class I MHC–presented antigens are produced in cytoplasm from 
processed viruses, phagocytosed microbes escaped from internalised vesicles, own non-functional 
proteins or the products of mutated genes, as in tumors. These cytoplasmic proteins are unfolded 
and ubiquitinated what ultimately leads to their proteolytic degradation by proteasomes (Abbas 
2009).  
Primed CD8+ T cells mature into cytotoxic T lymphocytes (CTLs) which, by secreting the content 
of intracellular granules, immediately induce apoptotic death of virus-infected cells. CD4+ T cells 
differentiate into subsets of effector cells such as Th1, Th2, Th17 or regulatory T cells (Treg) 
characterised by different sets of secreted cytokines and performed functions. Therefore, the 
response of CD4+ T lymphocytes to infection depends on the subset of an effector cell (Cooke 
2006). DC-released IL-12 differentiates naive CD4+ T cells into the Th1 subset. Th1 cells induce 
a classical pro-inflammatory pathway of macrophage activation resulting in phagocyte-mediated 
ingestion and killing of microbes (Figure 1.1). The major cytokine secreted by Th1 cells is anti-
viral IFN-γ, a potent activator of macrophages and B cells. IL-4- differentiated Th2 cells, on the 
other hand, induce an alternative pathway of macrophage activation by secreting IL-4, IL-5 and 
IL-13 (Figure 1.1). This set of cytokines inhibits microbicidal activities in macrophages and 
induces synthesis of extracellular matrix proteins thus promoting tissue repair by these cells. Apart 
from regulating macrophage function, Th2 cells stimulate phagocyte-independent eosinophil-
mediated defence against helminthic parasites (Romagnani 2000). IL-5 activates eosinophils, 
whereas IL-4 activates B cells to produce IgE antibodies. Antigen-bound IgE antibodies in turn 
activate mast cells, the major effector cells of hypersensitivity (allergic) reaction. IL-17- 
producing T helper cells (Th17) are the newly discovered subset of CD4+ T cells. The 
significance of Th17 has been recognised in the development of multiple autoimmune diseases 
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such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Th17 cells, 
similarly to Treg cells are induced by transforming growth factor-β1 (TGF-β). IL-6 is also 
required for Th17 differentiation but is inhibitory for Treg cells. Regulatory T cells maintain 
immune system homeostasis and tolerance to self-antigens by releasing immunosuppressive TGF-
β and IL-10 (Kimura and Kishimoto 2010). 
B cell-mediated immunity 
The major role of B lymphocytes in immunity is the production of antibodies, which when 
membrane-bound serve as antigen receptors, and when secreted neutralize and eliminate microbes 
and their toxins in the effector phase of humoral immune responses. Antibodies recognise antigens 
and toxins via their variable domain (Fab region) and bind to Fc receptors on phagocytes and to 
proteins of complement via their constant Fc region. Naive B cells only produce membrane-bound 
IgM and IgD isotypes. Upon antigen recognition, a B cell proliferates into antigen-specific clones 
(clonal expansion) and can differentiate into an effector cell (plasma cell) which is able to secrete 
specific antibodies. B cell response to protein antigens is dependent on T cells that mediate isotype 
switching and affinity maturation whereas the response to polysaccharide, lipids and other 
nonprotein antigens is T cell- independent (Janeway 2005). The complement system also greatly 
enhances B cell activation, as the binding of C3d protein, the product of complement proteolysis, 
to the CD2 receptor provides second signals for B cell proliferation and differentiation (Heyman 
2000). Conversely, if the antigen is a protein, effector B cells can also present the antigen to CD4+ 
T cells and provide co-stimulatory signals for T cell activation. B lymphocytes belong to 
professional APCs thus they are able to endocytose antigens bound to Ig receptors, process them 
in endosomal vesicles and ultimately present antigenic peptides on class II MHC molecules. 
However, unlike DCs, B cells can only activate previously differentiated effector T cells but not 
naive T cells (Abbas 2009).  
 
1.1.2 Macrophages as a bridge between Innate and Adaptive Immunity 
 
Monocytes (mononuclear phagocytes) originate from pluripotent progenitor cells in the bone 
marrow. The cells are subsequently released from the bone marrow into the bloodstream where 
they circulate for few days before migration into various tissues and organs. In the presence of 
growth factors such as macrophage colony stimulator factor (M-CSF) or granulocyte macrophage 
colony stimulator factor (GM-CSF), monocytes differentiate into macrophages (Barreda et al. 
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2004). Resident macrophages in the lungs are called alveolar macrophages, those in the liver are 
called Kupffer cells, whereas those in the central nervous system are known as microglia. Tissue 
macrophages share their progenitor cells with myeloid dendritic cells (DCs) and osteoclasts in the 
bone. Macrophages directly respond to the pathogenic agent through various PRRs and are 
involved in the activation of innate and adaptive immune response. Their role is to phagocytose 
cellular debris and microbes as well as to resolve inflammation and initiate the healing process of 
the inflamed tissue (Gordon 2003). The cells can be identified by flow cytometry by the 
expression of CD14 (lipopolisaccharide-binding protein), CD68 (sialoadhesin, a sialic acid 
binding lectin) or EMR1 (epidermal growth factor module-containing mucin-like receptor 1) 
(Khazen et al. 2005). 
Upon encounter with infectious agents, resident macrophages secrete cytokines such as tumor 
necrosis factor α (TNF) and interleukin (IL)-1 which in turn activates endothelial cells to produce 
selectins - the adhesion molecules for circulating phagocytes. The expression of selectins enables 
binding of blood leukocytes to the endothelium and initiates a sequence of events that ultimately 
leads to leukocyte migration through the endothelium and to microbe digestion. The process of 
phagocytosis consists of the following steps: phagocytic receptor-mediated binding of a microbe 
to neutrophils and macrophages, internalisation of the cellular membrane containing the pathogen 
and forming a phagosome as well as the formation of phagolysosome where the microbe is 
destroyed. A lysosome contains activated enzymes whose products such as reactive oxygen 
species (ROS) and nitric oxide (NO) have microbicidal activities. Lysosomal proteases, on the 
other hand, digest microbial proteins (Underhill and Gantner 2004). There is a plethora of 
phagocytic receptors, including fragment crystallisable (Fc), complement (CR1, CR3 and CR4), 
scavenger (SRA and MARCO) and mannose (CD206) receptors, various integrins, Dectin-1 or 
CD14. Fcγ receptors bind to the Fc region of IgG-opsonised particles, Fcε receptors bind to IgE-
opsonised particles whereas Fcα receptors are specific for IgA-opsonised antigens. Other 
molecules that are able to act as opsonins include C3b and C3bi; enzymatic products of the 
complement system cascade. Complement proteins are able to opsonise pathogens through 
antibody-dependent and antibody–independent methods (Underhill and Ozinsky 2002). 
Apart from eliminating invading agents, macrophages are also essential for clearance of apoptotic 
cells in the process called efferocytosis. The role of efferocytosis is the elimination of dead cells 
before their membrane breaks and toxic enzymes, oxidants and proteases are released into the 
surrounding tissue. Thus efferocytosis prevents inflammation or promotes inflammation 
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resolution. Ineffective efferocytosis is one of the hallmarks of the chronic vascular condition, 
atherosclerosis (Tabas 2010).  The role of macrophages in the resolution of inflammation can be 
further supported by the fact that the cells trigger apoptosis of surrounding immune cells by 
expressing cell surface Fas ligand (FasL) and releasing active soluble FasL. The binding of FasL 
to a death receptor expressed on neutrophils, eosinophils, lymphocytes, monocytes and 
macrophages leads to target cell apoptosis. FasL expression on the cell surface is induced by 
phagocytosis of opsonised zymozan or apoptotic neutrophils thus promoting a positive feedback 
loop (Brown and Savill 1999). Macrophage digestion of apoptotic cells is accompanied by the 
secretion of anti-inflammatory IL-10 and the inhibition of pro-inflammatory cytokine release such 
as TNF, IL-1 and IL-12 (Voll et al. 1997). 
Macrophages are also crucial for reparation of damaged tissue as they are a major source of 
growth factors including fibroblast growth factor (FGF), insulin-like growth factor (IGF-1) and 
transforming growth factor-β1 (TGF-β1). Together, these factors activate fibroblasts to secrete 
extracellular matrix-building proteins such as collagen. Macrophages also secrete vascular 
endothelial growth factor (VEGF) and epidermal growth factor (EGF) which promote 
angiogenesis and tissue regeneration (Butterfield et al. 2006).  
Due to wild-spread tissue distribution and responsiveness to many endogenous and exogenous 
stimuli, macrophages vary in their phenotype (Gordon 2003). Early studies showed that infection 
of mice with Mycobacterium bovis or Lysteria monocytogenes induced the antimicrobial activities 
of macrophages (Mackaness 1964). Studies since have shown that this „classical‟ immune 
activation of macrophages is dependent on pro-inflammatory cytokines produced by Th1 and NK 
cells.  The alternative activation of macrophages is dependent on Th2-mediated allergic, cellular 
and humoral responses to parasites and extracellular pathogens (Gordon 2003). Classical 
activation leads to the polarisation of macrophages into M1 phenotype whereas alternative 
activation leads to the development of M2 phenotype (Figure 1.1). The balance between the M1 
and M2 programs is crucial for effective combating of infection. M1 cells, which are considered as 
microbicidal and pro-inflammatory, are activated through IFN-γ and microbial product stimulation 
that leads to the production of inflammatory cytokines such as TNF, IL-6, IL-1, IL-12 and 
synthesis of NO and ROI. M2 cells are considered as immunomodulators involved in the 
resolution of inflammation. They are characterised by expression of alternative activation markers 
and are induced by IL-4 or IL-13 (M2a phenotype), agonists of TLRs or IL-1 receptors and 
ligation of Fc receptors to antibody coated immune complexes (M2b phenotype) or are induced by 
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IL-10 and glucocorticoids (M2c phenotype) (Benoit et al. 2008). It is important to emphasise that 
macrophage activation is a dynamic process and that the classification of macrophages as either 
type M1 or M2 could be an oversimplification. It has been shown that macrophages adapt to the 
changing microenvironment and can initially be involved in the pro-inflammatory reactions and 
later participate in the resolution of inflammation (Porcheray et al. 2005). Nevertheless, the 
imbalance between pro-inflammatory and immunoregulatory state can pose serious health 
consequences.  Prolonged M1 polarization caused by acute infections with Escherichia coli leads 
to tissue damage, multiple organ failure and ultimately death (Benoit et al. 2008). On the other 
hand, chronic infectious diseases are associated with macrophages adopting M2 phenotype. 
Inhibiting M2-associated cytokines such as IL-10 and IL-4 in susceptible mice infected with 
virulent Brucella abortus restores M1 phenotype and allows bacteria killing (Fernandes et al. 
1996).  
 
Finally, macrophages belong to professional APCs required for the activation of adaptive 
immunity CD4+ T cells and are the effector cells of cell-mediated immunity. Other professional 
APCs include DCs and B cells. DCs are derived from the same common precursor as 
macrophages and some argue that there are no markers, pathways of development and functions 
that distinguish these two cell types (Hume 2008). A network of residential DCs present in most 
of the tissues capturing invading microbes. Activation of resting DCs by PRR stimulation and 
cytokines changes their phenotype and leads to their detachment from the epithelium. Upon 
maturation, DCs downregulate phagocytic receptors and upregulate MHC molecules as well as co-
stimulatory molecules such as CD40, CD80, CD83 and CD86 (Banchereau and Steinman 1998). 
Effective DCs then migrate to the lymph nodes where they present antigens to T lymphocytes 
through class II MHC proteins (signal 1) and provide co-stimulatory molecules, such as B7-1 
(CD80) and B7-2 (CD86) (signal 2). B7 is recognised by the CD28 receptor on T cells and is 
essential for initiating the responses of naive T cells as interaction of TCR alone with proteins 
presented on MHC molecules is unable to activate T cells. Soluble antigens are also captured by 
DCs resident in the spleen where again they act as APCs. Conversely, upon stimulation with anti-
inflammatory IL-10 or corticosteroids, resting DCs induce immune tolerance via T cell deletion or 
induction of regulatory T cells (Tregs). Two major types of blood circulating DCs can be 
distinguished by surface markers; CD11c expressing myeloid DCs and CD11c negative 
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plasmacytoid DCs. Although both subsets activate T cells, they express distinct PRRs and 
therefore differ in pathogen recognition and function (Schreibelt et al.).  
 
 
 
Figure 1.1. Macrophage polarization by immune cells.  Macrophages polarize into M1 and M2 subsets 
upon encounter with pathogens and inflammatory mediators secreted by activated immune cells. IFN-γ and 
TLR ligands initiate classical macrophage activation. M1 in turn produce IL-12 which differentiates Th0 into 
Th1 cells as well as secreting microbicidal molecules such as NO and ROS (A). Alternative, M2a, 
polarisation of macrophages is driven by IL-4-differentiated Th2 cells, NK cells, basophils and eosinophils, 
all of which secrete IL-4 and IL-13 (B). Ligation of Fc receptors to antibody- covered immune complexes 
and LPS or IL-1β stimulation can induce M2b polarisation (C) whereas stimulation with IL-10 mainly by 
TGF-β- differentiated Tregs or glucocorticoid stimulation leads to M2c polarization (D). M2 macrophages 
promote Th2 response thus clearance of parasites. M2c macrophages mediate the resolution of 
inflammation. Th, helper T cell; Treg, regulatory T cell; TLR, Toll-like receptor; TGF-β, transforming growth 
factor β; NO, nitric oxide; ROS, reactive oxygen species; MHCII, class II major histocompatibility complex; 
IFN-γ, interferon-γ. Adapted from (Biswas and Mantovani 2010; Kimura and Kishimoto 2010).  
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1.2.3 Cytokines as mediators of inflammation 
 
Cytokines are soluble cell-signalling proteins, peptides or glycoproteins that are predominantly 
produced by the cells of immune system. Cytokines are either secreted or expressed on the cell 
surface and their major role is modulation of the immune response, including activation, 
differentiation, deactivation or chemoattraction of target cells. They are classified as interferons, 
interleukins, chemokines, haematopoietic colony stimulating factors or connective tissue growth 
factors and tumour necrosis factors. Cytokine can act on cells both through paracrine and 
autocrine mechanisms by binding to the specific receptors on the cell surface. Most cytokines are 
short-lived and modulate only the closest microenvironment. Others, such as chemokines are 
relatively long acting and can attract circulating blood cells to the site of inflammation.  Cytokines 
also modulate the action of other cytokines and disruption of cytokine network may lead to 
pathological consequences such as autoimmune and inflammatory diseases (Feldmann 2002). 
More than 50 cytokines have been identified and individual description of each is beyond the 
scope of this thesis. Thus, only key pro-inflammatory cytokines such as TNF, IL-6 and IFN as 
well as anti-inflammatory cytokine IL-10 are described in detail.  
Tumor Necrosis Factor α - TNF 
TNF was functionally described in mid 1970s as a macrophage derived product that caused 
necrosis of solid tumors (Carswell et al. 1975). The expression of TNF is induced by various 
factors including viruses, bacteria, parasites, tumour cells, complement or other cytokines. 
Monocytes and tissue macrophages are the primary source of TNF. However, this cytokine is also 
widely expressed in other immune cells as well as non-immune cells including fibroblasts, 
neurons, osteoblasts or smooth muscle cells. TNF is implicated in a variety of processes including 
1) growth, differentiation and metabolism; 2) can produce cachexia characterised by loss of 
weight, muscle atrophy, fatigue, weakness; 3) can trigger apoptosis in malignant and transformed 
cells, virus-infected cells, T cells and epithelial cells; as well as 4) initiate and perpetuate 
inflammation. TNF regulates the production of other cytokines (IL-1, IL-2, IL-4, IL-6, IL-10, IL-
12, IL-18, IFR-γ, TGF-β), hormones (cortisol, glucagon, insulin) as well as acute phase proteins, 
leukotrienes, ROS, NO, platelet-activating factor and prostaglandins. TNF also modulates T cell 
differentiation into the Th1 subset by inducing IL-12 and IL-18 production. Th1 cells in turn 
produce IFN-γ that leads to the activation of macrophages and increased production of TNF 
(Schottelius et al. 2004) (Table 1.1).  
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Due to its central role in inflammation, it is not surprising that TNF production is regulated on 
every expression level including transcription, post-transcription, translation and post-translation. 
The transcription of TNF is regulated by a plethora of transcription factors including NFκB, AP-1, 
Sp1 or Ets that can activate or inhibit depending on the dimer composition and which are mutually 
dependent (see section 1.2.4 for details). Apart from inducing transcription, pro-inflammatory 
stimuli also induce the stability of TNF mRNA, through a mechanism dependent on p38 MAPK 
signalling (see section 1.2.6 for details). TNF is approximately 3 kilobases in size, it is located on 
chromosome 6, is translated as a 233 amino acid, 26kDa pro-protein deficient in a classic signal 
peptide. Newly synthesised pro-TNF is embedded in the plasma membrane in the active form able 
to mediate inflammatory effects of TNF through cell-to-cell contact (Kriegler et al. 1988). Pro-
TNF is cleaved to its mature 157 amino acid long form by TNF-alpha-converting enzyme 
(TACE). TACE is a matrix metalloproteinase whose action is not only restricted to TNF as 
deletion of TACE, but not TNF, is developmentally lethal in mice (Moss et al. 1997; Peschon et 
al. 1998). Proteolytic cleavage of membrane pro-TNF provides another checkpoint in the 
regulation of TNF production.  
Mature 17-kDa soluble TNF forms homotrimers through the C-terminus and binds to the TNF 
receptors though the free N-terminus. There are at least 41 members of TNFR superfamily, 
including receptors for TNF (TNF-RI and TNF-RII), Fas, CD40 or RANKL. These receptors all 
share the extracellular ligand binding domain that contains different repeats of cysteine-rich 
domains (CRD), a transmembrane region and intracellular domains that largely vary between the 
family members. The first subclass of TNFR, to which TNF-RI belongs, possesses a death domain 
in their intracellular region. Following TNF binding, TNF-RI recruits the TNFR associated death 
domain (TRADD) adaptor molecule and the Fas-associated death domain (FADD) adaptor 
molecule leading to the activation of a caspase cascade and ultimately to apoptosis. Alternatively, 
TRADD associates with TNFR-associated factor (TRAF)2, TRAF1 and receptor interacting 
protein (RIP) to initiate the nuclear factor κB (NFκB) and mitogen- activated protein kinases 
(MAPK) signalling that promotes the transcription of inflammatory mediators and protects the cell 
against apoptosis. The second subclass of TNFR, to which TNF-RII belongs, does not contain 
death domains. Instead these receptors possess a sequence that facilitates association with TRAFs, 
called TRAF-interacting motifs (TIMs). Again, the engagement of TRAF family members leads to 
the activation of NFκB and MAPK signalling (Hehlgans and Pfeffer 2005). In addition to 
expression on the cell surface, TNFR can be cleaved and found in a soluble form. These soluble 
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receptors are antagonists for TNF, inhibiting the biological activity of TNF (Moosmayer et al. 
1996). 
Interleukin-6 - IL-6 
IL-6 (interferon-β2), a 21-28-kDa protein, was first cloned during the course of isolation and 
characterisation of viral-induced protein interferon-β in human fibroblasts treated with the 
synthetic double-stranded RNA, PolyI:C (Weissenbach et al. 1980). IL-6, which is mainly 
secreted by macrophages and monocytes, is the central mediator of the production of most acute 
phase proteins (Gauldie et al. 1987). Il6 knockout mice are unable to exhibit a normal immune 
response, the induction of acute phase proteins is largely inhibited and these mice do not lose body 
weight (Fattori et al. 1994). IL-6 can also induce the production of IL-8 and monocyte 
chemoattractant protein (MCP)-1 from endothelial cells as well as expression of adhesion 
molecules (Romano et al. 1997). During chronic inflammation, in addition to its role in inducing 
acute phase proteins, IL-6 initiates cellular immune responses and elicits a mucosal humoral 
response. In particular, IL-6 induces differentiation of activated B cells, which leads to the 
production of antibodies (Takatsuki et al. 1988). IL-6 also triggers proliferation of thymic and 
peripheral T cells, differentiation of Th0 into Th17 cells as well as activation of NK cells (Keller 
et al. 1996) (Table 1.1). IL-6 binds to IL-6R composed of two subunits; an alpha subunit and 
glycoprotein (gp) 130. Binding of IL-6 to this receptor induces cellular signalling events, such as 
activation of Janus protein tyrosine kinases (JAKs). Activated JAKs phosphorylate signal 
transducers and activators of transcription (STATs), leading to their activation, particularly 
STAT3. When phosphorylated, STAT3 dimerises and translocates to the nucleus leading to 
transcription of genes containing STAT3 response elements (Taniguchi and Takaoka 2001). 
 
Type I and II Interferons - IFNs 
Type I IFNs- IFN-α and IFN-β - are the main antiviral cytokines of the innate immune system. 
They are structurally unrelated to Type II IFNs such as IFN-γ.  Apart from driving antiviral 
response, IFNs are involved in immunomodulatory activities by activating NK cells, macrophages 
and DCs (Table 1.1). IFN-α/β induce the expression, but not the activation, of p53, a crucial 
element required for apoptosis of cancerous cells. Therefore, IFN-α/β can contribute to tumour 
suppression (Takaoka et al. 2003). Binding of IFN-α/β to the receptor comprising of two subunits, 
IFNAR-1 and IFNAR-2, activates JAK-STAT signalling. The intracellular domains of IFNAR 
interacts with Tyk2 and Jak1 which subsequently tyrosine phosphorylate STAT1 and STAT2. 
IFN-γ signals through a receptor comprising IFNGR-1 and IFNGR-2 subunits which bind to Jak1 
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and Jak2 but not Tyk. The engagement of STATs results in the recruitment of IFN- regulatory 
factor (IRF) 9 leading to downstream gene induction in an IFN-stimulated response elements 
(ISRE)-dependent matter (Takaoka and Yanai 2006). One of the IFN target genes is IP10. The 
product of this gene, IFN-inducible protein 10, is a chemokine of the CXC family. IP-10 is a 
central chemoattractant for T cells as Ip10
-/-
 mice injected with a neurotropic mouse hepatitis virus 
displayed impaired T cell trafficking into the brain as well as impaired T cell proliferation and Th1 
responses (Dufour et al. 2002). The IP-10 receptor is highly expressed on IL-2-activated T cells, 
but is not detectable in resting T cells, B cells, monocytes or neutrophils (Loetscher et al. 1996).  
Interleukin-10 - IL-10 
IL-10 was first discovered as a soluble factor, named cytokine synthesis inhibitory factor (CSIF), 
produced by murine Th2 lymphocytes, which inhibited the production of cytokines from pro-
inflammatory Th1 cells (Fiorentino et al. 1989). Subsequent studies performed in murine and 
human systems revealed that IL-10 is secreted by numerous cells including Th1, Th2, Th17, 
cytotoxic CD8+ T cells, B cells and myeloid cells (O'Garra et al. 2008). IL-10 is also the key 
cytokine secreted by Tregs which are defined by the expression of a transcription factor Foxp3. 
The pivotal physiological function of IL-10 is mediating control of signals that induce 
inflammation in the gut as mice deficient in IL-10 developed chronic enterocolitis under pathogen 
free conditions (Kuhn et al. 1993).  IL-10 exerts multiple anti-inflammatory actions. The major 
role of IL-10 is the inhibition of macrophage and monocyte effector functions including the 
production of NO and the production of pro-inflammatory mediators such as TNF, IL-6, IL-1, IL-
12, GM-CSF or chemokines MCP1, MCP5 or CCL5 (Moore et al. 2001). In addition to 
downregulation of cytokine expression, IL-10 up-regulates the production of soluble TNFR and 
the IL-1 receptor antagonist (IL-RA) which inhibit the biological activity of TNF and IL-1, 
respectively (Jenkins et al. 1994; Joyce et al. 1994). Furthermore, IL-10 also inhibits the antigen 
presentation to T cells by down-regulating the expression of class II MHC and the co-stimulatory 
molecules CD80/86 in human DCs (Buelens et al. 1995) (Table 1.1). IL-10 signals through the 
IL-10 receptor in myeloid cells which is comprised of two molecules of the IL-10R1 and two 
molecules of the IL-10R2 chain. Jak1 and Tyk2 have been shown to be permanently associated 
with the IL-10R. Activation of IL-10R results in the Jak1/Tyk2-dependent recruitment of STAT1 
and STAT3. STAT3 has been particularly found to mediate anti-inflammatory effects of IL-10 in 
human primary macrophages with examples including the inhibition of TNF and IL-6 production, 
the induction of soluble TNFR production and downregulation of class II MHC expression 
(Williams et al. 2004). 
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Cytokine Principal cell 
source(s) 
Principal cellular targets and biologic effects 
Tumor necrosis factor 
(TNF) 
Macrophages, DCs,  
T cells 
Endothelial cells: activation (inflammation, coagulation) 
Neutrophils: activation 
Liver: synthesis of acute phase proteins 
Muscle, fat: catabolism for energy conversion, cachexia 
(loss of weight, weakness) 
Hypothalamus: fever and sleep 
Fibroblasts: stimulates the synthesis of collagen and 
collagenase for scar tissue formation 
 
 
Interleukin- 1  
(IL-1) 
Macrophages, DCs, 
Endothelial cells, some 
epithelial cells 
Endothelial cells: activation (inflammation, coagulation) 
Liver: synthesis of acute phase proteins 
Hypothalamus: fever 
 
 
Chemokines  
(e.g IL-8) 
Macrophages, Endothelial 
cells, T cells, Fibroblasts, 
Platelets 
 
 
Leukocytes: chemotaxis, activation 
Interleukin-12  
(IL-12) 
Macrophages, DCs NK cells and T cells: IFN-γ production, increased 
cytotoxic activity 
T cells: Th1 differentiation 
 
 
Interferon-γ  
(IFN-γ) 
NK cells, T cells Activation of macrophages 
Stimulation of some antibody responses 
 
 
Type I IFNs  
(IFN-α, IFN-β) 
IFN-α: macrophages, DCs 
IFN-β: fibroblasts 
All cells: anti-viral state, increased class I MHC 
expression 
NK cells: activation 
 
 
Interleukin-10  
(IL-10) 
Macrophages, DCs,  
T cells 
Macrophages, DCs: inhibition of cytokine production, 
reduced expression of co-stimulators and class II MHC 
molecules 
 
 
Interleukin-6  
(IL-6) 
Macrophages, Endothelial 
cells,  
T cells 
Liver: synthesis of acute phase proteins 
B cells: proliferation of antibody-producing cells 
T cells: Th17 differentiation 
 
Table 1.1 Key cytokines of Innate Immunity, adapted from (Abbas 2009) 
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1.2 Initiation of the inflammatory response by Pattern Recognition Receptors 
 
The innate immune system is responsible for early detection and clearance of invading microbes. 
The PRRs used by the innate immune system to recognise microbial antigens are expressed on 
phagocytes, DCs, and many other cell types, including mast cells, NK cells and epithelial cells. 
These receptors are either secreted and play a major role in PAMP opsonisation, or are expressed 
on the cell membrane or intracellular compartments where microbes may be localised. TLRs, on 
the cell membrane and on endosomes, constitute one of the biggest families of PRRs able to 
recognise bacterial, fungal and viral components (PAMPs) as well as damage-associated 
molecular patterns (DAMPs) generated upon tissue injury such as the molecules released from 
necrotic cells and extracellular matrix (ECM) fragments. The activation of TLRs results in 
initiation of NFκB/ activator protein-1 (AP-1) as well as the interferon regulatory factor (IRF) 3/7 
pathways (Figure 1.3). Cytoplasmic caspase-recruiting domain (CARD) helicases, including RIG-
I/ MDA5 respond to viruses which directly enter the cytoplasm, or to double stranded (ds) RNA 
produced during active viral replication. Nucleotide-binding oligomerization domain (NOD)-like 
receptors participate mainly in cytoplasmic recognition of bacteria leading to NFκB or 
inflammasome activation. Antifungal immunity is mainly mediated by Dectin-1 which activates 
NFκB and promotes phagocytosis. The consequence of PRR ligation is the production of pro-
inflammatory cytokines and chemokines, and the induction of the complement pathways. The 
activation of the innate immune system also leads to the production of anti-inflammatory factors 
such as TGF-β, IL-10 and steroid hormones which control inflammation through a negative 
feedback loop mechanism (Lee and Kim 2007). 
 
1.2.1 TLRs in inflammation 
 
Toll proteins were first identified as crucial components in dorso-ventral development of the 
Drosophila melanogaster embryo (Anderson et al. 1985). Subsequent studies revealed that Toll 
proteins mediate innate immune responses against fungal infections in Drosophila, and that the 
signalling initiated by Toll activation resembles the human IL-1 receptor pathway in terms of 
NFκB engagement (Gay and Keith 1991; Lemaitre et al. 1996). Human homologues of Toll 
receptors, termed Toll-like receptors were next cloned and tested for the induction of 
inflammatory mediators (Medzhitov et al. 1997; Rock et al. 1998). Today, TLRs represent the 
best-characterised family of PRRs, crucial for pathogen recognition and for shaping adaptive 
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immunity. Apart from mediating inflammatory responses, TLRs may coordinate the efficiency of 
phagosome formation or maturation of newly formed phagosomes as TLR signalling activates 
many molecules that are involved in phagocytosis such as paxilin, an actin-binding protein, or 
protein kinase C. It has been also shown that Rac1, a Rho family GTPase, and PI3-kinase which 
are required for phagocytosis are also indispensable for TLR functionality. Furthermore, TLRs 
regulate the expression of multiple genes that participate in microbial recognition, actin 
cytoskeletal reorganisation, proteolysis and antigen presentation. Stimulation of TLR4 also 
upregulates the expression of phagocytic receptors such as certain members of scavenger receptor 
family or activating Fcγ receptors. Phagocytosis is essential for microbe elimination and 
processing of antigens for class II MHC antigen presentation that ultimately leads to activation of 
CD4+ T cells (Underhill and Gantner 2004). To date, ten TLRs have been identified in humans, of 
which TLRs 1, 2, 4, 5 and 6 are expressed on the cell surface whereas TLRs 3, 7, 8 and 9 are 
expressed on endosomes.  TLRs are type I transmembrane receptors that belong to the TLR/IL-1R 
superfamily which also includes receptors for IL-18 and IL-1. These receptors share cytoplasmic 
Toll/ IL-1 receptor (TIR) domain responsible for signal transduction but differ in the extracellular 
domain. The IL-1R family is characterised by the Ig-like domains whereas TLRs contain leucin-
rich repeats (LRRs) required for ligand recognition (Akira and Hemmi 2003) (Figure 1.2).  
 
Ligand recognition by TLRs localised on the cell membrane 
TLR4 was the first human homologue described. Researchers revealed the role of this receptor for 
cytokine production by using a TLR4 mutated vesion that contained the mouse CD4 region 
instead of the regular ectodomain. Expression of this constitutively active TLR4 in THP-1 cell line 
resulted in the induction of NFκB luciferase as well as IL-1, IL-6 and co-stimulatory molecule 
B7.1 (Medzhitov et al. 1997). A year later, the first TLR4 ligand, LPS, was discovered. This was 
achieved by genetic and functional mapping of the gene responsible for impaired response to LPS 
in mice (Poltorak et al. 1998). Since its discovery as the LPS receptor,  TLR4  has  been  
implicated  in  the  recognition of  mannan  from  Candida  albicans,  
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glycoinositolphospholipids from a protozoan parasite Tryponasoma cruzi as well as viral envelop 
protein from certain viruses (Lee and Kim 2007). TLR4 has been also reported to recognise 
endogenous ligands such as HMGB-1 released during cell necrosis, heparin sulphate and recently 
Tenascin-C, all of which are components of extracellular matrix (ECM) found at high levels 
around injuries and in rheumatoid arthritis (Yu et al. 2006; Tang et al. 2007; Midwood et al. 2009) 
(Figure 1.2). Signalling through TLR4 depends on co-receptor MD2 to bind LPS. MD2 is also 
required for TLR4 dimerisation. Other components of TLR4 complex include LPS-binding protein 
(LBP) and CD14 where soluble plasma LBP first binds to LPS and is subsequently recruited to 
TLR4 by CD14 (Kawai and Akira 2010).  
 
TLR2 was suggested to recognise LPS prior to the discovery that mutation of the TLR4 gene leads 
to LPS hyporesponsiveness (Kirschning et al. 1998). However, the role of TLR2 in recognition of 
LPS was later discarded due to the discovery of lipoprotein contamination of introduced LPS, and 
no responsiveness of TLR2-transfected cells to purified LPS (Hirschfeld et al. 2000; Tapping et al. 
2000). TLR2 is implicated in the recognition of lipopeptides from bacteria, peptidoglycan and 
lipoteichoic acid from Gram-positive bacteria, zymosan from fungi or the hemagglutinin protein 
from measles virus (Kawai and Akira 2010). Similarly to TLR4, TLR2 was shown to recognise 
endogenous HMGB-1 (Yu et al. 2006). The receptor also associates with other TLRs or non-TLR 
PRRs to increase its PAMPs recognition range. TLR2 generally interacts with TLR1 or TLR6. 
TLR1/2 heterodimers recognize a synthetic bacterial triacyl lipopeptide Pam3CSK4, and TLR1/6 
heterodimers recognize diacyl lipopeptides such as MALP2 (Mycoplasma-derived macrophage-
activating lipopeptide 2) (Figure 1.2). Additional molecules facilitate ligand recognition and 
discrimination. CD36 presents MALP2 and lipoteichoic acid but not zymosan to TLR2/TLR6 
heterodimers (Hoebe et al. 2005) similarly to CD14 presenting LPS to the TLR4/MD2 complex. 
TLR2 alone poorly responds to zymosan and it requires cooperation with Dectin-1 for enhanced 
recognition. Dectin-1, on the other hand, requires TLR2 to induce NFκB-dependent pro-
inflammatory cytokine production (Gantner et al. 2003).  
TLR5 was discovered in 1998 as the receptor that recognises flagellin, the main component of 
flagella derived from both gram-positive and gram-negative bacteria (Figure 1.2). Flagellin was 
purified and identified by tandem mass spectrometry from the fraction of Listeria monocytogenes 
culture supernatant which induced TLR5-mediated activation of NFκB luciferase (Hayashi et al. 
2001). Flagellin, unlike most other ligands, is a protein that can activate both innate and adaptive 
immunity. TLR5 has been found to function as endocytic receptor. Internalised flagellin can be 
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processed by APCs and subsequently presented on class II MHC molecules to CD4+ T cells. 
Interestingly, this function of TLR5 is independent of Myd88, an adaptor molecule crucial for 
TLR-induced cytokine production (Letran et al. 2011). Individuals who carry a stop codon 
polymorphism of TLR5 show impaired response to flagellin and are prone to developing 
pneumonia during infection with the flagellated bacteria Legionella pneumophila  (Hawn et al. 
2003). 
 
Nucleic acid recognition by endosomal TLRs  
TLRs 3, 7/8 and 9 are mainly localised in the endoplasmic reticulum (ER) prior to stimulation. 
Upon ligand internalisation, these receptors are rapidly sequestered from the ER and they traffic to 
endolysosomes (Kim et al. 2008). The inhibition of endolysosome acidification by chloroquine 
blocks TLR3, 7/8 and 9-induced responses indicating that endosomal maturation is a prerequisite 
for TLR activation (Sacre et al. 2008). 
TLR3 has been identified as the receptor recognising dsRNA in 2001 (Alexopoulou et al. 2001). 
This group has shown that Tlr3
-/-
 mice demonstrate impaired responses to a synthetic analogue of 
dsRNA, polyinosinic-polycytidylic acid (PolyI:C) in terms of NFκB activation and pro-
inflammatory cytokine production. Although TLR3 is predominantly expressed intracellulary, a 
recent report noted TLR3 expression on the cell surface in primary human endothelial cells. This 
endothelial cell surface TLR3 responded to small interfering (si) RNA of at least 21 nucleotides in 
length (Figure 1.2). As gene silencing through siRNA has been considered as a therapeutic tool, 
the potential pro-inflammatory effects of siRNA administration should be therefore carefully 
considered (Kleinman et al. 2008). Cellular single stranded (ss) RNA that forms hairpin loops can 
also act as endogenous dsRNA. Endogenous dsRNA released from necrotic cells has been shown 
to stimulate cultured rheumatoid arthritis synovial fibroblasts (RASFs) via TLR3 (Brentano et al. 
2005a). Interestingly, CD14, which was originally identified as an LPS co-receptor, was reported 
to enhance TLR3‟s response to dsRNA (Lee et al. 2006). TLR3 is a critical component of host 
defence against viral infections. In response to TLR3 activation, cells produce anti-viral type I IFN 
and inflammatory cytokines. TLR3- and TLR9-deficient mice are predisposed to lethal infections 
with murine cytomegalovirus, and TLR3 deficiency in humans is linked to susceptibility to herpes 
simplex virus type 1 (Tabeta et al. 2004; Zhang et al. 2007).  
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TLR7 was initially identified to recognise the double cyclic organic molecules, imiquimod and 
resiquimod (R848), which have antiviral and antitumor properties, ssRNA derived from RNA 
viruses, synthetic poly (U) RNA and certain siRNAs  (Jurk et al. 2002; Heil et al. 2004; Hornung 
et al. 2005) (Figure 1.2). TLR7 is mainly expressed on plasmacytoid pre-DCs where it serves as a 
sensor of infection with ssRNA (Kadowaki and Liu 2002). Recently, Beignot and colleagues have 
shown that endocytosed human immunodeficiency virus (HIV)-1 activates pDCs to produce type I 
IFN and TNF via TLR7-mediated recognition of RNA. The group therefore suggested that this 
adjuvant feature of HIV-1 RNA could be used for generation of vaccines for the prevention of 
AIDS (Beignon et al. 2005). Surprisingly, a TLR7 ligand, imiquimod appears to be an antagonist 
of TLR8 signalling, as it inhibits TLR8- induced TNF production from human primary 
macrophages (Sacre et al. 2008). TLR8 is evolutionary most similar to TLR7. In contrast to TLR7 
which is mostly expressed of pDCs, TLR8 is highly expressed on monocytes (Kadowaki and Liu 
2002). The receptor mediates the recognition of synthetic R848 and viral ssRNA in humans but 
not in mice. Its expression is upregulated after bacterial infections (Lee and Kim 2007). TLR9 
recognises bacterial and viral unmethylated 2‟-deoxyribo cytidine-phosphate-guanosine (CpG) 
DNA motifs that are rare in mammalian cells. TLR9 also responds to synthetic CpG 
oligonucleotides. Although native mammalian DNA has been shown to be a poor stimulator of 
TLR9, chromatin-containing immune complexes could stimulate TLR9 on B cells in an in vitro 
system (Viglianti et al. 2003). Positioning of the TLRs for nucleic acids in endosomal 
compartments protects the host from reacting to endogenous nucleic acids and consequently from 
developing autoimmune conditions.  Another protective mechanism involves post-transcriptional 
modifications of eukaryotic RNA that distinguishes self and foreign nucleic acid (Tluk et al. 
2009). 
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Figure 1.2 Endogenous and exogenous ligand recognition by TLRs. This figure was compiled from 
(Kawai and Akira 2007; Piccinini and Midwood 2010). 
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1.2.2 Activation of the Myd88-dependent and independent pathways by TLRs 
 
Following stimulation of TLRs, TIR domain-containing intracellular adaptor molecules are 
recruited. The adaptor molecule Myd88 is used universally by all TLRs except of TLR3. MyD88 
adaptor-like (Mal) molecule is additionally used as a bridging adaptor for TLR4 or TLR2/TLR1 
and TLR2/TLR6 heterodimers. TLR4 engages the most complex signalling cascade as it also 
requires two other adaptor molecules; TIR-domain-containing adaptor inducing IFN-β (TRIF) and 
TRIF-related adaptor molecule (TRAM). TLR3 engages only the TRIF molecule (Figure 1.2). 
The initiation of the Myd88-dependent pathway leads to activation of NFκB and MAPKs that 
ultimately results in inflammatory cytokine production. The Myd88-independent pathway, which 
employs the adaptor molecule TRIF, leads to activation of NFκB and IRF3 and consequently to 
the production of type I IFN as well as inflammatory cytokines. In response to ligand stimulation, 
the cell membrane-localised TLR4 initiates the Myd88-dependent pathway. The receptor is 
subsequently internalised through dynamin-dependent endocytosis, traffics to endosomes and 
initiates TRIF-dependent pathway that leads to IRF3 and late-phase NFκB activation (Kawai and 
Akira 2010) (Figure 1.4).  
Myd88 mediates the signalling of TLRs as well as IL-1 receptors. The protein is recruited to the 
receptors through its carboxyl terminal TIR domain and interacts with its downstream binding 
partners through its amino-terminal death domain. Upon activation, Myd88 recruits IL-1 receptor-
associated kinases (IRAKs) as well as TNF receptor associated factor (TRAF) 6. MyD88 first 
binds to IRAK4 which, in turn, phosphorylates IRAK1. IRAK1 subsequently induces TRAF6 
which binds to the TAB-TAK complex and activates TAK1 protein. TRAF6 is an E3 ligase that, 
in conjugation with the ubiquitin-conjugating enzyme (Ubc)13/ Uev1A complex, catalyzes the 
synthesis of polyubiquitin linked to lysine 63 (K63) on target proteins including IRAK1, TRAF6, 
TAB2, TAB3 and NFκB essential modulator (NEMO). Ubiquitination of TAB2 and 3, the adaptor 
proteins for TAK1, leads to TAK1 activation and subsequent initiation of the canonical NFκB 
pathway and MAPKs signalling (Takeda and Akira 2004) (Figure 1.4). Mice deficient in Myd88 
are resistant to LPS stimulation exemplified by the lack of TNF, IL-6 or IL-1β production from 
macrophages and defective B cell proliferation. At the same time, activation of NFκB and MAPK 
is delayed but not abolished in the Myd88
-/-
 macrophages (Kawai et al. 1999) indicating that the 
TRIF pathway can compensate for the loss of Myd88 in TLR4 signalling.  
Stimulation of TLR3 or TLR4 leads to the recruitment of TRIF, and in the case of TLR4 also 
TRAM. The engagement of TRIF results in Myd88-independent activation of the canonical NFκB 
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pathway, possibly also through a ubiquitination-dependent mechanism mediated by TRAF6. In 
addition, TRIF recruits receptor interacting protein (RIP)-1. RIP-1 requires adaptor TRADD and 
an E3 ubiquitin ligase Pellino-1 to induce NFκB (Figure 1.4). Interestingly, TRAF6 deficiency 
has been shown to be dispensable for TRIF-dependent TLR3 and TLR4 signalling in terms of IP-
10 production. In contrast, TRAF6 deficiency greatly decreased LPS-induced TNF and IL-6 
production (Gohda et al. 2004).  This is because the TRIF-dependent pathway also leads to the 
activation of the TRAF3/IKKi/TBK1 pathway and ultimately to the induction of IRF3. The 
consequence of the TRIF activation is the expression of IFN-inducible genes such as those 
encoding IFN-β, IP-10 and RANTES (regulated on activation, normal T expressed and secreted) 
(Kawai and Akira 2010).  
Prolonged activation of TLR signalling, which engages NFκB, MAPK and IRF pathways, leads to 
excessive production of pro-inflammatory cytokines that may result in multiple organ failure as 
seen in sepsis (Tsujimoto et al. 2008). Apart from the induction of anti-inflammatory mediators, 
TLR signalling is controlled by the network of regulatory molecules including phosphoinositide 3-
kinases (PI3Ks) and small GTPases of the Rho family. Studies using a general PI3K inhibitor, 
LY294002, in the THP-1 monocytic-like cell line have demonstrated impaired activation of NFκB 
upon TLR2 stimulation indicating that PI3K act as a positive regulator of TLR signalling (Arbibe 
et al. 2000). On the other hand, DCs derived from mice deficient in p85α (regulatory subunit of 
class IA PI3K), or treated with PI3K general inhibitor, wortmannin, exhibited increased LPS-
dependent IL-12 production. In this study, PI3K functioned as IL-12 suppressor via a p38-
dependent signalling cascade (Fukao et al. 2002). Also the role of GTPases of the Rho family 
appear to be dependent on the family member as dominant-negative Rac1N17, but not dominant-
negative Cdc42N17, has been shown to block NFκB gene transactivation upon TLR2 stimulation 
(Arbibe et al. 2000). TLR signalling can be also regulated by its own components. For instance, 
newly discovered fifth TIR adaptor molecule, sterile alpha and HEAT-Armadillo motifs (SARM), 
has been shown to negatively regulate TRIF-dependent TLR signalling. SARM physically 
associated with TRIF, and SARM siRNA-mediated downregulation increased TRIF-driven 
cytokine induction in HEK-TLR3 and HEK-TLR4 cells (Carty et al. 2006). 
 
1.2.3 Induction of NFκB by TLRs 
 
The transcription factor NFκB has been associated with the development and perpetuation of most 
chronic diseases. It regulates the expression of cytokines, genes involved in apoptosis, cell 
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adhesion, proliferation, oxidative stress responses as well as up-regulation of co-stimulatory 
molecules on DCs that provides an essential signal for CD4+ T cell activation. Dysregulation of 
NFκB has been linked to cancer, AIDS, atherosclerosis, asthma, arthritis, diabetes, Inflammatory 
Bowel Disease, stroke and viral infections (Gupta et al. 2010). 
NFκB forms homo- and heterodimers which are composed of molecules that contain Rel-
homology domains (RHDs) required for DNA binding at specific κB sites within the promoter and 
enhancer regions of a target gene. Five members of the NFκB family have been identified in 
mammals. These include RelA (p65), RelB, c-Rel, p105 (NFκB1; a precursor of p50) and p100 
(NFκB2; a precursor of p52). NFκB is retained in the cytoplasm in unstimulted conditions in an 
inhibitory complex with IκB. The IκB family consists of IκB, , ,  as well as IκB, Bcl-3 and 
IκBNS. IκB, ,  and  inhibit NFκB by blocking its nuclear localisation sequence and thus 
NFκB translocation to the nucleus. The remaining IκB, Bcl-3 and IκBNS are present in the 
nucleus where they control NFκB-mediated gene transcription (Kawai and Akira 2007).  
A heterodimer composed of RelA and p50 is the most common canonical NFκB form activated by 
TLRs. Following TLR stimulation, IκB is phosphorylated by TAK1-activated IκB kinase (IKK) 
complex, then ubiquitinated and subsequently degraded by the 26S proteasome. IKK complex 
comprises two catalytic molecules, IKKα and IKKβ, as well as a regulatory molecule NEMO. 
Following NFκB release from the inhibitory IκB complex, p65 is phosphorylated on Serines 276, 
529, 536 and 311; these residues are required for p65 translocation to the nucleus and p65-
mediated gene transactivation (Hayden and Ghosh 2008). p65 has been shown to be 
phosphorylated on Serine 276 by mitogen- and stress- activated protein kinase-1 (MSK1 and 
MSK2) and protein kinase A (PKA) (Zhong et al. 1998; Wang et al. 2000; Vermeulen et al. 2003). 
Casein kinase II was found to phosphorylate p65 on Serine 529, IKKα/β on Serine 536 whereas 
protein kinase C (PKC)δ on Serine 311 (Wang et al. 2000; Duran et al. 2003; Sakurai et al. 2003; 
Chen et al. 2005). The initiation of the Myd88-dependent pathway, which involves TRAF6 and 
TAK1 molecules, leads to an early canonical NFκB activation. The initiation of the TRIF-
dependent pathway by TLR3 and TLR4 stimulation results in a late canonical NFκB activation 
(Kawai and Akira 2007) (Figure 1.4). The inhibition of protein synthesis by cyclohexamide 
abrogated NFκB activation in Myd88-deficient mice indicating that the late NFκB induction is 
dependent on new protein synthesis (Covert et al. 2005). Although, similarly to Myd88, TRIF also 
utilises TRAF6 for TAK1 activation, this pathway also seems to be dependent on RIP1 as RIP1-
deficient cells exhibit defective TLR3-mediated NFκB activation (Cusson-Hermance et al. 2005).  
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The alternative, noncanonical, pathway involves the processing of p105 and p100 to p50 and p52, 
respectively. The long forms contain C-terminal ankyrin repeats, which similarly to IκB proteins 
in the canonical pathway, bind to RHD and inhibit NFκB nuclear translocation. Ubiquitin- 
dependent degradation of C-terminal region of p105 and p100 is a prerequisite for the generation 
of the mature NFκB forms. Phosphorylation of p100 is also required for p52 processing. This step 
is accomplished by IKKα- IKKα homodimer, which does not involve IKKβ or NEMO. It is 
unclear whether TLRs activate the noncanonical NFκB pathway (Kawai and Akira 2007).  
IKKi, another member of the IKK family, was first identified as an LPS-inducible protein. It 
interacts with TBK1, whose deficiency in mice leads to embryonic death (Bonnard et al. 2000). 
Interestingly, despite being members of the IKK family, the double Ikki and Tbk1 knockout does 
not result in reduced NFκB DNA binding or IκB degradation in embryonic fibroblasts stimulated 
with TLR3 or TLR4 ligands (Hemmi et al. 2004). Rather IKKi and TBK1 have a vital role in type 
I IFN induction via the transcription factor IRF3. IKKi/TBK1-mediated phosphorylation of IRF3 
allows its dimerisation and subsequent nuclear translocation. In the nucleus IRF3 binds to IFN-
stimulated response element (ISRE) and together with NFκB and ATF2/cJun regulates the 
expression of IFN-β (Fitzgerald et al. 2003). TLR3- and TLR4- induced IRF3 activation is 
mediated by the adaptor molecule TRIF and its binding partner TRAF3 (Figure 1.4). IRF3 
activation is independent of Myd88 as it is intact in Myd88-deficient mice. Conversely, the 
production of TLR7- and TLR9- induced type I IFN in pDC depends entirely on Myd88 indicating 
that another pathway mediating type I IFN production is utilised by these receptors. IRF7 has been 
since reported to control IFN-α production via the Myd88/IRAK4/TRAF6 pathway. 
Simultaneously, IKKi- and TBK1-deficient pDCs do not exhibit impaired IFN-α production upon 
TLR7 and TLR9 stimulation (Kawai and Akira 2007).  
 
1.2.4 NFκB-dependent regulation of TNF transcription 
 
TNF was initially recognised as a factor that could initiate apoptosis in malignant and transformed 
cells. Subsequent studies revealed that TNF is a potent inducer of immune responses and a central 
mediator of inflammation. Systemically administered TNF induces other cytokines, hormones as 
well as acute phase proteins, leukotrienes, ROS, NO, platelet-activating factor and prostaglandins 
(Schottelius et al. 2004). Because of its predominant functions, the regulation of TNF production 
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has been extensively studied and it is now clear that TNF is precisely regulated at every stage of 
gene and protein expression (Falvo et al. 2010).  
 
The human TNF 5‟ promoter and downstream 3‟ enhancer regions contain multiple transcription 
factors binding sites which have been described to be involved in the TLR-driven induction of 
TNF. These include NFκB (κB) sites, Ets, cAMP-responsive element (CRE), CCAAT/enhancer 
binding protein β (C/EBP) and AP-1-like (Kramer et al. 1995; Liu et al. 2000) (Figure 1.3). NFκB 
is the key transcription factor involved in TNF transcription as the overexpression of IκBα 
considerably decreases TNF production from LPS-stimulated human primary macrophages 
(Foxwell et al. 1998). There are three confirmed NFκB binding sites in the TNF promoter: κB site 
1 is located at position -673 base pairs (bp) upstream from the transcription start site, the cluster of 
κB site 2 starts at -627bp whereas κB site 3 starts at position -90bp and is localised in the core 
promoter of TNF. Additionally, κB site 4 is situated in the 3‟downstream region of TNF at the 
position +2981bp. NFκB site 4 has been shown to act as enhancer of LPS-mediated TNF induction 
(Kuprash et al. 1999). Previous studies revealed that p65 is recruited to all four κB sites in the 
TNF promoter upon LPS stimulation (Krausgruber et al. 2010; Smallie et al. 2010). However, 
deletion or site-directed mutagenesis of any single κB site from the TNF promoter has little effect 
on the induction of the gene by LPS (Goldfeld et al. 1990; Udalova et al. 1998), (Tim Smallie, 
thesis). The canonical form of NFκB is a dimer comprising of a p65 and p50 subunits. The 
composition of the dimer determines the site of DNA binding as well as the function of the 
complex.  p65/p50 heterodimer shows little variation in binding to κB sites 1, 2 and 3. p50/p50 
homodimer which is considered to be inhibitory, binds with high affinity to κB site 1 and to κB 
site 2a. On the contrary, the p65/p65 homodimer has been shown to be strongly recruited to κB 
site 2 but not 2a. In murine macrophages, κB site 4 has been shown to recruit NFκB complexes of 
p50 and p65 subunits (Udalova et al. 1998; Kuprash et al. 1999; Liu et al. 2000; Udalova et al. 
2000). 
 
NFκB recruitment to the promoters of inflammatory genes was reported to be dependent on p38 
MAPK. Particularly, the inhibition of p38 by SB203580 impaired phosphorylation and 
phosphoacelation of histone H3 in LPS-treated human DCs. Histone-DNA complexes when 
highly packed, limit the accessibility of the genome to transcription machinery. The post-
transcriptional modifications of histones such as acetylation, phosphorylation and methylation 
regulate chromatin folding and allow DNA-binding proteins to be recruited to gene regulatory 
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elements. p38 MAPK-mediated H3 phosphorylation on Serine 10 is required for NFκB access to 
promoters and for the transcription of target genes (Saccani et al. 2002).   
 
 
Figure 1.3 A schematic of the human TNF gene. TNF gene comprises of 5’ promoter region, followed by 
transcription start site (TSS), a segment of 4 exons (shown as black squares), 3’ UTR and 3’ enhancer 
region. Multiple transcription sites involved in TLR signalling, including NFkB, Ets,CRE/ATF, C/EBP, AP-1 
are localised in the promoter (shown as white squares). NFkB site 4 is localised in the 5’enhancer region. 
The location of the transcription factors in relation to TSS is shown numerically in base pairs.  
 
 
 
Chapter 1  Introduction 
28 
 
1.2.5 Induction of MAPK by TLRs 
 
MAPKs are involved in gene expression, mitosis, movement, metabolism, and programmed cell 
death. They phosphorylate specific serines and threonines of target protein substrates including 
other protein kinases, phospholipases, transcription factors, and cytoskeletal proteins. Apart from 
transcriptional regulation, MAPKs were found to regulate mRNA stability, transport and 
translation. Mammalian MAPK family includes members such as the extracellular-signal-
regulated kinase (ERK), JUN N-terminal kinase (JNK, also known as MAPK8) and p38 (also 
known as MAPK14). The activation of upstream cell surface receptors leads to the initiation of a 
cascade of sequential phosphorylation events, starting from the phosphorylation of MAPK kinases 
(MAPKKs) by MAPK kinase kinases (MAPKKKs). Triggered MAPKKs then phosphorylate 
MAPKs on threonine and tyrosine residues which changes MAPKs conformation and leads to 
their enhanced substrate accessibility. Activated MAPKs can translocate to the nucleus where they 
regulate the activity of transcription factors such as AP-1, activating transcription factor 2 (ATF2) 
or CRE-binding protein (CREB) (Figure 1.5). MAPKs are deactivated by dephosphorylation 
mediated by tyrosine, serine/threonine phosphatases such as mitogen-activated protein kinase 
phosphatases (MKPs), also known as dual-specificity protein phosphatases (DUSPs) (Johnson and 
Lapadat 2002). 
 
The ERK pathway is mainly activated by growth factors, cytokines, virus infection or carcinogens. 
Upon activation, the proto-oncogene GTPase Ras first recruits a MAPKKK called c-Raf, which in 
turn activates MAPKKs MEK1 and MEK2 to phosphorylate ERK1 and ERK2. One of the 
downstream targets of ERK1/2 in LPS signalling is the transcription factor Elk-1 that binds to Ets 
motifs in DNA (Figure 1.5). Phosphorylated Elk-1 also recruits serum response factor (SRF) to 
SRE sites in the target gene (Brook et al. 2006). TLR-activated ERK has been shown to induce the 
expression of the MKP-1 gene, and the MKP-1 stabilisation through phosphorylation. The 
activation of MPK-1 leads in turn to JNK and p38 dephosphorylation and as a consequence, to the 
graduate inhibition of TNF production (Liu et al. 2007).  The inhibition of ERK by a drug 
PD98059 reduces LPS-induced TNF and IL-1β release but does not block IL-10 synthesis (Foey et 
al. 1998).  
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Figure 1.4 Overview of Myd88-dependent and Myd88-independent pathways. TLR4 stimulation 
initiates the most complex TLR signalling cascade as the receptor utilises four adaptor molecules: TRAM, 
TRIF, Mal and Myd88. In contrast, endosomal TLR3 uses only TRIF, whereas endosomal TLRs 7, 8 and 9 
use only Myd88. The initiation of TRIF-dependent pathway by TLR4 and TLR3 induces TRAF3 which then 
activates the kinases TBK1 and IKKi, which phosphorylate and activate IRF3. TRIF also recruits TRAF6 
and TRADD which interacts with Pellino-1 and RIP1. Ubiquitinated RIP1 and TRAF6 together activate 
TAB2/TAB3/TAK1 complex to initiate late NFκB signalling. TAK1 first activates IKK complex comprising of 
NEMO and IKKαβ, which phosphorylate IκB and thus lead to p65-p50 release from the inhibitory IκB 
complex. p65 is then hosphorylated and transfers to the nucleus. TAK1 is also required for MAPK and 
subsequent AP-1 activation. Activation of Myd88 induces IRAKs and TRAF6 which then together with 
Ubc13 and Uev1A ubiquitinates the TAB2/TAB3/TAK1 complex leading to early NFκB activation. The 
recruitment of TRAF3 to the Myd88/IRAKs/TRAF6 complex also leads to induction of IRF7. Gene 
transactivation by IRF3, NFκB, AP-1 and IRF7 results in type I IFN expression. NFκB and AP-1 are also 
required for cytokine production. Adapted from (Kawai and Akira 2010).  
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The JNK pathway was initially characterized as a stress-activated protein kinase (SAPK) pathway. 
JNK is activated by MKK7, which itself is primary activated by cytokines and MKK4, as a result 
of environmental stress (Derijard et al. 1995; Tournier et al. 1997) (Figure 1.5). These two 
MAPKKs are activated by a variety of MAPKKKs including MEKK1-4 (Blank et al. 1996; Xu et 
al. 1996; Gerwins et al. 1997), TAK-1, apoptosis signal regulating kinases ASK1 and ASK2 
(Ichijo et al. 1997; Wang et al. 1998). Of these, MEKK1-3 can also activate ERK1/2 pathway 
whereas TAK1 and ASK1 can also initiate the p38 pathway. JNKs are central inducers of the AP-
1 transcription factor components such as cJun and ATF-2 (Gupta et al. 1996). Inhibition of JNK 
by a drug SP600125 prevents the induction of matrix destroying metalloproteinases (MMPs) as 
well as TNF and thereby blocking joint destruction in rodent models of rheumatoid arthritis. JNK 
inhibitors were also shown to enhance chemotherapy- induced blockage of tumor expansion 
(Johnson and Lapadat 2002). 
 
p38 MAPK was originally identified as a compound involved in the biosynthesis of pro-
inflammatory mediators. Apart from being activated upon TLR and cytokine receptor stimulation, 
the p38 MAPK pathway is also initiated by growth factors and environmental stress such as heat 
shock, radiation or ultraviolet light. There are four members of the p38 family: p38α, p38β, p38γ 
and p38δ. p38α has been shown to be to be the key member implicated in the immune and 
inflammatory responses. p38 MAPK is activated by several MAPKKs such as MKK6 and MKK3 
which were previously phosphorylated by small GTPases Rac and Cdc42 (Yong et al. 2009) or by 
TAK1 (Lee et al. 2000). p38 MAPK has been shown to be predominantly localised in the nucleus 
in a complex with MK2. The phopshorylation of MK2 by p38 exposes a nuclear export signal in 
the carboxyl terminal domain of MK2 thus allowing the translocation of p38 to the cytoplasm 
(Engel et al. 1998). p38 kinase has been reported to control the activation of numerous 
transcription factors including ATF-1, ATF-2, CREB, p53 and NFκB (Yong et al. 2009) (Figure 
1.5). In particular, the dominant negative mutant of p38 MAPK inhibited NFκB reporter activity 
in LPS-stimulated human primary macrophages at the level similar to IκBα (Campbell et al. 
2004). Expression of many inflammatory mediators including TNF, IL-6, IL-1, IL-8, iNOS, COX-
2, MMPs, c-Jun, c-Fos or JunB has been shown to be regulated by the p38 MAPK pathway (Yong 
et al. 2009). 
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1.2.6 p38 MAPK- dependent control of TNF mRNA stability 
 
Apart from being involved in the transcriptional regulation of inflammatory genes, p38 MAPK has 
been implicated in the post-transcriptional regulation of gene expression by mediating the stability 
of mRNA (Clark et al. 2003) . During the course of transcriptional maturation, RNA Polymerase 
II (Pol II) adds a 7-methylguanosine cap to the 5‟ termini of mRNA whereas poly (A) polymerase 
adds a poly(A) tail to the 3‟termini of mRNA. The removal of the poly (A) tail by deadenylase 
and subsequent decapping of the 5‟termini uncovers mRNA which is then degraded by 
exonucleases (Wilusz et al. 2001). p38 has been shown to stabilise mRNA by inhibiting 
deadenylation. All p38-regulated transcripts contain adenine and uridine-rich elements (ARE) in 
their 3‟ untranslated regions (3‟UTR). These elements attract ARE-binding proteins that can 
negatively regulate mRNA stability by promoting rapid deadenylation and subsequent decay of 
the transcript (Clark et al. 2003). 
The importance of ARE in post-transcriptional regulation of TNF was confirmed in mice lacking 
TNF 3‟UTR ARE. These mice exhibit chronic overproduction of TNF in serum and develop 
chronic inflammatory arthritis and inflammatory bowel disease (Kontoyiannis et al. 1999). The 
ARE-binding protein tristetraprolin (TTP) has been shown to regulate the stability of TNF mRNA. 
Several mechanisms of TTP-dependent TNF transcript decay were proposed and these include the 
proteasome pathway, the RNA processing-body (P-body) and the microRNA pathway (Deleault et 
al. 2008). Upon stimulation with an inflammatory agonist, p38 activates its substrate MK2 which 
in turn phosphorylates TTP and inactivates its destabilising function. TTP expression is enhanced 
upon LPS stimulation and paradoxically, activated p38 supports the stability of the TTP transcript 
(Figure 1.5). During the resolution of inflammation, the activity of p38 decreases and TTP is 
dephosphorylated. Reconstituted TTP binds to TNF mRNA resulting in destabilisation of the 
transcript. p38 MAPK can therefore play a double role by both promoting TNF production as well 
as preventing overproduction of TNF (Brook et al. 2006). 
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Figure 1.5 MAPK signalling pathways activated by LPS. LPS binding to TLR4 initiates Myd88-
dependnet pathway which leads to the activation of the MAPK signalling cascade. MAPKKK including c-
Raf, MEKK1/4 and TAK1 are activated first. This activation leads to MAPKK (MEK1/2, MKK4/7 and 
MKK3/6) and subsequent MAPK (ERK1/2, JNK and p38) phosphorylation. MAPK mediate the activation of 
multiple transcription factors. In addition, cytoplasmic p38 regulates the stability of an ARE binding protein 
TTP via MK2. TTP is bound to ARE in the 3’UTR of many inflammatory genes (e.g TNF) promoting mRNA 
deadenylation and subsequent degradation. MK2 deactivates TTP through phosphorylation resulting in the 
stability of TNF mRNA (adapted from (Guha and Mackman 2001; Brook et al. 2006). 
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1.2.7 Induction of AP-1 by TLRs 
 
The AP-1 family of transcription factors feature basic region-leucin zipper (bZIP) domains that 
facilitate dimerisation and DNA-binding domains which facilitate AP-1 binding to target 12-O-
tetradecanoylphorbol-13-acetate (TPA) response elements (5′-TGAG/CTCA-3′) or cAMP 
response elements (CRE, 5′-TGACGTCA-3′). AP-1 operates as a dimeric protein composed of 
members of the Jun (cJun, JunB, JunD), Fos (cFos, FosB, Fra1 and Fra2), Maf (c-Maf, MafB, 
MafA, MafG/F/K and Nrl) and ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) sub-families. 
MAPK are implicated in AP-1 activation as well as the expression of AP-1 components (Pramanik 
et al. 2003). A previous report by Kristof and colleagues showed that chemical inhibition of p38 
and ERK decreased LPS/IFNγ-induced AP-1 binding to the iNOS promoter (Kristof et al. 2001). 
The function of p38 in regulating AP-1 activity varies between p38 isoforms as p38β appears to 
induce whereas  p38δ and p38γ seems to inhibit or have no effect on AP-1-induced luciferase 
activity in human breast cancer cells (Pramanik et al. 2003). A subsequent study revealed that the 
activation of c-Jun and ATF-2 under genotoxic stress was inhibited by JNK inhibitors or JNK-
specific siRNA in human breast cancer cells (Hayakawa et al. 2004).  
 
cJun is regarded as one of the most important transcription activators as its deficiency leads to 
embryonic lethality in mice (Jochum et al. 2001). c-Jun/ATF-2 heterodimers have been reported to 
have a high affinity to the CRE/ATF site in the TNF promoter (Hayakawa et al. 2004) (Figure 
1.3). Deletion of both Ets and CRE/ATF sites completely abolishes cJun-dependent trans-
activation of the human TNF promoter (Kramer et al. 1995). It has been suggested recently that 
cJun homodimers bound to the TPA motif form a scaffold for a gene co-repressor complex which 
consists of the nuclear receptor corepressor (NCoR). NCoR together with other associated proteins 
(TBL1, transducin β-like protein 1; TBLR1, TBL1-related protein) actively represses gene 
transcription by cooperating with histone deacetylase (HDAC)3, an enzyme associated with 
inactive chromatin. TPA treatment of macrophages leads to c-Jun phosphorylation on Serine 63 
and 73 resulting in the release of the co-repressor complex. De-repression of cJun homodimers 
facilitates the exchange of one cJun subunits into the cFos subunit. Newly formed cJun/cFos 
heterodimer attracts a co-activator complex comprising histone acetyl transferases (HATs) 
allowing gene transcription (Ogawa et al. 2004) (Figure 1.6).   The process of NCoR clearance 
from cJun homodimers appears to be p65-dependent but JNK-independent in TLR signalling. 
Specifically, upon LPS stimulation, p65 is phosphorylated on Serine 536 to enable p65 
transactivation of target genes. When bound to the iNOS promoter, p65 acts as a courier for IKKε, 
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an enzyme able to phosphorylate cJun and as a consequence to initiate NCoR clearance (Huang et 
al. 2009).  
 
The role of AP-1 in inflammation is inconclusive. Cells lacking cJun or JNK demonstrate largely 
impaired production of monocyte chemotactic protein-1 (MCP-1) upon IL-1R stimulation 
probably caused by the decreased recruitment of NFκB and Pol II to the MCP-1 gene, Ccl2, as 
well as by deficient histone modifications (Wolter et al. 2008).  Downregulation of ATF-2, on the 
other hand, decreases LPS-induced expression of Socs-3 in murine macrophages (Hirose et al. 
2009). SOCS-3 has been described as a negative regulator of TLR4 signalling as stable 
transfection of Socs-3 resulted in an inhibition of NO, TNF, IL-6, and GM-CSF release from LPS-
treated murine macrophages (Berlato et al. 2002). JunB has been also reported to bind to the 
promoters of inflammatory genes. DCs subjected to JunB knockdown exhibit decreased  
 
 
 
 
Figure 1.6 Model of de-repression of AP-1 target genes. In basal conditions, transcription of AP-1 target 
genes is inhibited by cJun homodimers which attract a repression complex comprising NCoR, TBL1, 
TBLR1 and HDAC3. Upon stimulation cJun is phosphorylated on Serine 63 and 73 resulting in TBLR1-
dependent recruitment of ubiquitin noncovalent complex UbcH5, which ultimately leads to proteosomal 
degradation of NCoR and the release of the repression complex. cFos is then recruited to AP-1 motifs 
substituting one of the cJun components. cJun/cFos heterodimer binds a coactivator complex which 
subsequently leads to gene transcription. HDAC, histone deacetylase; TBL1, transducin β-like protein 1; 
TBLR1, TBL1-related protein; NCoR, nuclear receptor corepressor. Adapted from (Ogawa et al. 2004). 
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transcription activation of the TNF, IL-6 and IL12p40 genes upon LPS stimulation (Gomard et al. 
2010) suggesting that JunB promotes inflammatory response. In contrast, JunB/
 
cJun double 
knockout mice develop psoriasis-like phenotype also characterised by elevated expression of Tnf, 
Il1 and Il6 in epidermis (Schonthaler et al. 2009) indicating that these two AP-1 components may 
have anti-inflammatory properties.    
 
1.2.8 Induction of primary and secondary response genes by LPS 
 
The recruitment of transcription factors to DNA initiates the transcription of the genes. The first 
step involves the binding of Pol II and chromatin modifiers. The association of chromatin-
remodelling complexes reveals critical regulatory DNA regions previously restricted by tight 
histone-DNA assemblies. Transcription factors also recruit histone-modifying enzymes including 
HATs and HDACs. The histone post-transcriptional modifications such as methylation and 
acetylation provide a docking site for additional components of the transcriptional complex 
(Medzhitov and Horng 2009). 
Classical model of transcription by Pol II involves initiation, elongation and termination.  The 
initiation occurs when Pol II is recruited to the gene and when it is phosphorylated by TFIIH on 
Serine 5 (Ser5) of the C-terminal domain (CTD).  During initiation, Pol II produces short mRNA 
but halts after few dozen base pairs from the transcription start site. The second phosphorylation 
of Serine 2 (Ser2) of the CTD mediated by the P-TEFb complex derepresses Pol II allowing the 
elongation event (Medzhitov and Horng 2009). Fully activated Pol II is also required for mRNA 
maturation as the recruitment of polyadenylation factors to the 3‟termini of mRNA is impaired in 
the absence of Ser2 phosphorylation (Ahn et al. 2004). 
LPS induces the expression of hundreds of genes which can be divided into primary response 
genes (PRGs) and secondary response genes (SRGs). PRGs such as TNF, JUNB and FOS are not 
dependent on novel protein synthesis as a protein synthesis inhibitor, cyclohexamide, does not 
affect their expression. These genes also do not require chromatin remodelling thus as a 
consequence they are induced within an hour of stimulation.  The expression of PRGs is regulated 
by co-repressor complexes containing NCoR and HDAC3 which are recruited to NFκB and AP-1 
sites through transcription factors p50/p50 and cJun. The induction of SRGs such as IL6, on the 
other hand, is largely delayed as they rely on de novo protein synthesis and chromatin 
modifications. The regulation of SRGs expression appears to be independent of co-repressor 
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complexes as NCoR is not recruited to these promoters. One possible explanation is that closed 
chromatin may limit the access of transcription factors to the SRGs (Ogawa et al. 2004; Ramirez-
Carrozzi et al. 2006; Hargreaves et al. 2009).  
The promoters of PRGs rich in guanine and cytosine have been demonstrated to possess high 
levels of histone H3 modifications including H3K4me3 and H3K9Ac which are associated with 
active chromatin. In addition, Ser5-phosphorylated Pol II is preassembled to many PRGs prior to 
LPS stimulation.  This modified Pol II is able to produce full-length unspliced mRNA that is 
rapidly degraded. The engagement of TLR4 signalling leads to P-TEFb-mediated phosphorylation 
of Pol II on Ser2 what results in the production of mature mRNA (Hargreaves et al. 2009). This 
complex mechanism of gene expression allows rapid production of inflammatory mediators upon 
pathogen recognition. These mediators are required for pathogen clearance and activation of 
adaptive immunity. The induction of inflammatory genes is highly sensitive but at the same time 
is tightly regulated as multiple signals are required for effective gene transcription (Figure 1.7). 
 
 
 
 
Figure 1.7 Model of inflammatory gene induction by LPS. The promoters of primary response genes (a) 
rich in CpG islands are characterised by the presence of H3K4me3, H3K9Ac and Serine 5- phosphorylated 
Pol II. Transcription factors such as Sp1 form a scaffold for HAT. In basal conditions only unspliced 
transcript is produced. However, upon LPS stimulation Pol II is phosphorylated on Serine 2 by P-TEFb 
what allows the production of mature transcript. In contrast, secondary response genes (b) require 
chromatin remodelling to allow transcription factor and HAT binding. Pol II, RNA Polymerase II; P-TEFb, 
positive transcription elongation factor b; Ser, Serine; HAT, histone acetyltransferase; Sp1, specificity 
protein 1, NFκB, nuclear factor κB. Adapted from (Hargreaves et al. 2009; Medzhitov and Horng 2009). 
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1.3 TLRs in immune tolerance and autoimmunity  
 
 
Apart from playing a central role in host defence against danger, TLR activation has been 
implicated in the pathogenesis of many autoimmune diseases including systemic lupus 
erythematosus, inflammatory bowel disease, rheumatoid arthritis, type I diabetes, and multiple 
sclerosis. Autoimmunity is a failure of the immune system to remain unresponsive to self-antigens 
and non-infectious foreign antigens. Tolerance to self-antigens can be induced in lymphoid organs 
where immature T and B lymphocytes differentiate into mature cells, or in peripheral tissue. 
Immature lymphocytes which react to self-antigens undergo apoptosis, change their receptor 
specificity (B cells) or develop into Tregs (CD4+ T cells). Alternatively, some self-reactive 
immature lymphocytes can escape the negative selection or reprogramming and complete the 
maturation process in peripheral tissue. These cells are then inactivated in a process called anergy, 
undergo apoptosis or are inhibited by Tregs. Deficiency in FoxP3, a key regulator of Tregs, leads 
to the development of auto-reactive (autoimmune) diseases in humans (Gambineri et al. 2003; 
Stephens et al. 2005). Similarly, defects in apoptotic signalling, such as dominant mutations in the 
Fas death receptor pathway, leads to disregulation of self-tolerance (Fisher et al. 1995). The 
principal factors in the development of autoimmune diseases are gene mutations and 
environmental stress. Exogenous and endogenous ligands may modulate TLR responsiveness and 
induce abnormal activation of TLRs under pathophysiological conditions. TLR stimulation could 
lead to the activation of innate immunity as well as tissue injury resulting in increased production 
of co-stimulators and cytokines by tissue APCs. These inflammatory conditions may break T cell 
anergy and promote the activation of self-reactive lymphocytes. Multiple mutations, inherited and 
somatic, may be needed to bypass multistep tolerance checkpoints in lymphocytes. Mutations 
associated with MHC genes (HLA-DR alleles) are the most common ones, however, other 
deficiencies has been also increasingly identified in recent years (Goodnow 2007). Examples of 
autoimmune diseases are presented below. 
 
1.3.1 Systemic lupus erythematosus  
 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease affecting 40-200 per 
100,000 individuals with a 15-year survival rate of 80%. The cause of lupus is unknown but since 
90% of cases occurs in women it was suggested that female hormones or genes of the X 
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chromosome may be implicated (Rahman and Isenberg 2008). Mutations in the MHC genes 
(HLA-DR2, HLA-DR3) appear to increase chance of SLE development when triggered by 
environmental factors. But also mutations of IRF5, programmed death 1 (PD1) receptor or 
complement deficiencies C1Q, C2, C4 have been shown to increase a person‟s change of 
developing lupus (Gregersen and Behrens 2006). SLE is a Type III hypersensitivity reaction 
caused by antibodies reacting with self dsDNA released from the patient‟s apoptotic cells. Self 
dsDNA antibodies are present in serum of 70% patients with lupus distinguishing them from 
healthy individuals or RA patients and are likely to be generated as a consequence of impaired 
clearance of dying cells by phagocytes (Gaipl et al. 2007). It still remains unclear what activates 
autoimmune B cells. Endosomal TLRs, which recognise nucleic acids, have been proposed to 
initiate the inflammatory response resulting in the disease progression. In particular, as observed 
in lupus-prone MRL
lpr/lpr 
mice, the deficiency in TLR9 dramatically decreased the production of 
anti-dsDNA auto-antibodies (Christensen et al. 2005). In contrast to this observation, generation 
of Tlr9
-/-
 mice on different genetic background resulted in increased anti-DNA antibody 
production (Wu and Peng 2006). Similarly to the mice studies, the role of TLR9 in human SLE is 
inconclusive as the association of TLR9 gene polymorphisms with the disease varied between 
studies (Hur et al. 2005; Ng et al. 2005). On the other hand, stop codon polymorphism in TLR5 
has been linked to the resistance to SLE in humans. PBMCs carrying truncated TLR5 showed 
impaired production of pro-inflammatory cytokines. Furthermore, this truncated TLR5 allele was 
preferentially transmitted to offspring who were not affected by SLE (Hawn et al. 2005). The 
ligand for TLR5 in SLE, whether exogenous or endogenous, has not been indentified yet.  T cell-
mediated immunity also plays a crucial role in the pathogenesis of lupus. Enhanced antigen 
presenting capacity on class II MHC molecules on macrophages, DCs and B cells together with 
co-stimulatory signal such as CD40-CD40 ligand and CD28-B7 interactions activate auto-reactive 
T cells which in turn induce effector functions in phagocytes and B cells. Therefore, inhibition of 
CD40 ligand or a CD28-B7 contact is a potential treatment for lupus. Other drugs that are 
currently being evaluated in clinical trials target B cell receptors or B cell-inducing cytokines 
(Rahman and Isenberg 2008).  
 
1.3.2 Inflammatory Bowel Disease 
 
Inflammatory Bowel Disease (IBD) including two major clinical forms; Crohn‟s disease (CD) and 
ulcerative colitis (UC), is a chronic inflammatory condition of gastrointestinal track highly linked 
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to intestinal infections in a genetically susceptible host. The disease mainly affects individuals at 
15 to 30 years of age. Cigarette smoking has been associated with increased risk of CD but 
paradoxically former smokers or non-smokers are at greater risk of UC indicating that these two 
forms largely differ in the disease pathogenesis and course. Genes linked to IBD include 
nucleotide oligomerization domain 2 (NOD2) encoding intracellular PRR, components of 
interleukin-23-type Th17 pathway and autophagy. No specific pathogen has been identified to 
drive inflammation in IBD although an antibiotics treatment appears to ameliorate the disease 
symptoms. Rather, antigens that are normally present in the gut trigger the inflammation. In 
healthy individuals, an array of pro-inflammatory cytokines limits the entry of pathogens into the 
mucosa whereas anti-inflammatory mediators such as TGF-β and IL-10 regulate immune 
responses preventing extensive tissue damage and prolonged inflammation.  The healthy mucosa 
is also characterised by the homeostasis between Tregs and effector T cells (Th1, Th2 and Th17). 
In contrast, the gut in IBD shows an increased number of APCs that secrete pro-inflammatory 
cytokines.  Enhanced levels of TNF, IL-1β, IL-6, IL-12 has been associated with over-activation 
of NFκB, a mediator in the NOD2 pathway. The inhibition of pro-inflammatory cytokines, 
particularly TNF, is currently the most efficacious treatment for IBD (Kaser et al. 2010). The role 
of TLRs in IBD has not been fully elucidated. A few researchers have demonstrated the 
association of TLR polymorphisms to human IBD. TLR defects may alter receptor-mediated 
ligand recognition and mucosal immune tolerance leading to hypo- or hyperactivity. For instance, 
the TLR1-R80T and TLR2-R743Q polymorphisms appear to increase the risk of developing pan-
colitis in UC patients (Pierik et al. 2006). Apart from affecting the disease phenotype, none of 
these polymorphisms affected the susceptibility to IBD. In contrast, carriers of the TLR4-D299G 
allele, one of the most common TLR4 mutation that leads to impaired LPS signalling and 
increased susceptibility to infections, also demonstrated increased risk of developing CD and UC 
(Franchimont et al. 2004). 
  
1.3.3 Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a systemic disorder mainly affecting synovial joints but in 15% of 
patients, also causing symptoms such as lung fibrosis, renal amyloidosis, atherosclerosis and 
osteoporosis. Because the joint inflammation (synovitis) ultimately leads to joint destruction, 
deformation and loss of function, RA patients suffer from chronic pain and stiffness in joints, 
swelling and tenderness. The disease incidence is 1% of the global population with a higher 
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prevalence in older women. Although the cause of RA remains to be elucidated, it is clear that 
genetic factors and environmental factors such as smoking are involved. The disease has been 
associated with HLA-DR4 alleles and other loci including protein tyrosine phosphatase, non-
receptor type 22 (PTPN22), cytotoxic T-lymphocyte antigen 4 (CTLA4), Fc receptor for IgG 
(FcγRs) or various cytokines (TNF, IL-1, IL-10, IL-8) (McInnes and Schett 2007). Normal healthy 
synovial joint consists of articular capsule, which is a fibrous, avascular layer that surrounds the 
synovial cavity, an underlying synovial membrane inhabited mainly by fibroblasts and 
macrophages and cartilage that covers joint ends of bone. In pathological conditions such as RA, 
the synovial membrane becomes inflamed due to the massive infiltration of immune cells into 
joints forming a destructive tissue called the pannus. In early RA, the synovial membrane expands 
due to the proliferation of synovial cells and the formation of new blood vessels occurs. 
Angiogenesis together with enhanced expression of adhesion molecules on endothelium and the 
production of chemokines by resident synovial cells enables the recruitment of monocytes, T cells 
and B cells from the blood circulation to the synovial cavity. Monocytes mature into macrophages, 
become activated and produce pro-inflammatory cytokines which in turn promote a positive 
feedback loop and facilitates the recruitment of new immune cells. During the progression of the 
disease inflammatory tissue starts to invade cartilage and destroys bone (Choy and Panayi 2001). 
  
1.3.3.1 Targeting immune cells as a treatment strategy for RA 
 
Various cell types of the innate and adaptive immune systems are implicated in the initiation and 
progression of RA. Along with X-ray analysis of bone deformation, testing for the presence of 
rheumatoid factor (RF), an autoantibody specific for IgG Fc, in the blood is used for diagnosis. 
RF, however, is often absent during the first years of illness suggesting that B cells are an 
important component of the inflammatory response within the joints but are not necessarily the 
predominant cells responsible for the initiation of disease. More recently, immunoassays for the 
detection of autoantibodies directed against citrullinated proteins are widely used for diagnostic 
purposes. The presence of citrullinated proteins correlates with collagen-induced arthritis (CIA) 
severity and has been linked to the pathogenesis of RA (Lundberg et al. 2005). The significance of 
B cells in RA is further supported by the fact that the B cell specific drug Rituximab shows a 
benefit in 80% of subjects (Edwards et al. 2004). Rituximab is a chimeric IgG1 monoclonal 
antibody which binds to the CD20 molecule of B cells. The binding of the antibody initiates 
antibody-dependent cell-mediated cytotoxicity leading to B cell depletion (Uchida et al. 2004).  
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A correlation between RA and the HLA-DR4 allele (class II MHC genes), which is responsible for 
antigen presentation to CD4+ T cells, suggests that T lymphocytes also play an important role in 
the pathogenesis of RA. The activation of T cells influences the effector and inhibitory functions 
of macrophages. T cells require two signals for activation. The first one is the TCR-mediated 
recognition of antigens presented on class II MHC molecules on APCs. The second one is the 
binding of a costimulatory receptor on T cells such as CD28 or cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA4) to a ligand on APC such as CD80 (B7-1) or CD86 (B7-2). The inhibition of 
CD80 and CD86 by CTLA4Ig significantly improves the signs and symptoms of RA (Kremer et 
al. 2003). 
 
Mast cells, the residents of inflamed joints, are also being recognised as an important enhancer of 
chronic inflammation as they induce vascular permeability, leukocyte recruitment and activation 
of synovial fibroblasts and macrophages (Nigrovic and Lee 2007). In response to IL-33, mast cells 
produce a plethora of pro-inflammatory cytokines and chemokines. The stimulation of wild type 
mice with IL-33 led to acceleration of CIA indicating that activated mast cells significantly 
contribute to the development of chronic inflammation and that targeting IL-33 may be a 
promising treatment strategy for RA (Xu et al. 2008). 
 
Macrophages, the representatives of the innate immune response, are involved in both the 
initiation and perpetuation of RA-associated inflammation because they directly respond to 
injurious stimuli via PRRs. The outcome of this stimulation is the secretion of pro-inflammatory 
cytokines whose inhibition has proven effective in the treatment of RA (Suresh 2010). 
Macrophages are abundant in inflamed synovial membrane. The severity of pain and radiological 
joint destruction in RA correlates with the macrophage infiltration into the synovium (Mulherin et 
al. 1996). Furthermore, it has been shown that conventional anti-rheumatic drugs affect the 
effector functions of macrophages. For instance, methotrexate impairs monocyte chemotaxis and 
enhances the production of cytokine inhibitors whereas corticosteroids downregulate the 
expression of TNF, IL-1 and IL-6 (Kinne et al. 2000). Together with fibroblast-like synoviocytes 
(FLSs), macrophages activate adjacent cells and promote inflammation. FLSs secrete chemokines 
(IL-8) and cytokines (IL-6 and GM-CSF) which activate macrophages creating a positive 
feedback as macrophages in response to this stimulation produce FSL-activating cytokines, 
specifically TNF, IL-1 and IL-18 (Sweeney and Firestein 2004). Except for the interactions with 
FLSs, macrophages increase the proliferation of endothelial cells and therefore promote 
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angiogenesis, activate mast cells and neutrophils and promote the differentiation of naïve T cells 
into Th1/ 17 lineages. Macrophages are also closely related to bone degrading osteoclasts as both 
cell types have common precursor cells, monocytes (McInnes and Schett 2007). A monoclonal 
antibody, Denosumab, which targets receptor activator of nuclear factor-κB ligand (RANKL), the 
osteoclast differentiation factor, has recently been approved for the treatment of RA. The 
importance of macrophages and the network with other cell types important in RA is presented in 
Figure 1.8.  
 
1.3.3.2 Cytokines drive inflammation in RA  
 
Cytokines, soluble mediators of inflammation, play a significant role in the chronic inflammation 
observed in RA. Synovial fluid and supernatants derived from whole synovial membrane cultures 
contain significant amounts of pro-inflammatory cytokines such as TNF, IL-1 and IL-6 as well as 
anti-inflammatory cytokines such as IL-10 and TGFβ. However, despite the over-production of 
immunoregulatory mediators, the levels of IL-10 or TGFβ appear to be unable to neutralise all the 
secreted TNF and IL-1 (Feldmann et al. 1996). TNF, which is produced mainly by monocytes, 
macrophages, lymphocytes and fibroblasts, is believed to be a pivotal cytokine that controls the 
production of both pro-inflammatory mediators (MCP1, IL-8, IL-6, GM-CSF) as well as anti-
inflammatory mediators (IL-10, IL-1Ra, soluble TNFR, IL-11) (Butler et al. 1995) (Feldmann 
2002). Moreover, TNF facilitates immune cell infiltration into the joint by stimulating endothelial 
cells to express adhesion molecules, it also decreases collagen synthesis by fibroblasts, elevates 
the production of MMPs, plus it activates monocytes, neutrophils and lymphocytes (McInnes and 
Schett 2007). Another important function of TNF is the promotion of bone erosion by acting on 
osteoclast differentiation and activation. Osteoclast maturation from precursor cells requires two 
main signals; M-CSF and RANKL. TNF induces the production of these stimulants by synovial 
mesenchymal cells and T cells (both M-CSF and RANKL) as well as synovial fibroblasts 
(RANKL). IL-1, IL-6 and IL-17 are also known to induce the expression of RANKL (Kwan Tat et 
al. 2004; Horwood 2008). In 1998, infliximab (Remicade; Centocor), a chimeric monoclonal 
antibody directed against TNF was introduced for the treatment of RA. Infliximab, despite being a 
humanized antibody, does not initiate the development of neutralizing antibodies and can be used 
for many years in therapy. Anti-TNF therapy inhibits IL-1 dependent bone and cartilage 
destruction, decreases the production of cytokines and chemokines in joints as well as 
angiogenesis. Infliximab is successful in around 60% of cases (80% if the treatment is combined 
with the use of methotrexate) (Feldmann 2002). The approval of this drug stimulated interest in  
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Figure 1.8 Macrophage interactions and cytokine expression in RA. Monocyte- derived macrophages 
are central components in RA as upon activation they secrete multiple proinflammatory mediators which 
increase endothelial cells proliferation and therefore promote angiogenesis, activate FLS to secrete MMPs 
responsible for cartilage and bone degradation, promote the polarisation of naive CD4+ T cells into the Th1 
and Th17 subsets, or activate mast cells and neutrophils. TNF is a crucial cytokine that mediates 
macrophage effector functions. Among multiple roles, TNF triggers RANKL and M-CSF production, the 
factors which are required for monocyte differentiation into bone- degrading osteoclasts. Activated 
macrophages also secrete reactive oxygen species (ROS), nitric oxide (NO) which have microbicidal as 
well as tissue damaging activities. Macrophages can act as APCs to T cells. Cytokines secreted by 
macrophages also promote B cells proliferation and antibody secretion. IL, interleukin; VEGF, vascular 
endothelial growth factor; TNF, tumor- necrosis factor; FLS, fibroblast-like synoviocytes; MMP, matrix 
metalloproteinase; TGF-β, transforming growth factor-β; M-CSF, macrophage colony-stimulating factor; 
RANKL, receptor activator of nuclear factor-κB (RANK) ligand; Th, helper T cell; NO, nitric oxide; ROS, 
reactive oxygen species (Sweeney and Firestein 2004; McInnes and Schett 2007; Horwood 2008). 
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the development of a new generation of immunomodulatory drugs, or biologics, that inhibit 
inflammatory cytokines. Other commonly used drugs include TNF inhibitors; Etanercept (Enbrel), 
Adalimumab (Humira), the IL-1 inhibitor Anakinra (Kineret) and the IL-6 inhibitor Tocilizumab 
(Suresh 2010). 
  
IL-1 is secreted predominantly by activated macrophages, but also by synovial fibroblasts and 
activated T cells. In addition to its function in osteoclast maturation, IL-1 seems to play a major 
role in cartilage degradation as injection of antibodies directed against IL-1 reduced cartilage 
degradation in a rabbit model of RA (Joosten et al. 1996). It is now known that IL-1β inhibits 
chondrocyte-dependent matrix synthesis and promotes matrix degradation by MMPs (Eberhardt et 
al. 2000). Depletion of IL-18, another member of IL-1 superfamily, also proved successful in 
ameliorating CIA in mice (Plater-Zyberk et al. 2001). IL-18 stimulates naive T cells, NK cell and 
neutrophil activation and is pro-angiogenic for endothelial cells (McInnes and Schett 2007).  
 
A potential role for IL-6 in RA was suggested after the discovery that Il6 knockout mice are 
resistant to antigen-induced arthritis; these mice do not develop joint swelling upon injection with 
methylated bovine serum albumin (Boe et al. 1999). Similarly, when arthritis was induced by type 
II collagen (CII), IL-6-deficient DBA/1J mice showed delayed onset and less severe disease 
accompanied by decreased production of anti-CII antibody and fewer bone erosions (Alonzi et al. 
1998; Sasai et al. 1999). The main role of IL-6 in RA is to stimulate the production of acute phase 
proteins from the liver. Acute phase proteins induce pro-inflammatory cytokines, activate the 
complement system, mediate fever and induce neutrophil chemotaxis. IL-6 itself also stimulates 
lymphocyte migration by upregulating chemokine and adhesion molecule expression by 
endothelial cells. IL-6 is required for B cell proliferation and antibody production as well as T cell 
proliferation, differentiation and cytotoxicity. IL-6 can activate macrophage differentiation and 
induces MMP production leading to joint and cartilage degradation (McInnes and Schett 2007). 
Moreover, soluble IL-6R together with IL-6 activates osteoclast formation and excessive 
production of these factors may contribute to bone resorption (Tamura et al. 1993). Inhibition of 
IL-6 by Tocilizumab, a humanized monoclonal antibody specific for IL-6 receptor, suppresses 
disease activity and erosive progression in RA patients (Vitale et al. 2004). 
 
The anti-inflammatory cytokine, IL-10, is a potent inhibitor of inflammation as it blocks the 
secretion of several cytokines, including TNF and IL-1, as well as the release of NO. IL-10 also 
downregulates class II MHC molecule expression on macrophages leading to T cell anergy, 
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decreases MMP and collagen release from synovial fibroblasts as well as induces B cell isotope 
switching (McInnes and Schett 2007). The importance of IL-10 has been shown in vivo as mice 
lacking IL-10 demonstrated more severe arthritis than wild type counterparts (Finnegan et al. 
2003). IL-10 is present in the synovial fluid of RA patients but in concentrations that are 
insufficient to regulate the chronic inflammation. Because of strong immunomodulatory 
properties, IL-10 is considered to have a therapeutic role in RA. Unfortunately, the first clinical 
trials showed that RA patients did not exhibit clinical improvements when treated with exogenous 
IL-10 (Smeets et al. 1999).  
 
1.3.3.4 Evidence for a role for TLRs in RA 
 
Despite the role of cytokines in the pathology of RA, the evidence supporting the contribution of 
TLRs in the initiation or/and perpetuation of chronic inflammation in RA is limited. Expression of 
TLRs 2, 3, 4, 7 and 8 is elevated in the synovial tissue of RA patients in comparison to healthy 
donors (Radstake et al. 2004; Roelofs et al. 2005; Brentano et al. 2005a). Bacterial and viral 
infections have been proposed to contribute to the development of RA. However, no infectious 
pathogens have been identified and, furthermore, bacterial TLR ligands are detected both in 
human RA synovium and in healthy donors who exhibit no inflammatory response (Mackenzie 
2005). This may be due to the fact that the pathogens could no longer be detected when the patient 
develops RA symptoms. Alternatively, it has been proposed that endogenous TLR ligands may 
instead contribute to the development of RA as a wild range of these ligands, including 
hyaluronan, fibronectin, DNA, HMGB-1 and Tenascin-C has been detected in RA joints (Clanchy 
and Sacre 2010).   
 
Studies carried out at the Kennedy Institute revealed that TLRs 2 and 4 are present and functional 
in synovial membrane cells derived from RA patients and that their activation promotes 
inflammation in RA (Sacre et al. 2007a). Our group has subsequently demonstrated that the 
inhibition of MyD88 and Mal by dominant negative resulted in the blockage of TNFα, IL-6, IL-8, 
VEGF and MMPs spontaneous production from RA-derived cells (Sacre et al. 2007b). TLR2 has 
been reported to be the mediator of streptococcal cell wall (SCW)-induced joint inflammation as 
TLR2-deficient mice did not exhibit joint swelling or impaired cartilage matrix synthesis (Joosten 
et al. 2003). Similarly, an endogenous TLR4 ligand, Tenascin-C induced joint inflammation in 
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mice. Tenascin-C- deficient mice, on the other hand, were resistant to joint inflammation and 
tissue destruction during CIA (Midwood et al. 2009). The role of TLR4 in  
arthritis was further supported by the finding that an antagonist for TLR4 reduced disease 
progression in the CIA model (Abdollahi-Roodsaz et al. 2007).  Interestingly, blocking TLR2 and 
4 with specific antibodies did not suppress the spontaneous secretion of IL-6, one of the major 
mediators of inflammation, from RA synovial cultures suggesting that other TLRs may contribute 
to RA progression (Sacre et al. 2007b). 
 
Observations from several groups have implicated the importance of endosomal TLRs. In 
particular, the inhibition of these TLRs by chloroquine, an inhibitor of endosomal acidification, or 
antidepressant mianserine, blocked spontaneous release of proinflammatory cytokines from RA 
synovial membrane cultures (Sacre et al. 2008).  Moreover, patients lacking UNC93B1, a protein 
required for TLR3, 7, 8 and 9 delivery to endolysosomes, did not display autoreactive antibodies 
or develop autoimmunity (Isnardi et al. 2008). Additional analysis revealed a central role for 
TLR8 as the specific inhibition of TLR8 by imiquimod blocked spontaneous release of TNF from 
RA synovial cultures (Sacre et al. 2008). TNF is a pivotal cytokine in RA joints as its inhibition 
proved to be an effective treatment strategy for RA (Feldmann 2002). Furthermore, RNA released 
by necrotic synovial fluid cells derived from RA patients activated TLR3 on fibroblasts and 
resulted in the production of high levels of IFN-β, IP-10 and IL-6 (Brentano et al. 2005a). A recent 
study revealed that a widely used drug for the treatment of RA, Auranofin, apart from targeting 
TLR4 also inhibited TLR3 signalling by impairing PolyI:C-induced phosphorylation of IFR3 as 
well as IP-10 production (Park et al. 2010). Additionally, the administration of suppressive 
oligonucleotides that target TLR9 proved to be effective in ameliorating CIA symptoms in mice 
(Dong et al. 2004). Although these data support the possible role of endosomal TLRs in in vitro 
RA cultures, it still remains to be elucidated what could be a clinical advantage of blocking a 
particular TLR. Many of these studies are at the preclinical stage, however a few of them have 
already reached phase II clinical trials and could be soon available for the treatment of 
autoimmune diseases including multiple sclerosis, IBD, SLE or RA (Clanchy and Sacre 2010).    
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1.4 A role for Protein Tyrosine Kinases in TLR signalling 
 
Protein tyrosine kinases (PTKs) have attracted an increasing amount of interest over past 20 years 
as they are clearly involved in the regulation of cytokine production in PRR signalling. PTKs form 
a group of enzymes which catalyse the transfer of a phosphate group from ATP to a tyrosine 
residue of a substrate. The group consists of 20 families of receptor and 10 families of non-
receptor PTKs, representing a large proportion of the protein kinase complement of human 
genome, the kinome (Manning et al. 2002). First reports regarding the role of PTKs in PRR 
signalling showed that tyrosine phosphorylation is induced within 5 min in human monocytes and 
macrophages following LPS stimulation (Weinstein et al. 1991; Beaty et al. 1994). Tyrosine 
phopshorylation reached a maximum by 15 min and declined after 30-60 min. Treatment with 
Herbimicin A inhibited PTK activation as well as LPS-induced TNF production leading to the 
conclusion that PTKs are crucial components of TLR signalling (Weinstein et al. 1991; Mander et 
al. 1997). Since these initial observations four main non-receptor PTK families have been 
implicated in TLR signalling: the sarcoma (Src), tyrosine kinase expressed in hepatocellular 
carcinoma (Tec), spleen (Syk) and proline-rich (Pyk2) tyrosine kinase families. 
 
Src family kinases 
 
Src family tyrosine kinases (SFKs) form the largest group of non-receptor PTKs. The family 
consists of 9 members: Src, Fyn, Yes, Lck, Blk, Fgr, Hck, Yrk and Lyn, having distinct amino 
acid variations and expression patterns.  For instance, Hck, Lyn and Fgr are predominantly 
expressed in myeloid cells, Lck in T cells, and Blk in B cells. SFKs share domain structures 
comprising of N-terminal unique domain which facilitates membrane localisation, then Src 
homology (SH) 3 domain, followed by SH2 domain and C-terminal SH1 or kinase domain 
(Figure 1.9). SFKs are retained in inactive state in the cytoplasm. This state is characterised by 
tyrosine phosphorylation of the kinase by COOH-terminal Src kinase (Csk) and subsequent 
folding of SFKs. Active SFKs are characterised by unfolded state. Activation of SFKs requires 
initial dephosphorylation of C-terminal Tyr499 residue followed by auto-phosphorylation of 
Tyr388 in the catalytic domain as well as Tyr29 in the unique domain (for the SFK Hck) (Johnson 
et al. 2000). Once activated, SFKs induce downstream signalling cascades by phosphorylating 
immunoreceptor tyrosine-based activating motifs (ITAMs), Tec kinases and Pyk2. SFKs are 
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involved in numerous signalling pathways including antigen receptor pathways in lymphocytes, 
integrin, cytokine and TLR pathways (Page et al. 2009). 
  
SFKs are rapidly phosphorylated after TLR ligand binding (Beaty et al. 1994). LPS also induces 
the expression of SFKs in macrophages (Boulet et al. 1992). The importance of SFKs in 
regulating cytokine production was revealed through a specific inhibitor, a pyrazolo pyrimidine 
compound (PP2) which blocks the production of major pro- and anti-inflammatory cytokines (IL-
6, TNF, IL-10, IP-10) from human primary macrophages induced with TLRs 1, 2, 4-8. 
Interestingly, SFKs do not seem to engage MAPKs or NFκB to control cytokine production. 
Rather, PP2 treatment decreases AP-1 binding to its consensus site suggesting that SFKs may 
induce cytokine expression by activating the transcription factor AP-1 (Smolinska et al. 2008).  
 
Surprisingly, the deletion of Hck, Fgr and Lyn in mice did not affect LPS-induced cytokine 
production in macrophages (Meng and Lowell 1997). These researchers also claimed that only 
those three SFKs are expressed in murine macrophages. Although, this finding questioned the role 
of SFKs in LPS signalling it is now clear that distinct family members may have the ability to 
substitute for the absence of others. Three additional SFKs; Src, Yes and Fyn, have been since 
identified to be expressed in murine and human macrophages (Majeed et al. 2001; Smolinska et al. 
2008). The potential functional redundancy among SFK family members can be explained by the 
fact that the kinases were depleted in the germ line providing time for the compensatory 
mechanisms to develop. For instance, the kinase activity of Lyn has been reported to be largely 
increased in Hck-deficient murine macrophages subjected to LPS stimulation (Lowell et al. 1994). 
Similarly, the expression of Fyn, Lyn, Yes and Syk, but not Src was found to be increased in Hck
-/-
Fgr
-/-
 murine BMDM (Majeed et al. 2001). Temporary changes in protein levels may be more 
beneficial in assessing the role of a specific SFK.  By using RNAi or adenovirus-mediated 
overexpression it has been shown that Hck is particularly important for the regulation of LPS-
induced TNF production in murine or human macrophages (English et al. 1993), (Smolinska et al., 
manuscript submitted).  
 
Syk  
 
The Syk family consists of p72Syk and p70Zap. These proteins differ in structure from the Src 
family as they contain two tandem SH2 domains separated by interdomains (Figure 1.9). The 
tandem SH2 domains of Syk bind to ITAMs diphosphorylated by Src upon activation. In fact, 
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macrophages derived from Hck/ Fgr/ Lyn triple knockout mice demonstrated impaired ITAM 
phosphorylation and Syk activation (Fitzer-Attas et al. 2000). Syk has been shown to interact with 
ITAMs on TCRδ, FcεR1β and FcεR1γ as well as to be involved in BCR signalling and FcR-
mediated phagocytosis (Page et al. 2009). 
 
Syk associates with TLRs 4 and 9 as well as Myd88 in an ITAM-independent manner. The kinase 
has been also shown to undergo phosphorylation upon LPS and CpG stimulation in a variety of 
cells including macrophages, neutrophils and fibroblasts (Page et al. 2009). In spite of that, the 
kinase does not seem to regulate cytokine production in these pathways as Syk-deficient 
macrophages produce normal amounts of TNF, IL-6, IL-1 or IL-12 in response to LPS, whereas 
Syk-deficient DCs show no impairment in IL-12 production in response to CpG (Crowley et al. 
1997; Rogers et al. 2005). Instead, Syk appears to control chemokine production as Syk chemical 
inhibition or siRNA-mediated knockdown decreased the production of MCP-1 and RANTES in 
LPS-stimulated neutrophils and fibroblasts, respectively (Yamada et al. 2001; Arndt et al. 2004). 
 
Pyk2 
 
Pyk2 together with Focal adhesion kinase (FAK) form a family of proline-rich cytoplasmic 
tyrosine kinases. Both Pyk2 and FAK lack SH2 and SH3 domains. Rather, the kinase domain of 
Pyk2 is flanked by proline-rich FERM and FAT domains which mediate protein-protein 
interactions (Figure 1.9). Pyk2 is phopshorylated in monocytes and macrophages subjected to 
LPS stimulation (Williams and Ridley 2000). Furthermore, the inhibition of Src by PP2 abrogated 
TLR-induced phosphorylation of Pyk2 and its substrate, a cytoskeletal protein paxilin, in rat 
macrophages suggesting that Pyk2 and Src share the same signalling cascade (Hazeki et al. 2003).  
The role of Pyk2 in cytokine production is unclear. In human primary macrophages, the 
overexpression of Pyk2 or kinase dead version does not affect TNF, IL-6, IL-8 or IL-10 
production following LPS stimulation(Horwood et al. 2003). In contrast, Pyk2 was required for 
LPS-induced IL-8 production in endothelial cells. In addition, the chemical inhibition of Pyk2 
decreased p38 but not ERK MAPK phosphorylation in these cells indicating that Pyk2 is required 
for p38 MAPK activation in TLR signalling (Anand et al. 2008). The role of Pyk2 in regulating 
IL-8 production, the primary chemokine for neutrophils, suggests that Pyk2 is more likely to be 
involved in cellular migration than pro-inflammatory cytokine production. This hypothesis is also 
supported by the fact that Pyk2 is phosphorylated in response to MCP-1, one of the most potent 
chemokines to induce migration of monocytes. Furthermore, the inhibition of MCP-1-induced 
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Pyk2 phopshorylation by soluble chemokine fractalkine correlated with the inhibition of monocyte 
migration and impaired p38 MAPK activation (Vitale et al. 2004).  
 
Tec family kinases – structure and function 
 
The Tec family of tyrosine kinases is the second largest non-receptor tyrosine kinase family after 
SFKs. Tec family members were identified as tyrosine kinases involved in hepatocarcinogenesis 
(Mano et al. 1990) and 5 of them have been characterised in mammalian cells: Bruton‟s 
agammaglobulinemia tyrosine kinase (Btk), bone marrow kinase gene on X chromosome (Bmx), 
IL-2 inducible T-cell kinase (Itk), tyrosine kinase expressed in hepatocellular carcinoma (Tec) and 
T and X cell expressed kinase (Txk; also known as Rlk). Tec PTKs are generally expressed in 
hematopoietic cells but Tec, Bmx and Itk can be also found in other cell types. Btk is primarily 
expressed in B cells (but not in plasma cells), myeloid cells and platelets (de Weers et al. 1993; 
Smith et al. 1994) whereas Itk, Txt and Tec in T cells (August et al. 1994; Hu et al. 1995). The 
structure of Tec PTKs comprises five distinct domains (Figure 1.9). The N-terminal pleckstrin 
homology (PH) domain is responsible for membrane localisation; which is followed by the Tec 
homology domain which is unique for each Tec PTKs member, then by SH3 and SH2 domains 
which bind substrates and lastly by the kinase catalytic domain at the carboxyl tail. Exceptionally, 
PH domain- lacking Txk comprises a cysteine-string motif which enables anchoring the kinase to 
glycolipid enriched membranes (Debnath et al. 1999). Two tyrosine phosphorylation sites have 
been identified in the structure of Tec kinases. Phosphorylation of tyrosine 551, located in the 
activation loop of the catalytic domain, leads to conformational changes allowing further 
modifications. The second one is found in the SH3 domain of Tec kinases (tyrosine 223) and 
undergoes auto-phosphorylation (Park et al. 1996).  
 
Tec PTKs are involved in multiple signalling cascades in response to the stimulation of G-protein-
coupled receptors (GPCR), Fc receptors, integrins, antigen or cytokine receptors (Mohamed et al. 
2009). The activation of Tec PTKs influences calcium (Ca
2+
) response, actin remodelling, 
apoptosis, proliferation and gene expression. The involvement of Tec kinases in different 
signalling pathways is based on direct interaction with other proteins (Figure 1.9). For instance, it 
has been shown that the SH1 and PH domains of Tec PTKs interact with Fas, a death receptor 
involved in apoptosis. Proteins implicated in cytoskeletal reorganisation and, therefore, antigen 
presentation and processing such as WASP and Vav, also bind to Tec PTKs through its SH3 
domain (Sharma et al. 2009). The TH domain of Tec PTKs directly interacts with the members of 
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the SFKs (Fyn, Hck and Lyn) whereas theirs SH2 domain binds to B cell receptor (BCR) 
signalling proteins BLNK (Mohamed et al. 2009).  
 
The importance of Btk in the immune system was recognised after the discovery that point 
mutations in the BTK gene result in human XLA (X-linked agammaglobulinemia) (Thomas et al. 
1993). Alternations affecting human BTK range from missense, nonsense, in-frame to frame-shift 
mutations that affect all Btk domains as well as the gene non-coding sequences. The number of 
alternations exceeds 550 unique mutations in more than 800 families.  Arginine CpG codons 
(formed when cytosine is followed by guanine) are especially prone to mutations (Lindvall et al. 
2005). Mutation of arginine (R) at position 28 to a cysteine (C) at position 28 in the PH domain 
leads to murine X-linked immunodeficiency (Xid) (Tsukada et al. 1993). Xid mice are 
characterised by a 50% reduction in their peripheral B cell population and reduced levels of IgM 
and IgG3. As a result of poor B cell responses, Xid mice are highly susceptible to bacterial 
infections (Khan et al. 1995). In humans, XLA results in more severe symptoms as patients have 
less than 1% of mature B cells that are present in a healthy individual (Campana et al. 1990). 
Moreover, double knockout of Btk and Tec in mice still gives a milder phenotype than in XLA 
patients suggesting Tec PTK diversity in function and organisation between different species 
(Ellmeier et al. 2000). Detailed analysis of the role of Btk in B cells revealed that the kinase is 
critical for the differentiation of pre-B cells into immature B cells as well as the differentiation of 
IgM
high
IgD
low
 immature B cells into IgM
low
IgD
high 
mature B cells. Btk is also critical for B cell 
proliferation and survival (Kerner et al. 1995; Khan et al. 1995; Hendriks et al. 1996). 
 
Apart from being implicated in B cell signalling, Btk was also found to fulfil a crucial role in mast 
cell, erythrocyte, platelet, neutrophil, basophil and DC signalling networks (Schmidt et al. 2004). 
Mast cells are the key mediators of allergic reactions. Their activation, mainly through the high-
affinity IgE receptor (FcεRI), leads to secretion of histamines, leukotrienes and cytokines.  Btk 
deficiency was found to significantly reduce histamine secretion in activated murine mast cells. 
Both Btk and Tec were required for FcεRI-mediated TNF, IL-13 and GM-CSF production. 
However, in contrast to Tec
-/-
-derived mast cells which exhibited decreased production of IL-4, 
Btk
-/-
-derived cells produced increased levels of IL-4. Furthermore, Tec deficiency did not affect 
histamine production, but significantly impaired leukotriene C(4) levels indicating that the role of 
these two kinases in allergy may be dramatically different (Schmidt et al. 2009). Interestingly, 
activated basophils derived from Btk knockout mice also showed decreased production of 
histamine, once again confirming the role for Tec PTKs in allergic reactions (Kneidinger et al. 
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2008). Btk also plays a role in platelet activation by collagen. Effective platelet function is 
required for thrombus formation and cessation of bleeding after damage to the vasculature. 
Platelets derived from XLA patients demonstrated diminished aggregation, dense granule 
secretion and calcium mobilisation is response to collagen (Quek et al. 1998). The defects in 
platelet activation were further increased in double Btk/ Tec knockout mice as compared to Btk
-/-
 
mice suggesting that Tec may also contribute to platelet signalling (Atkinson et al. 2003). The 
latest studies also describe the involvement of Btk in osteoclast differentiation and suggest a 
possible regulatory mechanism for osteoclastogenesis through a transcription factor NFATc1, 
initiation of which is mediated by RANKL (Lee et al. 2008; Shinohara et al. 2008). Tec
-/-
Btk
-/-
 
mice showed an increase in bone volume correlated with decreased osteoclast number and 
osteoclastic bone resorption (Shinohara et al. 2008). The impaired osteoclast bone resorption was 
also observed in XLA-derived cultured osteoclasts. However, XLA patients did not demonstrate 
increased bone density despite having defective in vitro osteoclast activation. Analysis of XLA 
patients‟ serum revealed that TNF, IL-6 and IL-1 levels were elevated in these patients and that 
stimulation of osteoclasts with these cytokines increased osteoclast activity in vitro, suggesting 
that elevated inflammatory cytokines in the XLA serum conceals defects in osteoclast function in 
vivo (Danks et al. 2011).  Btk has been also involved in M-CSF receptor signalling pathway that 
regulate the survival of macrophages (Melcher et al. 2008) and FcγR-induced phagocytosis in 
macrophages (Jongstra-Bilen et al. 2008). 
 
Tec PTKs also modulate T cell responses. T lymphocytes express Rlk, Itk and Tec, and Rlk/Itk 
deficiency has been found to show reduced TCR-mediated Ca
2+
 mobilisation, proliferation and 
cytokine production. Rlk and Itk were also required for the immune response to the infection of 
mice with the intracellular parasite, Toxoplasma gondii (Schaeffer et al. 1999). Itk is also involved 
in T cell development as Itk deficiency in mice decreased the number of mature T cells. Itk 
appears to be more critical for CD4+ T cell development as the lack of the kinase decreased the 
ratio of mature CD4+ versus CD8+ thymocytes in the homozygous mutant (Liao and Littman 
1995). The study of the Itk function in T lymphocyte response to antigen recognition revealed that 
the kinase is rather involved in Ca
2+
 mobilisation that the formation of a stable T cell-APC 
synapse (Donnadieu et al. 2001). Increase in Ca
2+
 is concomitant to cytoskeleton reorganisation, 
the prerequisite for T cell adhesion and activation (Delon et al. 1998).  
 
Tec PTKs are also important components of the signalling pathways used by many cytokines and 
growth factors. In particular, in the context of inflammation, Btk and Tec are known to be 
Chapter 1  Introduction 
53 
 
involved in the IL-6 signalling pathway, by being constitutively associated with the gp130 
molecule, a component of the IL-6 family receptor. The stimulation of gp130 with IL-6 leads to 
tyrosine phosphorylation of Btk and Tec kinases. The same investigators found that Tec is also 
activated by IL-3 and granulocyte colony-stimulating factor (G-CSF) suggesting a general role of 
Btk and Tec in supporting the growth and differentiation of immune cells (Matsuda et al. 1995). In 
addition, Bmx has been implicated in signalling via TNFR2 and VEGFR2 and to play an 
important role in TNF/VEGF-mediated inflammatory angiogenesis (Pan et al. 2002; He et al. 
2006). In vitro experiments carried out on endothelial cells have shown that TNF stimulation of 
the cells results in the phosphorylation of Bmx whereas the introduction of dominant negative 
Bmx blocks TNF-induced angiogenesis, signifying a crucial role of Bmx in this developmental 
process (Pan et al. 2002).  
 
Activation, regulation and cellular localisation of Btk 
 
Multiple studies on B cells have shown that activation of Btk requires two steps. The first one is 
an association of the positively charged PH domain with negatively charged phosphate groups of 
phosphatidylinositol (3,4,5)-triphosphate (PIP3); a phosphoinositide 3-kinase (PI-3K) product. 
This electrostatic interaction enables Tec PTKs to localise to the cell membrane and respond to the 
second signal, which requires the engagement with Src family kinases (Ferguson et al. 1995; 
Rawlings et al. 1996; Li et al. 1997). Src tyrosine kinases such as Lyn, Fyn and Hck are associated 
with Btk tyrosine kinase in B and T cells as assessed by means of the yeast two-hybrid system 
(Cheng et al. 1994). The interaction between Src kinases and Btk is mediated by the Src-
homology domain (SH3) and leads to phosphorylation and activation of Btk under B cell receptor 
engagement (Cheng et al. 1994; Alexandropoulos et al. 1995; Wahl et al. 1997). 
 
Although predominantly cytoplasmic, Btk has been reported to continuously shuttle between the 
cytosol and the nucleus. The molecular mechanisms of this translocation are, however, still 
unclear. Although, the PH domain of the kinase contains classical nuclear localization signals they 
do not seem to play a critical role in nuclear translocation as the PH deletion resulted in even 
distribution of Btk between cytosol and the nucleus. Nuclear shuttling also seems to be 
independent on the Btk kinase activity as demonstrated using kinase-defective mutant. On the 
other hand, an SH3-deleted mutant displayed impaired auto-kinase activity and was found 
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predominantly in the nucleus (Mohamed et al. 2000). The importance of the auto-phosphorylation 
event in nuclear shuttling can be also supported by the fact that mutation of tyrosine 223, but not 
tyrosine 551, retained Btk in the nucleus (Mohamed et al. 2009). The role of Btk in the nucleus 
remains to be elucidated. There is, however, increasing evidence that the kinase may be involved 
in transcriptional regulation by being implicated in transcription factor activation. For instance, 
Xid mice-derived B cells demonstrate impaired NFκB signalling following BCR engagement 
(Petro et al. 2000). Btk has been also placed to be upstream of nuclear factor of activated T cells 
(NFAT) in BCR signalling (Hao et al. 2003). The kinase directly interacts with the general 
transcription factor TFII-I (also known as BAP-135). Upon BCR engagement, Btk phopshorylates 
TFII-I leading to nuclear translocation and gene transactivation (Yang and Desiderio 1997; 
Novina et al. 1999). Impaired production of antibodies by Xid mice-derived B cells could be 
explained by the fact that Btk interacts with Bright, the transcription factor that together with 
TFII-I initiates immunoglobulin heavy chain transcription (Webb et al. 2000; Rajaiya et al. 2006). 
The interaction between Btk and Bright does not seem to be dependent on Btk‟s catalytic function 
as Bright is not tyrosine phosphorylated by Btk (Webb et al. 2000). Finally, Btk has been shown to 
phosphorylate signal transducer and activator of transcription 5A (STAT5A) in the chicken B-cell 
line DT-40 and CREB during basic fibroblast growth factor (bFGF)-induced neuronal 
differentiation (Mahajan et al. 2001; Yang et al. 2004). 
 
Btk expression and activity is often regulated by the factors that require Btk in order to function. 
For instance, the inhibition of NFκB pathway suppresses BTK transcription. Further analysis 
revealed that both p65 and p50 NFκB subunits bind to the BTK promoter where two functional 
NFκB binding sites were identified (Yu et al. 2008). Moreover, Btk is negatively regulated by the 
transcriptional co-activator BAM11. At the same time, the kinase is required for BAM11-
dependent induction of gene transcription in COS7 cells. Both PH domain and kinase activity of 
Btk as well as TFII-I were shown to enhance BAM11 transactivation activity (Hirano et al. 2004). 
Btk is also negatively regulated by protein kinase C (PKC) β which phosphorylates Btk on Serine 
180 in the PH domain and disturbs Btk membrane binding in B cells (Kang et al. 2001). PKCθ, on 
the other hand, has been shown to activate Btk in platelets (Crosby and Poole 2002). Another 
protein inhibitor of Btk (IBtk) has been found to physically associate with the PH domain of Btk 
and to downregulate Btk kinase activity as well as Btk-mediated calcium mobilization and NFκB 
transcription in B cells (Liu et al. 2001). 
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Figure 1.9 Schematic representation of domains of PTK families and Btk domains with known 
interacting/ regulating partners. The common feature of SFKs, Tec, Syk and Pyk2 is the kinase domain. 
Apart from that, SFKs and Tec share SH2 and SH3 domains. They differ, however, in the N’ terminus as 
SFKs have a myristoylation site (M) in the unique domain, whereas Tec kinases have a membrane-
associating pleckstrin homology (PH) domain and the family specific Tec homology (TH) domain. The SH2 
domain of Syk is divided between interdomains A and B. The Pyk2 kinase domain is followed by two 
proline rich regions (PRR) and focal adhesion targeting (FAT) domains (A). Btk, a member of Tec family 
kinases, is activated by phosphorylation of tyrosine 551 and 223. Btk interacts with members of SFKs (Lyn, 
Fyn, Hck), requires Zn
2+
 binding for activity and stability, PIP3 for membrane localisation. Btk is involved in 
cytoskeleton reorganisation (interaction with F-actin, WASP and Vav), apoptosis (Fas), B-cell receptor 
signalling (BLNK), G-protein-coupled receptors or TLR. Btk activates transcription factors Bright and TFII-I 
as well as co-activators Bam11. At the same time, the kinase is regulated by PKC, Pin1, Caveolin-1 or IBtk 
(B). Not drawn to scale. Adapted from (Mohamed et al. 2009; Page et al. 2009). 
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1.5 A role for Tec tyrosine kinases in TLR signalling 
 
The notion that Tec PTKs might be involved in TLR signalling was suggested by the previous 
finding that peritoneal macrophages derived from Xid mice exhibited reduced responses to LPS 
(Mukhopadhyay et al. 1999; Mukhopadhyay et al. 1999; Mukhopadhyay et al. 2002).  Xid 
macrophages showed poor microbicidal activity, as well as produced reduced levels of NO, TNF 
and IL-1β, but increased levels of IL-12 in response to LPS. Increased IL-12 production correlated 
with increased Th1/Th2 ratio in Xid mice, suggesting that Th1 cell responses led to delayed 
pathogen clearance. Further experiments revealed, however, that Xid-derived Th1 cells showed 
unaltered rates of pathogen clearance indicating that the delayed clearance of injected microfilaria 
in Xid mice was mainly attributed to defective effector functions of macrophages (Mukhopadhyay 
et al. 2002). The involvement of Btk in TLR4 as well as TLR2 signalling was confirmed on 
monocytes derived from XLA patients as these cells are characterised by reduced production of 
TNF and IL-1β in response to TLR2 and TLR4 ligands, demonstrating a significant role of Btk in 
the expression of these pro-inflammatory cytokines (Horwood et al. 2003; Horwood et al. 2006). 
Simultaneously, results obtained from XLA PBMCs have shown that Btk has no impact on IL-6, 
IL-8 and IL-10 production when the cells were stimulated with LPS or Pam3Cys (Horwood et al. 
2006). Palmer and colleagues confirmed that Btk does not mediate the production of IL-6 and that 
overexpression of Bmx, another Tec kinase, leads to increased production of both TNF and IL-6 
in TLR 2-, 4- and 5- stimulated human macrophages (Palmer et al. 2008). This report shows that 
Tec PTKs are differentially involved in the production of cytokines despite being closely related. 
It is presently unclear why Bmx mediates the production of both TNF and IL-6 in LPS-stimulated 
human macrophages, whereas Btk mediates the production of TNF, but not IL-6. It also appears 
that the importance of Btk in TLR signalling may be restricted to certain cell types as the kinase 
was found to be dispensable for TLR4-mediated activation of murine mast cells in terms of TNF 
and IL-6 production (Zorn et al. 2009). Similarly, Btk deficiency had no effect on LPS-induced 
effector functions of neutrophils such as shedding of leukocyte surface CD62L, up-regulation of 
surface integrins or respiratory burst. Xid neutrophils also showed unchanged progression of 
apoptosis upon LPS stimulation indicating that the mechanisms that promote survival of activated 
neutrophils are independent of Btk (Marron et al. 2010). 
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Further studies have provided more evidence for the involvement of Tec kinases, particularly Btk, 
in TLR signalling. Investigations of protein-protein interactions by means of a yeast-two hybrid 
system have suggested that Btk interacts with the TIR domains of TLR4, 6, 8 and 9 (Jefferies et al. 
2003), however, the precise signalling mechanism of Tec activation following TLR engagement 
has not been elucidated. Starting from the upstream components in the TLR signalling cascade, it 
has been shown in the monocytic-like THP-1 cell line that Btk interacts with the adaptor proteins 
Myd88 and Mal under TLR4 receptor engagement (Jefferies et al. 2003). Furthermore, it has been 
suggested that Btk phosphorylates Mal after stimulation with TLR2 and TLR4 ligands resulting in 
polyubiquitination and degradation of this adaptor molecule (Gray et al. 2006; Mansell et al. 
2006). Accordingly, mutations of the tyrosine residues within the TIR domain of Mal leads to 
impaired Mal phosphorylation and reduced interaction with Btk (Piao et al. 2008). Studies in the 
murine macrophage cell line RAW 264.7 further revealed that Btk associates with PI3K to 
mediate TLR2 signalling. Btk and PI3K constitutively interacted with each other and increasingly 
bound to TLR2 upon Lipoteichoic acid (LTA) stimulation. Interestingly, Btk inhibition by a drug 
LFM-A13 decreased MIP-2, iNOS and TNF production at an earlier time point than PI3K 
chemical inhibition did (Liljeroos et al. 2007). Recently, Btk was also found to interact with 
intracellular class II MHC molecule in LPS-challenged murine macrophages. Moreover, Btk 
phosphorylation was reduced in class II MHC-deficient cells and  the lack of class II MHC 
attenuated LPS-, CpG- and PolyI:C-induced TNF, IL-6 and IFN-β production (Liu et al. 2011). 
Although studies regarding the position of Btk in TLR signalling have not been confirmed in 
human primary cells, recent investigations carried out on RA fibroblast-like synoviocytes (FLS) 
implicated Bmx in an interaction with integrin α5β1, Myd88 and focal adhesion kinase (FAK) and 
that the knockdown of Bmx or Mal results in decreased IL-6 production in response to LPS 
(Semaan et al. 2008).  
 
Data from primary human cells concerning the downstream components implicated in Tec PTK 
signalling are in contradiction with data obtained from mice and cell lines. Studies performed on 
Xid macrophages (Doyle et al. 2005) and the THP-1 cell line (Jefferies et al. 2003) have 
demonstrated that LPS-activated Btk engages the NFκB pathway by promoting p65 subunit 
transactivation and nuclear localization. The chemical inhibition of Btk activity also decreased p65 
phosphorylation on Ser536 as well as NFκB binding to DNA in TLR2-stimulated murine 
RAW264.7 (Liljeroos et al. 2007). In human XLA PBMC, however, Btk appears to function 
independently of NFκB and operate through the p38 MAPK signalling pathway following 
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stimulation with TLR2 and TLR4 ligands (Horwood et al. 2006). Interestingly, Bmx which 
regulates both TNFα and IL-6 production in human macrophages does not involve either NFκB or 
p38 MAPK pathways. However, similarly to Btk, Bmx maintains the stability of mRNA of the 
cytokines it regulates (Palmer et al. 2008). It still remains to be revealed what the exact position of 
Tec kinases in the TLR signalling cascade in human primary macrophages actually is. In 
particular, questions remain concerning the upstream localisation of Tec kinases relative to the 
adaptor molecules and interactions with SFK in human cells as well as the exact mechanism of 
Tec-dependent regulation of gene expression.  
In particular, little is known about the involvement of Tec kinases in the signalling of the 
endosomal TLRs. The work of Jefferies and colleagues has shown that Btk had the strongest 
interaction with TLR8 compared to all of the other TLRs (Jefferies et al. 2003). A study from the 
same group further demonstrated that Btk is important for both TLR8 and 9 signalling and that it 
is implicated in NFκB activity in cell lines (Doyle et al. 2007). TLR8 is an intracellular receptor 
that binds ssRNA obtained from viruses or released from necrotic cells. Interestingly, XLA 
patients demonstrate lower resistance to enteroviral infections (Winkelstein et al. 2006) whilst Xid 
mice suffer from higher susceptibility to acute mouse adenovirus type-1 (MAV-1) infection 
(Moore et al. 2004) which implies an important role for Btk in the immune response to viral 
infections. To further emphasise a possible role of Tec kinases in endosomal TLR signalling, the 
response of DCs obtained from XLA patients to ssRNA has been shown to be significantly 
decreased in terms of IL-6 and TNF production (Sochorova et al. 2007). This was partially 
confirmed by another group which observed the inhibition of TNF but not IL-6 or IL-12p70 
production by DCs from XLA patients stimulated with TLR2, TLR3, TLR4 and TLR7/8 ligands 
(Taneichi et al. 2008). In contrast, the deficiency of Btk in B cells led to increased responsiveness 
to the TLR9 ligand, CpG DNA, as the cells produced elevated levels of TNF, IL-6 and IL-12p40 
but less of the inhibitory cytokine IL-10 (Hasan et al. 2008). This observation was further 
confirmed by Lee and colleagues who also found that increased IL-12 production in Btk
-/-
 B cells 
led to greater Th1 type IgG2b and IgG3 antibody production upon TLR9 stimulation. 
Paradoxically, Btk deletion also decreased p65 translocation to the nucleus in these cells 
suggesting decreased NFκB activation. However, decrease in NFκB activity was independent of 
IL-12 and IL-10 production as p65
-/-
 B cells could respond similarly to wild type B cells in terms 
of cytokine production (Lee et al. 2008). There are no reports regarding the role of Tec kinases in 
endosomal TLR signalling in human macrophages.  
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1.6 Aims of study 
1.6.1 Rationale 
 
TLRs are crucial components of the innate and adaptive immune system. They facilitate the 
recognition of pathogen-derived as well as endogenous proteins and nucleic acids. There is 
increasing evidence that TLRs may be involved in the initiation or/and perpetuation of numerous 
autoimmune diseases, thus the inhibition of a particular TLR signalling pathway may prove to be a 
promising treatment strategy for RA, SLE or IBD (Clanchy and Sacre 2010). TLR8 seems be the 
central TLR in RA as its inhibition blocked spontaneous release of the predominant cytokine, 
TNF, from RA synovial cultures (Sacre et al. 2008).  
 
Many studies have shown that the Tec tyrosine kinases, Btk and Bmx, control the TLR-induced 
production of major pro-inflammatory cytokines in monocytes and macrophages, and that the 
inhibition of the tyrosine kinases significantly reduces the effector functions of immune cells. The 
majority of these studies were performed in LPS-stimulated cells and there is limited knowledge 
describing the role of Tec PTKs in endosomal TLRs. The tyrosine kinases are differently involved 
in cytokine production which poses an interesting question regarding the regulatory mechanisms 
of cytokine production. For instance, Btk has been shown to regulate the production of TNF but 
not IL-6, IL-8 or IL-10 in human primary macrophages (Horwood et al. 2003; Horwood et al. 
2006). In contrast, Bmx was reported to control both TNF and IL-6 production in LPS-stimulated 
cells (Palmer et al. 2008). Further studies are necessary to assess whether Btk exclusively 
regulates TNF production, as determined in TLR4, 2 and 5 signalling, or whether it is involved in 
the regulation of a broader spectrum of cytokines and chemokines in endosomal TLR signalling. 
 
Furthermore, Btk appears to utilise the p38 MAPK pathway to control the stability of TNF mRNA 
in LPS-challenged human macrophages (Horwood et al. 2003; Horwood et al. 2006). However, 
other studies revealed that Btk controls NFκB activation by promoting p65 nuclear localization 
(Jefferies et al. 2003; Doyle et al. 2005). These studies were not, however, gene specific as they 
did not measure the effect of Btk on NFκB recruitment to a target gene. Furthermore, these studies 
did not involve cytokine measurement and most of all, they were performed in murine 
macrophages and cell lines. The exact control mechanism of gene expression by Tec kinases is 
therefore poorly understood and requires further investigation. The question remains whether Btk 
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controls TNF production at the transcriptional level. If so, which transcriptional factors are 
involved in the Btk-dependent regulation of TNF transcription? 
 
Another unanswered question concerns the upstream and downstream binding partners of Tec 
kinases in TLR signalling. One study performed on a cell line demonstrated that Btk 
phosphorylates Mal (Gray et al. 2006). However, this model can not apply to all TLRs as 
endosomal TLRs do not utilize Mal. Due to the role of endosomal TLRs in RA, the investigation 
of the signalling cascades that are activated following receptor stimulation is particularly 
important. This investigation may reveal novel molecules that are involved in the production of 
pro-inflammatory cytokines and the control mechanisms that would facilitate the development of 
new therapeutic strategies.  
 
1.6.2 Aims of research 
 
1. To investigate whether Btk plays a role in the endosomal TLR3 and TLR8 signalling 
cascades by measuring the effect of Btk overexpression and downregulation on cytokine 
and chemokine production in human primary macrophages. 
2. To develop a human monocytic cell line model to investigate the role of Btk in TLR3, 4 
and 8 signalling. This would then be used for affinity tag purification of downstream and 
upstream molecules that interact with Btk following endosomal TLR stimulation. 
3. To decipher the mechanisms of TNF gene control regulated by Btk. Which regions of TNF 
are required for Btk-dependent regulation and can Btk control the transcription of TNF in 
TLR-stimulated human primary macrophages?  
4. To determine whether Btk activates transcription factors NFκB and AP-1 to regulate TNF 
expression in TLR8-stimulated human primary macrophages.  
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2.1 Materials 
 
All chemicals and reagents were purchased from Sigma-Aldrich (Dorset, UK) or BDH Chemicals 
(Dorset, UK) unless stated otherwise. 
2.1.1 Tissue culture reagents and transformed cell lines 
 
For the culture of cell lines and human primary macrophages the following tissue culture reagents 
were used: 
 Roswell Park Memorial Institute 1640 (RPMI) medium containing 25 mM L-glutamine, 
Dulbecco‟s Modified Eagle‟s Medium (DMEM) with glucose, L-glutamine and Hank‟s 
Balanced Salt Solution (HBSS) were purchased from PAA, Austria. RPMI 1640 without 
phenol red was purchased from Gibco-Invitrogen, Paisley, UK. 
 Heat inactivated foetal bovine serum (FBS) (PAA, Yeovil, UK), Penicillin/Streptomycin 
(Pen/Strep) (PAA), non-essential amino acids (NEAA), sodium pyruvate, bovine insulin, 
oxaloacetic acid (all from Sigma) were used as medium supplements.  
 Cell dissociation media (Sigma) and Trypsin/EDTA (PAA) were used for sub-culturing.  
 Cell culture was performed in FalconTM plastics obtained from BD Biosciences, Oxford, 
UK. 
The list of transformed cell lines used in the project is shown in Table 2.1. 
 
Cell line Description Source 
AD-293  Derived from human embryonic kidney (HEK293) cells 
 Allow virus production by expressing E1 gene 
Stratagene, CA, USA 
HSF  Human foreskin fibroblast Prof J. Saklatvala, KIR, 
London 
THP-1  Human monocytic leukemia cell line ATCC 
U937  Human monocytic leukemia cell line ATCC 
Monomac-6  Human monocytic leukemia cell line ATCC 
   Table 2.1 Cell lines 
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2.1.2 Antibodies  
 
Antibodies for ELISA, western blotting (WB), immunoprecipitation (IP), kinase assay (KA), 
EMSA, TransAm, ChIP and FACS are listed in Tables 2.2 and 2.3. 
 
Specificity Species Application Concentration Source 
hIL-6  
         
Coat 
Detect 
- 
- 
ELISA  1 μg/ml 
0.5 μg/ml 
BD Pharmingen, San Diego, 
USA 
hTNF Coat 
Detect 
- 
- 
ELISA 4 μg/ml 
0.5 μg/ml 
BD Pharmingen 
hIL-10 Coat 
Detect 
- 
- 
ELISA 1 μg/ml 
1 μg/ml 
BD Pharmingen 
hIP-10 Coat 
Detect 
- 
- 
ELISA 2 μg/ml 
0.1 μg/ml 
BD Pharmingen 
Btk mouse WB 1:2000 BD Biosciences (Oxford, UK) 
Hsp90 mouse WB 1:2000 BD Biosciences 
Streptavadin rabbit WB 1:2000 Sigma (Dorset, UK) 
STAT3 mouse WB 1:2000 New England Biolabs (UK) 
Hck mouse WB 1:2000 BD Biosciences 
GFP rabbit WB 1:2000 Abcam (Cambridge, UK) 
IκBα rabbit WB 1:2000 Santa Cruz Biotechnology (CA, 
USA) 
Phospho-p65 
Ser536 
rabbit WB 1:2000 Cell Signalling Technology, 
Inc., MA, USA 
TAK1 rabbit WB 1:2000 Cell Signalling Technology 
Phosphotyrosine clone 
4G10,HRP 
- WB 1:10000 Millipore, CA, USA 
Phospho-ERK 
Thr202/Tyr204 
rabbit WB 1:2000 Cell Signalling Technology, Inc. 
Phospho-JNK 
Thr183/Tyr183 
rabbit WB 1:2000 Cell Signalling Technology, Inc.  
Phospho-p38 
Thr180/Tyr182 
rabbit WB 1:2000 Cell Signalling Technology, Inc.  
Total-p38 rabbit WB/KA 1:2000 Prof J. Saklatvala, KIR 
α-Tubulin mouse WB 1:3000 Sigma  
GAPDH  WB 1:2000 Abcam  
Btk rabbit IP/KA 1:250 Dr M. Tomlinson,  University of 
Birmingham, UK 
IgG control rabbit IP/KA 1:250 Harlan Sera-Lab, UK 
p50 (NFκB1) (C-19)X rabbit EMSA 200μg/μl Santa Cruz Biotechnology 
p65 (relA) (F-6)X rabbit EMSA 200μg/μl Santa Cruz Biotechnology 
p65 (ralA) (ab46540-1) rabbit ChIP 2μg/ml Abcam 
cJun rabbit EMSA/ChIP 200μg/μl/ 2μg/ml Santa Cruz Biotechnology 
cFos rabbit EMSA/ChIP 200μg/μl/ 2μg/ml Santa Cruz Biotechnology 
JunB rabbit EMSA/ChIP 200μg/μl/ 2μg/ml Santa Cruz Biotechnology 
JunD rabbit EMSA/ChIP 200μg/μl/ 2μg/ml Santa Cruz Biotechnology 
ATF2 rabbit EMSA/ChIP 200μg/μl/ 2μg/ml Santa Cruz Biotechnology 
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phospho-cJun rabbit TransAm 200μg/μl Active Motif (CA, USA) 
Pol II (sc-9001-X) rabbit ChIP 2μg/ml Santa Cruz Biotechnology 
IgG rabbit ChIP 2μg/ml Abcam 
TLR-3 FITC mouse FACS 1:25 Imgenex, San Diego, USA 
TLR-4 FITC mouse FACS 1:25 Imgenex, San Diego, USA 
TLR-8 FITC mouse FACS 1:25 Imgenex, San Diego, USA 
IgG1 FITC mouse FACS 1:25 Imgenex, San Diego, USA 
IgG2a FITC mouse FACS 1:25 Imgenex, San Diego, USA 
Table 2.2 Primary antibodies used for WB, IP, KA, ChIP, TransAm and ELISA 
Specificity Species Application Concentration Source 
Anti-mouse IgG, HRP sheep WB 1:2000 Amersham, Little Chalfont, UK 
Anti-rabbit IgG, HRP donkey WB 1:2000 Amersham, Little Chalfont, UK 
Table 2.3 Secondary antibodies used for WB 
 
2.1.3 Cytokines 
 
Recombinant cytokines used for ELISA standards and cell culture and stimulation are listed in 
Table 2.4. 
Cytokine Application Concentration Source 
IL-6 ELISA 13-10000 pg/ml Peprotech, London, UK 
TNF ELISA 13-10000 pg/ml Peprotech, London, UK 
 Cell stimulation 40000 pg/ml  
IL-10 ELISA 13-10000 pg/ml Peprotech, London, UK 
IP-10 ELISA 13-10000 pg/ml RnD, Minneapolis, USA 
M-CSF Cell culture 100 ng/ml Peprotech, London, UK 
Table 2.4 Human recombinant cytokines 
 
2.1.4 TLR ligands 
 
Toll-like receptor ligands used for cell stimulation are summarised in Table 2.5. 
Receptor Ligand Description Source 
TLR 3 PolyI:C synthetic dsRNA ALEXIS, Nottingham, UK 
TLR 4 LPS lipopolysaccharide from E.coli ALEXIS 
TLR 7/8 R848 imidazoquinoline resiquimod ALEXIS 
Table 2.5 TLR ligands 
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2.1.5 Inhibitors 
 
The list of enzyme inhibitors is presented in Table 2.6. RNA oligonucleotides for RNA 
interference (RNAi) are summarised in Table 2.7. 
Inhibitor Cellular Target Source 
100x Protease Inhibitor Cocktail (PIC) proteases Sigma 
Protease Inhibitor Tablet (PIT) proteases Roche 
Sodium fluoride protein phosphatases Sigma 
Sodium Orthovanadate protein phosphatases Sigma 
Geldanamycin Hsp90 inhibitor Invitrogen 
Table 2.6 Enzyme inhibitors  
 
Target Type Catalogue Number Source 
Btk #9 Duplex J-003107-09 Dharmacon, IL, USA 
Btk #11 Duplex J-003107-11 Dharmacon 
Non targeting siControl
 TM
 D-001206-13 Dharmacon 
Table 2.7 RNAi oligonucleotides 
 
2.1.6 Custom designed oligonucleotide primers 
 
The oligonucleotide primers used in this study were all purchased from MWG (Germany) and 
stored at -20°C. The primers were diluted in TE buffer to a final concentration of 100pmol/μl. 
2.1.6.1 PCR primers 
 
Primers used for primary and mature transcript RT PCR, PCR and ChIP are listed in Tables 2.8, 
2.9 and 2.10, respectively.  
Name Sequence (5’-3’) 
TNF_mature_forward (for)1 CCTGCTGCACTTTGGAGTGATCGG 
TNF_mature_reverse (rev)1 GTACAGGCCCTCTGATGGCACCACC 
TNF_primary_forward (PT_F2)  GCAGTCAGATCATCTTCTCG 
TNF_primary_reverse(PT_R2) AGGTACAGGCCCTCTGATGGCAC 
ARP_for CGACCTGGAAGTCCAACTAC 
ARP_rev ATCTGCTGCATCTGCTTG 
Table 2.8 Primers used for detecting primary and mature TNF transcripts in RT-PCR 
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Name Sequence (5’-3’) 
Btk-SpeI_for TCACTAGTATGGCCGCAGTGATTC 
Btk-SalI_rev CAGTCGACGGATTCTTCATCCATG 
Table 2.9 Primers used for PCR to introduce SpeI and SalI restriction sites upstream of the ATG 
transcription start codon and instead of transcription stop codon of human Btk, respectively. 
 
Name Sequence (5’-3’) 
TNFdown_for  
TNFdown_rev  
TNF TSS(+1)_for  
TNF TSS(+1)_rev  
κBsite1for  
κBsite1rev  
κBsite2for  
κBsite2rev  
κBsite4for  
κBsite4rev  
κBsite3for   
κBsite3rev     
GGCAGTCAGTAAGTGTCTCCAA 
TTACCTACAACATGGGCTACAGG 
CAGCAAGGACAGCAGAGGAC 
TCCCGGATCATGCTTTCAGT 
CCACATGTAGCGGCTCTGAG 
AGGCTCTTTCACTCCCTGGG 
GAAGAAGGCCTGCCCCAGTGG 
GGTAGCAGGGACAAGCCTGG 
ATATTCCCCATCCCCCAGGAAACA 
CTGCAACAGCCGGAAATCTCACC 
GCTTGTGTGTCCCCAACTTT 
GGGGAAAGAATCATTCAA 
Table 2.10 Primers used for ChIP 
 
2.1.6.2 Primers used for human Btk gene sequencing 
 
Table 2.11 presents a list of primers that allowed full Btk gene sequencing.  
 
Primer internal name Sequence 5’-3’ 
Btkseq_rev2 CAACCTGGAAGGGATAAGGG 
Btkseq_rev3 GGCTCTGAGGTGTGGAACAC 
Btkseq_for2 AAAAGCCACTACCGCCCTGAG 
Btkseq_for3 CCCCATCTTCATCATCACTG 
Btkseq_for15 TCATCTGGCTTCAGAGAAGG 
Btkseq_for16 GAGCCTTTGTGCTCCCACTC 
Table 2.11 Primers used for gene sequencing 
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2.1.7 Oligonucleotides used for EMSA 
 
Table 2.12 presents a list of consensus oligonucleotides used for EMSA.  The double-stranded 
oligonucleotide is designed with 5`- OH blunt ends.  
 
Name Sequence (5’-3’) Source 
AP-1 CGCTTGATGAGTCAGCCGGAA Promega 
NFκB AGTTGAGGGGACTTTCCCAGGC Promega 
Table 2.12 AP-1 and NFκB consensus oligonucleotides used for EMSA  
2.1.8 Restriction enzymes used for cloning 
 
The restriction enzymes used in these studies were purchased from New England Biolabs 
(Hitchin, UK) and are presented in Table 2.13. 
 
      Enzyme       Buffer   10x BSA            Temperature 
SpeI NEB2 + 37°C, inactivation at 65°C 
SalI NEB3 + 37°C, inactivation at 80°C 
BgLII NEB3 - 37°C 
EcoRV NEB3 + 37°C, inactivation at 80°C 
AleI NEB4 - 37°C, inactivation at 65°C 
BamHI NEB3 + 37°C 
Table 2.13 Restriction enzymes and the reaction conditions 
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2.1.9 Adenoviral constructs 
 
All adenoviral constructs used for these studies expressed Green Fluorescent Protein (GFP) 
allowing the determination of virus infection. They are listed in Table 2.14. 
 
Virus  Insert Virus generated by 
AdBtk Human Btk wild type  
 
Mrs Brenda Mutch 
AdCon Empty control, carrying Gateway® (Invitrogen)  
pENTRY4.3.F vector 
 
Mrs Brenda Mutch 
AdBtk-Strep Human Btk wild type with C-terminal 31amino acid SBP tag 
 
Ms Anna Urbaniak 
AdStrep Control 31 amino acid SBP tag 
 
Dr Ale Lanfrancotti 
AdBtk-NTAP Human Btk wild type with N-terminal Protein G/TEV/SBP tag 
 
Ms Anna Urbaniak 
AdNTAP Control Protein G/TEV/SBP tag 
 
Ms Anna Urbaniak 
AdTAK1 
 
Human TAK1 wild type Ms Kate Willetts 
Ad5‟Luc Firefly luciferase gene driven by human TNF 5‟ promoter 
 
Dr Agnes Denys 
Ad5‟Luc 3‟UTR Firefly luciferase gene flanked by human TNF 5‟ promoter and 
the 3‟UTR 
 
Dr Tim Smallie 
Ad5‟Luc 3‟1037bp Firefly luciferase gene flanked by human TNF 5‟ promoter and  
3‟1037bp sequence containing the 3‟UTR plus 252bp enhancer 
 
 
Dr Agnes Denys 
Ad5‟Luc 3‟1251bp Firefly luciferase gene flanked by human TNF 5‟ promoter and  
3‟1251bp sequence containing the 3‟UTR plus 466bp enhancer 
 
Dr Tim Smallie 
Ad5‟Luc 3‟site 4X Firefly luciferase gene flanked by human TNF 5‟ promoter and  
3‟1251bp sequence carrying a κB site 4 point mutation 
Dr Tim Smallie 
   
Ad5‟Luc 3‟ 
site 1/2/3/4X 
Firefly luciferase gene flanked by human TNF 5‟ promoter and  
3‟1251bp sequence carrying κB sites 1,2,3 and 4 point 
mutations 
Dr Tim Smallie 
Table 2.14 Adenoviruses 
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2.1.10 Solutions 
 
2.1.10.1 General buffers 
 
Phosphate buffered saline (PBS) 4.3 mM Na2HPO4 
1.4 mM KH2CO3 
1.4 mM KCl 
137 mM NaCl 
pH 7.2 
 
Tris buffered saline (TBS) (10x) 20 mM Tris/HCl 
137 mM NaCl 
pH 7.6 
 
Tris Borate EDTA buffer (TBE) (10x) 0.89 M Tris/HCl pH 8.0 
0.89 M boric acid 
2 mM EDTA 
 
 
Sodium orthovanadate stock solution  100 mM Na3VO4 pH 10.0 
Boiled for 60 – 90 min, stored at 4°C 
   
2.1.10.2 ELISA reagents 
 
ELISA blocking buffer PBS +  2% (w/v) bovine serum albumin (BSA)  
 
ELISA stop solution 940 ml dH2O + 60 ml H2SO4, 
 
ELISA wash buffer (PBS/Tween) PBS + 0.01% (v/v) Tween-20  
  
 
2.1.10.3 Protein extraction buffers for Western blotting and Immunoprecipitation 
 
NP-40 lysis buffer 1% (v/v) NP40 
20 mM Tris-Base pH 7.6 
125 mM NaCl 
 
RIPA lysis buffer 
 
 
 
 
 
 
 
1% (v/v) NP-40 
50 mM Tris-Base pH 7.6 
150 mM NaCl 
10 mM tetrasodium pyrophosphate 
1 mM EDTA 
25 mM β-glycerophosphate 
0.5% (w/v) sodium deoxycholate 
0.1% (w/v) SDS 
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10 mM DTT, 100 μM Na2VO3, 5 mM NaF, 1x PIC (Table 2.6) were added freshly to the lysis buffers 
2.1.10.4 SDS-PAGE and Western blotting reagents 
 
SDS-PAGE running buffer 25 mM Tris-Base 
192 mM Glycine 
0.1% (w/v) SDS 
 
SDS-PAGE resolving buffer 3 M Tris-Base pH 8.8 
0.6% (w/v) SDS 
  
SDS-PAGE stacking buffer 140 mM Tris-Base pH 6.8 
0.11% (w/v) SDS 
 
5x protein gel sample buffer (20ml) 250 mM Tris-HCl pH 6.8 
10% (w/v) SDS 
50% (v/v) glycerol 
12.5% (v/v) β-mercaptoethanol (ME) 
(mix Tris, SDS, water. Heat to 50°C.  
Add glycerol, β-ME and bromoethanol blue) 
 
WB transfer buffer 25 mM Tris-Base 
192 mM Glycine 
20% (v/v) Methanol 
 
WB wash buffer (TBS/Tween) TBS 
0.1% (v/v) Tween-20 
(Sigma-Aldrich, product no. P-1379) 
 
Blocking buffer (BSA) TBS/Tween 
2% (w/v) bovine albumin serum 
 
Blocking buffer (milk) TBS/Tween 
5% (w/v) skimmed milk powder 
 
 
2.1.10.5 Luciferase assay reagents 
 
Luciferase assay buffer (LAB) 1% (v/v) Triton X-100 
25mM Tris-phosphate pH 7.8 
8 mM MgCl2 
1mM EDTA 
15% (v/v) Glycerol 
 
CAT Lysis buffer 0.65% (v/v) NP40 
10 mM Tris-HCl pH 8 
1mM EDTA 
150 mM NaCl 
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2.1.10.6 EMSA reagents 
 
Buffer A 10 mM Hepes pH 7.9 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
 
Buffer B 20 mM Hepes pH 7.9 
0.4 M NaCl 
1 mM EDTA 
1 mM EGTA 
 
5% TBE gel (40ml) 5% acrylamide (6.6ml of 30% stock) 
1x TBE (4ml of 5x TBE) 
1.5% (v/v) glycerol 
300μl 10% (w/v) APS 
25μl TEMED 
 
Buffers A and B were supplemented with 1mM DTT and 1:50 000 PIT (Table 2.6) 
2.1.10.7 ChIP reagents 
 
Cytoplasmic lysis buffer  
 
50 mM Tris, pH 8.0 
2 mM EDTA, pH 8.0 
0.1% NP40 
10% Glycerol 
 
Nuclear lysis buffer 50 mM Tris pH, 8.0 
5 mM EDTA 
1 % SDS 
 
Dilution buffer (DB) 50mM Tris, pH 8.0 
5mM EDTA 
200mM NaCl 
0.5 % NP40 
 
Washing Buffer (WB) 20mM Tris, pH 8.0 
2mM EDTA 
0.1 % SDS 
1 % NP40 
500 mM NaCl 
 
Extraction Buffer (EB) 1X TE 
2 % SDS 
 
 
All the buffers were supplemented with fresh 1mM DTT and 1:50 000 PIT (Table 2.6) 
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2.1.10.8 One-Strep purification reagents 
 
 
Cytoplasmic lysis buffer 0.5%NP-40 
5mM PIPES pH 8.0 
85mM KCl 
Alternatively: 100ug/ml of avidin, 
1ug/ml of a DNAse 
 
Nuclear lysis buffer (RIPA) 1% (v/v) NP-40 
50 mM Tris-Base pH 7.6 
150 mM NaCl 
10 mM tetrasodium pyrophosphate 
1 mM EDTA 
25 mM β-glycerophosphate 
0.5% (w/v) sodium deoxycholate 
0.1% (w/v) SDS 
Alternatively: 100ug/ml of avidin, 
1ug/ml of a DNAze 
 
Washing buffer (WB) 1 and 2 20mM Tris 
50mM NaCl (WB1) or 150mM NaCl (WB2) 
0.2mM EDTA 
0.2%NP-40 
5% Glycerol 
 
Elution buffer  100mM Tris pH 8 
150mM NaCl 
2mM Biotin 
 
10 mM DTT, 100 μM Na2VO3, 5 mM NaF, 1:50 000 PIT (Table 2.6) were added fresh to the lysis buffers 
 
2.1.10.9 Molecular biology solutions 
 
 
Lennox L broth base (LB) 20g LB (Invitrogen, Paisley, UK) 
1l dH2O (Autoclave before use) 
 
Lennox L agar (LB agar) 32g LB agar (Invitrogen, Paisley, UK) 
1l dH2O (Autoclave, add antibiotics once cooled, and 
then pour into plates before it sets) 
 
Ampicillin 100 mg/ml Ampicillin ( Sigma, Poole, UK) 
(Diluted in autoclaved sterile dH2O) 
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Kanamycin 30 mg/ml Kanamycin 
(Diluted in autoclaved sterile dH2O) 
 
SYBR Green II Use at 10% (v/v) in DNA solutions  
(Molecular probes, Eugene, Oregon, USA) 
 
DNA Hyperladders 5 μl loaded per lane (Bioline, London, UK) 
 
Ethidium bromide Used at a final concentration of 0.1μg/ml (Sigma, 
Poole, UK) 
  
10x DNA gel sample buffer (DNA GSB) 80% (v/v) glycerol 
1% (v/v) 5xTBE 
0.025% (w/v) bromophenol blue 
0.025% (w/v) xylene cyanol 
 
2.1.10.10 Adenovirus purification reagents 
 
  
Phosphate buffered saline 
2+
 (PBS
2+
)  PBS 
0.01% (w/v) CaCl2 
0.01% (w/v) MgCl2 
 
Saturated Caesium Chloride (CsCl) 
 
0.01M Tris/Base pH8 
1mM EDTA 
CsCl added until saturated 
 
1.34g/ml density Caesium Chloride 
 
85% (v/v) 1.4g/m density CsCl 
15% (v/v) PBS
2+
 
 
1.4g/ml density Caesium Chloride 
 
53.4% (w/v) CsCl 
 
 
2.1.10.11 Kinase assay reagents 
 
Kinase lysis buffer 20 mM HEPES pH 7.4 
50 mM β glycerophosphate 
2 mM EGTA 
1% Triton X 100 
 
Kinase wash buffer (3X) 60 mM HEPES pH 7.4 
600 mM NaCl 
60 mM β glycerophosphate 
1.5 mM EDTA 
1.5 mM EGTA 
30 mM MgCl 
0.15% Brij 
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10 mM DTT, 100 μM Na2VO3, 5 mM NaF, 1:50 000 PIT (Table 2.6) were added fresh to the lysis buffers 
 
 
2.1.10.12 Remaining reagents 
 
 
 
 
MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide)  
5mg/ml MTT in sterile PBS 
 
 
MTT lysis buffer 100g SDS, 1ml of conc. HCl per 1l of H2O 
  
Buffer ‘41’ for Amaxa 90 mM Sodium Phosphate Buffer pH 7.2 (68.4 ml 
of 1 M Na2HPO4 + 31.6 ml of 1 M NaH2PO4) 
5 mM KCl 
10 mM MgCl2 
20 mM HEPES 
 
2.1.11 Bacteria strains 
 
Electrocompetent E.coli XL-1 Blue (Stratagene, Cambridge, UK) 
Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 (Tetr)] 
 
Electrocompetent E.coli BJ5183 EC (Q-Biogene, Cambridge, UK) 
Genotype: endA sbcBC recBC galK met thi-1 bioT hsdR (Str
r
) 
 
Chemically competent E.coli Top10 (Invitrogen) 
Genotype: F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
 
Key to genotypes: www.invitrogen.com  
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2.2 Methods 
 
2.2.1 Cell culture 
2.2.1.1 Endotoxin testing 
 
All reagents and solutions used for siRNA transfection, cell culture and stimulation underwent 
endotoxin testing by Limulus Amebocyte assay (Biowittaker, Berkshire, UK) by Mr Sunil Modi 
prior to use. A solution of 0.1 EU/ml endotoxin (equivalent to 100 pg/ml) was serially diluted in 
LPS-free H20 and used as a standard for calibration. Test samples, the standard and a blank (H2O) 
were added to the 96-well micro plate (previously pre-equilibrated to 37°C) in 50μl volumes in 
duplicate. An equal volume of Limulus amebocyte lysates was added to each well and incubated 
for 10 min at 37°C. 100 μl of substrate solution was added to each well and incubated for a further 
6 min at 37°C, prior to the addition of 100 μl of stop reagent. The absorbance was read at 410 nm 
and the sensitivity of the assay was >10 pg/ml. 
 
2.2.1.2 Isolation of Human Peripheral Blood Monocytes 
 
Human Peripheral Blood Mononuclear Cells (PBMC) were isolated from buffy coat formed after 
centrifugation of whole blood obtained from the North London Blood Transfusion Service 
(Colindale, UK) through a Ficoll- Histopaque gradient. Buffy coats (approximately 50ml) were 
diluted 1:2 in HBSS and layered onto 20ml Lymphocyte
®
-H Solution (Cedarlane Laboratories 
Ltd, Ontario, Canada). The tubes were then spun at 2200rpm for 30min, PBMC layer was 
extracted from the interface between the bottom Ficoll-red blood cell fraction and the top HBSS 
fraction, washed once with HBSS at 2000rpm for 10min and resuspended in  RPMI, 1% FCS prior 
to elutriation.  
 
2.2.1.3 Elutriation 
 
Monocyte fractions at a purity of greater than 80% were isolated from PBMC by centrifugal 
elutriation at 2500rpm in a Beckman JE6 elutriator (Beckman Coulter, High Wycombe, UK). 
Separation due to cell size and granularity is achieved in an elutriator by the opposing effects of 
centrifugal force and fluid velocity in a specialised chamber (Figure 2.1). A suspension of cells is 
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pumped into a funnel-shaped chamber at a low flow rate. The cells position where the fluid 
velocity force and the centrifugal force are balanced. As smaller and less dense cells are under a 
low centrifugal force, they are positioned close to the outlet of the chamber.  Low flow rate and its 
gradual increase forces smaller and less dense cells to exit the chamber first, where they are 
collected and analysed by flow cytometry and CellQuest software. Larger cells, which are under a 
high centrifugal force, require a higher flow rate to overcome the centrifugal force which retains 
them by the inlet of the chamber. Therefore, large cells emerge later. T lymphocytes emerge from 
the chamber first (flow rate between 11-14ml per min) followed by monocytes (18-22ml per min) 
and granulocytes (>20ml per minute). Elutriation was carried out in RPMI, containing 1% FCS. 
 
 
 
 
Figure 2.1 Centrifugal elutriation. Illustration shows cross section of an elutriation chamber.  The 
chamber rotates around the axis at 2500rpm creating a centrifugal force.  The peristaltic pump creates an 
opposing flow.  The funnel shaped chamber causes the velocity of the fluid to slow, forming a defined 
gradient.  Cells of different densities migrate to the point where the two opposing forces balance. Cell 
populations of increasing sizes elute with increasing flow rate overcoming limiting centrifugal force which 
keeps large cells by the inlet of the chamber. Monocytes are typically eluted at a flow rate of 18mls per 
minute.  Purities of >80% are routinely obtained as determined by flow cytometry. 
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2.2.1.4 Production of M-CSF-derived macrophages 
 
Primary human monocytes (>80% purity) were cultured at 1 x 10
6
 cells / ml in RPMI 1640 
supplemented with 5% heat-inactivated FCS and 1% penicillin (100U/ml) and streptomycin 
(100U/ml) (Pen/Strep) cocktail at 37°C in 5% CO2.  Macrophage colony stimulating factor (M-
CSF) at a concentration of 100 ng/ml was added to the culture. After 96h, non-adherent cells were 
removed and cell dissociation media was applied onto differentiated macrophages for 45min. 
Cells were scraped and 5% RPMI was added to neutralise cell dissociation media. After washing, 
macrophages were counted and plated in experimental dishes in complete medium without M-
CSF. Typically, 50% of plated peripheral blood mononuclear cells fully differentiated into 
macrophages. 
 
2.2.1.5 Culture of transformed cell lines 
 
Human monocytic leukemia cell lines THP-1, U937 and Monomac-6 were obtained from the 
American Type Culture Collection (ATCC). THP-1 and U937 cell lines were grown in RPMI 
1640 supplemented with 5% FCS and 1% Pen/Strep at 1x10
6
 cells/ ml in 75cm
2
 flasks and sub-
cultured at a ratio of 1:3 every 3 days. Cells were differentiated by the addition of phorbol-12-
myristate-13-acetate (PMA) (Sigma) (10ng/ml) for 24h. Cells were then washed and plated in 96-
well plates in PMA-free medium for another 24h before stimulation. Monomac-6 cells were 
cultured in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 1% non-essential amino 
acids, 1 mM sodium pyruvate, 10 μg/ml bovine insulin, 1mM oxaloacetic acid, 1% Pen/Strep and 
maintained at 0.3-1.0 x 10
6
 cells/ml in 24-well plates. Monomac-6 cells were sub-cultured at a 
ratio of 1:3 every 3 days. Human embryonic kidney (HEK293)-derived AD-293 cells (Stratagene, 
California, USA) were cultured in DMEM supplemented with 10% FCS and 1% Pen/Strep. Cells 
were maintained in 150cm
2
 flasks, passaged at a confluence of 80-90% and dissociated from the 
bottom of the flask by applying Trypsin/EDTA solution for 5min. All the cell lines were incubated 
at 37°C in a humidified atmosphere containing 5% CO2.  
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2.2.1.6 MTT cell viability Assay 
 
A colorimetric MTT assay was utilized to assess the viability of the cells. The assay is based on 
the ability of living cells to reduce yellow MTT (Section 2.1.10.12) to purple formazan by 
mitochondrial enzymes. Cells were cultured in 96-well plates, supernatants were harvested, 
replaced with RPMI media containing 5μg/ml MTT for 12-18h. MTT lysis buffer at equal volume 
was added and left for a minimum of 4 hours. Absorbance of formazan was read at 620nm using a 
Fluostar Omega (BMG Labtech, Aylesbury, UK) plate reader and accompanied MARS data 
analysis software. The absorbance values reflect the proportion of living cells. 
 
2.2.2 Molecular biology techniques 
2.2.2.1 RNA Interference 
 
RNA interference (RNAi) is a naturally occurring process involved in gene downregulation, host 
defence against viruses and transposones as well as development control. There are two types of 
RNAi molecules; 20-25 nucleotide (nt) long small interfering (si) RNA and microRNA. SiRNA is 
generated from >200 nt long double-stranded (ds) RNAs by an enzyme called Dicer. Next, RNA-
induced silencing complex (RISC) incorporates one strand of each siRNA and pairs it with the 
complementary sequence of messenger (m) RNA. This enables a component of RISC complex, 
argonaute, to cleave the target gene and leads to post-transcriptional gene silencing. The 
phenomenon of selective gene downregulation makes RNAi a widely used research technique. 
However, as mammalian cells develop an anti-viral phenotype upon encounter of external long 
(>30nt) dsRNA, only short pre-synthesised siRNAs are used for targeted gene silencing (Elbashir 
et al. 2001). 
 
Human primary monocytes (5x10
6
) were transfected with 100-300nM siRNA targeting Btk 
mRNA (Btk SMARTpool M-003107-01, Dharmacon, IL) and with non-targeting control 
oligonucleotide (siControl D-001206-13). The siRNA was first suspended in 100µl of buffer „41‟ 
(Section 2.1.5.11). The cells were spun and the medium was replaced with buffer „41‟. Cells were 
immediately placed in electroporation cuvettes and subjected to electroporation using the Y-001 
programme on Amaxa Nucleofector
®
 Device (Lonza Cologne GmbH, Germany). Cells were then 
left to recover in 6-well plates for 1 day in 10% FCS RPMI media without phenol red 
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supplemented with 100ng/ml M-CSF. Cells were scraped, counted and plated in full 5% FCS 
RPMI media with phenol red and M-CSF and incubated for a further 72h prior to stimulation. 
 
2.2.2.2 RNA extraction from primary human macrophages  
 
The blood RNA extraction kit (Qiagen, UK) was used to extract total RNA from human primary 
macrophage cultures. Macrophages (0.5 x 10
6
 per well) were initially washed with PBS. Cells 
were lysed in the provided RLT buffer supplemented with β-mercaptoethanol and further 
homogenised by use of shredder columns provided. The lysate was applied to a second RNA-
binding column in order to remove impurities by extensive washing. RNA was eluted in RNase 
free dH20 and stored at -80°C. Contaminating DNA was removed using the Ambion TURBO 
DNA-free
TM
 kit. 
 
2.2.2.4 Reverse Transcription of total RNA to cDNA 
 
The AMV-reverse transcriptase kit (Promega) was used to convert total RNA to cDNA. The 
reaction was run at 42°C for 2h followed by 65°C for 10min to inactivate the enzyme in the 
following 50μl volume:  
Reagent volume 
1μg RNA template 20 μl 
5 x AMV buffer 10 μl 
dNTP (10 mM) 2.5 μl 
DTT (100 μM) 2.5 μl 
Random hexamer primers 2 μl 
AMV reverse transcriptase (1 U/μl) 1 μl 
dH2O 12 μl 
 
2.2.2.5 Primary and Mature Transcript SYBR green PCR 
 
Quantitative real-time PCR was used to amplify and simultaneously quantify targeted DNA in a 
sample by measurement of SYBR-green fluorescence. The SYBR Green I dye nonspecifically 
binds to nucleic acid. Upon intercalation with dsDNA the fluorescence of the dye increases 1000-
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fold. The intensity of the signal increases as the target is amplified thus it is proportional to the 
amount of target DNA present.  
RNA from human primary macrophages was extracted using the Blood RNA extraction kit 
(Qiagen, UK) (Section 2.2.2.2). RNA was then purified from genomic DNA with the TURBO 
DNAfree
TM
 kit (Ambion) and converted into cDNA (Section 2.2.2.4).The primers for the PCR 
reaction were designed to distinguish between primary and mature TNF transcripts (Table 2.8) 
such that the primer set spanning exon-intron boundary was used to detect the primary transcript 
whereas the primer set spanning exon-exon boundary was used for the mature transcript 
amplification.  
Samples were run in triplicate on the Rotor-Gene 6 (Corbett Research UK Ltd., Cambridge, UK). 
The DNA was denaturated at 95°C for 5min, and then 40 cycles of 95°C for 10sec (denaturation), 
59°C for 30sec (annealing), and 78°C for 20sec (elongation). Real-time PCR reactions were set as 
follows: 
Reagent Volume 
DNA 10μl 
SYBR Premix ExTaq (2x) Lonza (Takara) 10μl 
Forward Primer (Table 2.10) 0.04μl 
Reverse Primer (Table 2.10) 0.04μl 
 
Relative
 
quantification of gene expression was determined using the comparative
 ΔΔCT method 
using the RotorGene 6000 software. Briefly, threshold cycle (Ct) values of ARP were subtracted 
from TNF Ct values and additionally normalised to the untreated control. The detailed method of 
calculating is as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
 
If the reaction has a perfect amplification efficiency (E), then the template is doubled in each 
amplification cycle (E=2). The difference in Ct values will be then determined by the equation 2
n
, 
where „n‟ is the number of cycles between two Ct values of the fluorescent curves. ∆∆Ct values 
are then calculated as shown: 
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2.2.2.6 Isolation of plasmid DNA by mini- and maxi-preps 
 
Harvesting plasmid DNA, transformed into E.coli was performed using mini- and maxi-prep kits 
purchased from Qiagen (Crawley, UK) according to the manufacturer‟s instructions. Briefly, 
bacteria were lysed in alkaline conditions allowing the separation of plasmid and genomic DNA. 
Pre-cleared lysates were then applied onto a silica gel membrane that selectively binds plasmid 
DNA. The membrane was then washed to remove any contaminants prior to elution with dH20. 
Mini-prep plasmid DNA purification yielded approximately 0.2μg/μl DNA per 1.5ml bacterial 
culture, whereas maxi-prep purification yielded 0.6-1.0 μg/μl DNA per 200ml culture.   
 
2.2.2.7 Polymerase Chain Reaction  
 
Polymerase Chain Reaction (PCR) was used to introduce restriction sites into the Btk gene through 
the DNA amplification process. The primers (Table 2.9) containing a restriction site and the Btk 
sequence annealed to the template in two steps thus two sets of annealing temperatures had to be 
optimised. The first step is when only the Btk complementary sequence of the primer annealed to 
the template. This results in the incorporation of the restriction sites in the Btk sequence. The 
second step is when the whole primer anneals to the template. The MWG-Biotech Primus 96 
machine was programmed as follows:  
 
Initial melting step: 92°C for 1min 
Amplification Step 1 (5 cycles of): 92°C for 30sec 
47°C for 30sec 
 68°C for 3min 
Amplification Step 2 (30 cycles of): 92°C for 30sec 
64°C for 30sec 
68°C for 3min 
Final elongation step:   72°C for 10min 
 
 
PCR was performed using Thermus aquaticus (Taq) DNA polymerase called Titanium
TM 
Taq 
Polymerase (Clontech, USA).  Betaine (Promega) was used to increase the efficiency of the 
reaction as it protects the Taq polymerase from denaturation and dissolves secondary structures.  
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The PCR reaction was set as follows: 
Reagent Volume 
DNA template (10 ng)  10μl  
dNTPs (100 mM) 1μl 
10X PCR buffer 9μl 
Forward Primer 4μl  
Reverse Primer 4μl 
Taq DNA polymerase (5 U/μl) 1μl 
dH2O 61μl 
 
2.2.2.8 DNA agarose gel 
 
The efficiency of PCR, restriction digests or ligation was evaluated on 0.7% (w/v) agarose gels in 
1X TBE buffer with 1/10,000 SYBR Green II (Molecular Probes, Oregon, USA). DNA 
Hyperladder (Bioline, London, UK) was run along with the sample DNA. 10X DNA gel sample 
buffer (Section 2.1.10.9) was added to the digests, and the bands were visualised using a Dark 
Reader Transilluminator (model DR88M, BRI Itd., UK).  
2.2.2.9 Restriction digest of DNA 
 
DNA was digested with restriction enzymes (Table 2.13) at the temperature suggested by a 
supplier (New England Biolabs, MA, USA) for 2h. Reaction conditions which were used in this 
study are as follows: 
Reagent Volume 
DNA (2 μg) x μl 
10x NEB buffer 1 μl 
BSA 2 mg 
Enzyme (10 000U/ml)  0.5 μl 
dH2O up to 10μl total 
 
The efficiency of digests was evaluated on a DNA agarose gel (Section 2.2.2.9). The bands were 
purified using Wizard SV Gel and PCR Clean-Up system (Promega). 
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2.2.2.10 Blunt- ending of 5’ overhangs using Pfu polymerase 
 
Pfu DNA polymerase, along with a 5‟ to 3‟ polymerase activity, also has a 3' to 5' exonuclease 
proofreading activity. It therefore fills in 5‟ overhangs with dNTPs and cleaves nucleotides from 
the 3‟ termini of a polynucleotide chain resulting in blunt-ended DNA fragments. DNA cohesive 
ends generated by restriction enzyme digestion were polished with the Pfu polymerase (Promega, 
Southhampton, UK) treatment at 72°C for 30min. The reaction was set as follows: 
 
Reagent Volume 
DNA (2 μg) 40 μl 
10X Pfu buffer 6 μl 
Pfu polymerase (2-3 U/μl) 5 μl 
dNTPs (1 nM) 6 μl 
dH2O 3 μl 
 
2.2.2.11 Dephosphorylation of DNA ends 
 
The 5‟ ends of digested vector DNA were dephosphorylated by shrimp alkaline phosphatase 
(SAP) (Promega, Southhampton, UK) treatment at 37°C for 30min followed by inactivation of the 
enzyme at 65°C for 15min. The reaction was set as follows: 
 
Reagent Volume 
DNA (2 μg) 10 μl 
10X SAP buffer 1.5 μl 
SAP 1 μl 
dH2O 2.5 μl 
 
2.2.2.12 Ligation of DNA 
 
Prior to ligation DNA was purified using Wizard SV Gel and PCR Clean-Up system (Promega). 
Ligations of purified digested DNA were carried out using T4 DNA ligase (New England Biolabs, 
Hitchin, UK) at a molar ratio 4 (insert) to 1 (vector). The reaction was set as follows: 
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Reagent Volume 
Vector DNA 1 μl 
Insert DNA 4 μl 
10X T4 buffer  1 μl 
T4 ligase 1 μl 
dH2O 4 μl 
 
Ligation mixture (4μl) together with the vector or insert alone controls were then transformed into 
the 50μl electrocompetent XL1-Blue E.coli cells as described in the next section. The efficiency of 
ligation was evaluated by diagnostic digestion with restriction enzymes (Section 2.2.2.9). 
 
2.2.2.13 Transformation of electrocompetent E.coli 
 
A maximum volume of 4μl DNA was transformed into 50- 80μl of electrocompetent E.coli cells 
(Section 2.1.11) by electroporation at 2000V. The bacteria were then allowed to recover in 0.5ml 
of antibiotic-free LB (Section 2.1.10.9) for an hour and plated on agar plates containing 100μg/ml 
ampicillin (Invitrogen). Bacteria were incubated at 37°C overnight prior to colony collection. The 
colonies were then cultured in 5ml LB broth containing 100μg/ml  ampicillin at 37°C overnight 
and plasmid DNA was isolated from the whole cell lysate using miniprep kits purchased from 
Qiagen (GmbH, Germany) according to the manufacturer‟s instructions (Section 2.2.2.6). The 
efficiency of the ligation was evaluated by diagnostic digestion with restriction enzymes (Section 
2.2.2.9). 
 
2.2.2.14 Precipitation of DNA using Sodium Acetate and Ethanol 
 
100μl of DNA was precipitated by adding 7μl of 3M NaAc (pH 5.2) and 321μl of 100% EtOH. 
The sample was left at -20°C for 1h then spun at 13000 rpm for 5min. The supernatant was 
carefully removed and the pellet was gently washed in 0.5ml 70% ice-cold EtOH to remove the 
leftover salt. DNA was resuspended in either dH2O or the required buffer/media. 
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2.2.2.15 PCR fragment cloning using pCR-Blunt II-TOPO 
 
The pCR-Blunt II-TOPO PCR cloning system (Invitrogen) allows rapid cloning of blunt ended 
PCR fragments. The TOPO vector is supplied linearized and contains single 3‟ thymidine 
overhangs together with Topoisomerase covalently bound to the vector. The vector accepts PCR 
fragments that terminate with a single deoxyadenosine. The linearization is facilitated by 
Topoisomerase I from Vaccinia virus.  Positive selection is obtained by the inactivation of the 
lethal E.coli ccdB gene fused to the C-terminus of the LacZ fragment, permitting growth of 
successful recombinants upon transformation. 
 
A 5μl reaction was set up containing 1μl of the TOPO vector, 1μl of 4x diluted salt solution (also 
supplied with the kit), 100ng of the PCR fragment and dH2O. The reaction was conducted at 16°C 
overnight. 
 
2.2.3 Adenoviral production 
 
Recombinant adenoviruses are replication-defective adenoviral vectors used for gene transfection. 
The advantage of using this system is the high level of transgene overexpression and high 
efficiency of infection of a broad spectrum of cells, including non-dividing cells. In addition the 
adenoviral backbone can accommodate large transgenes up to 35 kb. Adenoviral infection begins 
with the binding of the virus to the specific receptor on the host cell membrane followed by 
endocytosis. Adenoviruses then escape the endosomes and translocate from the cytoplasm to the 
nucleus where viral transcription and replication proceeds. Recombinant adenoviruses lack early 
genes required for propagation therefore the infection does not result in host cell apoptosis (Luo 
2007). In the current study, adenoviruses were used for transgene overexpression in human 
primary macrophages. Two recombination systems, AdEasy
TM 
(Q-BIOgene, CA, USA) and 
Gateway ® Technology (Invitrogen), were used to generate transgene expressing adenoviruses. 
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2.2.3.1 The AdEasyTM  recombination system 
 
The AdEasy
TM
 recombination system involves the use of two vectors; the „transfer‟ and 
„backbone‟ plasmids. The transfer vector carries the cloned gene of interest and is used for 
recombination with the backbone vector. The latter contains most of the viral genome but lacks 
genes required for virus propagation. The homologous recombination of a PmeI- linearized 
transfer vector with a backbone vector is then conducted in modified BJ5183 bacteria. Finally, 
PacI-digested recombinant adenoviral DNA is transfected into HEK-293 cells which contain the 
E1 gene required for virus propagation. The overview of the system is presented in Figure 2.2. 
 
The transfer vector used in this study was pAdSK16 (9.45kb) constructed by Dr Clive Smith. The 
vector was derived from commercially available pAdTrack.CMV (9kb) (Q-Biogene, CA, USA) by 
modifying the multiple cloning site (MCS) and by removing the EcoRI site from the vector. The 
N-terminal Protein G- TEV- SBP (NTAP) tag was cloned into pAdSK16 by Ms Kate Willetts and 
used as a control for the tandem affinity purification protocol (Section 2.2.5).  Human Btk was 
cloned into pAdSK16-TAP using standard molecular biology techniques (Section 2.2.2).  The 
backbone vector used in this study was commercially available pAdEasy-1 (Q-BIOgene, CA, 
USA) (Figure 2.2).  
 
The transfer vector was first linearized by PmeI as described (Section 2.2.2.9) and purified using 
Wizard SV Gel and PCR Clean-Up system (Promega). Electrocompetent BJ5183 E.coli cells (Q-
Biogene, Cambridge, UK) (80μl) were co-transfected with 200ng of pAdEasy and 600ng of 
pAdSK16 in a total volume of 4μl of DNA (Section 2.2.2.13). After 1h incubation in antibiotic-
free LB, the cells were spread onto kanamycin (0.3μg/ml)- containing agar plates and incubated at 
37°C overnight. The following day representative colonies were collected and cultured in 5ml LB 
broth media at 37°C overnight.  Plasmid DNA was extracted and digested with PacI.  Plasmids 
with diagnostic digestion pattern of 3kb or 4.5kb, and 35kb were further transformed into XL-1 
blue E.coli to increase plasmid yield. Plasmid DNA (10μg) was then extracted from bacteria, 
linearized with PacI and subsequently precipitated using the NaAc/EtOH protocol (Section 
2.2.2.14) prior to transfection into AD-293 cells (Section 2.2.3.3). 
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Figure 2.2 Generation of a recombinant adenovirus using AdEasy
TM
. The AdEasy
TM
 protocol involves 
three steps. In the first step, cDNA of the gene of interest is cloned into the transfer vector. The transfer 
vector is linearized with PmeI and co-tranformed with the adenovirus backbone vector lacking the genes 
involved in virus propagation (Ad5ΔE1ΔE3) into the BJ5183 bacterial strain. Following homologous 
recombination plasmid DNA is isolated from bacteria, linearized with PacI and transfected into HEK-293 for 
amplification. ITR: inverted terminal repeats, LITR: left-hand ITR, RITR: right-hand ITR, MCS: multiple 
cloning site, Kan: kanamycin resistance, Amp: ampicillin resistance gene, Ori: bacterial origin of replication. 
The diagram is adapted from www.qbiogene.com. 
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2.2.3.2 The Gateway® recombination system 
 
Similarly to the AdEasy
TM
 system, the Gateway ® Technology system involves the use of transfer 
and backbone vectors. The transfer vector does not, however, have to be linearized prior to site-
specific recombination with the backbone, which increases the efficiency of virus generation. 
Moreover, recombined vectors do not have to be transformed into two sequential bacterial strains 
as only the Top10 E.coli strain is used for plasmid amplification. The technology is based on the 
lambda recombination system to facilitate transfer of heterologous DNA sequences, flanked by att 
sites, between transfer and backbone vectors. The overview of the system is presented in Figure 
2.3A. 
 
The transfer vector used in this study, pBENT2 containing C-terminal SBP (Strep) tag (4590bp), 
was kindly provided by Dr Irina Udalova and was utilised to generate the control adenovirus for 
One-Strep purification (Section 2.2.5.1) (Figure 2.3B). Human Btk was cloned into the vector 
using standard molecular biology techniques (Section 2.2.2). The backbone vector used in this 
study was pAd/PL-DEST
TM
 (Invitrogen) (Figure 2.3C). 
 
Gateway LR Clonase Enzyme mix (Invitrogen) was used for the recombination of the transfer and 
backbone vectors. A 10μl reaction was set up containing 2μl (300ng) of Btk-Strep-pBENT, 2μl 
(300ng) of pAdPL-DEST, 2μl of LR Clonase enzyme, 2μl of LR Clonase buffer and 2μl of TE 
buffer. The sample was incubated at 25°C overnight. 
 
Chemically competent One Shot® Top10 E.coli cells (Q-Biogene, Cambridge, UK) (80μl) were 
transfected with 2μl of the recombination mixture. Briefly, the bacteria were incubated with DNA 
on ice for 30min. The cells were then subjected to 42°C heat shock for 30sec and put back on ice 
for 2min. The cells were left to recover in antibiotic-free LB broth (Section 2.1.10.9) for 1h at 
37°C, spread onto ampicillin- containing agar plates and incubated at 37°C overnight. The 
following day representative colonies were collected and cultured of either 5ml ampicillin or 
chloroamphenicol- containing LB broth overnight at 37°C. If recombination had occurred, 
chloroamphenicol resistance was lost. Plasmid DNA was extracted from the bacteria cultured in 
ampicillin- containing LB broth media and digested with BamHI.  Plasmids with a diagnostic 
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digestion pattern of 500bp, 3.5kb, and above 14kb were considered positive clones. Plasmid DNA 
(10μg) was then linearized with PacI and subsequently precipitated using the NaAc/EtOH 
protocol (Section 2.2.2.14) prior to transfection into AD-293 cells (see below). 
 
 
 
Figure 2.3 Generation of a recombinant adenovirus using the Gateway® Technology. The technology 
is based on the site-specific recombination between attL and attR using LR Clonase (A). The transfer 
vector used in this project was Btk-Strep-pBENT containing attL sites (B), whereas the backbone vector 
containing attR sites was pAd/PL-DEST (C). Upon recombination the chloroamphenicol resistance gene 
(Cm
R
) is lost enabling the selection of positive clones. Ori: bacterial origin of replication, TK: Herpes 
Simplex Virus thymidine kinase polyadenylation signal, wt Ad5 (ΔE3): human adenovirus type 5 sequence 
with E3 early gene deletion, ITR: inverted terminal repeats, EGFP: Enhanced Green Fluorescent Protein, 
CMV: Cytomegalovirus promoter.  Diagrams A and C were adapted from www.invitrogen.com. 
 
 
2.2.3.3 Transfection of viral genomic DNA into AD-293 cells 
 
AD-293 cells were plated at 8 x 10
5
 cells per well in a 6-well plate and incubated at 37°C 
overnight to reach 90% confluence. The cells were transfected with PacI- linearized and 
NaAc/EtOH- precipitated recombinant adenovirus vectors using Lipofectamine
TM
 2000 
transfection reagent (Invitrogen). Briefly, 15μl of Lipofectamine 2000 was mixed with 400μl of 
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Opti-MEM® medium (Invitrogen) and incubated at RT for 5min. The mix was added to 100μl of 
DNA, agitated and left at RT for a further 30min. In the mean time the culture media was removed 
from AD-293 cells and replaced with 1ml of pre-warmed Opti-MEM® medium for 30min. The 
Lipofectamine/DNA mixture was added to the cells and replaced with DMEM/10% FCS after 2h 
incubation. The next day  DMEM/10% FCS was removed and the cells were covered with 3ml of 
pre-warmed 0.75% (w/v) sea-plaque agarose; 1 x MEM, 2% (v/v) FCS and 1% (v/v) penicillin/ 
streptomycin. The mixture was allowed to solidify at RT for 5min before continued incubation at 
37°C.  The cells were incubated for 10-14 days to allow virus plaques to develop in the monolayer 
of AD-293 cells. 
 
2.2.3.4 Plaque purification and virus recovery 
 
Plaque purification is essential in the production of viruses de novo. The plaques are formed by 
the infection and lysis of neighbouring cells and are easily seen by eye or with the assistance of a 
microscope. 8-10 plaques were picked using a 10μl Gilson pipette and filter tips and subsequently 
diluted in 0.5ml of serum-free DMEM. Virus-infected media was left at 37°C in an incubator 
overnight allowing viral dissociation from cellular debris or agar constituents as well as 
preliminary detection of bacterial/ yeast contamination. The 0.5ml of infected media was applied 
onto one well of AD-293 monolayer cultured in a 12-well plate. After 2h incubation at 37°C the 
virus infected media was replaced with 1ml of 2% DMEM. The cells were thereafter incubated for 
3-5 days until the plate exhibited a full cytopathic effect (CPE) characterised by cell swelling and 
detachment due to adenoviral infection. One clone was selected for adenovirus large scale grow-
up. 
 
2.2.3.5 Adenovirus large scale grow-up  
 
The amplification of adenovirus consisted of infection of confluent AD-293 cells plated in 
successively larger dishes. Initially, AD-293 cells were cultured in 6-well plates. Adenovirus from 
the archive stock was introduced in 100μl volume to the culture in 1ml serum- free (SF) DMEM. 
After 2h, 1ml of DMEM supplemented with 4% FCS and 2% Pen/Strep was added to the cells. 
AD-293 cells were then incubated for 2 days for a full CPE to be obtained. Viral lysate was 
prepared by freeze-thawing in liquid nitrogen 3 times to ensure that adenovirus was entirely 
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released from the cells.  At the next step, AD-293 cells in T75cm
2
 culture flask were infected with 
1ml of this lysate in 5ml of SF DMEM as described above. Again cells were incubated for 2 days 
for a full CPE. Lysate was frozen-thawed and used for the infection of 10x T175cm
2
 flasks 
containing 80-90% confluent AD-293. Cells were incubated in 20ml of 2% FCS medium for 40h 
until they became non-adherent but not lysed as this would prevent virus concentration. The cells 
were then harvested into 4 50ml (200ml of medium total). Falcon tubes and spun at 1000 rpm for 
5min. The pellets were then resuspended in SF DMEM, pooled together into one tube and spun 
again. Supernatants were discarded and cells were re-suspended in 10ml of 0.1mM Tris (pH 8.0) 
and placed into 2 cryovials. AD-293 cells were then frozen-thawed and passed through a 19-gauge 
needle 4 times to shear chromatin.  Lysates were then spun at 2000 rpm for 5min to pellet cell 
debris.  
 
2.2.3.6 Purification of Adenovirus from large scale grow-up 
 
Purification of the adenovirus was performed to remove contaminants such as viral capsid proteins 
and to increase the yield of infection (Cotten et al. 2003). Virus-containing supernatant was placed 
into a new tube, made up to 11.4ml with 0.1M Tris-HCL and to 18ml with saturated CsCl. The 
solution was then transferred to 9ml Sorvall ultracentrifuge tubes (RC-M150 GX, Kendro 
laboratory products, UK) and spun at 60 000 g overnight at 4°C. The next day, the tube was 
pierced with a 19-gauge needle and the virus band was drawn into the 5ml syringe. Virus material 
from two tubes was pooled together, injected into a new ultracentrifuge tube and filled to the top 
with 1.34g/ml density CsCl. The rotor was balanced and the tube was spun as before.  
 
The band with the virus was removed in less than 2.5ml volume total and injected onto a PD10 
column previously equilibrated with 25ml PBS
2+
.  The virus was eluted by further addition of 
3.5ml PBS
2+
 and collected into a bijou containing 10 drops of sterile glycerol. Virus was then 
aliquoted and frozen at -70°C.  
 
 
Chapter 2  Materials and methods 
92 
 
2.2.3.7 Adeno-XTM rapid titre kit 
 
Virus titre was determined using the AdenoX
TM
 titre kit (BD Biosciences). AD-293 cells were 
seeded at 5x10
5
 cells per well in a 12-well plate. The cells were cultured in 1ml of standard growth 
medium (DMEM supplemented with 5% FCS and 2% Pen/Strep) overnight. The next day, the 
viral sample dilutions (5 x 10
-5
, 1 x 10
-5
, and 5 x 10
-6) made up in 100μl SF DMEM were applied 
to each well. 28h later the medium (1ml + 100μl) was aspirated and cells were allowed to dry in a 
hood for 5min prior to fixation with 1ml ice-cold 100% methanol. The plate was incubated at -
20°C for 10min. Methanol was aspirated and the wells were gently rinsed 3 times with 1ml PBS 
containing 1% (w/v) BSA. A mouse anti-hexon antibody at a 1:1000 dilution in PBS (1% BSA) 
was incubated with the cells for 1h at 37°C. The wells were washed 3 times with 1ml PBS (1% 
BSA) prior to a 1h incubation with rat anti-mouse antibody (HRP conjugate) diluted 1:500 in PBS 
(1% BSA). After the final wash, a colorimetric reaction was carried out using DAB working 
solution (10X DAB substrate 1:10 with 1X Stable Peroxidase Buffer). A minimum of 3 fields of 
brown/black positive cells were counted using a microscope with a 20X objective. The mean 
number of positive cells in each well was counted. The titre (number of viral particles per ml) was 
calculated from the dilution which gave around 50 positive cells per field (PC). The number of PC 
was multiplied by 573 (the number of fields in the well) and divided by the result of multiplication 
of 0.1 (virus volume diluted 1:10 in medium) by the dilution factor to determine the viral titre.  
 
2.2.3.8 Replication competency test 
 
To test if adenovirus regained replication competency outside AD-293 cells, a small flask of non-
adherent human foreskin fibroblast (HFS) cells were infected with the virus in SF DMEM. After 
2h the medium was removed and replaced with 10% FCS DMEM. Cells were incubated for 7-10 
days. If a cytopathic effect was not observed, the batch of virus was used for experiments. 
 
2.2.3.9 Adenoviral gene transduction of human macrophages 
 
Human primary monocytes were differentiated into macrophages using M-CSF. M-CSF was 
essential to upregulate the low expression of the αvβ3 and αvβ5 integrins which are necessary for 
adenoviral entry into the cells (Huang et al. 1995). Human primary macrophages were then 
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detached from culture plates with cell dissociation media for 45min and subsequently scraped. 
They were counted and plated in experimental dishes in 5% RPMI without M-CSF and incubated 
overnight. Adenovirus was diluted in SF RPMI to final multiplicity of infection (moi) from 50 to 
150 infectious virus particles per cell then added to the cells. After 2h medium was removed and 
replaced with 5% RPMI. Cells were incubated for 24-48h. The extent of viral infectivity was 
determined by visualisation of GFP under UV light. For double infection, cells were first infected 
with adenovirus at moi 100 for 2h, rested for 4h in 5% RPMI prior to secondary infection at moi 
50 as described before. 
 
2.2.4 Biochemical Techniques 
 
2.2.4.1 Whole cell lysis 
 
Cells designated for Western blotting analysis were first lysed in 1% NP40 buffer (Section 
2.1.10.3) for 20 min on ice. Nuclei and insoluble debris were removed by centrifugation at 13000 
rpm for 8 min at 4°C. Supernatants were transferred to fresh Eppendorfs. 5X denaturating protein 
gel sample buffer containing SDS was added and samples were boiled for 5 min prior to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
 
2.2.4.2 Protein concentration estimation by BCATM protein assay kit 
 
The bicinchoninic acid (BCA) assay (ThermoScientific) was used to determine the total protein 
concentration in cell lysates prior to the kinase or TransAm assays. For the BCA assay, 5μl of 
fresh lysate was diluted in 5μl of H2O and transferred to a 96-well U-shape Microtest plate 
(Becton Dickinson) in triplicate, along with a series of BSA concentrations as standard. The BCA 
solutions were mixed at volume ratios of 50:1 (assay reagents A:B) and 200μl of the mixture was 
added to each well. Samples were incubated for 30 min at 37°C and the absorbance was read at 
562nm wavelength on a Fluostar Omega (BMG Labtech, Aylesbury, UK) plate reader and 
accompanied by MARS data analysis software. 
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2.2.4.3 SDS-PAGE 
 
SDS-PAGE is a technique that allows protein separation based on molecular size. The separation 
occurs in an electric field. Denaturated proteins, which are negatively charged due to addition of 
SDS at the lysis stage, migrate toward the positively charged anode. Electrophoresis gels consist 
of an upper, stacking, 3% (pH 6.8) gel containing wells designated for sample loading and 
concentration. The bottom, resolving layer (7-10%, pH 8.8) separates the proteins. The gel was 
cast in the Bio-Rad Protein Cell II apparatus (Bio-Rad, Herts, UK) and submerged in a running 
buffer (Section 2.1.10.4). Protein samples and Full Range Rainbow molecular weight marker 
RPN800 (Amersham Biosciences) were loaded into individual wells and run at 55V overnight.  
Gels were made as follows:  
 
Reagent 4% stacking gel 7% resolving gel 10% resolving gel 
30% Acrylamide 1.25 ml 9.33 ml 13.33 ml 
Resolving buffer n/a 15 ml 15 ml 
Stacking buffer 1.5 ml n/a n/a 
10% (w/v) APS 100 μl 250 μl 250 μl 
TEMED 10 μl 25 μl 25 μl 
water 7.14 ml 15.4 ml 11.4 ml 
total 10 ml 40 ml  40 ml 
 
 
2.2.4.4 Protein transfer 
 
Proteins resolved by SDS-PAGE were transferred onto polyvinylidene diflouride (PVDF) (Perkin 
Elmer Life Sciences Inc, MA, USA) or NitroBind membrane (GE Water and Process 
Technologies, USA) by using a wet transfer technique. PVDF membrane was first moistened in 
methanol and then together with other layers placed in transfer buffer. The gel was removed from 
the electrophoresis apparatus and placed onto three layers of filter paper and a cloth. It was then 
covered by membrane and stacked into another three layers of filter paper and a cloth on the top. 
The structure was then compressed into a plastic cassette (Bio-Rad, UK) and placed with the 
membrane side facing the anode (+) into a transfer tank filled with cooled transfer buffer. The 
transfer was run at 100V for 90min. 
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2.2.4.5 Western blotting 
 
The membrane was removed and blocked for 1h in TBS-Tween (0.1%) containing 2% BSA for 
the detection of phosphorylated proteins or in 5% skimmed milk for the detection of other 
proteins.  Primary antibodies (Table 2.2) made up in the blocking buffer were then applied for a 
minimum of 1h at RT. The membrane was washed for 30min in frequently changed TBS-Tween 
(0.1%) and horseradish peroxidase (HRP) conjugated secondary antibodies (Table 2.3) at a 
dilution of 1:2000 were added for an hour. The membrane was washed again as before and ECL
TM
 
(Amersham Biosciences) reagent applied for 1min to visualize the reaction. The luminescence of 
the product was detected by placing Hyperfilm
TM
 (Amersham Biosciences) on the top of the 
membrane and subsequent development of exposed films in an AGFA Cruis-60 film processor 
(AGFA-Gaevert, Brentford, UK). If necessary, blots were re-probed with other antibodies after 
stripping of the membrane with Re-blot stripping solution (Chemicon International Inc, CA, USA) 
for 5min. 
2.2.4.6 Luciferase assay 
 
The luciferase assay involved the use of adenoviruses carrying DNA constructs consisting of the 
luciferase gene flanked by the 5‟ TNF promoter and different portions of the 3‟ TNF untranslated 
and enhancer regions (Table 2.14).  The luciferase enzyme catalyses mono-oxygenation of beetle 
luciferin in the presence of Mg
2+
 and ATP, resulting in the release of photons (fluorescence) 
(Gould and Subramani 1988). This fluorescence can be measured using a luminometer, and the 
activity of the element regulating the luciferase gene can thereby be quantified. 
 
Cells were cultured in 96-well plates and following infection with adenovirus containing the 
firefly luciferase enzyme (as detailed in Section 2.2.3.9), cells were washed in ice cold PBS then 
lysed on ice in 100μl CAT buffer (Section 2.1.10.5) for 10min. Samples were either stored at -
20°C until further use, or assayed directly. 50μl of the lysates was transferred to a luminometer 
plate with 120μl LAB containing 1mM ATP and 0.5mM DTT per well. The cocktail was assayed 
in a Luminometer (Labsystems Luminoskan) by the addition of 30μl luciferin and the 
measurement of photon release over a 10sec period. Values were recorded as relative luciferase 
units (RLU).  
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2.2.5 Affinity Tag Purification and Mass Spectometry 
 
Mass Spectometry (MS) is a powerful tool for the identification of novel protein-protein 
interactions (Vasilescu and Figeys 2006).  Although MS is a highly sensitive and effective 
technique, the purification of proteins still remains difficult due to the low abundance of the 
proteins and the instability of the protein-protein complexes in vivo. A commonly used technique 
for the purification of endogenous proteins, such as immunoprecipitation (IP), requires a high 
number of cells and a long purification procedure. Moreover, as the procedure is highly dependent 
on the antibody used for the pull-down of the bait, the yield of the purified protein varies between 
different proteins and antibody batches. These limitations led to the development of affinity tag 
purification systems based on the strong interactions of the tag with its target (Lichty et al. 2005). 
A novel tandem affinity purification (TAP) strategy does not rely on the use of antibodies, the 
proteins are purified rapidly and still remain biologically active (Puig et al. 2001). This strategy 
has been extensively used since 2002, when Gavin and colleagues performed a large scale 
purification of yeast and eukaryotic proteins. In their studies, the group tagged 1,739 genes to a 
TAP tag and successfully purified 589 protein assemblies providing an extensive network of 
biological interactions (Gavin et al. 2002).  
 
The TAP system involves the fusion of bait to the tag and subsequent column purification of the 
protein complexes. The TAP tag consists of the 136 amino acid long Protein G, a cleavage site for 
tobacco etch virus (TEV) protease and streptavidin-binding peptide (SBP) moieties. During the 
first step of purification, a tagged protein together with its interacting partners binds to IgG 
sepharose through Protein G. The complex is then cleaved by a TEV protease. Eluted protein 
complexes are then sequestered by streptavidin sepharose through SBP and undergo an extensive 
wash in order to remove any contaminants and the remaining TEV protease. A tagged protein 
together with its binding partners is subsequently eluted with biotin, which competitively binds to 
the streptavidin column (Figure 2.4) (Burckstummer et al. 2006). The use of the two-step 
purification system decreases the background by limiting the occurrence of non-specific proteins 
in the elution fraction. On the other hand, the introduction of the 136 amino acid long tag 
increases the risk of interfering with a native conformation of the bait and may lead to impaired 
protein interactions.  
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An alternative is the introduction of a shorter version of the tag composed of only an 8 to 31 
amino acid long SBP, called a Strep tag (www.iba-go.com).  The use of the One-Strep system has 
been shown to result in excellent, cost-effective purification with good yields as compared to other 
affinity tags such as HIS, calmodulin-binding peptide (CBP) or FLAG (Lichty et al. 2005). The 
tagged bait is first purified through a Strep-Tactin ® column, extensively washed and eluted with 
biotin in native conditions within a short period of time.  The recovered material is then run on an 
SDS-PAGE gel and analysed by several methods including Western blotting or MS. The first 
approach is used to confirm the efficiency of the system as it facilitates the detection of known 
protein-protein interactions. The second approach is used to identify new binding partners, 
provided that the protein complex is adequately purified in reasonable quantity.   
 
 
 
Figure 2.4 Overview of the TAP purification strategy. The full length TAP tag consists of a Protein G, 
which facilitates the binding to an IgG sepharose column, a TEV protease cleavage site that enables the 
first elution of the complex, and a streptavidin binding protein (SBP) that facilitates the binding to the 
second affinity column. The One-Strep purification process is used when the target protein is tagged to the 
SBP only (shaded square). The complex is eluted with biotin and submitted for mass spectrometry analysis 
(adapted from (Burckstummer et al. 2006)).   
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2.2.5.1 One-Strep purification 
 
Human primary macrophages previously infected with AdStrep or AdBtk-Strep were plated at 7 x 
10
6 
cells per 10cm
2
 Petri dish. Following stimulation the cells were washed 3 times in ice cold 
PBS, scraped and resuspended in cytoplasmic lysis buffer (Section 2.1.10.8). After 20min on ice 
the sample was spun at 12000rpm for 1min at 4°C. The supernatant was kept as the cytoplasmic 
fraction. The pellet was resuspended in nuclear lysis buffer and incubated with gentle agitation for 
15min at 4°C. The lysate was finally spun at 13000rpm for 10min at 4°C to remove nuclear 
insoluble fractions. The supernatant was kept as the nuclear fraction.  
 
Btk-Strep complexes were purified on a Bio-Spin® gravity flow chromatography column (Bio-
Rad, CA, USA) containing Strep-Tactin Macroprep (IBA GmbH, Germany) resin. 200μl of the 
resin was applied onto a column and equilibrated by adding 400μl of washing buffer (WB).  The 
cell lysate was then applied to the column. 10% of the Input and 10% of the Flow Through was 
kept for further analysis. The column was then washed 10 times with 1ml of WB. 10% of each 
WB fraction was kept as previously detailed.  Btk-Strep complexes were eluted in 6 fractions of 
200μl elution buffer containing 2mM Biotin. Eluted fractions were concentrated on a Vivaspin 
500 column (Sartorius Stedim Biotech, France) prior to applying onto an SDS-PAGE gel.  
 
2.2.5.2 Silver staining of an SDS-PAGE gel 
 
Visualisation of proteins on an SDS-PAGE gel was performed using the Pierce Silver Stain kit 
(Thermo Scientific, IL, USA). Proteins bind silver ions, which can be reduced under appropriate 
conditions and form black elementary silver (Chevallet et al. 2006). According to the 
manufacturer‟s protocol, the gel was washed in dH20 and fixed in fixing solution (30% ethanol, 
10% acetic acid) on rotation for 15min. 10% ethanol wash was added for 10min followed by 2 
times 5min wash with dH20. The gel was then sensitised with provided Silver Stain Sensitizer and 
washed again with dH20 twice for 1min. Silver Stain Enhancer was incubated with the gel for 
5min followed by two brief dH20 washes. Developer working solution was added immediately to 
the gel until protein bands appeared. The reaction was stopped with 5% acetic acid. 
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2.2.5.3 Protein identification by tandem mass spectrometry 
 
The identification of Btk-Strep protein complexes by MS was performed by Dr Robin Wait. Silver 
stained gel bands were excised with a scalpel, and proteins were trypsin digested in gel, using an 
Investigator Progest robot (Genomic Solutions, Huntingdon, UK) as previously described (Wait et 
al. 2002).  
Samples were analysed by high performance liquid chromatography coupled to electrospray 
ionisation tandem mass spectrometry (HPLC ESI MS/MS). HPLC was carried out on a CapLC 
liquid chromatography system (Waters, Manchester UK). Aliquots (6 µl) of peptide mixtures were 
injected onto a Pepmap C18 column (300 µm x 0.5 cm; LC Packings, Amsterdam, The 
Netherlands) and eluted with an acetonitrile/ 0.1% formic acid gradient to the nanoelectrospray 
source of a Q-Tof spectrometer (Micromass, Manchester, UK) at a flow rate of 1 l/min. The 
spray voltage was set to 3500 V and data dependent MS/MS acquisitions were performed on 
precursor peptides with charge states 2, 3, or 4, over a survey mass range 440-1400, using argon 
collision gas. Product ion spectra were recorded over the range 100-1800, transformed onto a 
singly charged m/z axis using a maximum entropy method (MaxEnt3, Waters, UK), and 
centroided peaklist (pkl) files were extracted using the MassLynx routine peptide auto (Waters, 
Manchester UK). 
Proteins were identified by correlation of uninterpreted spectra to entries in SwissProt (Release 
2010_04: 516,081 entries) using Mascot (version 2.2: www.matrixscience.com). MS/MS ion 
searches specified up to two missed cleavages per peptide, a precursor mass tolerance of ± 100 
ppm and a fragment ion mass tolerance of ± 0.5 Da. Carbamidomethylation of cysteines and 
methionine oxidation were specified as fixed and variable modifications respectively. 
MS/MS based peptide and protein identifications were validated using Scaffold (Proteome 
Software Inc., Portland, Oregon: version 3.01). Peptide identifications were accepted if they could 
be established at greater than 95.0% probability as specified by the Peptide Prophet algorithm 
(Keller et al. 2002).  
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2.2.6 Immunological Techniques 
2.2.6.1 Flow cytometry  
 
Flow cytometry is a technique that enables quantitative measurements on single cells at very high 
rates of speed. The flow cytometer consists of fluidics, optics and a detecting system. The fluidics 
system brings a cell into the light beam, where it is then illuminated and the scatter of light is 
collected by photodetectors, which are located at different positions. The one that is located in 
front of the illuminating beam detects the forward scatter (FSC), others that are situated at angles 
detect the side scatter light (SSC). FSC gives the information about the size and volume of the 
cell, whereas SSC photodetector is related to the surface and internal structure of the cell. Flow 
cytometers can also detect fluorescence signal emitted from fluorochrome- conjugated monoclonal 
antibodies. The illuminating beam will excite the fluorochrome which then emits light at different 
wavelengths. The light is then selectively collected by photodetectors, converted into electrical 
impulses and interpreted by the computer software. 
In the present study, human monocytic-like cell lines and human primary macrophages were 
stained with Fluorescein isothiocyanate (FITC)-conjugated anti-TLR4, anti-TLR3, anti-TLR8, or 
control IgG1 or IgG2 antibodies (Imgenex). For external staining (TLR4 and IgG2 control), cells 
were first washed and then blocked in PBS containing 5% human serum and 0.1% sodium azide. 
After 30min incubation on ice, antibodies (20μg/ml) were added for another hour. Cells were 
washed 3 times in PBS and directly analysed on BD Bioscences LSR flow cytometer. For the 
staining of internal antigens (TLR3, TLR8 and IgG1 control), cells were additionally fixed in 2% 
paraformaldehyde for 5min on ice, washed 3 times in PBS and then permeabilized  with 0.1% 
saponin during the blocking step.  
 
2.2.6.2 Immunoprecipitation and phospho-tyrosine detection 
 
Human primary macrophages (5 x 10
6
 per time point) were plated on 10cm
2
 Petri dishes and 
serum starved for 2h before TLR stimulation. Cells were lysed in 1% NP40 lysis buffer (Section 
2.1.10.3) and insoluble debris and nuclei were removed by centrifugation at 13000 rpm for 8min. 
Supernatants were transferred to new tubes. Immunoglobulin-binding proteins A and G, which are 
covalently bound to Sepharose
TM
 beads (GE Healthcare, Sweden), were mixed at equal volumes 
and washed 3 times in the 1% NP40 lysis buffer to remove ethanol. Supernatants were then pre-
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cleared with 50μl of Protein A/G mix at 4°C for an hour to remove proteins that bind non-
specifically to Protein A/G. Non-specifically bound protein complexes were further removed by 
centrifugation at 13000 rpm for 3min and supernatants were incubated with anti-Btk antibody 
(gifted by Dr M. Tomlinson) or isotype control rabbit IgG, at 4°C for an hour. Protein A/G mix 
was introduced to pull down antibodies conjugated with target proteins. After a 2h incubation, 
Sepharose- ProteinA/G- Btk complexes were isolated by centrifugation at 13000rpm for 3min, 
supernatants were discarded and the pellets were washed 3 times in 1% NP40 lysis buffer. All 
steps were performed at 4°C with constant agitation. Protein gel sample buffer was added and 
samples were boiled for 5min before loading on an SDS-PAGE gel. Proteins were transferred to 
nitrocellulose membrane as described before. The membrane was blocked in 2% BSA and 
incubated with HRP-conjugated 4G10 antibody directed against tyrosine phosphorylated proteins 
(section 2.2.4). 
 
2.2.6.3 In vitro kinase assays 
 
In vitro kinase assays utilising radiolabelled ATP were used to assess Btk auto-kinase activity or 
p38 activity in the presence of the specific substrate, MK2 (Millipore, Dundee, UK). Adenovirus-
infected human primary macrophages (2 x 10
6 
per time point) were subjected to TLR stimulation 
and lysed in 0.4ml of kinase lysis buffer (Section 2.1.10.11) for 10min on ice. Lysates were 
centrifuged (10 min, 13000 rpm, 4°C) and the cleared nuclear lysates was transferred to new 
Eppendorfs. The quantity of the protein was assessed using the BCA assay (Section 2.2.4.2). 
Samples were further divided into two fractions of which one was analysed for equal loading 
control using Western blotting analysis and the remaining 500μg of protein was used for the 
kinase assay.  
 
Protein A/G-Sepharose
TM
 beads (GE Healthcare, Sweden) were washed 3 times in 1x kinase wash 
buffer. The lysate and 3 μl of the IP antibody (Table 2.2) were added to the 30μl of the beads. The 
sample was incubated on a rotator at 4°C overnight. The supernatant was then discarded, beads 
were washed 4 times in 1ml of ice cold RIPA buffer followed by two washes in 1ml of ice cold 1x 
kinase wash buffer. The excess of the buffer was removed from the beads using an aspirator. The 
beads were then incubated with 30µl of kinase assay mastermix containing 10µl of 3x kinase 
assay buffer, 1µl (1µg) of substrate, 0.1µl of 6mM cold ATP, 0.4µl of γ32P- ATP (or an equivalent 
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of 4µCi) and 18.5µl of dH2O. The substrate was omitted in the auto-kinase assays. The reaction 
tubes were incubated at RT for 30min with gentle agitation. The samples were spun down to avoid 
lid contamination and the reaction was stopped by adding 8μl of 5x reducing gel sample buffer 
and boiling for 5min. The samples were then loaded on a 12% SDS-PAGE gel and run overnight 
at 55V (Section 2.2.4.3). The gel was subsequently fixed for 30min in dH2O, methanol and acetic 
acid at the respective ratios 5:4:1 and dried for 2h. Enzyme activity was assessed by 
autoradiography.    
 
2.2.6.4 Sandwich enzyme linked immuno-sorbent assay  
 
Enzyme linked immune-sorbent assays (ELISA) were used for a quantitative detection of 
cytokines in the supernatants collected from cultured cells stimulated with TLR ligands. ELISA 
plates were initially coated with 50μl of cytokine specific antibodies (Table 2.4) for an hour at 
37°C and washed 3 times in 1x PBS with 0.001% Tween20. The plates were then blocked in 2% 
BSA made up in 1x PBS at RT for another hour and washed as before. Samples and standard 
curve cytokines at concentrations ranging from 10,000-13.72pg/ml were applied overnight. After 
washing, wells were filled with biotin-labelled detection antibody diluted in 1x PBS and incubated 
for 1 hour at RT. The wells were washed and loaded with HRP/streptavidin conjugates at 1:400 
dilution in 1x PBS and incubated again for 1 hour at RT. Wells were washed and 1 volume of a 
HRP substrate, tetramethylbenzide dichloride (TMB), was added until the visualization of the 
standard curve was satisfactory. To stop the reaction 1 volume of 2M H2SO4 was applied, 
absorbance was read at 450nm wavelength using a Fluostar Omega (BMG Labtech, Aylesbury, 
UK) plate reader and analysed using MARS data analysis software. Samples were analysed in 
triplicate whereas standards in duplicate. 
 
2.2.7 Electrophoretic Mobility Shift Assay  
 
Electrophoretic Mobility Shift Assay (EMSA) is a technique that allows the characterisation of 
nuclear complexes bound to a DNA motif. In the assay, nuclear extracts derived from cultured 
cells are incubated with double-stranded oligonucleotides that are pre-labelled at their termini with 
γ32P-ATP. The samples are then run on a non-denaturating gel. The formation of DNA-protein 
complexes retards the electro-mobility of the DNA probe in the gel resulting in a shift of the band. 
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To characterise components of the complex, specific antibodies are added to the nuclear extracts 
prior to the DNA binding reaction. If the antibody target is present in the DNA-protein complex 
this will result in an additional shift of the band, thus identifying complex components binding to 
the DNA probe. 
 
2.2.7.1 Preparation of cytosolic and nuclear protein extracts 
 
Human primary macrophages were grown at 8 x 10
6
 cells per 10cm
2
 petri dish. Following 
stimulation, the cells were washed twice with ice-cold PBS containing 1:50000 PIT. Cells were 
scraped and re-suspended in 0.5ml ice-cold hypotonic lysis buffer A (Section 2.1.10.6). Cells were 
kept on ice for 15min prior to addition of 32μl NP-40 to a final concentration of 0.0064%. The 
samples were vortexed for 10sec and incubated on ice for an additional 5min prior to 
centrifugation for 1min at 12000 rpm at 4°C. Pellets were washed with 0.5ml buffer A, vortexed 
for 10sec and spun as previously. Hypertonic lysis buffer B (150μl) was added to the pellets for 
nuclear extraction for 3h. The samples were kept on ice and occasionally vortexed to enhance 
lysis. Nuclear debris was removed by centrifugation for 15min at 12000 rpm at 4°C. The 
supernatant was collected into a new pre-cooled tube and the protein concentration was assessed 
by BCA
TM
 protein assay (2.2.4.2). The samples were stored at -20°C. 
  
2.2.7.2 γ32P-ATP end-labelling of double stranded oligonucleotides 
 
The AP-1 and NFκB consensus double-stranded oligonucleotides (Table 2.12), each possessing 
5‟-OH blunt ends, were radiolabelled with γ32P-ATP by polynucleotide kinase as described in the 
following binding reaction: 
 
Reagent Volume 
Consensus oligonucleotide (1.75pmol/μl) 2μl 
T4 polynucleotide kinase buffer (Promega) 1μl 
20μCi γ 32P-ATP 1μl 
dH2O 5μl 
10 x T4 polynucleotide kinase (Promega) 1μl 
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The reaction mixture was incubated for 20min at 37°C followed by the addition of 1μl of 0.5M 
EDTA to stop the reaction and 89μl of TE (10mM Tris pH 8, 1mM EDTA) to dilute the probe.  
Unincorporated γ 32P-ATP was removed by using a G-25 microspin column (GE Healthcare). 
Briefly, the column was pre-equilibrated by centrifugation for 1min at 13000rpm prior to applying 
the radiolabelled probe. The probe was thereafter stored at -20°C. 
 
2.2.7.3 DNA binding reaction and EMSA gel electrophoresis 
 
Binding reactions between radiolabelled probe and nuclear protein were set up as follows: 
 
Reagent Volume 
Nuclear extract (5μg) as determined by BCA assay 
Probe 1μl 
5x binding buffer (Promega) 2μl 
Buffer B (Section 2.1.5.6) to a total of 10μl 
 
 
For the supershift experiment, 1μl of concentrated ChIP grade antibody (Table 2.2) was incubated 
with the nuclear extract for 30min at RT prior to the probe binding reaction.  
The probe binding reaction was then left shaking at RT for 20min. DNA loading dye 5X Orange G 
(50μM Tris, 10μM EDTA, 65% (v/v) glycerol, 0.2% (w/v) Orange G) was added to the probe 
binding reaction to a final dilution of 1X. The samples were spun down and loaded on a 5% TBE 
gel (Section 2.1.5.6). The gel was run at 140V for 3-4h, dried for 1h on a Bio-Rad Model 583 gel 
dryer and exposed to Hyperfilm
TM
 overnight. The film was subsequently developed by an 
automatic film processor (AGFA Cruis-60, AGFA-Gaevert, Brendford, UK). 
 
2.2.8 TransAm assay 
 
TransAm (Active Motif) is an ELISA-based assay used for detection and quantification of 
transcription factor activation. The assay employs a 96-well plate pre-coated with a specific 
transcription site binding oligonucleotide. Nuclear extracts are applied onto the wells where 
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activated transcription factors (TF) bind to DNA. The presence of activated TF is then detected by 
a specific antibody. Addition of a secondary antibody conjugated to a horseradish peroxidise 
(HRP) provides sensitive colorimetric readout.  
Nuclear extract prepared as described previously (Section 2.2.7.1) was applied at 5μg per well in 
duplicate. The activation of cJun was measured by the detection of phospho-cJun binding to a 
TPA-responsive element (TRE). TPA-stimulated K-562 nuclear extract was used as a positive 
control. The assay was performed as described by the manufacturer (Active Motif) in the kit. 
Tetramethylbenzide dichloride (TMB), a substrate for HRP, was added to enable the colorimetric 
reaction to occur. To stop the reaction, 1 volume of 2M H2SO4 was applied, absorbance was read 
at 450nm wavelength using a Fluostar Omega (BMG Labtech, Aylesbury, UK) plate reader.  
 
2.2.9 Chromatin Immunoprecipitation  
 
Chromatin Immunoprecipitation (ChIP) is a genomics technique that allows the detection and 
quantification of transcription factor (TF) recruitment to specific motifs of genes or the 
characterisation of unknown TF target sequences. The advantage of using ChIP is that it illustrates 
the real events occurring in a living cell thus taking into account chromatin complexity. Following 
an experimental treatment, the cells are subjected to formaldehyde crosslinking that freezes any 
DNA- protein interactions. The cells are subsequently lysed and the nuclear fraction containing 
DNA-protein complexes is isolated and subjected to DNA fragmentation by sonication. DNA-
protein complexes are then immunoprecipitated by specific antibodies and intensively washed to 
remove any contaminants. The samples are subjected to reverse cross-linking and the released 
DNA is purified. Analysis of bound DNA can then be performed by PCR, microarray or 
sequencing (Collas 2010). For the purpose of the current project, the enrichment of the human 
TNF gene motifs to NFκB and AP-1 transcription factors was examined by RT-PCR. This 
protocol was optimised by Dr Tim Smallie. Antibodies used in these studies are listed in Table 2.2 
with the primers used for RT-PCR listed in Table 2.10. A schematic representing the major steps 
involved in ChIP is presented in Figure 2.5.  
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Figure 2.5 ChIP and various methods of analysis. Cells are first subjected to formaldehyde crosslinking 
and subsequently lysed. The nuclear fraction is extracted and the chromatin fragmented by sonication. 
Specific antibodies are added to immunoprecipitate DNA-protein complexes.  DNA is then purified and 
subjected to various types of analysis. The figure is adapted from (Collas 2010).  
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2.2.9.1 Preparation of nuclear extracts 
 
Human primary macrophages were cultured at 8 x 10
6
 cells per 10cm
2
 petri dish. Following 
experimental treatment, formaldehyde at a final concentration of 1% was added for 10min. The 
crosslinking reaction was stopped by addition of Tris pH 7.5 at a final concentration of 125mM. 
Cells were subsequently rinsed twice in ice cold PBS, scraped and then pelleted by centrifugation 
at 1000rpm at 4°C. 900μl cytoplasmic lysis buffer (Section 2.1.10.7) was added and the lysate was 
transferred to prechilled Eppendorf Lobind tubes (Cambridge, UK). After 5min on ice the sample 
was spun at 3000rpm for 5min. The nuclear pellet was resuspended in 600μl of nuclear lysis 
buffer and frozen at -80°C.  
 
2.2.9.2 Sonication 
 
Nuclear lysate was gradually thawed on ice. Chromatin was fragmented using sonication 
conditions optimised for human primary macrophages. A Sonics Vibra Cell
TM 
sonicator (Boston, 
USA) was set to 20% amplitude and a 12sec long pulse. 6 pulses were required to shear DNA into 
200-800 base pair long fragments, the resolution sufficient for different primer sets to exclusively 
span target sequence during RT-PCR.  
 
2.2.9.3 Immunoprecipitation 
 
600μl of previously sonicated sample was divided into 5 aliquots of 120μl each. An aliquot was 
first diluted 10 times with DB buffer (Section 2.1.10.7). To pre-clear 80μl of Protein G slurry was 
added to the diluted sample for 2h. Protein G slurry was prepared  by adding Salmon Sperm DNA 
(Invitrogen) into Protein G Sepharose (GE Healthcare) at a ratio of 1:10, subsequently incubated 
at 4°C for 2h and beads washed 3 times in WB. Protein G slurry was removed from the lysate by 
centrifugation at 3000rpm for 1min. The supernatant was transferred to a new tube and incubated 
with 2μg of IgG control antibody and then a further 60μl of Protein G slurry for 2h. Again 
following incubation Protein G was spun at 3000rpm for 1min and 2μg of a ChIP antibody 
directed against a transcription factor (Table 2.2) was added to the lysate. After an overnight 
incubation with rotation at 4°C, 60μl of Protein G slurry was added to the sample for a maximum 
of 25min. The sample was spun at 13000 rpm, 300μl of the supernatant was kept as an Input 
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fraction and the rest discarded. Protein G– antibody complexes were then washed 4 times in 500μl 
of WB and additional 3 times with TE buffer. After the final spin, TE buffer was aspirated and 
Protein G slurry was resuspended in 200μl of TE buffer containing 2%SDS for 15min to elute 
protein-DNA complexes. The sample was spun at 13000 rpm allowing the collection of the 
Protein G-free supernatant, which was thereafter used as a ChIP fraction. Both the Input (300μl) 
and ChIP fractions (200μl) were subjected to reverse crosslinking by incubation at 65°C 
overnight. 
 
2.2.9.4 DNA purification 
 
Purification of DNA from the Input and ChIP fractions was performed using the Qiaquick PCR 
purification kit (Qiagen). Briefly, 3 volumes of pre-warmed PB buffer were added to the fractions. 
The samples were then applied onto a column and spun at 13000 rpm for 1min. The columns were 
washed with PE buffer containing EtOH and additionally spun at 13000 rpm for 1min. DNA was 
eluted with 200μl (ChIP) or 300μl (Input) of pre-warmed dH20. 
 
2.2.9.5 Real-time PCR analysis 
 
DNA from both the Input and ChIP fractions was subjected to Real-time PCR. The reaction was 
set up as follows: 
 
Reagent Volume 
DNA 10μl 
SYBR Premix ExTaq (2x) Lonza (Takara) 10μl 
Forward Primer (Table 2.10) 0.04μl 
Reverse Primer (Table 2.10) 0.04μl 
 
Samples were run in triplicate on the Rotor-Gene 6 (Corbett Research UK Ltd., Cambridge, UK). 
The DNA was denaturated at 95°C for 5min, and then 40 cycles of 95°C for 10sec (denaturation), 
59°C for 30sec (annealing), and 78°C for 20sec (elongation) were performed. Relative
 
quantification of gene expression was determined using the comparative
 ΔCt method through the 
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RotorGene 6000 software. Briefly, threshold cycle (Ct) values of the Input were subtracted from 
ChIP Ct values. The outcome value was then raised to the power of 2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 
2.2.10 Bioinformatic analysis 
 
Genomic human Btk sequence (Ref: NG_009616.1) and human TNF sequence (Ref: 
NG_007462.1) were derived from www.ncbi.nlm.nih.gov. Multiple sequence alignments were 
performed using the ClustalW algorithm at www.ebi.ac.uk/clustalw. A search for transcription 
factor binding site was performed using the MatInspector software at www.genomatix.de.  
 
2.2.11 Statistical analysis 
 
Repeated measures ANOVA with Dunnett's post test or Student‟s t-test was performed using 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). A p value 
below 0.05 was considered significant. 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Results I 
110 
 
 
 
 
 
 
 
Chapter 3 - Results I 
Purification of Btk protein complexes – optimization of the 
Strep-tag system in human primary macrophages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Results I 
111 
 
3.1 Introduction 
 
Increasing evidence suggests that TLRs contribute to the development of autoimmune diseases as 
they sense both pathogens and necrotic cell derived self-antigens (reviewed in (Marshak-Rothstein 
2006)). Expression of TLRs 2, 3, 4, 7 and 8 has been shown to be elevated in the synovial tissue of 
rheumatoid arthritis (RA) patients in comparison to healthy donors (Radstake et al. 2004; Roelofs 
et al. 2005; Brentano et al. 2005a). A study carried out at the Kennedy Institute has shown that 
TLRs 2 and 4 are present and functional in synovial membrane cells derived from RA patients, 
and that their activation promotes inflammation in RA (Sacre et al. 2007a). The inhibition of 
endosomal TLRs by the antidepressant mianserine, on the other hand, decreased the production of 
TNF or IL-6 from RA synovial membrane cultures indicating that targeting endosomal TLR 
cascades could have therapeutic potential in RA (Sacre et al. 2008). TLR8 may be of the greatest 
importance as the inhibition of TLR8 by imiquimod in RA cultures resulted in the decreased 
spontaneous release of TNF (Sacre et al. 2008).  
 
Protein tyrosine kinases have been recognised as mediators in TLR signalling since the discovery 
that LPS stimulates protein tyrosine phosphorylation in macrophages (Weinstein et al. 1991). First 
reports on Btk showed that Xid mice do not develop collagen induced arthritis (CIA) (Jansson and 
Holmdahl 1993) and that TNF and IL-1β production from LPS-stimulated Xid macrophages is 
reduced (Mukhopadhyay et al. 2002). Similarly in humans, Btk is implicated in TLR4 signalling 
as monocytes derived from XLA patients exhibit reduced TNF production when treated with LPS 
(Horwood et al. 2003). In contrast, overexpression of Btk increases LPS-induced TNF production 
in human primary macrophages (Horwood et al. 2003). Since the initial describtion of the function 
of Btk in TLR4 signalling, the kinase has also been implicated in TLR2, 4 and 5 signalling 
pathways by regulating the production of TNF, but not IL-6, IL-8 or IL-10, in XLA-derived 
PBMCs and in AdBtk- infected human macrophages (Mukhopadhyay et al. 2002; Jefferies et al. 
2003; Horwood et al. 2006) Palmer, thesis). However, despite numerous reports focusing on the 
Btk-dependent regulatory mechanism of cytokine production in the TLR4 pathway, relatively little 
is known about the involvement of Btk in the signalling of endosomal TLRs. Using the yeast two-
hybrid system Jefferies and colleagues showed thatTLR8 interacts more strongly with Btk than the 
other TLRs examined (Jefferies et al. 2003). Functional studies by Sochorova (2007) 
demonstrated  that DCs obtained from XLA patients produced significantly less IL-6 and TNF 
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when treated with ssRNA (Sochorova et al. 2007). There are no reports implicating Tec kinases in 
endosomal TLR signalling in human macrophages.  
Btk has been shown to interact with multiple proteins involved in cell proliferation, 
differentiation, mobility and antigen recognition. These studies mainly focused on the early 
signalling events of the B cell receptor (BCR) pathway, and little work has been done to identify 
Btk downstream components in the TLR pathway (Figure 1.9). The approaches used for mapping 
the Btk signalling network included screening of cDNA expression libraries or co-
immunoprecipitation of epitope-tagged proteins. It has been shown that the SH1 and PH domains 
of Btk interact with the Fas protein which is a death receptor involved in apoptosis. Proteins which 
are implicated in cytoskeletal reorganisation and, therefore, antigen presentation and processing, 
such as WASP and Vav, also bind to Btk through its SH3 domain. The TH domain of Btk directly 
interacts with the members of the SFK (Fyn, Hck and Lyn) whereas its SH2 domain binds to BCR 
signalling proteins BLNK and BASH (reviewed in (Lindvall et al. 2005)). Using the yeast two-
hybrid system it has also been demonstrated that Btk interacts with TIR domains of TLRs 4, 6, 8 
and 9. Co-immunoprecipitation experiments also showed that Myd88 and IRAK-1 form 
complexes with Btk in HEK293 cells (Jefferies et al. 2003).  
 
The objectives of this study were to determine the role of Btk in TLR3 and TLR8 signalling 
pathways in human primary macrophages and to identify TLR-induced Btk-protein interactions 
that might be relevant to TLR signalling. To achieve the latter goal an affinity tag purification 
approach has been used (section 2.2.5). The tandem affinity purification (TAP) system was 
previously successfully used for the detection of Btk interaction with Dasatinib, a drug that blocks 
BCR-ABL kinases, in a chronic myelogenous leukemia cell line (Hantschel et al. 2007). Due to 
the therapeutic potential of Btk inhibition in lymphomas, autoimmune diseases and allergic 
inflammation (Di Paolo 2010; Honigberg et al. 2010), continuous and thorough investigation of 
the Btk signalling cascade is required. Novel binding partners of the kinase could also provide 
attractive drug targets whose inhibition may demonstrate greater selectivity and longer duration of 
action. 
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3.2 Results 
3.2.1 Overexpression of Btk results in increased TNF production in human macrophages 
 
Prior to the investigation of Btk protein interactions in endosomal TLR cascades, it was important 
to ascertain the involvement of Btk in TLR3 and TLR8 signalling. It was previously demonstrated 
in our laboratory that adenoviral overexpression of Btk increased TNF production in TLR1/2-, 
TLR2/6-, TLR5- and TLR4- challenged primary human macrophages ((Horwood et al. 2003; 
Horwood et al. 2006) Palmer, thesis). To determine the role of Btk in TLR3 and 8 signalling in 
primary human macrophages, the effect of Btk overexpression on cytokine production was 
examined. M-CSF-differentiated macrophages were infected with adenoviruses carrying either the 
wild type BTK gene (AdBtk) or an empty vector (AdCon); both viruses also expressed green 
fluorescent protein (GFP) to determine infection efficiency. Cells were allowed to express the 
protein for a minimum of 24h prior to stimulation with either R848, LPS or PolyI:C for 18h. LPS 
was used as a positive control as it has previously been shown that Btk overexpression super-
induces TNF with this TLR4 ligand (Horwood et al. 2006). The efficiency of infection was 
assessed by Western blotting. The level of GFP increased with increasing multiplicity of infection 
(moi) in both AdBtk and AdCon macrophages, whereas the expression of Btk was only increased 
in the presence of AdBtk at 10 to 150 moi (Figure 3.1). Subsequent analysis of cytokine 
production revealed that Btk overexpression significantly increased the production of TNF 
following either LPS or R848 stimulation (Figure 3.2). Btk had no effect on IL-6 secretion  
 
 
 
 
 
 
Figure 3.1 The efficiency of adenoviral gene transfer on human macrophages. Differentiated 
macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) were infected 
with Btk (AdBtk) or control adenovirus (AdCon) at moi ranging from 10 -150 for 24h (section 2.2.3.9). The 
protein level of Btk, GFP and GAPDH was assessed by SDS-PAGE and Western blotting.  
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in LPS-challenged cells, whereas in R848-challenged macrophages there was a significant 
increase in IL-6 with AdBtk at a moi of 150; illustrating the first major difference in the role of 
Btk between these two TLR cascades (Figure 3.2A/B). No consistent changes in the LPS- or 
R848-induced production of IL-10 could be observed when comparing AdBtk and the control 
adenovirus, indicating that the Btk effect may be specific to pro-inflammatory cytokines (Figure 
3.2C). Furthermore, Btk did not affect the secretion of IP-10, an IFN-inducible chemokine, 
following either TLR4 or TLR3 stimulation (Figure 3.2D). These data suggest that Btk signalling 
may be involved in the production of LPS-induced TNF and R848-induced TNF and IL-6, whilst 
Btk did not affect PolyI:C-induced IP-10 production.  As the TLR3 pathway seems to be 
unaffected by Btk overexpression, this suggests that Btk is not an intrinsic part of the TLR3 
signalling pathway.  
 
3.2.2 Human monocytic-like cell lines express TLRs 3, 4 and 8 at the protein level 
 
The identification of Btk binding proteins needs to be performed in a system that allows the 
purification of large protein yields. The accessibility of cell lines and their ability to grow in large 
volumes make them an ideal model for the optimization of the TAP method prior to employing 
TAP in human primary macrophages.  Btk is known to be expressed in all myeloid cells as well as 
monocytic cell lines such as THP-1 and U937 (Smith et al. 1994; Doyle et al. 2007). There are 
three monocytic cell lines available in the lab (Monomac-6, THP-1 and U937) and all three were 
tested for TLR3, 4 and 8 expression in comparison to human primary macrophages. Unstimulated 
cells were stained with FITC-conjugated monoclonal antibodies directed against TLRs 3, 4 and 8 
and analysed on the flow cytometer. THP-1 and U937 cell lines required treatment for 48h with 
phorbol-12-myristate-13-acetate (PMA) to induce differentiation into macrophage-like cells.  As 
shown in Figure 3.3, human monocytic cell lines, similarly to primary cells, expressed cell 
surface TLR4 and intracellular TLRs 3 and 8, as the mean fluorescent intensity of the peak 
representing FITC-TLR staining was higher than FITC-IgG control and unstained cells. The result 
obtained from this experiment indicated that the human monocytic cell lines retain the phenotype 
of primary macrophages as they express TLR 3, 4 and 8 protein. It was therefore possible that 
these cell lines also maintained the native TLR signalling machinery enabling them to respond to 
pathogens and other danger signals. This assumption, however, had to be confirmed in a 
functional assay.  
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Figure 3.2 Btk overexpression results in increased TNF production in human macrophages. 
Differentiated macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) 
were infected with adenovirus at moi ranging from 10 to 150 virus units per cell (section 2.2.3.9). Cells were 
incubated for 24hrs and stimulated with R848 (1µg/ml), LPS (10ng/ml) and PolyI:C (20μg/ml) for 18hrs. The 
cytokine concentration was assessed by ELISA (A-D). Control values (black bars) represent cells infected 
with adenovirus carrying empty vector. Btk overexpression values were normalised to the control at 
relevant moi. Unstimulated cells are not shown as values were undetectable. Cytokine levels are 
expressed as means of triplicate repeats +/- SEM. Results shown are representative of at least 3 donors. 
Statistical analysis: repeated measures ANOVA, *P<0.05,  ***P<0.001 as compared to stimulated AdCon. 
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Figure 3.3 Human cell lines express TLRs 3, 4 and 8 at the protein level. Human primary 
macrophages, Monomac-6, PMA-differentiated THP-1 and U937 cells (0.3x10
6
) were blocked in 5% human 
serum and stained with FITC-TLR3, 4 or 8. For internal staining (TLRs 3 and 8) cells were fixed (2% PFA) 
and permeabilised (0.1% saponin) before applying antibody (Section 2.2.6.1). As a control, an isotype 
matched relevant FITC-IgG was used. The graphs represent one of 3 independent experiments. 
TLR                        IgG control                         No staining 
%
 o
f 
M
a
x
 
FITC 
Chapter 3  Results I 
117 
 
3.2.3  Human monocytic-like cell lines produce cytokines in response to TLR4, but not TLR3 
and TLR8 stimulation 
 
The activity of TLRs 3, 4 and 8 in Monomac-6, THP-1 and U937 cells was examined by analysing 
the production of cytokines from stimulated cells.  Cell lines and human primary macrophages 
were stimulated with LPS, R848 or PolyI:C for 4, 6 and 24h. Supernatants were collected and 
analysed by ELISA for TNF, IL-6, IL-10 and IP-10 production. Human primary macrophages 
were used as a reference as they responded to all three TLR ligands (Figure 3.4A). Stimulation 
with LPS resulted in the highest TNF production at 4h followed by a decline at 24h, as opposed to 
the increasing secretion of IL-6, IL-10 and IP-10 over the time course followed. Activation with 
R848 yielded similar results to LPS stimulation with regard to IL-10 expression, however there 
was consistently higher production of TNF and IL-6. R848-initiated production of IP-10, a 
chemokine involved in the interferon pathway, differed between donors and was observed in 60% 
of cases.  Activation of the TLR3 pathway by PolyI:C resulted in the production of IP-10 at 24h.  
In contrast to primary macrophages, the human cell lines, Monomac-6, PMA-treated THP-1 and 
U937, all responded to LPS but failed to secrete cytokines upon R848 or PolyI:C stimulation 
(Figure 3.4/3.5). Pre-treatment of THP-1 and U937 with PMA is required for their differentiation 
into cells with functional characteristics of mature macrophages (Tsuchiya, 1982; Zarember and 
Godowski, 2002). Stimulation with LPS triggered the production of TNF, IL-6, IL-10 and IP-10 in 
Monomac-6 and U937/PMA cells. The expression profile of cytokine production in these two cell 
lines was similar to human macrophages, as TNF production peaked at 4h, whereas IL-6, IL-10 
and IP-10 production continued to increase to 24h. In contrast, the secretion of TNF, IL-6 and IP-
10 peaked at 24h in LPS-stimulated THP-1/PMA cells and the production of anti-inflammatory 
IL-10 was below the level of detection. In the absence of PMA, U937 and THP-1 cells did not 
produce pro-inflammatory cytokines in response to the TLRs 3, 4 and 8 stimulations (data not 
shown).  
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Figure 3.4 Cytokine expression pattern in human primary macrophages and Monomac-6 cells. M-
CSF-differentiated human primary macrophages (h. macrophages) (A) and Monomac-6 cells (B) were 
plated onto 96-well plates (1x10
5
 cells/well) and stimulated with 10ng/ml LPS, 1μg/ml R848 or 20μg/ml 
PolyI:C. Supernatants were collected after 4, 6 and 24h and analysed for TNF, IL-6, IL-10 and IP-10 by 
ELISA. 
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Figure 3.5 Cytokine expression pattern in PMA-treated U937 and THP-1 cells. PMA-differentiated 
U937 (A) and THP-1 cells (B) were plated onto 96-well plates (1x10
5
 cells/well) and stimulated with 
10ng/ml LPS, 1μg/ml R848 or 20μg/ml PolyI:C. Supernatants were collected after 4, 6 and 24h and 
analysed for TNF, IL-6, IL-10 and IP-10 by ELISA. 
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The data obtained in this section clearly demonstrate that there is a major discrepancy in TLR 
signalling between human primary macrophages and the cell lines examined. In contrast to 
primary macrophages, human cell lines did not respond to either R848 or PolyI:C stimulation. All 
the cell lines, on the other hand, secreted cytokines in response to LPS showing that only the 
TLR4 pathway is functional in those cells. These results were disappointing as the screened cell 
lines could not be used for the optimisation of the TAP system. Human primary macrophages 
were therefore used for the optimisation and purification of Btk complexes formed upon TLR8 
stimulation.  
 
3.2.4 Overview of the cloning strategy for the affinity tag purification system 
 
The importance of Btk in the immune system is increasingly recognised and many Btk inhibitors 
are currently in clinical trials for the treatment of lymphomas (Honigberg et al. 2010). The 
potential benefits of Btk blockade are also seen in the treatment of rheumatoid arthritis as 
chemical inhibition of Btk blocked BCR-dependent B cell proliferation and autoantibody 
production as well as FcγRIII-dependent TNF, IL-6 and IL-1 production in macrophages (Di 
Paolo 2010). The recognition of the Btk signalling network is critical for the development of more 
specific drugs and in predicting possible side effects of Btk inhibition. The results thus far have 
implicated Btk in the production of TNF, and possibly IL-6, in R848-challenged human 
macrophages (Figure 3.2). Activation of TLR8 appears to be central for TNF production in RA 
cultures (Sacre et al. 2008), therefore it is of importance to determine whether interference with 
Btk or its signalling partners would have therapeutic benefit. The affinity tag purification system 
(see section 2.2.5 for the full describtion) was used to identify the Btk binding partners upon 
TLR8 stimulation in primary human macrophages.  The protocol required cloning the gene of 
interest, human BTK, into a vector carrying either the N-terminal or C-terminal tag. Standard 
cloning techniques were used to incorporate BTK in-frame with the coding region of the tag. The 
ligated construct was then cloned into an adenoviral backbone and the activity of the construct was 
examined. The details of the cloning strategies are discussed below. 
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3.2.5  Cloning procedure for fusing Btk to the N- terminal full length tandem affinity 
purification tag. 
 
The tandem affinity purification (TAP) system involves the fusion of the tag comprising full 
length N-terminal Protein G and streptavidin binding protein (NTAP) to the target gene, human 
BTK. Protein G and streptavidin binding protein (SBP) are separated with the cleavage site for 
tobacco etch virus (TEV) protease. The advantage of using the double tag is that the bait is 
purified through two subsequent columns, IgG sepharose and streptavidin sepharose, which 
reduces contamination from non-specific binding. The cloning process required three major 
subcloning steps. Firstly, BTK was excised from the pMB.SP vector with blunt-end cutting AleI 
within the 5‟UTR and cohesive-end cutting BamHI within the 3‟UTR of BTK. In order to blunt 
end the 3‟ terminus, the Pfu polymerase, which adds nucleotides to the pre-existing 3‟ terminus, 
was used (Figure 3.6A). The blunt-ended Btk insert was then ligated into an EcoRV pre-linearised 
and shrimp alkaline phosphatase (SAP) pre-treated NTAP-SK16 vector (Figure 3.6B). To ensure 
the efficiency of the ligation and the correct orientation of BTK, plasmid DNA was isolated for a 
diagnostic digestion with XbaI. Clones with the plasmid digestion patterns consisting of 2kb and 
10kb size bands were sent for sequencing. The positive plasmid was then linearised with PmeI and 
subsequently co-transfected into BJ5183 E.coli together with the destination vector, pAdEasy-1 
(Figure 3.7). The BJ5183 strain is designed for homologous recombination as, unlike most 
common laboratory strains, it is recA proficient, which enables recombination with high 
efficiency. Recombinants were identified and confirmed by restriction analysis using PacI. Clones 
with a PacI digestion pattern consisting of a 4.5kb and a 41kb band were considered as positives. 
The plasmid was then transfected into replication deficient XL-1 blue E.coli, to amplify the 
recombined adenovirus plasmid. The purified plasmid was then linerised with PacI and 
transfected into the HEK293A cell line to initiate virus production (section 2.2.3.3). 
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Figure 3.6 Subcloning strategy for the manufacture of Btk-NTAP-SK16 from Btk-pMB.SP. Btk was 
extracted from pMB.SP using AleI and BamHI enzymes, and then gel purified and blunt ended by Pfu 
polymerase (section 2.2.2). Prior to the ligation with Btk, the NTAP-SK16 transfer vector underwent a 
digestion with EcoRV, it was SAP treated and subsequently gel purified using Wizard SV Gel and PCR 
Clean-Up system (Promega) (A). The ligation reaction was performed overnight at 4
o
C and the construct 
was transfected into the XL-1 cells. The positive clones were identified by XbaI digestion and sequenced 
(B). Red arrows indicate the predicted fragment sizes of a digested Btk-pMB.SP or NTAP-SK16 plasmids 
(A) or the positive clones digested with XbaI (B). 
 
 
Chapter 3  Results I 
123 
 
 
 
Figure 3.7 Subcloning strategy for the manufacture of Btk-NTAP-SK16-pAdEasy from Btk-NTAP-
SK16. PmeI- linearised Btk-NTAP-SK16 was gel purified using Wizard SV Gel and PCR Clean-Up system 
(Promega) and co-tranfected into the BJ5183 cells together with pAdEasy-1 (section 2.2.2/ 2.2.3). The 
recombinants were screened by using PacI diagnostic digestion for the predicted band sizes of 4.5kb and 
41kb (red arrows). The picture of pAdEasy was adapted from www.qbiogene.com. 
 
3.2.6 AdBtk-NTAP is unable to increase TNF protein production following LPS or R848 
stimulation 
 
The expression of Btk-NTAP was confirmed at the protein level, whereas the functionality of the 
construct was assessed by the ability of over-expressed Btk-NTAP to increase TNF production in 
human primary macrophages. Differentiated macrophages were infected overnight with either 
Btk-NTAP or control NTAP adenoviruses at mois ranging from 10 to 100 viral particles per cell. 
The cells were either lysed the next day for Western blotting analysis or stimulated with LPS or 
R848 for 18h for ELISA. Due to the large size of the NTAP tag (Figure 3.8A), Btk-NTAP 
(~95kDa) and endogenous Btk (78kDa) could be individually detected  by the anti-Btk antibody 
on a Western blot indicating that the Btk-NTAP adenoviral construct was efficiently expressed 
(Figure 3.8B). However, the expression of the construct at increasing moi failed to enhance TNF 
production upon LPS or R848 stimulation in human primary macrophages (Figure 3.8C). One of 
the possible reasons  why Btk fused to the N-terminal tag lost its activity could be the location of 
the tag. Since NTAP was attached to the PH domain of Btk, the tag could have disrupted the 
membrane localisation of the kinase and consequently affected the activity of Btk. Secondly, the 
size of the tag (136 amino acids in length) could have interfered with the native conformation of 
Btk leading to impaired protein interactions. 
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Figure 3.8 Btk-NTAP construct is expressed but does not increase LPS- and R848-induced 
production of TNF in human primary macrophages. Differentiated macrophages (obtained by 4 day 
culture of monocytes in M-CSF supplemented medium) were infected with AdBtk-NTAP (A), control 
AdNTAP at moi ranging from 10-100 virus particles per cell or left uninfected (NI) (section 2.2.3.9). Cells 
were incubated for 24h, lysed for Western blotting (B) or stimulated with LPS (10ng/ml) or R848 (1µg/ml) 
for 18h. TNF production was then analysed by ELISA (C). Cytokine levels are expressed as means of 
triplicate repeats +/- SEM. Results shown are representative of at least 3 donors. The analysis performed 
with Student’s t-test as compared to stimulated AdNTAP did not show any statistical significance.  
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3.2.7 Cloning procedure for fusing Btk to the C- terminal short length Strep- tag 
 
To overcome the limitations derived from the use of a large tag attached to the N-terminus of Btk, 
the C-terminus of Btk was next fused to the short (31 amino acids in length) tag comprising only 
streptavidin-binding protein (Strep-tag). Benefits presented by the utilisation of the One-Strep 
purification system would also include an easier and faster purification process and reduction in 
sample dilution. 
The cloning process of fusing Strep-tag to the C-terminus of Btk required four major sub-cloning 
steps. The first cloning step involved the addition of an SpeI restriction site upstream of the BTK 
transcriptional START codon simultaneously with the addition of a SalI site in place of the STOP 
codon by PCR. This approach allowed the isolation of BTK from its original vector followed by its 
insertion into the pCRII-TOPO vector (Figure 3.9A/B).  To monitor the efficiency of the ligation, 
plasmid DNA was isolated for diagnostic digestion with SpeI and SalI enzymes. Clones with 
plasmid digestion patterns consisting of 2kb and 3.9kb size bands were sent for sequencing. After 
excluding potential missense or frame shift mutations by sequencing, the chosen Btk-pCRII-
TOPO clone was used for further sub-cloning steps (Figure 3.10A/B); the insertion of BTK into a 
transfer vector CTAP-pBENT by using SpeI and SalI enzymes and the subsequent recombination 
of a positive Btk-CTAP-pBENT with an adenoviral destination vector pAd/PL-DEST
TM
. 
Recombinants were identified and confirmed by restriction analysis using BamHI. The purified 
plasmid was then digested with PacI and transfected into the HEK293 cell line to initiate virus 
production (section 2.2.3.3). 
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Figure 3.9 Subcloning strategy for the manufacture of Btk-pCRII-TOPO from Btk-pMB.SP. Btk was 
excised from pMB.SP in a PCR reaction by using a forward primer containing SpeI site (sequence in red) 
together with a reverse primer containing SalI site (sequence in red) (A). Transcription start and stop 
codons are shown in green, underlined. The purified Btk insert (B) was then ligated with pCRII®-TOPO 
overnight at 4
o
C and electroporated into the XL-1 cells. The positive clones were identified by SpeI/SalI or 
SalI digestion and sequenced (B). The insert was gel purified using Wizard SV Gel and PCR Clean-Up 
system (Promega) (section 2.2.2). Red arrows indicate the predicted size of the Btk insert (A) or fragment 
sizes of a digested plasmid obtained from a positive clone (B). The picture of pCRII®-TOPO was adapted 
from www.invitrogen.com. 
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Figure 3.10 Subcloning strategy for the manufacture of Btk-Strep-pBENT-DEST from Btk-Strep-
pBENT. The Btk insert was cut out from pCRII®-TOPO with SpeI and SalI, gel purified and ligated with 
Strep-pBENT by using SpeI and SalI sites present in the MCS. The construct was transfected into DH5α 
cells and the subclones were identified by the BglII digestion (A). An expression clone was generated by 
performing an LR recombination reaction between Btk-Strep-pBENT and a Gateway® destination vector 
(pAd/PL-DEST
TM
)(B). The construct was transfected into the Top10 cells and the positive recombinants 
were screened by using BamHI digestion (B) (section 2.2.2).  Red arrows indicate the predicted fragment 
sizes of a digested plasmid obtained from a positive clone. The picture of pAd/PL-DEST
TM
 was adapted 
from www.invitrogen.com. 
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3.2.8 AdBtk-Strep increases TNF production following LPS and R848 stimulation 
 
The expression of the Btk-Strep was confirmed at the protein level whereas the functionality of the 
construct was assessed by the ability of overexpressed Btk-Strep to increase TNF production in 
human primary macrophages. Differentiated macrophages were infected with either AdBtk-Strep 
or control AdStrep at mois ranging from 10 to 100 viral particles per cell. The cells were either 
lysed the next day for Western blotting or stimulated with LPS or R848 for 18h and supernatants 
taken for ELISA. As shown in Figure 3.11B, the infection with AdBtk-Strep resulted in moi-
dependent expression of Btk-Strep. The addition of the Strep tag to Btk increased the size of the 
kinase only by 31aa, thus the tagged and endogenous Btk were indistinguishable on a 10% SDS-
PAGE gel (Figure 3.11A). The expression of the Btk-Strep construct significantly increased the 
production of TNF at 50 moi upon either LPS or R848 stimulation in human primary macrophages 
demonstrating the functionality of the construct at low moi (Figure 3.11C).  The experiment 
provided data regarding the expression level of Btk-Strep as well as the minimum moi of AdBtk-
Strep that could be used in the subsequent optimisation of the purification process.  
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Figure 3.11 Overexpression of the Btk-Strep construct increases LPS- and R848-induced 
production of TNF in human primary macrophages. Differentiated macrophages (obtained by 4 day 
culture of monocytes in M-CSF supplemented medium) were infected with AdBtk-Strep (A), control AdStrep 
at moi ranging from 10-100 virus particles per cell or left uninfected (NI) (section 2.2.3.9). Cells were 
incubated for 24hrs, lysed for Western blotting (B) or stimulated with LPS (10ng/ml) or R848 (1µg/ml) for 
18hrs. TNF production was then analysed by ELISA (C). Cytokine levels are expressed as means of 
triplicate repeats +/- SEM. Results shown are representative of at least 3 donors. Statistical analysis: 
Student’s t-test, *P<0.05, as compared to stimulated AdStrep.  
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3.2.9 Btk-Strep is efficiently removed from the column by using competitive biotin elution 
 
The preceding experiment proved the functionality of Btk fused to the Strep tag by examining the 
effect of Btk-Strep overexpression on TNF production. To determine the activity of the Strep tag, 
the ability of the Btk-Strep (bait) to bind to a Strep-Tactin ® MacroPrep ® column and the 
subsequent elution of the bait was assessed. Differentiated macrophages were infected with either 
AdBtk-Strep or control AdStrep at 50 moi for overnight. They were allowed to express for another 
24h and subsequently lysed. The total cell extract (input), was passed over 200μl of the resin 
(column volume, V=200μl) and washed in 0.2% NP40 (50mM NaCl) followed by a competitive 
elution with biotin at 0.5V (section 2.2.5.1). The eluted fractions were then run on an SDS-PAGE 
gel and the bands were visualised by Western blot using an anti-Btk antibody. Figure 3.12A 
illustrates that Btk-Strep was eluted from the column in fractions E2-6 demonstrating that the 
Strep tag could bind to tactin. The increase in biotin volume to 1V resulted in more concentrated 
Btk-Strep in the elution fractions as only fractions E2-4 had to be collected (Figure 3.12B).  It has 
been previously shown in our laboratory that Btk constitutively interacts with the Src tyrosine 
kinase family member, Hck, and with a transcription factor involved in IL-10 signalling, Signal 
transducer and activator of transcription 3 (STAT3) (Maria Smolinska-Bylanska, thesis, Theresa 
Page, unpublished). This was shown by immunoprecipitating endogenous proteins from human 
primary macrophages by using either Hck or Btk antibodies. To examine if Btk-Strep attracted the 
same binding partners, and to prove the reproducibility and selectivity of the Strep system, the 
Western blot membrane from Figure 3.12B was subsequently probed with anti-STAT3 and anti-
Hck antibodies. As shown in Figure 3.12C, STAT3 and Hck were present in the flow through 
(FT) and wash (W) fractions compared to the input, indicating that the proteins did not bind to 
Btk-Strep which remained on the column. A small portion of STAT3 and Hck were, however, 
eluted with Btk-Strep in the fraction E2 demonstrating that the proteins interacted with Btk. One 
possible explanation for weak detection of the interacting proteins could be that binding of Btk-
Strep to the column represents a high affinity interaction, whereas most of the target interactions 
are going to be of lower affinity. Furthermore, Btk could only bind to a small fraction of STAT3 
and Hck which were also involved in other signalling cascades. Independnetly confirming the 
previous results, the Strep system proved to be functional and efficient in identifying Btk binding 
partners in human primary macrophages. It was then required to optimise purification conditions 
to obtain the optimal number of Btk- associated proteins and to limit the occurrence of false 
positives. 
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Figure 3.12 Efficient elution of Btk-Strep interacting with STAT3 and Hck from the Strep-Tactin ® 
MacroPrep ® column. 2.5x106 differentiated macrophages (obtained by 4 day culture of monocytes in M-
CSF supplemented medium) were infected with AdBtk-Strep or control AdStrep at moi 50 (section 2.2.3.9). 
After 36h the cells were washed twice with 1xPBS and lysed in 1ml of 1%NP40 lysis buffer. The lysates 
were applied onto 200ul of settled resin (V=1) (Input) and flow through (FT) was collected. Columns were 
washed with 0.2%NP40 (50mM NaCl) (W1-5), and eluted with biotin (E1-6) at V=0.5 (A) or V=1 (B) (section 
2.2.5.1). Fractions were concentrated on Vivaspin 500 columns. 90% of the elution and 10% of Input, FT 
and each wash fraction were run on a 4-20% SDS-PAGE gel. Western blotting analysis with anti-Btk (A,B), 
anti-STAT3 and anti-Hck (C) antibodies was performed.  
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3.2.10 Optimisation of Btk-Strep purification conditions 
3.2.10.1 Mild washing conditions of Btk-Strep complexes result in high background on a silver 
stained gel 
 
A protocol previously optimised by Dr David Saliba in our laboratory for the purification of IRF5-
Strep from HEK293 cells was initially used for the purification of Btk-Strep from human primary 
macrophages (Krausgruber et al. 2010). Differentiated macrophages were infected with either 
AdBtk-Strep or control AdStrep at 50 moi, overnight. The cells were allowed to express for 
another 24h and were subsequently stimulated for 5min with R848. This time point was chosen as 
a rapid Btk auto-activation under TLR4 stimulation has previously been demonstrated (Horwood 
et al. 2003) indicating that TLR-mediated Btk protein associations are likely to occur early. The 
present data also support this finding as Btk is tyrosine phosphorylated between 5-10min and auto-
activated within 5min following R848 challenge (Chapter 4, section 4.2.3). Total cell lysate was 
then applied onto Strep-Tactin ® MacroPrep ® column and washed with 0.2% NP40 buffer 
containing a low concentration of NaCl (50mM). Btk complexes were then eluted with 1V biotin 
in E2-4 elution fractions. To prevent high protein background in the lanes, only 9% of the wash 
fraction and 90% of E2-4 was run on the SDS-PAGE gradient gel which was subsequently 
subjected to silver staining, whereas only 1% of the input and 10% of E2-4 were subjected to 
Western blotting with the anti-Btk antibody. As visualised in Figure 3.13A, Btk-Strep was present 
in the input and in the elution volume of the AdBtk-Strep infected cells but absent in the W 
fraction. The utilisation of the mild washing conditions resulted in the formation of multiple bands 
on the silver stained gel both in AdBtk-Strep and AdStrep-infected cells (Figure 3.13B). Despite 
high background, which interfered with the detection of the differences between the treatments, 
one distinguishable band of the size of tagged Btk was detected in AdBtk-Strep infected cells. 
There were, however, no differences in the band patterns between R848-stimulated and 
unstimulated cells. More stringent washing conditions were required to eliminate non-specific 
protein contamination from the Btk complexes. 
Chapter 3  Results I 
133 
 
 
 
 
Figure 3.13 Low salt concentration in the wash buffer results in high background of Strep 
purification on a silver stained gel. 25mln differentiated macrophages (obtained by 4 day culture of 
monocytes in M-CSF supplemented medium) were infected with AdBtk-Strep or control AdStrep at moi 50 
(section 2.2.3.9). After 24h cells were stimulated with 1μg/ml R848 for 5min, washed twice with 1xPBS and 
lysed in 1ml of 1%NP40 lysis buffer. The lysates were applied onto Strep-Tactin ® MacroPrep ® column 
and washed with 0.2%NP40 (50mM NaCl). Btk-Strep complexes were eluted with biotin at V=1 in elution 
fractions E2-4 (section 2.2.5.1). Fractions were concentrated on Vivaspin 500 columns. 1% of the input (I) 
and the last wash fraction (W) together with 10% of E2-4 were analysed by Western blotting with the anti-
Btk antibody (A). 10% of the last wash fraction (W) and 90% of E2-4 were applied onto 4-20% SDS-PAGE 
gel which was subsequently subjected to silver staining (B). Two distinguishable bands of the size of 
tagged Btk (black arrows) were detected in AdBtk-Strep infected cells. 
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3.2.10.2 The application of Formaldehyde and  more stringent washing conditions of Btk-Strep 
complexes results in the formation of undistinguishable bands on the silver stained gel 
 
The use of strong washing conditions can result in the loss of actual binding partners from the bait. 
This is because many interactions are transient in nature and the proteins are expressed at low 
levels. To preserve these weak and temporary interactions, cross-linking reagents are commonly 
used for mapping protein-protein interactions through affinity purification (Vasilescu and Figeys 
2006). Formaldehyde is a reversible cross-linker of proteins and DNA. The reagent binds closely 
interacting molecules by fixing amino groups of one molecule with other nearby nitrogen atoms 
through –CH2- linkage and thus was chosen for the current protocol.  Differentiated macrophages 
were infected with either AdBtk-Strep or control AdStrep and stimulated for 15min with R848. As 
Btk appears to be activated within 5-10min following R848 challenge (Chapter 4, section 4.2.3) it 
is likely that the major protein-protein interaction events occur at later time points justifying the 
change in R848 stimulation time from 5 to 15min as compared to the previous section. Prior to 
lysis, the cells were subjected to 1% formaldehyde treatment. Nuclear and cytoplasmic fractions 
were isolated to further clarify the lysate and reduce the appearance of multiple bands. DNase was 
added to the lysis buffers to eliminate the formation of protein-DNA complexes. The lysates were 
then applied onto Strep-Tactin ® MacroPrep ® column and washed with 0.2% NP40 buffer 
containing a higher concentration (150mM) of NaCl than in previous experiments. Eluted 
fractions were subjected to the reverse cross-linking reaction by heating overnight and resolved on 
a SDS-PAGE gel. Btk-Strep was present in both cytoplasmic and nuclear elution fractions of the 
AdBtk-Strep infected cells (Figure 3.14A). The use of more stringent washing conditions resulted 
in the reduction of band accumulation in the cytoplasmic fraction of the control samples (Figure 
3.14B). Unfortunately, the resolution of the bands did not improve with the formaldehyde pre-
treatment. On the contrary, the bands in the control and Btk-Strep lanes were smeary and 
consequently indecipherable, which hindered the detection of a distinguishable Btk-Strep band.  
These results indicate that either the utilization of the formaldehyde pre-treatment or the reverse 
cross-linking reaction conditions used are unable to obtain highly distinguishable bands on a 
silver-stained gel. This could be a result of high presence of contaminants that were also non-
specifically cross-linked to Btk by the formaldehyde treatment. The use of an increased NaCl 
concentration in the washing buffer did, however, reduce the high background of the control 
samples and was therefore used for the further optimization steps.  
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Figure 3.14 Formaldehyde treatment of macrophages together with high salt concentration in the 
wash buffer results in the formation of smears on a silver stained gel. 25mln differentiated 
macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) were infected 
with AdBtk-Strep or control AdStrep at moi 50 (section 2.2.3.9). After 24h cells were stimulated with 1μg/ml 
R848 for 15min, fixed in 1% formaldehyde for 10min, washed twice with 1xPBS and lysed. Nuclear and 
cytoplasmic lysates were applied onto Strep-Tactin ® MacroPrep ® column and washed with 0.2%NP40 
(150mM NaCl). Btk-Strep complexes were eluted with biotin at V=1 in elution fractions E2-4 (section 
2.2.5.1). Fractions were concentrated on Vivaspin 500 columns. 90% of E2-4 were applied onto a 4-20% 
SDS-PAGE gel which was subsequently subjected to silver staining (A). 1% of the input (I) and the last 
wash fraction (W) together with 10% of E2-4 were analysed by Western blotting with the anti-Btk antibody 
(B).  
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3.2.10.3 Avidin and DNAse pre-treatment of the lysates together with stringent washing 
conditions greatly improve the clarity of the bands on a silver stained gel 
 
One explanation for the high background on a gel could be the contamination of the Strep-Tactin 
® MacroPrep ® column with biotinylated proteins derived from the cells and present in the RPMI 
medium (Moore et al. 1967). Biotin, or Vitamin H, fulfils many crucial roles in a cell as it is 
necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino 
acids. It is a cofactor for CO2 transfer and usually attaches to its substrate via an amide bond to the 
ε-amino group of a lysine residue. These biotinylated proteins non-specifically bind to the column 
and are subsequently eluted with the bait (www.iba-go.com). To remove such potential 
contaminants avidin, which has a high affinity to biotin, was used to purify the lysates. Thus, 
differentiated macrophages were infected with either AdBtk-Strep or control AdStrep and 
stimulated for 15min with R848. DNAse and avidin were added to the nuclear and cytoplasmic 
lysis buffers and subsequently spun down to remove avidin-biotin complexes in the pellet. The 
supernatants were then applied onto a Strep-Tactin ® MacroPrep ® column and washed with 
0.2% NP40 buffer containing 150mM NaCl. The new purification conditions resulted in the 
formation of distinguishable bands of the Btk-Strep lanes and low background in the control lanes 
on a silver stained gel (Figure 3.15). There were, however, no differences in the band patterns 
derived from unstimulated and R848-stimulated cells. Nevertheless, all the bands were extracted 
from the gel and submitted for LC-ESI-MS/MS analysis in collaboration with Dr Robin Wait 
(K.I.R).  
The data generated from MS analysis revealed that Btk was present in 50% of the bands ranging 
from 40kDa to 140kDa thus masking the detection of additional proteins. The highest 
accumulation of Btk on the gel is shown with arrows in Figure 3.15. The identification of the 
peptide spectra with Mascot also recognised the presence of AP-3 adaptor-like complex 
components which are implicated in intracellular biosynthesis and transport, as well as the 
presence of heat shock protein (Hsp) 90. The identity of the remaining bands could not be 
determined due to the proportionally high presence of trypsin used for MS sample digestion and 
peptides of foreign origin (Figure 3.16).  
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Figure 3.15 Pre-cleaning of the lysates with avidin and DNaze together with high salt concentration 
in the wash buffer results in low background on a silver stain gel. 2.5 x 10
6 differentiated 
macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) were infected 
with AdBtk-Strep or control AdStrep at moi 50 (section 2.2.3.9). After 24h cells were stimulated with 1μg/ml 
R848 for 15min, washed twice with 1xPBS and lysed. Nuclear and cytoplasmic lysates were treated with 
100μg/ml avidin and 1μg/ml DNaze , the insoluble pellets were spun down whereas the supernatants were 
applied onto Strep-Tactin ® MacroPrep ® column and washed with 0.2%NP40 (150mM NaCl). Btk-Strep 
complexes were eluted with biotin at V=1 in elution fractions E2-4 (section 2.2.5.1). Fractions were 
concentrated on Vivaspin 500 columns. 90% of fractions E2-4 were analysed by 4-20% SDS-PAGE gel 
which was subsequently subjected to silver staining. All the bands were cut out of the gel and analysed by 
MS by Dr Robin Wait.  
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Figure 3.16 Screen print from the Scaffold analysis of the hits obtained from Btk-Strep purification. 
14 proteins were identified by Mascot/Scaffold analysis of the peptide spectra. The hits included Btk, which 
was a predominant protein; trypsin, which was used for the protein digestion; the members of AP-3 
complex and Hsp90. Hits with a probability over 95% are shown in green, whereas hits with a probability 
between 50-95% are shown in yellow and orange. Hits below 50% probability are not shown as they were 
not considered valid.  
 
 
 
3.2.10.4 The prolongation of the R848 stimulation time to 30min does not lead to the 
identification of novel Btk binding partners.  
 
Btk is known to be activated by TLRs as early as 5min post ligand binding in human primary 
macrophages (Horwood et al. 2003; Horwood et al. 2006). At the same time it was suggested that 
Btk is implicated in early stages of TLR signalling, and in overexpression systems in HEK293 and 
THP-1 cells it has been shown to constitutively interact with Myd88, IRAK1 and the TIR domains 
of TLRs 4, 6, 8 and 9. It has also been shown to phosphorylate Mal in response to LPS (Jefferies 
et al. 2003; Gray et al. 2006). The downstream components of Btk-mediated TLR-signalling 
remain uncharacterised.  
The experiments above (section 3.2.10.3) did not detect differences in band patterns between 
unstimulated and 15min-stimulated macrophages.  Using the same purification protocol as in 
Chapter 3  Results I 
139 
 
Section 3.2.10.3, the differences in the band patterns were further examined in unstimulated and 
30min stimulated macrophages. As demonstrated in Figure 3.17, prolonging the R848 stimulation 
time of AdBtk-Strep-infected cells did not result in a change of band pattern as compared to 
unstimulated cells.  Nevertheless, all the bands were extracted from the gel and analysed by LC-
ESI-MS/MS and a subsequent Mascot search engine by Dr Robin Wait. The Btk-interacting 
proteins identified by MS included components of the transcription machinery (pre-mRNA-
splicing factor 3b (SF3B4)), translation machinery (eukaryotic translation elongation factor 1 
alpha 1 (EEF1A)), and also proteins involved in intracellular biosynthesis and transport (AP3), 
calcium-dependent exocytosis (annexin A2), and cytoskeleton reorganisation (tubulin, actin, 
strumpellin (KIAA0196)) (Figure 3.18). Many of these interactions were non-specific as EEF1A, 
actin, annexin2a and GAPDH were also present in the control AdStrep lanes. The others, SF3B4, 
AP-3 or KIAA0196 have not previously been linked to TLR signalling.  
The molecular chaperone, Hsp90, was once again detected in the complex and appears to be 
constitutively bound to Btk.  In addition, the co-chaperone of Hsp90, cell division cycle protein 37 
(Cdc37), was also detected. The Hsp90-Cdc37 complex has been previously shown to be crucial 
for TLR signalling as the pharmacological inhibition of Hsp90 led to degradation of IRAK1, and 
as a consequence, to the reduction of LPS-induced cytokine production. The overexpression of 
Cdc37, on the other hand, led to enhanced IRAK1 activation (De Nardo et al. 2005). The results 
suggest that Hsp90 is involved in Btk signalling but the association of Hsp90 with Btk is not TLR-
dependent, since it was present both prior to and post R848 stimulation.  
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Figure 3.17 Lack of differences in the Btk-Strep band patterns between unstimulated and 30min- 
stimulated human primary macrophages. Differentiated macrophages (obtained by 4 day culture of 
monocytes in M-CSF supplemented medium) at 25 x 10
6
 cells per treatment were infected with AdBtk-
Strep or control AdStrep at moi 50 (section 2.2.3.9). After 24h cells were stimulated with 1μg/ml R848 for 
30min, washed twice with 1xPBS and lysed. Nuclear and cytoplasmic lysates were treated with 100μg/ml 
avidin and 1μg/ml DNaze. The insoluble pellets were spun down whereas the supernatants were applied 
onto Strep-Tactin ® MacroPrep ® column and washed with 0.2%NP40 (150mM NaCl). Btk-Strep 
complexes were eluted with biotin at V=1 in elution fractions E2-4 (section 2.2.5.1). Fractions were 
concentrated on Vivaspin 500 columns. 90% of fractions E2-4 were applied onto a 4-20% SDS-PAGE gel 
that was subsequently subjected to silver staining. All the bands were cut out of the gel and analysed by 
MS by Dr Robin Wait.  
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Figure 3.18 Screen print from the Scaffold analysis of the hits obtained from Btk-Strep purification. 
20 proteins were identified by Mascot/Scaffold analysis of the peptide spectra. The hits included Btk, which 
was a predominant protein; trypsin which was used for the protein digestion, the members of AP-3 
complex; SF3B4, which is a splicing factor; annexin A2, which is involved in exocytosis and Hsp90 were 
identified. Hits with a probability over 95% are shown in green, whereas hits with a probability between 50-
95% are shown in yellow and orange. Hits below 50% probability are not shown as they were not 
considered as valid. The numbers of unique peptides on which the identification was based are displayed 
in each colored patch. 
 
 
3.2.11 Hsp90 is constitutively bound to Btk and regulates the production of TNF, IL-6 and IL-
10 upon TLR4 and 8 stimulation. 
 
The formation of the Hsp90-Btk complexes was further validated by Western blotting. 
Differentiated macrophages previously infected with either AdBtk-Strep or AdStrep were 
stimulated with R848 for 30min and lysed. Btk-Strep complexes were purified as discussed 
previously (section 3.2.10.3). The eluted fractions were run on an SDS-PAGE gel. Western 
blotting analysis confirmed that Hsp90 was specifically and constitutively bound to Btk and that 
this interaction remained unchanged upon R848 stimulation (Figure 3.19A).  
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To determine whether Hsp90 has a role in TLR signalling, the effect of Hsp90 inhibition by 
geldanamycin (GA) on cytokine production was assessed by ELISA. GA is an inhibitor of Hsp90 
which has been widely used for determination of Hsp90 function (De Nardo et al. 2005).  In the 
current system, GA dose-dependently decreased the production of TNF, IL-6 and IL-10 from 
LPS- and R848- stimulated human primary macrophages without affecting the viability of the 
cells (Figure 3.19B-D). These results suggest that even though Hsp90 interactions with Btk are 
not dependent on TLR stimulation, the chaperone is important for the production of cytokines 
induced by TLR signalling. The data also demonstrate that Hsp90 function is not specific to Btk as 
GA blocked the production of all three cytokines as opposed to Btk which appears to only regulate 
LPS-induced TNF or R848-induced TNF and IL-6 (section 3.2.1).  
 
Hsp90, a molecular chaperone that protects the function of its client proteins, is the most abundant 
protein expressed in cells (Csermely et al. 1998). The molecule maintains the conformational 
integrity of its clients and guards them against misfolding during exposure to heat shock and other 
stress (Tsan and Gao 2009). Hsp90 interacts with numerous molecules involved in TLR 
signalling. This explains why the use of GA, which leads to destabilisation and degradation of 
Hsp90 client proteins, results in the inhibition of cytokine production. For instance, Hsp90 has 
been involved in the activation of NFκB by directly binding to IKK and in the activation of 
MAPK (Broemer et al. 2004; De Nardo et al. 2005). The inhibition of Hsp90 by a small molecular 
inhibitor decreased the activation of JNK and ERK in RA synovial fibroblasts as well as 
inflammation and pannus formation in RA animal models providing foundation for the use of 
Hsp90 inhibitors in the future clinical trials for the treatment of RA (Rice et al. 2008). Hsp90 has 
been also shown to interact with another member of the PTK family, Src (Koga et al. 2006).  
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Figure 3.19 The inhibition of Hsp90 which is consistently bound to Btk decreases the cytokine 
production upon TLR4 and 8 stimulation. 1 x 10
6 differentiated macrophages (obtained by 4 day culture 
of monocytes in M-CSF supplemented medium) were infected with AdBtk-Strep or control AdStrep at moi 
50 (section 2.2.3.9). After 24h cells were stimulated with 1μg/ml R848 for 30min, washed twice with 1xPBS 
and lysed. Total lysates were treated with 100μg/ml avidin and 1μg/ml DNaze. The insoluble pellets were 
spun down whereas the supernatants were applied onto Strep-Tactin ® MacroPrep ® column and washed 
with 0.2%NP40 (150mM NaCl). Btk-Strep complexes were eluted with biotin at V=1 in elution fractions E2-
4 (section 2.2.5.1). Fractions were concentrated on Vivaspin 500 columns and run on a 4-20% SDS-PAGE 
gel. Anti-Btk and anti-Hsp90 anybodies were used for Western blotting (A). Differentiated macrophages 
plated in 96-well plates were pre-treated for 1h with 0.005- 5μM  geldanamycin and stimulated with 10ng/ml 
LPS or 1μg/ml R848 for 8h. The toxicity of geldanamycin was assessed by the MTT assay (B). 
Supernatants were collected and analysed for TNF, IL-6 and IL-10 by ELISA (C,D). 
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3.3 Discussion 
 
This study has shown that Btk is required for TLR8 but not TLR3 signalling in human primary 
macrophages as the overexpression of the kinase increases R848-induced TNF production but not 
PolyI:C-induced IP-10 production. However, the approaches used to dissect Btk signalling 
downstream of TLR8 activation were not successful. Firstly, the monocyte-like cell lines, which 
are broadly used for determining the signalling mechanism of pattern recognition receptors, lack 
functional TLR3 and 8. Secondly, although data obtained from the use of optimised One-Strep 
system has revealed that Btk constitutively interacts with chaperone Hsp90, this interaction was 
not exclusive to Btk and was not dependent on TLR8 activation.  
Human monocyte-like cell lines (THP-1/ PMA, U937/ PMA and Monomac-6), which were 
intended to be used for the optimisation of the Btk affinity purification system, failed to induce 
cytokine production upon TLR3 and TLR8 stimulation (Figure 3.4/3.5). The majority of studies 
regarding the role of Btk in TLR signalling have been performed on cell lines that frequently are 
unable to express TLRs or in which the functionality of TLRs has not been previously validated 
(Jefferies et al. 2003; Doyle et al. 2005; Gray et al. 2006; Doyle et al. 2007). For instance, TLR-
lacking HEK293 cells transfected with tagged versions of both Btk and Myd88 or Mal were used 
to detect the interactions between the kinase and the adaptor molecules (Jefferies et al. 2003). The 
studies performed in THP-1 cells focused mainly on analysing TLR8 or TLR9-activated signalling 
pathways and did not refer to the ability of TLR to induce cytokine expression (Doyle et al. 2007).  
Interestingly, potential defects in TLR signalling in the examined cell lines did not affect the 
TLR4 pathway (Figure 3.4/3.5) which is known to be the most complex TLR pathway as it 
utilizes 4 adaptor molecules; TRIF, TRAM, Mal and Myd88, as compared to TLR8 which uses 
only Myd88 and TLR3 which uses only TRIF (Kawai and Akira 2010).  A hypothetical defect in 
one of the adaptor molecules could be compensated by an alternative adaptor molecule allowing 
LPS signalling to function normally. Although THP-1 cells were unable to produce cytokines 
upon TLR8 activation in this study, the stimulation of undifferentiated THP-1 cells with R848 has 
been previously shown to effectively induce the expression of the CD1d molecule that in turn 
activated a subset of T cells (Salio et al. 2007). An extensive literature search did not identify any 
reports that would address the functionality of TLR3 and 8 in terms of cytokine production in 
THP-1, U937 or Monomac-6 cells.  
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Due to the differences in cytokine production between cell lines and primary macrophages, the 
investigation of Btk interacting partners was undertaken in primary cells. The initial fusion of Btk 
to a large N-terminal NTAP tag proved unsuccessful as AdBtk-NTAP was unable to increase 
LPS- or R848- induced production of TNF in human primary macrophages (Figure 3.8) as 
compared to wild type AdBtk (Figure 3.2). The underlying reason could be the large size of the 
tag (136aa) or its N-terminal location which could interfere with the PH domain binding to the 
membrane. The TAP tag attached to the C-terminus of Btk was previously successfully applied for 
the identification of Btk interaction with the inhibitor Dasatinib (Hantschel et al. 2007). Therefore 
it was unlikely that tag size precluded Btk from inducing TNF, rather the location of the TAP tag 
interfered with the activation and function of the kinase. The second attempt involved the fusion 
of a smaller Strep-tag (31aa) to the C-terminus of Btk where the kinase domain is located. 
Fortunately, AdBtk-Strep proved to be efficient in the induction of cytokine production (Figure 
3.11) and therefore was used for the subsequent purification experiments. 
 
The use of the One-Strep system has been shown to result in efficient purification with good 
yields as compared to other affinity tags such as HIS, calmodulin-binding peptide (CBP) or FLAG 
(Lichty et al. 2005). The initial purification protocol has been previously used for the purification 
of the transcription factor IRF5 from fixed HEK293 cells (Krausgruber et al. 2010). The 
purification of predominantly cytoplasmic Btk from unfixed human primary macrophages 
required modification of the protocol. The optimisation of the One-Strep system included the 
following steps: determination of the minimum cell number required, modification of the lysis and 
washing conditions as well as the adjustment of elution volumes. The final established protocol 
engaged the use of minimum 2.5 x 10
7
 human primary macrophages per treatment, the use of 
avidin and DNase in a lysis buffer as well as the use of a wash buffer containing 150mM NaCl. 
Avidin, which has a high affinity to biotin was used to deplete biotinylated contaminants from the 
lysates, DNase to minimise the formation of protein-DNA complexes and as a consequence the 
purification of indirect interacting partners, and high salt to increase the stringency of the wash. 
Despite the visible improvements in the background level on a silver stained gel (Figure 3.15/3.17 
as compared to Figure 3.13/3.14), there were no differences in band patterns between R848-
stimulated and unstimulated cells. This suggests that the washing conditions were not stringent 
enough to remove non-specific bands. Potentially, if cell number was increased together with 
more stringent washing conditions to remove contaminants, subtle changes in the band patterns 
may be identified. The average elutriation of PBMCs obtained from 10ml blood cones and 
subsequent differentiation of human primary monocytes allows the acquisition of on average 1-2 x 
Chapter 3  Results I 
146 
 
10
8
 macrophages in total which were all used for one One-Strep experiment. The increase of cell 
number would require the pooling of the donors together, which may mask donor-dependent 
differences. Ideally, macrophages at the same culture time should be used for the experiment as 
One-Strep purification has to be performed on a day of lysis to retain protein interaction. 
 
Analysis by MS demonstrated that Btk was present in the majority of the bands impeding the 
detection of interacting proteins (Figure 3.15/3.17). The problem could be removed by decreasing 
the expression level of Btk or by modifying the elution step. The expression of a tagged protein 
must, however, remain at a level high enough to compete over the endogenous Btk which also 
interacts with binding partners. Alternatively, to eliminate Btk in the final fraction, the biotin 
elution step could be avoided.  Btk complex chemically fixed prior to the lysis stage could 
undergo reverse-cross linking on a column allowing the Btk binding partners but not Btk itself to 
be released from the column. The reverse cross-linking fraction could then be analysed by MS to 
allow the identification of more binding partners undisturbed by the presence of Btk.  
 
Specific proteins interacting with Btk included a member of the WASH complex involved in 
cytoskeletal reorganisation, strumpellin, the subunits of AP3 complex known to be involved in 
intracellular biosynthesis and transport, transcription splicing factor SF3B4, and components of a 
chaperone complex, Cdc37 and Hsp90 (www.genecards.org). Btk has been long known to have a 
profound effect on cytoskeletal reorganisation and cell motility therefore the identification of 
strumpellin in the Btk complex was not surprising. The kinase interacts with F-actin through its 
PH domain, WASP and Vav through its SH3 domain (Lindvall et al. 2005). The function of Btk in 
cell motility is critical as B cells derived from Xid mice or XLA patients lose integrin-mediated 
cell adhesion and migration abilities (Spaargaren et al. 2003).  Moreover, osteoclasts derived from 
XLA patients also exhibit impaired resorption activity known to be dependent on F-actin ring 
formation (Danks et al. 2011). On the other hand, Btk has not been previously implicated in 
mRNA maturation thus the detection of SF3B4 in the Btk complex was novel. The kinase has, 
however, been previously linked to transcription initiation as it interacts with and directly activates 
a transcription factor TFII-I (Novina et al. 1999), whereas another member of Tec family kinases, 
Bmx, has been demonstrated to tyrosine phosphorylate STATs 1, 3 and 5 (Tsai et al. 2000). 
 
Both Hsp90 and its co-chaperone Cdc37 were found in the Btk complex. Hsp90 has a crucial role 
in cancer development and there are now 13 Hsp90 inhibitors in clinical trials for different types 
of malignancy (Kim et al. 2009). The presence of Hsp90 was not stimulation-dependent as the 
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chaperone was constitutively bound to Btk. In order to determine the role of Hsp90 in the TLR8 
pathway, attempts to downregulate Hsp90 with siRNA directed against Hsp90α and β were 
undertaken. However, as this approach did not prove successful (data not shown), potentially due 
to the high abundance of the protein in the cells, a drug called geldanamycin was used to inhibit 
Hsp90. Geldanamycin, a natural occurring antitumor antibiotic, competitively binds the substrate 
pocket of Hsp90 blocking the chaperone function and resulting in the degradation of its client 
proteins (Stebbins et al. 1997). As Hsp90 has been shown to be required for the stability or 
activation of the TLR pathway components including IKK, TAK1, Lck or Src (Broemer et al. 
2004; Giannini and Bijlmakers 2004; Koga et al. 2006; Liu et al. 2008), it is not unexpected that 
the inhibition of Hsp90 led to decreased production of TNF, IL-6 or IL-10 upon TLR4 or 8 
stimulation. Previous research  has demonstrated that Btk did not affect IL-6 production from 
LPS-challenged human primary macrophages (Horwood et al. 2003), suggesting that the observed 
effect of Hsp90 inhibition on the cytokine secretion was not restricted to Btk alone.  
 
In summary, the identification of Btk interacting partners downstream of TLR8 signalling did not 
reveal any molecules exclusively binding to Btk after R848 stimulation. Instead, the identification 
of Hsp90 as being constitutively bound to Btk revealed a complex protein interaction mechanism 
where interruption affects the production of cytokines. Furthermore, Btk overexpression was able 
to super-induce cytokine production upon TLR8 stimulation. Therefore the mechanism of action 
needs to be investigated further. 
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4.1 Introduction 
 
 
The data obtained from Btk overexpression studies suggest that the kinase may be differentially 
involved in TLR4 and TLR8 signalling due to the fact that Btk regulated LPS-induced TNF 
production as compared to R848-induced TNF and possibly IL-6 production. At the same time, 
Btk overexpression did not change the level of IP-10 production from PolyI:C-stimulated 
macrophages suggesting that the kinase is not involved in TLR3 signalling. These observations 
have to be, however, confirmed in another experimental setting. The TLR4 and TLR8 signalling 
cascades differ fundamentally in many aspects. First of all, TLR4 has been designed to detect 
bacterial and viral proteins whereas TLR8 responds to viral ssRNA or synthetic imidazoquinoline 
resiquimod (R848) stimulation. Secondly, TLR4 is primarily localised on the cell membrane as 
opposed to endosomal TLR8. Furthermore, the TLR4 pathway appears to be far more complex as 
it utilises four adaptor molecules in contrast to TLR8 which employs only Myd88. The complexity 
of TLR signalling network may explain why Btk does not regulate IL-6 production as other Tec 
family members can fulfil this role instead. For instance, Bmx and Tec kinases can be activated in 
response to TLR signalling (Horwood et al. 2003; Palmer et al. 2008). Recent studies in primary 
human macrophages and rheumatoid synovial fibroblasts (RASFs) have also demonstrated that 
Bmx can mediate TLR4 signalling by affecting IL-6 production (Palmer et al. 2008; Palmer et al. 
2008).  
TNF is believed to be a pivotal cytokine that controls the production of both pro-inflammatory and 
anti-inflammatory cytokines (reviewed in (Feldmann 2002)). Due to its central role in the 
pathology of RA and many other autoimmune and inflammatory disorders, the regulation of the 
TNF gene has been widely studied. Currently, there are two major theories describing the 
mechanism through which Btk could control TNF production. The first one suggests a role for Btk 
in transcription. Studies performed on Xid macrophages and the THP-1 cell lines have 
demonstrated that LPS-activated Btk engages the NFκB pathway by promoting p65 subunit 
transactivation and nuclear localisation (Jefferies et al. 2003; Doyle et al. 2005).  However, 
experiments performed in our laboratory showed that Btk does not affect an early expression of 
TNF indicating that the kinase is more likely to be involved in the post-transcriptional than 
transcriptional control. In particular, XLA-derived PBMCs or AdBtk-infected human 
macrophages did not exhibit impaired or enhanced, respectively, expression of LPS-induced TNF 
at an early 4h time-point as compared to the 18h time-point. Later reports have demonstrated no 
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decrease in IκBα degradation in XLA-derived PBMCs and confirmed the positive effect of AdBtk 
on the stability of TNF mRNA as shown by Actinomycin D chase experiments on LPS-challenged 
human primary macrophages (Horwood et al. 2003; Horwood et al. 2006). The direct role of Btk 
in TNF transcription, however, has never been examined, therefore it cannot be excluded that both 
transcriptional and post-transcriptional mechanisms are implicated.   
Work presented in this chapter focuses on the role of Btk in the production of TNF, IL-6, IL-10 
and IP-10 following stimulation with the TLR4 ligand, LPS, and the TLR8 synthetic ligand, R848 
in human primary macrophages. After establishing the positive role of Btk on cytokine production 
in R848-challenged cells, the effect of Btk downregulation on TNF gene expression was 
examined. By using primary-transcript (PT)-PCR and the Polymerase (Pol) II ChIP technique, the 
mechanism of Btk-dependent control of TNF expression was established.  
 
 
 
4.2 Results 
 
4.2.1 Major differences in general tyrosine phosphorylation patterns were detected in human 
primary macrophages stimulated with the TLR4 or TLR8 ligands 
 
Protein tyrosine kinases are essential signalling mediators of macrophages cytokine responses as 
the inhibition of tyrosine phosphorylation by genistein and herbimycin inhibits TNF and IL-10 
production from LPS- or zymozan-challenged cells ((Mander et al. 1997), John McDaid, thesis). 
Prior to the investigation of the role of Btk in TLR signalling, the overall tyrosine phosphorylation 
pattern was examined in human macrophages to establish the involvement of protein tyrosine 
kinases in the TLR4 and 8 signalling cascades. Cells were stimulated with LPS or R848 for 30min 
and lysed. The samples were then analysed by western blotting by using a 4G10 antibody directed 
against tyrosine phosphorylated proteins. Stimulation with the ligands triggered the 
phosphorylation of multiple proteins (Figure 4.1) providing the evidence that tyrosine kinases are 
active during TLR signalling. As the macrophages were obtained from the same donor, the 
experiment also allows a direct comparison of patterns between different stimulations. Major 
differences in tyrosine phosphorylation patterns were detected between LPS and R848 
Chapter 4  Results II 
151 
 
stimulations. This was particularly visible at the 38kDa level, where the TLR4-triggered increase 
in tyrosine phosphorylation was detectable at 10min, comparing to 20min with R848. Similarly, 
an early signal triggered by LPS was observed at around 78kDa level compared to a 10min delay 
for R848. Although this type of analysis does not allow identification of individual kinases or 
substrates, reblotting of the membrane suggested that the protein that is tyrosine phosphorylated at 
38kDa molecular weight is likely to be p38 MAPK (Figure 4.2).  
 
 
 
 
 
Figure 4.1 The differences in tyrosine phosphorylation patterns under TLR3, 4 and 8 stimulation. 
Macrophages obtained by 4 day culture of monocytes in M-CSF supplemented medium were stimulated for 
30min with 10ng/ml LPS or 1µg/ml R848. Cells were lysed, the samples were run on 10% SDS-PAGE gel 
and transferred on PVDF membrane. The membrane was probed with 4G10 antibody which detects 
tyrosine phosphorylation. The red arrows represent different phosphorylation patterns between TLR 
treatments. The result is representative of 3 separate experiments. 
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4.2.2 Stimulation of human primary macrophages with LPS or R848 leads to the activation of 
MAPK and NFκB pathways.  
 
TLR signalling triggers numerous signalling cascades that are responsible for the regulation of 
cytokine production. The ability of Btk to control cytokine production has previously attributed to 
NFκB and MAPK activation (Horwood et al. 2003; Jefferies et al. 2003). In this study, the signals 
initiated following stimulation of TLR4 and 8 in human primary macrophages were characterised 
prior to further investigation of the role of Btk in TLR signalling. M-CSF- derived human 
macrophages were stimulated with TLR ligands for 10, 20 and 30min and examined for the 
activation of MAPK as well as NFκB. As illustrated in the western blots and relative density 
graphs in Figure 4.2, the stimulation with LPS resulted in increased and sustained 
phosphorylation of p38, ERK and JNK MAPK from 10min mirrored by simultaneous IκBα 
degradation. The stimulation with R848 led to similar outcomes, although the kinetics of MAPK 
phosphorylation and IκBα degradation appeared to be delayed by 10min when compared to LPS. 
This observation could be explained by the extracellular and intracellular localisation of TLR4 and 
TLR8, respectively. The initiation of TLR8 pathway, in contrast to TLR4, requires the 
internalisation of the ligand (Kawai and Akira 2010) which could result in a delayed response. 
Taken together, these results highlight the substantial discrepancies in the ERK, JNK, p38 or 
NFκB involvement in the TLR4 and 8 pathways. Whether Btk is implicated in these different 
signalling cascades and whether its presence is indispensible for the cytokine production was then 
thoroughly investigated.  
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Figure 4.2 LPS and R848 activate MAPK and NFκB pathways in human primary macrophages. 
Macrophages obtained by 3 day culture of monocytes in M-CSF supplemented medium were plated at  
1x10
6
 cells and stimulated for 30min with 10ng/ml LPS or 1µg/ml R848. Cells were lysed, the samples were 
run on 10% SDS-PAGE gel and transferred on PVDF membrane. Subsequent probing with anti p-JNK, p-
p38, p-ERK antibodies was used to detect the phosphorylation of MAPK. The membrane was then probed 
with anti IκBα IgG and anti α-tubulin IgG for a loading control. Between each step, the membrane was 
stripped and blocked in 2%BSA (phospho-westerns) or 5%milk. The blots are representative of 3 separate 
experiments. 
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4.2.3 Btk is activated in response to LPS and R848 in human primary macrophages 
 
It has been described before that LPS stimulation of human macrophages leads to the rapid 
phosphorylation of Btk (Horwood et al. 2003) and that the kinase may play a role in endosomal 
TLR signalling pathways in THP-1 cell line (Doyle et al. 2007). In B cells, Btk activation requires 
three steps; the association of the PH domain with PIP3 to enable membrane localization, the 
phosphorylation on a tyrosine residue Y551 in the kinase domain by Src followed by auto-
phosphorylation of a tyrosine residue Y223 in the SH3 domain (Park et al. 1996) (Figure 4.3A). 
After the comparison of the general tyrosine phosphorylation patterns and the initiation of 
common signalling cascades between the TLR4 and 8 pathways, the activation of Btk following 
TLR stimulation was examined. Due to the unavailability of anti-Btk antibodies efficient in the 
detection of the kinase phosphorylation state, an alternative, more technically demanding approach 
was chosen. Btk was immunoprecipitated from the whole cell lysate using a gifted anti-Btk 
antibody and its tyrosine phopshorylation state was subsequently detected by using 4G10 
antibody. Stimulation with either LPS or R848 resulted in similar levels of Btk activation. The 
highest two-fold increase in phosphorylation was detected within 10 min of LPS stimulation and 
decreased after this time (Figure 4.3B). With R848, the phosphorylation peak remained stable 
between 10 and 15min (Figure 4.3C).   
To extend previous data on Btk activation obtained by using 4G10 antibody, a Btk auto-kinase 
assay was performed. The assay involves immunoprecipitation of Btk from the cell lysates 
followed by the incubation of the isolated kinase with P
32 
radiolabelled ATP, a coenzyme which is 
utilised by Btk to phosphorylate itself. Figure 4.4 demonstrates that auto-phosphorylation of the 
kinase occurred rapidly after LPS or R848 stimulation, reaching a pick at 5min and slowly 
decreasing thereafter. No signal was detected with an IgG control antibody as illustrated on the 
blot and confirmed in the relative density graph.  In summary, these results show that Btk becomes 
activated in both TLR4 and 8 signalling at comparable time-points. To determine if Btk is equally 
involved in cytokine production in these two pathways, the differences of the Btk-dependent 
control of cytokine production between the TLR4 and 8 signalling cascades were next examined.  
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Figure 4.3 LPS and R848 stimulation phosphorylates Btk in human macrophages. Differentiated 
macrophages (obtained by 3 day culture of monocytes in M-CSF supplemented medium) were plated at 
10x10
6
 cells per time point in 5cm
2
 Petri dishes and incubated overnight. They were then serum starved for 
2hrs and stimulated with 10ng/ml LPS or 1µg/ml R848 for 20 min. The cells were lysed and Btk was 
immunoprecipitated (section 2.2.6.2). Samples were run on 10% SDS-PAGE gel and transferred on 
nitrocellulose membrane where the tyrosine phosphorylation was detected by 4G10 antibody. Anti-rabbit 
IgG was used as an isotope control. The blots represent 3 separate experiments.  
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Figure 4.4 LPS and R848 stimulation leads to auto-phosphorylation of Btk in human macrophages. 
Differentiated macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) 
were plated at 10x10
6
 cells per time point in 10cm
2
 Petri dishes and incubated overnight in RPMI with 0.5% 
serum. They were then stimulated with 10ng/ml LPS or 1µg/ml R848 for 0, 1, 4, 10 and 15 min and lysed. 
Total Btk was immunoprecipitated with anti-Btk or IgG control antibodies. Following immunoprecipitation, 
kinase activity was assessed as described in section 2.2.6.3 (A). Relative density was calculated by 
normalising values from stimulated cells to unstimulated cells using AIDA software (B). The blot represents 
one out of 2 separate experiments. 
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4.2.5 Downregulation of Btk expression results in decreased TNF production in human 
macrophages 
 
Previous reports have shown that the genetic dysfunction of Btk in XLA patients leads to the 
impaired release of TNF from LPS-stimulated PBMCs and both TNF and IL-6 from ssRNA-
stimulated DC (Horwood et al. 2003; Sochorova et al. 2007). To confirm the results previously 
obtained with an overexpression system (Section 3.2.1), the effect of siRNA-mediated Btk 
knockdown on cytokine production was examined in this section. Freshly elutriated human 
monocytes were transfected with individual siRNA duplexes and subsequently differentiated into 
macrophages in the presence of M-CSF for 4 days and stimulated with TLR ligands for 18h. The 
efficiency of Btk knockdown was assessed by western blotting and the production of cytokine, by 
ELISA. To reduce off-target effects of gene silencing occurring when the siRNA sequence has 
homology to mRNA transcripts other than the gene of interest, two separate siRNA duplexes were 
first tested to downregulate BTK (section 2.1.6.2). Although both RNAi oligos similarly decreased 
Btk expression as well as TNF and IL-6 production from LPS- and R848-challenged cells (Figure 
4.5), only the effects of the more efficient siRNA, „Btk #9‟, are presented in this thesis.  
The increasing concentration of siBtk#9 did not affect the efficiency of Btk knockdown as 
evaluated using western blotting analysis (Figure 4.6A). Figure 4.6B illustrates that after Btk 
targeted knockdown, the LPS and R848- mediated production of TNF was significantly decreased. 
The reduction was much stronger for R848 (75%) than for LPS (35%) suggesting that TLR8 
signalling depends more on Btk than TLR4 signalling does.  Downregulation of the kinase did not 
affect IL-6 production induced by LPS but surprisingly had a significant effect on R848 signalling 
at 200nM but not 300nM siRNA concentration (Figure 4.6C). The knockdown of Btk did not 
change IL-10 production induced by either LPS or R848 (Figure 4.6D) thus confirming the results 
obtained from the Btk overexpression study.  
 
 
 
 
Chapter 4  Results II 
158 
 
0
2000
4000
6000
8000
10000
siBtk #9
siBtk #11
siCon
  NS                     LPS
T
N
F
 [
p
g
/m
l]
0
5000
10000
15000
20000
siBtk #9
siBtk #11
siCon
  NS                    R848
T
N
F
 [
p
g
/m
l]
0
500
1000
1500
2000
2500
siBtk #9
siBtk #11
siCon
  NS                     LPS
IL
-6
 [
p
g
/m
l]
0
2000
4000
6000
8000
10000
12000
siBtk #9
siBtk #11
siCon
  NS                    R848
IL
-6
 [
p
g
/m
l]
A)
  B)           LPS (10ng/ml)         C)          R848 (1g/ml)
 TNF                                                        TNF
  IL-6                                                         IL-6
 
 
Figure 4.5 The comparison of two siRNA duplexes to downregulate Btk expression in human 
macrophages. Monocytes were transfected with 200nM Btk #9, Btk #11 or Control siRNA using the 
Amaxa Human Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days with M-CSF cells were 
stimulated with LPS (10ng/ml) or R848 (1µg/ml) over 18hrs. The protein level was assessed by SDS-PAGE 
and western blotting to ensure the efficiency of the knockdown (A) whereas TNF and IL-6 protein 
production was assessed by ELISA (B-C). Data are expressed as mean +/- SEM of triplicate 
measurements for a single donor. 
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Figure 4.6 Btk knockdown results in decreased TNF production in human macrophages. Monocytes 
were transfected with siRNA at concentrations ranging from 100-300nM, electroporated in Amaxa buffer 
lacking siRNA (B+) or left untreated (B-) (section 2.2.2.1). After 3 days with M-CSF cells were either lysed 
or stimulated with R848 (1µg/ml) or LPS (10ng/ml) for 18h. The protein level was assessed by SDS-PAGE 
and western blotting (A) whereas the cytokine concentration was assessed by ELISA (B-D). Control values 
(black bars) represent cells transfected with non-targeting siRNA at relevant concentrations. Btk 
knockdown values were normalised to the control. Unstimulated cells are not shown as values were 
undetectable. Cytokine levels are expressed as means of triplicate repeats +/- SEM. Results shown are 
representative of at least 3 donors. Statistical analysis: repeated measures ANOVA, *P<0.05,  ***P<0.001 
as compared to stimulated siCon.  
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4.2.6 Downregulation of Btk results in decreased TNF production at an early stage 
 
The results strongly support the role of Btk in TLR8 signalling as both Btk overexpression and 
downregulation altered TNF and IL-6 production upon stimulation. To further establish the 
magnitude and the earliest time point of TNF and IL-6 production affected by Btk, a detailed time 
course of R848-induced cytokine production under Btk knockdown was carried out. As 
previously, freshly elutriated human monocytes were transfected with individual siRNA duplexes, 
subsequently differentiated into macrophages in the presence of M-CSF for 4 days and stimulated 
with TLR 4 and 8 ligands for 18hrs. Supernatants were collected every 2hrs and analysed for TNF 
and IL-6 production using ELISA. The results summarized in Figure 4.7 demonstrate that TNF 
production was considerably decreased in the presence of Btk knockdown for both LPS- and 
R848-stimulated human macrophages. The decrease in TNF release was significant for as early as 
4hrs for LPS and 2hrs for R848 which implies that Btk involvement in TLR8 signalling is more 
profound. Following Btk knockdown, the largest reduction in TNF levels in the presence of Btk 
knockdown was 60% at 8h under R848 stimulation as compared to 50% at 10h under LPS 
challenge (Figure 4.7A). The TLR4 pathway is the most complex one as the receptor utilises four 
adaptor molecules as opposed to only one, Myd88, used by TLR8. It is likely that other Tec 
tyrosine kinases are involved in the TLR4 pathway and that the absence of Btk is substituted by 
another kinase compensating for the deficit in cytokine production. IL-6 levels were also 
unaffected by Btk ablation with LPS, as opposed to R848 stimulation (Figure 4.7B). The effect of 
Btk on IL-6 was, however, greatly delayed as it was visible at 8h and reached the significance only 
at 18h post R848 stimulation. These results indicate that Btk selectively regulates cytokine 
expression in human primary macrophages.  
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Figure 4.7 Btk knockdown affects early stage TNF production in human macrophages. Monocytes 
were transfected with 200nM Btk or Control siRNA using the Amaxa Human Monocyte Nucleofector® Kit 
(section 2.2.2.1). After 4 days with M-CSF cells were stimulated with LPS (10ng/ml) or R848 (1µg/ml) over 
18hrs. The protein level was assessed by SDS-PAGE and western blotting to ensure the efficiency of the 
knockdown (data not shown) whereas TNF (A) and IL-6 (B) protein production was assessed by ELISA. 
Cytokine levels are expressed as means of triplicate repeats +/- SEM. Results shown are representative of 
at least 3 donors. Statistical analysis: student t-test, *P<0.05,  **P<0.01, as compared to stimulated siCon.  
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4.2.7 Btk protein ablation affects IL-6 production upon TLR8 stimulation 
 
It is evident from the previous results that Btk alters IL-6 production under TLR8 but not TLR4 
engagement. TNF has been previously shown to regulate cytokine expression as the 
administration of TNF into cultured synoviocytes induces the production of TNF, IL-6 and IL-1 
(Mander et al. 1997; Feldmann 2002). Therefore, it is possible that the observed decrease in IL-6 
from siBtk-transfected macrophages could be a consequence of strongly reduced TNF production. 
To rule out this possibility, the level of TNF between siBtk- and siCon- treated macrophages was 
evened by adding excess TNF to the supernatants of the cultured cells. The effect of Btk 
downregulation on R848-induced IL-6 was then examined 8h post-stimulation by ELISA. This 
particular time point was chosen as the earliest reduction in IL-6 production in siBtk-transfected 
cells was previously observed at 8h (Figure 4.7B). Figure 4.8B confirms that the addition of TNF 
equilibrated the cytokine levels between the cells transfected with either siBtk or siCon. The 
presence of excess TNF also increased the production of IL-6 proving the bioactivity of the added 
cytokine (Figure 4.8A). Btk protein ablation decreased the production of IL-6 at 48% as 
compared to 31% in the TNF-treated cells following R848 stimulation. This result indicates that 
Btk is likely to be directly involved in IL-6 production upon TLR8 stimulation. At the same time, 
the effect of TNF on IL-6 production cannot be excluded as the decrease in IL-6 production upon 
Btk knockdown was smaller when the TNF level was evened (Figure 4.8B). This data supports 
the role of Btk in the regulation of R848-induced IL-6 secretion that again emphasises the 
differences of the kinase involvement in the TLR4 and 8 pathways. The Btk effect on R848-
induced IL-6 production was, however, much delayed as compared to TNF suggesting that two 
separate mechanisms of Btk-dependent gene control may be involved. Due to the time restrictions 
and the availability of tools required for examining TNF regulation, further work in this chapter 
focused on decoding the Btk-dependent pathway involved in the regulation of TNF expression.   
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Figure 4.8 Btk knockdown directly affects IL6 production upon R848 stimulation in human 
macrophages. Monocytes were transfected with 200nM Btk or Control siRNA using the Amaxa Human 
Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days with M-CSF cells were challenged with 30ng/ml 
of recombinant TNF and 1µg/ml of R848 for 8 hrs. The protein level was assessed by SDS-PAGE and 
western blotting to ensure the efficiency of the knockdown (data not shown) whereas TNF and IL6 protein 
production was assessed by ELISA. Btk knockdown values were normalised to the control. Unstimulated 
cells are not shown as values were undetectable. Cytokine levels are expressed as means of triplicate 
repeats +/- SEM. Results shown are representative of at least 3 donors. 
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4.2.8 Btk control of TNF expression requires the 3’ distant region of TNF to induce the 
Luciferase Activity 
 
To further characterise the mechanism by which Btk determines the level of TNF, the mapping of 
Btk-dependent regions of TNF was performed using a luciferase assay.  The assay involves the use 
of adenoviruses carrying DNA constructs consisting of the luciferase gene flanked by 5‟ TNF 
promoter and different lengths of the 3‟ TNF untranslated and enhancer regions. The 3‟ 
untranslated region (UTR) has been previously implicated in the destabilisation of TNF mRNA as 
the deletion of the adenine and uridine-rich elements (ARE) within the region increases TNF 
message stability in macrophages derived from TNF
ΔARE
 mice (Kontoyiannis et al. 1999).  The 
252bp enhancer region localised downstream of the 3‟UTR has been implicated in the 
transcriptional control of TNF as p65 and IRF5 transcription factors are recruited to this region 
following LPS activation (Krausgruber et al. 2010; Smallie et al. 2010).  The adenoviruses used in 
this project were 5‟Luc, 5‟Luc 3‟UTR and 5‟Luc 3‟1037bp (Figure 4.9A). The expression of 
5‟Luc was the strongest as this construct lacks the 3‟UTR element responsible for the negative 
regulation of the TNF message stability (Figure 4.9B). In contrast, the introduction of the 3‟UTR 
resulted in the weakest expression of 5‟Luc 3‟UTR.  The addition of the 252bp enhancer region to 
3‟UTR increased the expression of 5‟Luc 3‟1037bp as compared to 5‟Luc 3‟UTR. This was 
expected as 3‟ enhancer regions have been long known to be essential positive regulators of gene 
transcription (Meyer et al. 1990). As the relative levels of luciferase activities reflected the 
predicted TNF expression pattern, the constructs were used for further investigation of the Btk-
dependent regulatory mechanism.  
It has been shown before that Btk targets 3‟UTR region of TNF following LPS stimulation, as the 
double infection of macrophages with AdBtk and the 5‟Luc construct deprived of the 3‟UTR did 
not result in increased luciferase activity, while infection with an adenovirus carrying the 3‟UTR- 
containing luciferase construct did (Horwood et al. 2003).  Closer analysis of the 3‟region in these 
constructs has revealed that, in addition to the 3‟UTR (785bp), the construct used by Horwood et 
al. (2003) also contained 252bp long enhancer region (now named 5‟Luc 3‟1037bp adenovirus) 
implicated in transcriptional regulation of TNF. The importance of the 252bp long enhancer region 
was not established at that point due to the lack of the 5‟Luc 3‟UTR constructs. The 5‟Luc 3‟UTR 
and 5‟Luc 3‟1037bp adenoviruses have been constructed in house to facilitate the investigation of 
specific TNF 3‟elements targeted by Btk in TLR4 and 8 signalling.  Human differentiated 
macrophages were sequentially infected with AdBtk and luciferase adenoviruses. Cells were 
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thereafter stimulated with either LPS or R848 for 6h and the luciferase activity was measured. As 
displayed in Figure 4.10, AdBtk did not super-induce 5‟Luc indicating that the lacking 3‟region is 
required for Btk-dependent regulation in TLR4 and 8 signalling. The addition of 3‟UTR also did 
not result in AdBtk-regulated increase in luciferase activity. However, AdBtk elevated the 
expression of 5‟Luc 3‟1037bp as compared to AdCon signifying that the kinase is likely to target 
the 252bp enhancer region of the TNF gene.  
Previous evidence from our laboratory indicated that Btk relies on 3‟UTR region of TNF to 
stabilise the cytokine mRNA levels in TLR4 signalling. This was further supported by the 
Actinomycin D chase experiment where the rate of TNF mRNA decay was rescued by AdBtk 
(Horwood et al. 2003). Detailed inspection of the TNF 3‟ region has revealed, however, that the 
3‟UTR itself is not sufficient for the Btk-dependent super-induction of luciferase and that the 
additional enhancer region containing transcriptional elements may be required. As the 3‟UTR 
was shown to downregulate TNF expression (Figure 4.9B), it is not surprising that Btk, a positive 
regulator of TNF production, was not dependent on this region.  
 
 
 
 
 
 
 
Chapter 4  Results II 
166 
 
0
50
00
0
10
00
00
15
00
00
20
00
00
5'Luc 3'1037 bp
5'Luc 3'UTR
5'Luc
R848 (1g/ml)
LPS (10ng/ml)
NS
Luciferase units
A)
B)  Induction of Luciferase by R848 or LPS
 
Figure 4.9 The induction of Luciferase activity by LPS or R848 in human macrophages. Differentiated 
macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) were plated at 
0.07x10
6
 cells per well and incubated overnight. The cells were then infected with adenovirus carrying 
different luciferase contructs (A) at moi 50 and allowed to express for 24h (section 2.2.3.9). Cells were then 
stimulated with LPS (10ng/ml) or R848 (1µg/ml) and lysed 6h post stimulation. Luciferase activity was 
measured as described in section 2.2.4.6.  Values are expressed as means of triplicate repeats +/- SEM. 
Results shown are representative of at least 3 donors (B).  
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Figure 4.10 Btk requires 3’ distant region of TNF to induce Luciferase activity in response to LPS or 
R848 in human macrophages. Differentiated macrophages (obtained by 4 day culture of monocytes in M-
CSF supplemented medium) were plated at 0.07x10
6
 cells per well and incubated overnight. The cells were 
then infected with AdBtk or AdCon at moi 100 and allowed to express for 4hrs. Following primary infections 
cells were infected with 5’Luc, 5’Luc 3’UTR or 5’Luc 3’1037bp adenoviruses at moi 50 and allowed to 
express for further 24h (section 2.2.3.9). Cells were then stimulated with LPS (10ng/ml) or R848 (1µg/ml) 
and lysed 6h post stimulation. Luciferase activity was measured as described in section 2.2.4.6.  Values 
are expressed as means of triplicate repeats +/- SEM. Results shown are representative of at least 3 
donors. Statistical analysis: repeated-measures ANOVA, *P<0.05, **P<0.01 as compared to stimulated 
AdCon. 
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4.2.9 Btk regulates the transcription of TNF following TLR8 but not TLR4 activation 
 
The early effect of siBtk on TNF protein production suggests that the kinase may regulate TNF 
expression on a level of transcription, message stability, translation or the release of soluble TNF 
from the membrane. To investigate the first hypothesis, also supported by Results 4.2.8, the levels 
of TNF primary and mature transcripts were compared by using Primary Transcript (PT) - PCR. 
The technique was initiated by (Lipson and Baserga 1989) and enables the detection of pre-mature 
mRNA by using the primer set covering intron-exon boundary as opposed to the detection of 
mature  TNF transcript with primers spanning exon-exon sequence of approximately 200bp 
(Figure 4.11).  Freshly elutriated human monocytes were transfected with individual siRNA 
duplexes, subsequently differentiated into macrophages and stimulated with either TLR4 or TLR8 
ligands. Supernatants were collected every 2h up to 10h and analysed for TNF mRNA by using 
PT-PCR approach. As illustrated in Figure 4.12, both LPS and R848 highly induced the levels of 
TNF primary and mature transcripts within 2h. The LPS-induced TNF mRNA levels dropped 
sharply after this period as compared to R848 stimulation where the induction of the primary 
transcript was sustained for 4h. The introduction of siBtk decreased the synthesis of the primary 
TNF transcript by 25% and the mature TNF transcript by 10% at 2h following LPS stimulation 
(Figure 4.12A). The effect of Btk ablation on TNF mRNA was much more striking in R848-
challenged macrophages as the difference amounted to 80% at 2h for both the primary and mature 
TNF transcripts (Figure 4.12B). The strong Btk effect on both primary and mature mRNA 
indicates that the kinase is involved in the regulation of TNF transcription upon R848 stimulation 
whilst Btk is less likely to participate in LPS-induced transcription. As the TLR4 cascade is 
considered to be much more complex, it is possible that the ablation of the kinase may be 
substituted by others resulting in a weaker effect on TNF transcription.  
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Figure 4.11 Schematic representing the synthesis of mature TNF transcript.  Primary transcript is 
generated from genomic DNA during transcription. In this process the gene DNA sequence, composed of 
UTR regions (white boxes), coding exons (black boxes) and introns (lines between exons), is converted 
into mRNA sequence. The maturation of the primary transcript involves the splicing of the exons with 
simultaneous removal of introns and the attachment of PolyA tale. Red arrows indicate the primer binding 
sites for the distinction of the primary and mature transcripts in PT-PCR.   
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Figure 4.12 Btk knockdown affects the levels of TNF mRNA in human macrophages stimulated with 
R848. Monocytes were transfected with 200nM Btk or Control siRNA using the Amaxa Human Monocyte 
Nucleofector® Kit (section 2.2.2.1). After 4 days with M-CSF cells were stimulated with LPS (10ng/ml) or 
R848 (1µg/ml) over 10hrs. The protein level was assessed by SDS-PAGE and western blotting to ensure 
the efficiency of the knockdown (data not shown) whereas TNF primary (A) and mature (B) transcript levels 
were measured by RT-PCR using One-Step SYBR kit (section 2.2.2.5). Data are expressed as mean +/- 
SEM of triplicate measurements for a single donor representative of 3 independent experiments using 
different donors.  
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4.2.10 Downregulation of Btk decreases the initiation of transcription as assessed by RNA 
Polymerase II recruitment to the upstream region of TNF 
 
To further confirm the role of Btk in TNF transcription upon R848 stimulation, the analysis of 
RNA Polymerase II (Pol II) recruitment to TNF was performed by using chromatin 
immunoprecipitation (ChIP) methodology.  By designing primers targeting the transcription start 
site (TSS) and the downstream region of TNF, this technique allows the identification of the effect 
of Btk on the transcriptional initiation and elongation (Figure 4.13B). The application of ChIP for 
human primary macrophages was optimised by Dr Tim Smallie from our laboratory and among 
others; it required the optimisation of sonication conditions, cell numbers and PCR primers 
targeting specific TNF sites. Sonication of the chromatin is one of the initial steps and involves the 
shearing of the genome in the fragments that are on average 200-1000 bp in length (Figure 
4.13A). This guarantees that the accurate resolution can be obtained and that using primers 
spanning a particular DNA fragment will result in a PCR signal specific for the target sequence. 
The melt curve analysis was performed in every PCR run to assess the primer set specificity and 
the presence of non specific products such as primer dimers (Figure 4.13E-F). Peaks in the melt 
curve analysis represent the highest fluorescence signal generated by the dye binding to double 
stranded (ds) DNA in the PCR reaction. The presence of only one peak at around 85°C indicates 
specific products of TNF TSS (1+) or TNF Downstream primer sets. The analysis of PCR results 
also requires the normalisation of the threshold cycle (Ct) values obtained from ChIP to the Ct 
values obtained from the input. The input was derived from DNA remained from 
immunoprecipitated Pol II or IgG and therefore represents the initial size of an individual sample. 
Both the ChIP and input samples were subjected to the same PCR reaction (Figure 4.13C-D). The 
Ct values for the inputs were on average 8 times lower than for the ChIP samples indicating, as 
expected, that there were fewer TNF fragments in the immunoprecipitated samples than in the 
total nuclear extracts.  
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Figure 4.13 Optimisation steps required in ChIP.  Fixed cells are lysed and subjected to sonication 
which shears the genomic DNA. To ensure that the DNA fragments are on average 200-1000bp in length, 
the samples are sonicated 6 times (pulses of 12 sec) as optimised by Dr Tim Smallie (A). Pol II is then 
immunoprecipitated from the lysates and the purified DNA is analysed by PCR with the primers covering 
TSS(+1) or Downstream regions (B). Only when the melt curves result in sharp peaks (E, F) and the cycle 
values of inputs (black lines) are lower than the cycle values of ChIP (silver lanes) on the profile runs (C,D), 
the results are considered as valid and further analysed. The threshold line indicates the cycle values used 
for the calculations (C-F) (section 2.2.9.5). 
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To determine whether Btk downregulation affects the initiation or the elongation of TNF 
transcription, the recruitment of Pol II to the upstream and downstream region of TNF was 
examined. Primary monocytes were subjected to transfection with individual siRNA duplexes and 
differentiated into macrophages in the presence of M-CSF for 4 days. Cells were stimulated with 
R848 for 1 and 3h and subjected to ChIP with the Pol II or the IgG control antibody. Btk was 
previously shown to affect TNF primary transcript synthesis at 2h and that the level of the mature 
transcript is the highest at 2h post R848 stimulation (Figure 4.12B). The 1h time point for the 
ChIP was thus chosen to detect Pol II recruitment prior the transcript elongation and termination. 
Interestingly, a high background level of Pol II bound to TNF TSS(+1) but not TNF Downstream 
was detected in resting macrophages suggesting that Pol II is constitutively bound to the upstream 
TNF region but does not elongate the transcript without stimulation (Adelman et al. 2009) (Figure 
4.14).  Activation with the TLR8 ligand increased the recruitment of Pol II to the TSS(+1) and 
downstream sites of TNF. The highest recruitment was observed at 1h and then slightly dropped at 
3h. The signal for IgG antibody was negligible illustrating the specificity of the Pol II antibody. In 
the presence of Btk siRNA, there was substantially less recruitment of Pol II to both upstream and 
downstream element of TNF indicating that Btk affects the initiation of TNF transcription. 
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Figure 4.14 Btk knockdown inhibits the recruitment of Pol II to upstream and downstream regions 
of TNF in human macrophages stimulated with R848. Monocytes were transfected with 200nM Btk or 
Control siRNA using the Amaxa Human Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days with M-
CSF cells were treated with R848 (1µg/ml) for 3h, fixed and lysed as described in section 2.2.9. ChIP was 
performed using the Pol II or IgG antibodies and primers specific for upstream (TSS+1) (A) or downstream 
(B) TNF region (section 2.2.9). Data are expressed as mean +/- SEM of triplicate measurements for a 
single donor representative of 3 independent experiments using different donors. Statistical analysis: 
Student’s t-test was performed on dCt values on one donor, *P<0.05, **P<0.01, ***P<0.001 as compared to 
siCon. 
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4.3 Discussion 
 
Since the discovery that LPS stimulates protein tyrosine phosphorylation in macrophages 
(Weinstein et al. 1991; Beaty et al. 1994) and that the inhibition of tyrosine phosphorylation by 
Herbimycin A and Genistein blocks TNF production (Mander et al. 1997), protein tyrosine 
kinases have been increasingly investigated in the context of TLR signalling. The endosomal 
TLRs which are able to detect exogenous and endogenous nucleic acids have attracted significant 
interest in recent years and increasing experimental data has provided evidence for their 
importance in cytokine expression in rheumatoid arthritis synovium (Roelofs et al. 2005; Roelofs 
et al. 2008; Sacre et al. 2008; Roelofs et al. 2009). Studies presented in this and the previous 
chapter show that Btk signalling differentially controls cytokine production in human primary 
macrophages in response to various TLR stimuli. In particular, Btk affects TNF and IL-6 
production in R848-stimulated cells as opposed to only TNF in LPS-stimulated cells. Also, the 
dependence of the TLR8 pathway on Btk is more profound when compared to TLR4. At the same 
time, the kinase does not affect the production of IP-10 following PolyI:C stimulation indicating 
that Btk signalling is not implicated in the TLR3 pathway; the only TLR not to use Myd88 but to 
use TRIF instead. Lastly, the kinase is clearly involved in the R848-induced transcription of TNF 
as Btk protein ablation decreases the synthesis of the primary TNF transcript and Pol II 
recruitment to the gene.  
 
Earlier reports concerning the role of Btk in TLR signalling have been mainly focused on the 
investigation of the TLR2 and 4 pathways. The current results replicate the previously published 
data which showed rapid phopshorylation of Btk in response to LPS stimulation in primary human 
and mouse macrophages (Figure 4.3/4.4) (Horwood et al. 2003; Schmidt et al. 2006). Extensive 
analysis revealed that the kinase is also phosphorylated and auto-phosphorylated in response to the 
TLR8 stimulus. The participation of Btk in TLR4 and 8 cascades could be explained by the fact 
that they both share common stages of signal transduction mechanisms, involving the adaptor 
protein Myd88. Btk has been previously shown to be associated with Myd88 as demonstrated in 
co-immunoprecipitation experiment from HEK293 cells or with Myd88-dependent TLRs 4, 6, 8 
and 9 as shown in yeast two-hybrid screening (Jefferies et al. 2003). Bmx, another member of Tec 
family kinases, was also found to form a complex with Myd88 in LPS-challenged synovial 
fibroblasts isolated from rheumatoid arthritis joint tissue (Jefferies et al. 2003; Semaan et al. 
2008). Myd88 is used by numerous TLRs including TLRs 2 and 4 which proved to be 
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dysfunctional in XLA-derived PBMC (Horwood et al. 2006) supporting the dependence of Myd88 
on Btk. Furhermore, Btk has been shown to phosphorylate the adaptor molecule Mal which forms 
a scaffold for Myd88 in TLRs 2 and 4 signalling cascades (Gray et al. 2006). The association of 
Mal with Btk supports the role of the kinase in early TLR signalling events and places it in the 
complex with adaptor molecules (Figure 4.15).   
 
The results obtained by using adenovirus overexpression and RNAi techniques demonstrated that 
Btk regulates cytokine production in R848-challenged macrophages (Figure 3.2, 4.5-4.8). The 
impact of the kinase on TNF release was much stronger in the TLR8 pathway than in the TLR4 
one. Again, this could arise from the complexity of the TLR4 cascade which involves four 
different adaptor molecules, compared to only one found in TLR8 (Figure 4.15). It is possible, 
that different members of Tec family kinases are involved in one TLR cascade and substitute for 
the absence of another kinase rescuing the functionality of a TLR pathway. This hypothesis was 
supported by the observation that the expression of Tec increased in M-CSF-treated monocytes 
derived from XLA patients as compared to healthy donors (Horwood et al. 2003). Also in other 
systems, functional redundancy among Tec family members has been proposed. For instance, Btk 
has been shown to have an important signalling function in platelet activation. However, Btk 
depletion does not affect platelet-dependent bleeding tendency probably because the 
phopshorylation of Tec is increased as shown in collagen-stimulated plateles derived from XLA 
patients (Oda et al. 2000). By utilising a more complex adaptor molecule network, TLR4 could 
employ a wider range of Tec family kinases. For instance, Bmx has been shown to regulate both 
TNF and IL-6 production from human primary macrophages stimulated with either LPS or 
Pam3Cys indicating that one TLR pathway can involve numerous Tec family kinases which differ 
in function (Palmer et al. 2008).  
 
Similarly to the LPS pathway, Btk did not influence R848-induced IL-10 production in human 
macrophages (Figure 3.2, 4.5). In contradiction to these results, Btk appears to be implicated in 
the production of LPS-induced IL-10 in murine macrophages emphasising the difference in TLR 
signalling between species (Schmidt et al. 2006). Furthermore, in contrast to the TLR4 pathway, 
Btk displayed a consistent effect on IL-6 production upon TLR8 stimulation suggesting that the 
same kinase may exhibit a different range of cytokine control in various TLR cascades. The effect 
of Btk on R848-induced IL-6 production was less profound than the effect on TNF. Although, the 
pathways distinguishably regulating TNF and IL-6 production still remain to be elucidated, it is 
clear that there are major differences in how these two cytokines are regulated. For instance, the 
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chemical inhibition of p38 MAPK resulted in decreased production of TNF but super-induction of 
IL-6 production from LPS-stimulated human primary macrophages (Page et al. 2010). The effect 
of Btk on IL-6 secretion upon R848 stimulation in human primary macrophages can be supported 
by studies performed on DC derived from XLA patients and confirmed by using the non-specific 
inhibitor of Btk, LFM-A13 (Sochorova et al. 2007).  
 
The kinetics of TLR-induced IL-6 production was largely delayed as compared to TNF production 
(Figure 4.7). This was consistent with the classification of the TNF and IL6 genes as respective 
primary and secondary response genes (Hargreaves et al. 2009). Primary genes do not require new 
protein synthesis what results in their rapid induction, whereas secondary genes depend on new 
protein synthesis and chromatin remodelling at their promoters what leads to their delayed kinetics 
(Ramirez-Carrozzi et al. 2006; Natoli 2009). Downregulation of Btk decreased early TNF 
production as opposed to IL-6. Although IL-6 release was detectable at 4h, Btk appeared to 
regulate R848-induced IL-6 production at the late 8h time point. This finding suggests that two 
separate mechanisms of Btk-dependent gene control may be implicated. Btk seems to be directly 
involved in the early stages of TNF expression as opposed to IL-6 regulation. Further work should 
focus on expanding on the role of Btk in the IL-6 gene expression and on establishing the 
involvement of transcriptional, translational and cellular release control.  
 
In the current system Btk did not regulate IP-10 production in LPS- or PolyI:C-activated human 
primary macrophages (Chapter 3, Figure 3.2), implying that the kinase is not involved in the 
interferon pathway dependent on the adaptor molecule TRIF. This result disagrees with data 
derived from XLA DC stimulated with a TLR3 ligand where the production of TNF, but not IL-6, 
was significantly decreased comparing to healthy donors (Taneichi et al. 2008). Human primary 
macrophages do not, however, express TNF or IL-6 in response to PolyI:C. The engagement of 
TLR3 also does not lead to IκBα degradation, NFκB luciferase induction or p38 MAPK 
phopshorylation in macrophages (Lundberg et al. 2007). As both p38 MAPK and NFκB pathways 
have been implicated in Btk-regulated cytokine expression it was not unexpected that the lack of 
MAPK or NFκB activation correlated with the lack of Btk involvement in the TLR3 pathway.   
 
Previous studies suggest that Btk-mediated TNF expression is controlled transcriptionally in an 
NFκB-dependent manner. Most of the studies describing NFκB activation were, however, done in 
B cells (Bajpai et al. 2000; Petro et al. 2000), on cell lines of non-myeloid origin which do not 
endogenously express Btk or TLR4, in mouse cells or by using LFM-A13 (Jefferies et al. 2003) 
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which displays high toxicity in human primary macrophages (McDaid, unpublished). The findings 
of this work showing the early involvement of Btk in regulating TNF production as well as the 
dependence of Btk on the TNF enhancer region in the luciferase assay suggested that Btk  may  be  
implicated  in the  transcription of TNF in  R848  signalling (Figure 4.10). Indeed, downregulation 
of Btk extensively decreased the synthesis of primary TNF transcript under TLR8 engagement as 
opposed to TLR4 signalling where this effect was weaker (Figure 4.12). The weak effect of Btk 
on LPS-induced TNF transcription can be explained by previous studies performed in human 
primary macrophages where it has been suggested that Btk does not regulate the transcription, 
rather TNF message stability through p38 MAPK (Horwood et al. 2006). 
 
 
 
 
 
 
Figure 4.15 Schematic representing major differences in the signalling components of TLRs 3, 4 
and 8. The initial activation of TLR4 involves the recruitment of Mal and Myd88, followed by the activation 
of early NFκB and MAPK. TLR4 can translocate to endosomes when it engages TRAM and TRIF to 
activate late NFκB and IRF3. IFR3 is also activated by PolyI:C which activates TLR3 and an adaptor 
molecule TRIF. TLR8 stimulation by R848 recruits Myd88 and activates MAPK and NFκB. The 
consequence of IRF3 activation is the production of Type I IFN, whereas the activation of MAPK and NFκB 
leads to the production of Inflammatory cytokines such as TNF and IL-6 (adapted from (Kawai and Akira). 
Btk interacts with TLRs 4 and 8 as well as with Myd88 and Mal (Jefferies et al. 2003). 
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The process of gene transcription includes the initiation, elongation and termination. The initiation 
involves the binding of multiple transcription factors to DNA which then recruits RNA 
Polymerase II (Pol II) and chromatin modifiers (Kadonaga 2004). In basal conditions Pol II 
phosphorylated on Serine 5 is bound to promoters of primary response genes and is able to 
produce unspliced TNF transcripts which are rapidly degraded (Hargreaves et al. 2009). This is 
consistent with the results obtained in the chapter as Pol II bound to the TNF TSS(+1) was 
detected in unstimulated cells (Figure 4.14). The stimulation with R848 increased Pol II initiation 
of TNF transcription but was strongly affected by Btk downregulation. The utilisation of the ChIP 
technique confirmed the role of Btk in the TNF transcription giving insight into how this 
regulation occurs. Numerous transcription binding sites are localised in the TNF gene including 
NFκB and AP-1-like site. Whether they are implicated the Btk-dependent initiation of R848-
mediated TNF transcription has been not described yet.  
 
In summary, the studies presented in this chapter have revealed a critical role for Btk in the TLR-
dependent regulation of cytokine and chemokine production in human primary macrophages. In 
particular, it has been demonstrated that Btk affects R848-triggered TNF and IL-6 production to a 
much higher extent than the production of TNF in LPS-stimulated cells revealing the differential 
role of Btk on cytokine production in various TLR pathways as well as different level of Btk 
dependence between TLR4 and 8. Subsequent experiments revealed that a potential mechanism 
that regulates Btk-dependent TNF production in R848-stimulated macrophages is related to TNF 
transcription. The clear effect of Btk on the transcription initiation also indicates that the kinase 
affects the components on nucleoprotein complexes, known as enhanceosomes, with transcription 
factors being obvious candidates undergoing this regulation. Therefore, the aim of the next chapter 
was to investigate the involvement of NFκB and AP-1 transcription factors in Btk signalling. 
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Btk regulates TNF expression through NFκB and AP-1 
transcription factors in R848-stimulated human primary 
macrophages 
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5.1 Introduction 
 
The results from the previous chapter clearly indicate that Btk affects the initiation of TNF 
transcription under inflammatory conditions in human primary macrophages. Transcription 
initiation involves the signal-dependent binding of transcription factors to target promoters, 
enabling the recruitment of various components of the transcription initiation machinery including 
Polymerase (Pol) II. The human TNF 5‟ promoter and 3‟ enhancer which is located downstream of 
the 3‟UTR region contain multiple cis-acting elements that are binding motifs for transcription 
factors (TF). The motifs that have been described to be involved in the TLR-driven induction of 
TNF in macrophages include NFκB sites 1, 2, 3 and 4, Ets, cAMP-responsive element (CRE), 
CCAAT/enhancer binding protein β (CEB/P) and AP-1-like sites (Kramer et al. 1995; Liu et al. 
2000) (Figure 5.1).  
In the previous chapter, Btk was shown to be dependent on the 252bp long 3‟ enhancer region of 
the TNF gene as the removal of this region abrogated Btk-dependent super-induction of luciferase. 
This region contains various TF binding sites including κB site 4. NFκB is a dominant 
transcription factor required for the production of inflammatory cytokines (Foxwell et al. 1998; 
Udalova et al. 1998). Previous studies have revealed that κB sites 1, 2 and 3 in the TNF promoter 
as well as κB site 4 in the TNF 3‟enhancer are all involved in the transcription of TNF upon LPS 
stimulation (Krausgruber et al. 2010; Smallie et al. 2010). The canonical form of NFκB is a dimer 
comprising p65 and p50 subunits. The composition of the dimer determines the site of DNA 
binding as well as the function of the complex.  p65/p50 heterodimer shows little variation in 
binding to κB sites 1, 2 and 3. p50/p50 homodimer which is considered to be inhibitory, binds 
with high affinity to κB site 1 and to κB site 2a. On the contrary, the p65/p65 homodimer has been 
shown to be strongly recruited to κB site 2 but not 2a ((Udalova et al. 1998; Liu et al. 2000; 
Udalova et al. 2000). The deletion or site-directed mutation of single κB sites in the TNF promoter 
decrease, but not completely abrogate, the induction of a luciferase reporter construct (Goldfeld et 
al. 1990; Tsai et al. 2000; Udalova et al. 2000). Also the inhibition of NFκB by dominant negative 
p65 or overexpression of IκBα does not completely abolish LPS-induced TNF expression 
suggesting that other transcription factors may play an equally important role (Foxwell et al. 
1998).  
 
The AP-1 family of transcription factors has also been shown to regulate TNF production (Liu et 
al. 2000; Steer et al. 2000). The binding sites for the AP-1 family members include CRE/ATF and 
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AP-1-like sites localised in the core promoter of the TNF gene. Among the best studied AP-1 
components are Jun proteins (c-Jun, JunD and JunB) which form dimers between themselves or 
heterodimerize with Fos proteins. Depending on the composition of the dimer, AP-1 can be 
inhibitory or activatory with higher or lower affinity to the AP-1-like site (Gomard et al. 2010).  
AP-1 members can also dimerize with components derived from other TF families such as ATF-2, 
a member of the ATF/cAMP response element-binding (CREB) protein family of bZIP proteins. It 
has been shown that c-Jun/ATF-2 heterodimer has a high affinity for the CRE/ATF site in the TNF 
promoter under genotoxic stress such as a cisplatin treatment (Hayakawa et al. 2004). Deletion of 
both Ets and CRE/ATF sites completely abolishes cJun-dependent trans-activation of the human 
TNF promoter (Kramer et al. 1995).  
 
There remain unresolved questions regarding the position of Btk in the TLR signalling cascade in 
human primary macrophages as well as the exact mechanism of Btk-dependent regulation of gene 
transcription. Studies performed on Xid macrophages and the THP-1 cell line have demonstrated 
that LPS-activated Btk engages the NFκB pathway by promoting p65 subunit transactivation and 
nuclear localization (Jefferies et al. 2003; Doyle et al. 2005) . In human XLA PBMC, however, 
Btk appears to function independently of NFκB, as the degradation of IκBα remained intact,  and 
operate through the p38 MAPK signalling pathway following stimulation with TLR2 and 4 
ligands (Horwood et al. 2003; Horwood et al. 2006). Btk has been also implicated in the activation 
of AP-1 in LPS-stimulated murine macrophages (Schmidt et al. 2006).  
The current chapter focuses on determining the role of Btk in activating NFκB and AP-1 upon 
R848 stimulation in human primary macrophages. After establishing the importance of Btk in 
regulating the binding of NFκB and AP-1 to their consensus sites, more detailed analysis of the 
involvement of p65, cJun, cFos and ATF-2 was performed. The findings in this chapter confirm 
the role of Btk in the initiation of TNF transcription and provide clues as to which signalling 
pathways may be involved. 
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Figure 5.1. A schematic of the human TNF gene. TNF gene comprises of 5’ promoter region, followed by 
transcription start site (TSS), a segment of 4 exons (shown as black squares), 3’ UTR and 3’ enhancer 
region. Multiple transcription sites involved in TLR signalling, including NFkB, Ets,CRE/ATF, C/EBP, AP-1 
are localised in the promoter (shown as white squares). NFkB site 4 is localised in the 5’enhancer region. 
The location of the transcription factors in relation to TSS is shown numerically in base pairs.  
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5.2 Results 
5.2.1 NFκB mutations abrogate the Btk-dependent super-induction of TNF production under 
R848 stimulation. 
 
It has recently been demonstrated in our laboratory that κB sites located in the TNF 5‟promoter as 
well as κB site 4 located in the downstream 3‟enhancer region are all implicated in the initiation of 
TNF transcription in response to LPS (Udalova et al. 1998; Krausgruber et al. ; Smallie et al. 
2010). In the previous chapter, Btk was shown to be dependent on the 252bp long region of the 
3‟enhancer where putative κB site 4 is located. To determine the role of NFκB in Btk signalling, 
the effect of κB mutations on the Btk-dependent induction of TNF luciferase reporter was 
investigated.  
The luciferase viruses utilised in this experiment included a full length 5‟Luc 3‟ 1251bp construct, 
a construct containing a mutant κB site 4 (5‟Luc 3‟ site 4X) and a construct where all κB sites 
(5‟Luc 3‟ site 1/2/3/4X) had been mutated. A construct lacking the 3‟enhancer but containing the 
3‟UTR (5‟Luc 3‟ UTR) was used as an additional control (Figure 5.2).  Human M-CSF-derived 
macrophages were sequentially infected with AdBtk and luciferase adenoviruses. The cells were 
then stimulated for 6hrs with R848 and a luciferase assay was performed.   
As illustrated on Figure 5.3A, simultaneous mutations in all the κB sites increased the basal 
R848-induced luciferase expression. This effect can be explained by the fact that κB sites are the 
binding motifs for both activatory and inhibitory NFκB dimers (Udalova et al. 2000). Mutations in 
all 4 κB sites must therefore affect the balance of these various dimers and perhaps promote the 
transcription of TNF. On the other hand, the site-directed mutagenesis of κB site 4 did not alter 
basal levels of R848-induced TNF or abrogate the effect of Btk overexpression on luciferase 
induction. In fact the ability of Btk to super-induce luciferase expression was only decreased when 
the adenovirus carrying the construct with all the κB sites mutated was used. This result is 
supported by previous research from our laboratory describing collective role of all 4 κB sites in 
regulating TNF expression. In particular, in these studies, the inhibition of TNF expression by IL-
10 was unaffected by one κB mutation in the TNF luciferase reporter as compared to the 
mutations of all κB sites (Tim Smallie, thesis). The inability of κB site 4 to impair R848-mediated 
TNF expression and Btk signalling could derive from the fact that other unknown transcription 
factor sites in the 3‟ 1251bp long region remained intact and compensate for the NFκB function.  
Chapter 5  Results III 
185 
 
To assess the efficiency of Btk overexpression in this system, an ELISA was performed on the 
supernatants from the R848-stimulated cells. The levels of TNF protein production and the 
induction by AdBtk overexpression were equal between all the luciferase viruses confirming that 
the results obtained from the luciferase assay were unaffected by the quality of the virus titres or 
the efficiency of transduction (Figure 5.3B). Taken together, these findings indicate that Btk 
requires all intact κB sites to enhance R848-induced TNF transcription. The mutation of κB site 4 
alone as compared to the deletion of 252bp long region where κB site 4 is located was insufficient 
to abrogate Btk signalling. The collective findings from the present and previous chapters, 
therefore, suggest that Btk requires NFκB to regulate TNF production but also may involve other 
TF whose binding sites are located in the 1037bp long 3‟ enhancer.  
 
 
 
 
 
 
 
Figure 5.2 Schematic showing details of mutated κB site adenovirus luciferase reporters.  
Adenoviral luciferase reporters based on the human TNF gene are shown in the top panel.  Full length 3’ 
1251bp construct was used as a control for the constructs carrying either kB site 4 or all 4 kB sites mutated 
or for the construct lacking the 5’ enhancer region. The NFκB mutations are denoted as black crosses. 
Specific mutations of κB site 1, cluster 2, site 3 in the 5’ promoter or κB site 4 in the 3’enhancer are shown 
in red and compared to wild type sequence shown in black. The mutants were generated by Dr Tim 
Smallie.  
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Figure 5.3 The presence of NFκB site mutations in the TNF luciferase reporter interferes with the 
Btk-dependent induction of luciferase. Differentiated macrophages (obtained by 4 day culture of 
monocytes in M-CSF supplemented medium) were plated at 0.07x10
6
 cells per well and incubated 
overnight. The cells were then infected with AdBtk or AdCon at moi 100 and allowed to express for 4hrs. 
Following primary infections cells were infected with 5’ Luc 3’1251bp, 3’site 4X, 3’site 1/2/3/4X or 3’UTR 
adenoviruses at moi 50 and allowed to express for further 24h (section 2.2.3.9). Cells were then stimulated 
with R848 (1µg/ml) and lysed 6h post stimulation. Luciferase activity was measured as described in section 
2.2.4.6 (A). The efficiency of Btk overexpression was assesed by analysing TNF and IL-6 protein 
production in the same supernatants by ELISA.  Values are expressed as means of triplicate repeats +/- 
SEM. Results shown are representative of at least 3 donors. Statistical analysis: repeated measures 
ANOVA, *P<0.05, **P<0.01, ***P<0.001 as compared to stimulated AdCon. 
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5.2.2 Downregulation of Btk expression reduces NFκB binding to its consensus DNA sequence 
following TLR8 stimulation 
 
To further confirm the role of NFκB in Btk signalling under R848 stimulation, the effect of Btk 
downregulation on the binding of NFκB to its consensus site was examined. This was 
accomplished through using an electrophoretic mobility shift assay (EMSA). Human primary 
macrophages previously subjected to Btk knockdown were stimulated with R848 for 1hr and 
lysed. Nuclear extract was then incubated with P
32 
ATP- labelled NFκB oligonucleotide and run 
on an SDS-PAGE gel.  As demonstrated in Figure 5.4, 1h stimulation with R848 resulted in a 
rapid increase of the protein:DNA complexes in cells that were not subjected to Btk knockdown. 
On the contrary, the binding of NFκB was abrogated when Btk was depleted from the cells 
indicating that the kinase is involved in the DNA binding activity of NFκB. In the presence of 
NFκB unlabeled probe, named as competitor, there was no accumulation of protein:DNA 
complexes proving the specificity of the probe. The canonical form of the NFκB complex is 
known to include p65-p50 heterodimers which have a high affinity for the TNF promoter. 
However, p50-p50 homodimers can also bind to the NFκB sites within the TNF promoter and act 
as transcriptional repressors (Udalova et al. 2000). Additional analysis of the NFκB supershifts 
revealed that the p50 and p65 members of the NFκB family were present in the complex (Figure 
5.4). The complex is considered to be comprised of the p65/p50 heterodimer (top part) and of the 
p50/p50 homodimer (bottom part). Therefore, upon addition of anti-p50 antibody the whole 
doublet shifts up, whereas in the presence of anti-p65 antibody only the upper part of the doublet 
disappears. Although the results obtained from EMSA revealed the importance of Btk in the 
R848-driven NFκB activity, this technique utilises short consensus DNA fragments which are not 
gene specific and therefore one may argue that this approach does not reflect the real in vivo 
situation. Other techniques such as ChIP which considers the complexity of chromatin and is gene 
specific was required to determine if the defect in NFκB activation in Btk depleted cells affects 
TNF transcription.  
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Figure 5.4 R848-mediated NFκB activity is regulated by Btk. Monocytes were transfected with 200nM 
Btk or Control siRNA using the Amaxa Human Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days 
with M-CSF cells were stimulated with R848 (1µg/ml) for 1h and 5μg of nuclear extract was subjected to 
EMSA with consensus probes for NFκB (section 2.2.7). A supershift assay was performed with antibodies 
against p50 and p65. As a control, a competitor wild type non-radiolabelled NFκB oligonucleotide was 
added in excess into one of the samples. The blot is a representative example of 3 independent 
experiments. 
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5.2.3 Btk downregulation increases the phosphorylation of NFκB component p65 under R848 
stimulation. 
 
Previous studies performed on XLA-derived and control PBMCs have shown that IκBα 
degradation is not affected in cells lacking functional Btk under LPS challenge which led to the 
conclusion that Btk does not affect the NFκB pathway in TLR4 signalling (Horwood et al. 2003). 
However, a later report has shown that p65 can be activated by IκBα-independent mechanisms 
marked by the phosphorylation of p65 on Serine 536 (Sasaki et al. 2005). To define whether Btk 
affects NFκB activation through IκBα- dependent or independent pathway in R848 signalling, the 
degradation of IκBα and the phosphorylation of p65 on Serine 536 was examined. Human primary 
monocytes were subjected to RNA interference with Amaxa Nucleofector ®Kit, differentiated 
into macrophages in the presence of M-CSF for 4 days and subsequently stimulated for 90min 
with R848.  The results obtained from western blotting demonstrate that the degradation of IκBα 
during the course of R848 stimulation was not affected by the Btk knockdown (Figure 5.5A). On 
the other hand, the phosphorylation of p65 on Serine 536, was significantly decreased in the 
absence of Btk as calculated from 3 independent donors and presented on the relative density 
graph (Figure 5.5B). The effect of Btk ablation on phospho- p65 was much stronger at early time 
points than later, suggesting that some compensatory mechanisms were later activated. 
Furthermore, Btk downregulation decreased the basal level of phospho-p65. Btk and Tec have 
been described to be implicated in the M-CSF receptor signalling pathway required for the 
macrophage survival. The apoptosis rate was significantly increased in Tec
-/-
Btk
-/-
 macrophage 
culture but rescued by excess M-CSF (Melcher et al. 2008). As M-CSF, which is present in the 
culture medium, induces NFκB binding to DNA (Oster et al. 1992) it was not unexpected that Btk 
ablation decreased phosphorylation of p65 even prior to R848 stimulation. These results support 
the role of NFκB in Btk signalling and give some more insights into how Btk may regulate the 
NFκB cascade. Having evidence that Btk regulates the phosphorylation of p65 which then leads to 
the binding of p65 to its consensus site it was reasonable to investigate further how Btk affects the 
binding of p65 to TNF upon R848 stimulation. 
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Figure 5.5 Btk knockdown impairs the phosphorylation of p65 in human macrophages stimulated 
with R848. Monocytes were transfected with 200nM Btk or Control siRNA using the Amaxa Human 
Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days with M-CSF cells were stimulated with R848 
(1µg/ml) for 90min. The phosphorylation of p65 and degradation of IκBα was assessed by SDS-PAGE and 
western blotting with anti-p-p65 (Tyr536) and anti-IκBα antibodies (A).  Relative density was calculated by 
normalising values from p-p65 bands to GAPDH bands at relevant time points from 3 independent 
experiments and using Phoretix
TM
 1D software (B). The blot represents one out of 3 independent 
experiments. Statistical analysis: Student’s t-test, *P<0.05 as compared to stimulated siCon. 
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5.2.4 Btk abrogation affects the recruitment of p65 to the TNF gene following TLR8 activation. 
 
The use of a variety of molecular biology and biochemistry techniques presented herein has 
provided results strongly indicating that Btk affects the transcription of TNF as well as NFκB 
activation. ChIP is a technique whose application allows a simultaneous analysis of multiple 
variables involved in the process of transcription as it combines data obtained from EMSA and 
Primary Transcript-PCR. Data presented here has shown that mutation of all 4 NFκB sites 
prevents the ability of Btk to up-regulate TNF. ChIP was therefore used to determine if Btk affects 
the recruitment of p65 to specific NFκB sites of the TNF 5‟ promoter or 3‟ enhancer (Figure 5.6).  
 
 
 
 
 
 
Figure 5.6 Primer sets used for ChIP. The primer sets spanning κB site 1 (NFκB_1), a cluster of 
κB2/ε/κB2b (NFκB_2), ATF/CRE, κB site 3 and AP-1 motifs (NFκB_3) in the 5’ promoter as well as κB site 
4 (NFκB_4) in the 3’ enhancer of human TNF were used to detect the enrichment of these sites to 
immunoprecipited transcription factors. Black circles illustrate the κB sites, white circles show the ATF/CRE 
and AP-1-like sites, whereas triangles shown the location of the primers. The primers were designed and 
optimised by Dr Tim Smallie.    
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Freshly elutriated human monocytes were transfected with individual siRNA duplexes, 
subsequently differentiated into macrophages in the presence of M-CSF for 3-4 days and 
stimulated with a TLR8 ligand for 1 and 3 hours. Cells were then fixed with formaldehyde to 
ensure that the transcription factors were firmly bound to DNA. Macrophages were subsequently 
lysed and the ChIP assay was performed with the use of IgG antibody as a control and anti-p65 
antibody.  The run profiles of the Real-Time PCR are illustrated in Figure 5.7A and show the 
recruitment patters of p65 to NFκB sites 1, 2, 3 and 4 of the TNF gene upon R848 stimulation. The 
binding of p65 to κB sites 1, 3 and 4 at 1h increased as opposed to κB site 2 where the recruitment 
of p65 was the highest prior stimulation. p65 was released from κB site 4 at 3h but remained 
attached to κB sites 1 and 3 indicating that the kinetics of p65 recruitment to various κB motifs 
differs. The % Input values for the isotope control were much lower than for the p65 antibody, 
they did not increase and remained constant, demonstrating the specificity of the p65 antibody. In 
the presence of Btk knockdown the recruitment of p65 to κB sites 2 and 4 but not to the remaining 
sites was significantly reduced prior to R848 stimulation. However, Btk downregulation inhibited 
the recruitment of p65 to all κB sites following R848 stimulation. Although the experiment was 
performed on 4 independent donors resulting in similar p65 recruitment patterns, the different Ct 
values obtained from each blood donor prevented the data to be combined for the statistics to be 
applied. Therefore, only dCt values from one representative donor were statistically analysed and 
the outcome presented in this report (Figure 5.7A). The use of melt curve analysis indicated that 
the PCR primers designed for different NFκB sites resulted in a specific amplification product as 
only one peak at around 85-90°C was visible (Figure 5.7B). This data confirms that Btk acts on 
TNF transcription and that p65, an NFκB component, is one of the transcription factors that may 
be involved in this regulation. Although Btk controlled the recruitment of p65 to all four κB sites, 
a single mutation of κB site 4 did not abrogate Btk- dependent regulation of TNF expression. 
These results are in line with the recent publication from our group describing the mechanism of 
the TNF transcriptional control dependent on all κB sites. In particular, IL-10 decreased p65 
recruitment to all κB sites despite the fact that no single κB mutation in the TNF luciferase 
construct abrogated the effect of IL-10 on TNF production ((Smallie et al. 2010), Tim Smallie, 
thesis). 
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Figure 5.7 Btk knockdown inhibits the recruitment of p65 to NFκB sites of TNF in human 
macrophages. Monocytes were transfected with 200nM Btk or Control siRNA using the Amaxa Human 
Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days with M-CSF cells were treated with R848 
(1µg/ml) for 3h, fixed and lysed as described in section X. ChIP was performed using anti-p65 or isotope 
antibodies with primers specific for NFκB sites 1, 2, 3 or 4 of human TNF gene (A) (section 2.2.9). The 
efficiency of the primers was assessed using melt curve analysis of immunoprecipitated DNA (ChIP) or 
remaining DNA (Input) (B). Data are expressed as mean +/- SEM of triplicate measurements for a single 
donor representative of 3 independent experiments using different donors. Statistical analysis: Student’s t-
test was performed on dCt values on one donor, *P<0.05,**P<0.01, ***P<0.001 as compared to siCon. 
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5.2.5 Downregulation of Btk expression reduces AP-1 binding to its consensus DNA sequence 
following TLR8 activation. 
 
Although NFκB is likely to be a major transcription factor involved in the transcription of TNF in 
macrophages, the inhibition of NFκB by dominant negative p65 or wild type IκBα adenoviruses 
decreases but does not completely abolish LPS-induced TNF expression (Foxwell et al. 1998; Liu 
et al. 2000). This observation suggests that other transcription factors may play a role in TNF 
induction by TLR ligands (Figure 5.1). CRE/ATF and AP-1 sites are located in close proximity to 
the κB site 3 in the core promoter of TNF (Figure 5.8) and studies by (Yao et al. 1997) have 
demonstrated that NFκB and AP-1 components interact with each other and are mutually 
dependent as increasing the spacing between CRE and κB site 3 abolished LPS-driven induction 
of TNF. Btk has also been shown to be important for the activation of both NFκB and AP-1 as 
Btk-depleted murine macrophages exhibit impaired binding of NFκB and AP-1 to the consensus 
sites upon LPS activation (Schmidt et al. 2006). These studies provided a basis for the hypothesis 
that Btk may also affect AP-1 activation upon TLR8 induction.  
 
 
 
Figure 5.8 Transcription factor sites localised in the core promoter of TNF.  NFκB site 3 (-98) is 
flanked by CRE/ATF (-106) and AP-1 (-65) sites (in blue, underlined) in the core promoter of TNF. 
Transcription and translation start sites are shown in red. 5’UTR is localised upstream of the first exon 
(underlined) followed by the first intron of TNF. Adapted from Mr Thomas Krausgruber. 
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Initially, EMSA was employed to test if Btk downregulation affects the binding of AP-1 to its 
consensus site. Human primary macrophages previously subjected to Btk knockdown were 
stimulated with R848 for 1hr and lysed. Nuclear extract was then incubated with P
32 
ATP- labelled 
AP-1 consensus and run on an SDS-PAGE gel.  As illustrated in Figure 5.9A, stimulation with 
R848 resulted in a rapid increase of the protein:DNA complexes. The intensity of the complexes 
was consistently lower in the cells subjected to Btk knockdown demonstrating that Btk depletion 
impairs AP-1 binding. Moreover, Btk ablation changed the size of the complex as the bands were 
lower than in control cells. This may indicate that the absence of Btk changed the composition of 
the AP-1 dimer as one of the AP-1 members could no longer be efficiently activated. In the 
presence of an AP-1 unlabeled probe, here named as competitor, there was no accumulation of 
protein:DNA complexes proving the specificity of the probe.  
An additional analysis of the AP-1 components has revealed that cFos, JunD and possibly cJun 
and JunB members of the AP-1 family were present in the complex. Antibodies against cJun and 
JunB blocked the formation of the DNA-protein complexes visualised as a clear complex 
disappearance whereas the addition of anti-cFos or anti-JunD antibodies blocked the formation of 
the DNA-protein complexes visualised as supershifts (Figure 5.9A). The absence of the complex 
displacement with anti-cJun and anti-JunB antibodies indicates that these antibodies were not 
efficient for supershift experiments. An anti-ATF-2 antibody did not cause a supershift or a band 
disappearance signifying that ATF-2 was not present in the AP-1 site- binding complex. 
An alternative for a radiolabelled EMSA is a TransAm kit based on a sandwich enzyme- linked 
immunosorbent assay. Specifically, the bottom of 96-well TransAm plate is covered with AP-1 
consensus sequences which are binding motifs for the AP-1 transcription factors present in the 
nuclear extract. By using primary antibodies against specific AP-1 components and HRP-
conjugated secondary antibodies, the kit enables the measurement of the activation state of these 
transcription factors. For the purpose of this study, the nuclear extracts prepared previously for 
EMSA were analysed by TransAM for cJun activation. As illustrated in Figure 5.9B, the 
recruitment of phosphorylated cJun to the AP-1 motif increased upon R848 stimulation and was 
significantly decreased in the cells subjected to Btk knockdown. The control used in this 
experiment was TPA-stimulated K-562 extract supplied by the kit. These results demonstrate for 
the first time that Btk affects AP-1 binding to its consensus site in TLR8 signalling. Based on 
these novel findings, further characterisation of particular AP-1 components dependent on Btk 
was performed in more detail. 
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Figure 5.9 R848-mediated AP-1 activity is regulated by Btk. Monocytes were transfected with 200nM 
Btk or Control siRNA using the Amaxa Human Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days 
with M-CSF cells were stimulated with R848 (1µg/ml) for 1h and 5μg of nuclear extract was subjected to 
EMSA with consensus probes for AP-1 (section 2.2.7). A supershift assay was performed with antibodies 
against cJun, cFos, JunB, JunD and ATF-2. As a control, a competitor wild type nonradiolabelled AP-1 
oligonucleotide was added in excess into one of the samples. The blot represents one out of 3 independent 
experiments (A). Nuclear extracts from EMSA were used for TransAm assay where anti-p-cJun antibody 
was applied to detect the activation of cJun (B) (section 2.2.8). Values for TransAm are expressed as 
means of triplicate repeats +/- SEM. Results shown are representative of 3 donors. Statistical analysis: 
Student’s t-test, *P<0.05, as compared to stimulated siCon. 
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5.2.7 Btk depletion increases the basal and R848- induced recruitment of cJun and ATF-2 to 
the human TNF gene. 
 
The ChIP technique was employed to gain an insight into the mechanisms actually occurring in 
the context of chromatin complexity. Specifically, the technique was used to investigate the effect 
of Btk on particular AP-1 components which are recruited to the TNF gene upon stimulation with 
R848. Freshly elutriated human monocytes were transfected with siRNA duplexes against Btk or 
control siRNA, subsequently differentiated into macrophages in the presence of M-CSF for 4 days 
and stimulated with R848 for 3 hours. The ChIP assay was performed with the use of IgG 
antibody as a control and anti-cJun, anti-ATF-2 and anti-cFos antibodies. cJun and cFos homo- 
and heterodimers are known to bind the AP-1-like site whereas cJun/ATF-2 heterodomers have 
been demonstrated to bind the ATF/CRE site of human TNF upon LPS stimulation (Diaz and 
Lopez-Berestein 2000). The primer set used was TNF NFκB_3 (Figure 5.6), as it amplifies the 
DNA sequence covering both CRE/ATF and AP-1 sites. The shearing of chromatin during the 
sonication step allows obtaining DNA fragments of 100-200bp in length. It was therefore 
impossible to design primers specifically for CRE/ATF or AP-1 sequence alone as the sites are 
clustered together and the resolution of ChIP was not sufficient at that point to distinguish 
between a few base pairs in the cluster (Figure 5.8). 
The run profiles of the Real-Time PCR are demonstrated in Figure 5.10 and show that the 
recruitment of total cJun and ATF-2 to the CRE/ATF-2/AP-1 site dropped upon stimulation with 
R848. In contrast, cFos was recruited to DNA and reached a maximum at 1h. Interestingly, the 
similar pattern could be observed around κB site 4 where there are no confirmed ATF/CRE or AP-
1 sites. However, detailed bioinformatics analysis performed with the Matinspector programme 
revealed that there is a putative AP-1 site in the 3‟enhancer region localised at position +3071 
(Figure 5.11), close enough to the κB site 4 to be detected with the TNF NFκB_4 primer set 
(Figure 5.6).  The depletion of Btk let to the enrichment of CRE/ATF/AP-1 sequence to cJun and 
ATF-2 at basal and 1 hour post-stimulation with no effect on cFos. A less profound but still 
significant effect of Btk on the AP-1 binding to the 3‟enhancer region of TNF was observed. 
Unexpectedly, it was shown in Results 4.2.8 that Btk is dependent only on the 252bp long 3‟TNF 
enhancer element, but not on the downstream region where the AP-1 site is located, to induce 
luciferase. Together, these findings indicate that although Btk affects the recruitment of AP-1 to 
sites located in the 5‟promotor and 3‟enhancer, the deficiency of one of the AP-1 motifs does not 
impede Btk-induced TNF transcription. The values for the isotope control were considerably 
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lower showing the specificity of anti-cJun, anti-cFos and anti-ATF-2 antibodies. The experiment 
was performed on 4 independent donors resulting in similar AP-1 recruitment patterns, but the 
different Ct values obtained from each blood donor prevented the data to be combined for the 
statistics to be applied. Therefore, only dCt values from one representative donor were statistically 
analysed. Other tested antibodies for ChIP included anti-JunD which proved inefficient in 
immunoprecipitating JunD from the genome as no recruitment of this AP-1 component to TNF 
was detected by Real-Time PCR.  
These data demonstrate that Btk affects cJun and ATF-2 recruitment both to the TNF 5‟ and 3‟ 
regions but has no effect on cFos. Interestingly, Btk depletion increased the recruitment of total 
cJun to TNF as shown by ChIP but decreased phospho-cJun binding to the AP-1 consensus site as 
shown by TransAm (Results 5.2.6). This discrepancy may be derived from the differences in the 
assays themselves as TransAm utilised the AP-1 consensus sequence whereas the primers used in 
ChIP were TNF specific. Alternatively, AP-1 activation is known to be complex as AP-1 
components may be inhibitory or activatory depending on their phosphorylation status (Ogawa et 
al. 2004). Therefore, although Btk depletion affected the levels of total cJun and phospho-cJun 
recruitment to DNA differently, the final effect on TNF expression still resulted in decreased 
transcription. Interestingly, despite the negligible AP-1:DNA complex formation in unstimulated 
cells as visualised by EMSA (Results 5.2.6), there was on average 2 fold enrichment of cJun to 
TNF before stimulation as compared to R848-stimulated cells (Figure 5.10A). On the other hand, 
the recruitment of cFos to the TNF gene increased with R848 stimulation following the AP-1 
binding pattern observed in EMSA. The decreased recruitment of c-Jun and ATF-2 to TNF upon 
R848 stimulation indicates that these AP-1 components may have an inhibitory role in TLR 
signalling. To test this hypothesis, numerous attempts at downregulating cJun, ATF-2 and cFos 
were made by using an Amaxa Human Monocyte Nucleofector® Kit and lipid based Dharmafect1 
reagents. The attempts proved to be unsuccessful (data not shown) preventing further investigation 
of the role of particular AP-1 members in TNF transcription. Nevertheless, the collective results 
obtained from EMSA, TransAm and ChIP show that Btk regulates the activation of AP-1 upon 
R848 stimulation which results in the transcription of TNF.  
 
 
Chapter 5  Results III 
199 
 
si
B
tk
si
C
on
si
B
tk
si
C
on
si
B
tk
si
C
on
0.0
0.2
0.4
0.6
0.8
1.0
NS         1hr R848      3h R848
IgG CHIP
cJun CHIP
***
**%
 I
n
p
u
t
si
B
tk
si
C
on
si
B
tk
si
C
on
si
B
tk
si
C
on
0.0
0.5
1.0
1.5
2.0
2.5
NS         1hr R848      3h R848
IgG CHIP
cJun CHIP
*
%
 I
n
p
u
t
si
B
tk
si
C
on
si
B
tk
si
C
on
si
B
tk
si
C
on
0.0
0.2
0.4
0.6
0.8
1.0
NS         1hr R848      3h R848
IgG CHIP
ATF-2 CHIP
**
*
%
 I
n
p
u
t
si
B
tk
si
C
on
si
B
tk
si
C
on
si
B
tk
si
C
on
0.0
0.5
1.0
1.5
2.0
NS         1hr R848      3h R848
IgG CHIP
ATF-2 CHIP*
*
***%
 I
n
p
u
t
si
B
tk
si
C
on
si
B
tk
si
C
on
si
B
tk
si
C
on
0.00
0.03
0.06
0.09
0.12
0.15
0.18
NS         1hr R848      3h R848
IgG CHIP
cFos CHIP
%
 I
n
p
u
t
si
B
tk
si
C
on
si
B
tk
si
C
on
si
B
tk
si
C
on
0.00
0.05
0.10
0.15
NS         1hr R848      3h R848
IgG CHIP
cFos CHIP
%
 I
n
p
u
t
A) TNF   NFB_3        TNF NFB_4
B)
C)
 
Figure 5.10 Btk knockdown increases the recruitment of cJun and ATF-2 to CRE/ATF/AP-1 site of 
TNF in human macrophages. Monocytes were transfected with 200nM Btk or Control siRNA using the 
Amaxa Human Monocyte Nucleofector® Kit (section 2.2.2.1). After 4 days with M-CSF cells were treated 
with R848 (1µg/ml) for 3h, fixed and lysed as described in section 2.2.9. ChIP was performed using anti-
cJun, anti-ATF-2, anti-cFos or isotope antibodies with primers specific for CRE/ATF/AP-1 site in 5’ 
promoter or NFκB site 4 in 3’ enhancer of human TNF gene (A). Data are expressed as mean +/- SEM of 
triplicate measurements for a single donor representative of 3 independent experiments using different 
donors. Statistical analysis: Student’s t-test was performed on dCt values on one donor, *P<0.05, **P<0.01, 
***P<0.001 as compared to siCon. 
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Figure 5.11 Transcription sites localised in the TNF enhancer.  NFκB_4 cluster (+2981, +2996, +3016) 
is localised in high proximity to the AP-1 site (+3071) in 3’ enhancer region of TNF (bold, underlined). The 
termini of 256bp region of 5’Luc 3’1037bp construct is shown in green. Transcription and translation stop 
sites are shown in red. 3’UTR is localised downstream of the fourth exon (black,underlined). Adapted from 
Dr Tim Smallie and Mr Thomas Krausgruber. 
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5.2.8 The activation of MAPK under R848 stimulation is not affected by Btk overexpression in 
human primary macrophages. 
 
MAPK are implicated in AP-1 activation as well as expression of AP-1 components (Pramanik et 
al. 2003). A previous report by (Kristof et al. 2001) has shown that the chemical inhibition of p38 
and ERK decreased LPS/IFNγ-induced AP-1 binding to iNOS promoter. The function of p38 in 
regulating AP-1 activity varies between p38 isoforms as p38β appears to induce activity whereas  
p38δ and p38γ seems to inhibit or have no effect on AP-1 driven reporter genes luciferase activity 
(Pramanik et al. 2003). Another study revealed that the recruitment of c-Jun and ATF-2 to the 
TNF promoter under genotoxic stress was inhibited by JNK inhibitors or JNK-specific siRNA 
(Hayakawa et al. 2004). The involvement of MAPK in Btk signalling under TLR stimulation is 
still unresolved and seems to be largely dependent on the cell model and species (Horwood et al. 
2006; Zemans and Arndt 2009). To examine the effect of Btk on R848-driven MAPK activation, 
the outcome of Btk overexpression on p38, JNK and ERK phosphorylation or p38 kinase activity 
was investigated. In vitro differentiated human macrophages were infected with adenovirus 
carrying the wild type BTK gene or an empty vector. Cells were left to express the protein for a 
minimum of 24h and stimulated with R848 for 40min. Western blotting analysis showned that the 
phosphorylation of p38, JNK and ERK increased within 10min of stimulation with R848 and that 
there were no significant differences in the phosphorylation patterns between AdBtk- and AdCon- 
infected cells (Figure 5.12A).  
The lack of the effect of Btk on MAPK activation may have been due to the fact that the 
antibodies did not detect phosphorylation sites affected by Btk activity. To rule out this possibility, 
a kinase assay was carried out to monitor the activity of p38 as this particular kinase has 
previously been implicated in LPS-induced Btk signalling (Horwood et al. 2006). The assay 
involves the use of P
32 
radiolabelled ATP, a coenzyme which is utilised by p38 to phosphorylate 
its substrate MK2. Radiolabelled MK2 is then visualised on a SDS-PAGE gel. Figure 5.12B 
illustrates that the phosphorylation of MK2 was apparent at 10min, peaked between 20 and 30min 
followed by a gentle drop at 40min. The activation pattern of p38 visualised in the kinase assay 
differed from the results obtained in western blotting, where the phosphorylation of p38 stably 
increased and was the highest at 40min. Nevertheless, there was again no change in MK2 
phosphorylation under the excess of Btk providing further evidence that activation of p38 is not 
affected by Btk under R848 stimulation (Figure 5.12A/B). This result indicates that it is unlikely 
that Btk regulates AP-1 through MAPK activation. Other molecules regulating AP-1 activation 
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such as TAK1 (Shim et al. 2005), or AP-1 stability and degradation such as members of the Src 
family kinases; respective c-Abl and CSK (Xie and Sabapathy 2010) may be therefore implicated 
in Btk signalling instead. 
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Figure 5.12 Btk overexpression does not affect MAPK activation under R848 stimulation. 
Differentiated macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) 
were infected with adenovirus at 100 moi (section 2.2.3.9). Cells were incubated for 24h and stimulated 
with R848 (1µg/ml) for 40min. The phosphorylation of p38, ERK and JNK was assessed by SDS-PAGE 
and western blotting (A) whereas the activation of p38 was assessed by a radioisotope kinase assay using 
MK2 as a substrate (B) (section 2.2.6.3). Relative density of the bands derived from the p38 kinase assay 
was calculated by normalising values from stimulated cells to unstimulated cells using Phoretix
TM
 1D 
software (C). The blots represent one out of 3 independent experiments.  
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5.2.9 R848-induced TNF and IL-6 production is dependent on TAK1 in human primary 
macrophages. 
 
Transforming growth factor (TGF) beta-activated kinase 1 (TAK1) has been described to be 
implicated in IL-1, TNF and TLR4 signalling (Landstrom 2010). The first evidence demonstrating 
the importance of this kinase in LPS signalling, provided by Irie and colleagues, showed that co-
transfection of the TAK1 dominant negative vector together with an NFκB reporter into murine 
macrophages decreased LPS-induced luciferase activity (Irie et al. 2000). It was thereafter 
demonstrated that the activation of AP-1 is significantly impaired in Tak1
m/m 
MEF
 
cells stimulated 
with LPS (Shim et al. 2005) implicating that TAK1 controls both NFκB and AP-1 activities. 
Although there is no literature addressing the role of TAK1 in tyrosine kinase signalling, the 
findings describing the dependence of NFκB or AP-1 on TAK1 led to a question regarding the 
potential role of TAK1 in Btk signalling. In order to investigate this possibility, the effect of 
dominant negative TAK1 K63W (TAK1 DN) and wild type TAK1 (TAK1 WT) adenoviruses on 
TNF and IL-6 production was examined. The TAK1 DN construct was previously successfully 
used for determining the role of TAK1 in TGFβ signal transduction (Yamaguchi et al. 1995).  
Human differentiated macrophages were infected with the adenovirus at moi ranging from 50 to 
150 virus particles per cell. The cells were subsequently stimulated with R848 for 18h to measure 
TNF, IL-6 or IL-10 production. The level of TAK1 protein was monitored by western blotting and 
showed that both TAK1 DN and WT adenoviruses efficiently overexpressed TAK1 as compared 
to AdCon (Figure 5.13A/B). The overexpression of TAK1 WT moi- dependently increased the 
production of both TNF and IL-6 from R848-stimulated macrophages. This was mirrored by an 
moi-dependent drop in cytokine secretion in cells infected with AdTAK1 DN (Figure 5.13C/D). 
Surprisingly, only AdTAK DN significantly decreased the production of IL-10 which was not 
accompanied by the super-induction of IL-10 by AdTAK WT. This observation is consistent with 
data obtained from LPS-stimulated macrophages (Dr Lynn Williams, personal communication). 
These data demonstrate that the kinase is involved in the production of both TNF and IL-6 thus 
revealing a novel role for TAK1 in TLR8 signalling. Furthermore, the effect of TAK1 on cytokine 
production resembles the effect of Btk on TNF and IL-6 expression upon R848 stimulation.  
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Figure 5.13 TAK1 regulates the production of TNF and IL-6 under R848 stimulation. Differentiated 
macrophages (obtained by 4 day culture of monocytes in M-CSF supplemented medium) were infected 
with TAK1 wild type (AdTAK1 WT), TAK1 dominant negative (AdTAK1 DN) or control adenovirus (AdCon) 
at moi ranging from 50 -150 virus particles per cell (section 2.2.3.9). Cells were incubated for 24hrs and 
stimulated with R848 (1µg/ml) for 18hrs. The protein level was assessed by SDS-PAGE and western 
blotting (A-B) whereas the cytokine concentration was assessed by ELISA (C-D). Unstimulated cells are 
not shown as values were undetectable. Cytokine levels are expressed as means of triplicate repeats +/- 
SEM. Results shown are representative of at least 3 donors. Statistical analysis: Student’s t-test, *P<0.05, 
**P<0.01, ***P<0.001 as compared to stimulated AdCon at relevant moi. 
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5.2.10 Overexpression of TAK1 WT increases NFκB and AP-1 binding to the consensus DNA 
sequences following TLR8 activation. 
 
To further characterise the role of TAK1 in TLR8 signalling and to gather evidence about the 
potential interactions between TAK1 and Btk, the effect of TAK1 WT overexpression on NFκB 
and AP-1 binding to the consensus DNA fragments was assessed by EMSA. Human differentiated 
macrophages were infected with either AdTAK1 WT or AdCon, subsequently stimulated with 
R848 for 1h and lysed. Nuclear extract was then incubated with P
32 
ATP- labelled NFκB or AP-1 
oligonucleotides and run on an SDS-PAGE gel. Figure 5.14 shows that the formation of NFκB or 
AP-1 complexes increased upon stimulation in AdCon- infected cells. In the presence of 
overexpressed TAK1 the binding of NFκB to DNA also considerably increased and was higher 
than control both before and after stimulation. Comparable results were found in the AP-1 EMSA, 
as TAK1 overexpression significantly increased the recruitment of AP-1 to its consensus site at 
both time points. The high presence of NFκB and AP-1 complexes in unstimulated cells 
previously infected with TAK1 indicates that TAK1 was slightly pre-activated and could be 
explained by the fact that the kinase is known to be induced by many stimuli such as growth 
factors, environmental stress and inflammatory cytokines (Landstrom 2010). The pre-activation of 
TAK1 is therefore unavoidable as M-CSF is added to the culture medium for monocyte 
differentiation and low levels of inflammatory cytokines are secreted by cells upon adenovirus 
infection. In the presence of NFκB or AP-1 unlabeled probes, named as competitor, there was no 
accumulation of protein:DNA complexes proving the specificity of the probes. TAK1 signalling 
appears to follow the same pattern as Btk which also affected the binding of NFκB and AP-1 to 
DNA.  
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Figure 5.14 R848-mediated NFκB and AP-1 activity is regulated by TAK1. Differentiated macrophages 
(obtained by 4 day culture of monocytes in M-CSF supplemented medium) were infected with TAK1 wild 
type (AdTAK1 WT) or control adenovirus (AdCon) at moi 100 (section 2.2.3.9). Cells were incubated for 
24hrs and stimulated with R848 (1µg/ml) for 1hrs. Cells were lysed and 5μg of nuclear extract was 
subjected to EMSA with consensus probes for NFκB or AP-1 (section 2.2.7). As a control, a competitor wild 
type nonradiolabelled NFκB or AP-1 consensus was added in excess into one of the samples. The blots 
represent one out of 2 independent experiments. 
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5.2.11 Btk-induced TNF and IL-6 production is dependent on TAK1 in human primary 
macrophages. 
 
Both TAK1 and Btk affected the binding of AP-1 and NFκB to DNA as well as the secretion of 
TNF and IL-6 under TLR8 stimulation suggesting that these two kinases might share the same 
signalling pathway in human primary macrophages. To validate this hypothesis, the effect of 
TAK1 DN adenovirus on Btk-dependent super-induction of TNF and IL-6 was examined in R848-
stimulated cells. Human differentiated macrophages were sequentially infected with AdBtk or 
AdCon followed by the infection with AdTAK1 DN or AdCon. The cells were then stimulated 
with R848 for 18h and the efficiency of the adenoviral transfection or the level of cytokine 
production was measured by western blotting or ELISA, respectively. Figure 5.15A shows that 
both AdTAK1 DN and AdBtk expressed efficiently and that the double infection did not affect the 
expression of either of the proteins. Infection with AdTAK DN significantly decreased the 
production of R848-induced TNF and IL-6, whereas AdBtk significantly increased the production 
of TNF and to a lesser extent the production of IL-6. Double infection with AdTAK1 DN and 
AdBtk significantly abrogated Btk-induced TNF and IL-6 production (Figure 5.15B). These 
results provide further evidence that both TAK1 and Btk are required for R848-induced TNF and 
IL-6 production and that they co-operate with each other as dysfunctional TAK1 impaired the Btk 
effect on cytokine production.  
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Figure 5.15 Btk-induced TNF and IL-6 production is dependent on TAK1. Differentiated macrophages 
(obtained by 4 day culture of monocytes in M-CSF supplemented medium) were plated at 0.07x10
6
 cells 
per well and incubated overnight. The cells were then infected with AdBtk or AdCon at moi 100 and allowed 
to express for 4hrs. Following primary infections cells were infected with AdTAK1 DN or AdCon at moi 50 
and allowed to express for further 24h (section 2.2.3.9). Cells were then lysed for western blotting or 
stimulated with R848 (1µg/ml) for 18h. The efficiency of Btk and TAK1 overexpression was determined on 
a protein level (A) and the level of TNF and IL-6 secreted by the infected cells was measured by ELISA (B). 
Values are expressed as means of triplicate repeats +/- SEM. Results shown are representative of at least 
3 donors. Statistical analysis: repeated measures ANOVA, *P<0.05, **P<0.01, ***P<0.001. 
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5.3 Discussion 
 
In these studies, the involvement of Btk in the R848-mediated control of TNF transcription via 
two families of transcription factors, namely NFκB and AP-1 has been proposed. Furthermore, it 
is evident from the results that Btk does not engage p38, ERK or JNK to regulate AP-1 activity, 
rather signalling through other kinases, such as TAK1.  These data extend current knowledge 
regarding the involvement of Tec kinases in the regulation of cytokine production in response to 
R848 by providing a potential mechanism of transcriptional control. 
Much of the research in previous years has been focused on indentifying downstream components 
of the Btk signalling pathway initiated by TLRs localised on plasma membranes. The conflicting 
results, describing the effect of Btk on transcription factors such as NFκB, appear to be largely 
dependent on the cell system used and still remain unclear (Doyle and O'Neill 2006; Horwood et 
al. 2006).  Few studies have focused on the Btk-dependent induction of NFκB under endosomal 
TLR stimulation (Doyle et al. 2007).  The data reported here has shown that the kinase is clearly 
involved in the activation of NFκB under R848 stimulation since it affected the formation of 
protein:DNA complexes as visualised in EMSA experiments (Figure 5.4). Furthermore, the data 
strongly demonstrate for the first time that Btk affects the recruitment of NFκB to the TNF gene in 
a natural genomic state (Figure 5.7) and that mutations of NFκB sites 1, 2, 3 and 4 in the TNF 
reporter construct significantly abrogate Btk-induced luciferase activity (Figure 5.3).  
Downregulation of Btk also decreased the phosphorylation of p65 on Serine 536, an event which 
is considered to be independent of the IκBα pathway (Sasaki et al. 2005) and did not affect the 
degradation of IκBα under R848 stimulation (Figure 5.5). This is consistent with results obtained 
by Lee and colleagues showing that B cells derived from Btk
-/- mice did not display impaired IκBα 
degradation following TLR9 engagement (Lee et al. 2008).  In common with the results reported 
here, Btk also affected the p65 phosphorylation on Ser 536 but not IκBα degradation in LPS-
stimulated Xid macrophages or HEK293-TLR4 cells (Doyle et al. 2005). The activation of p65 
requires two distinctive steps; one is the release of p65 from the inhibitory IκBα complex which 
allows nuclear translocation whilst the other is post-translational modification including the 
phosphorylation of p65 on Serine 536. It is this phosphorylation event that is required for 
transactivation of gene expression (Doyle et al. 2005). p65 can be phosphorylated on Serine 536 
by IKKα and IKKβ (Sakurai et al. 2003). Mutation of Ser536 to alanine has been reported to 
abolish the interaction of p65 with coactivators p300 and CREB-binding protein (CBP) and as a 
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consequence to decrease transcriptional activation (Chen et al. 2005). Neither of these molecules 
has been described to interact with Btk. Alternatively, Btk has been described to directly 
phopshorylate CREB at Serine 133 during neuronal differentiation indicating that the kinase 
activity of Btk is not only restricted to tyrosine phosphorylation and that the kinase can directly 
interact with transcription factors (Yang et al. 2004). The present results show that Btk is more 
likely to be involved in p65 transactivation than its release from the inhibitory IκB complex.  
Although NFκB is a major regulator of TNF transcription, it has been shown before that the 
inhibition of the NFκB pathway does not fully abrogate the production of TNF (Foxwell et al. 
1998; Liu et al. 2000). Similarly in the current system, the mutations of all four NFκB sites in the 
TNF reporter construct did not decrease the production of luciferase under R848 stimulation 
(Figure 5.3). Taken together, these data imply that there are other families of transcription factors 
involved in the regulation of TNF transcription in TLR signalling.  The AP-1 family has been 
described to be controlled by NFκB, as the transient transfection of human pancreatic tumor cell 
line with mutant IκBα impeded both the AP-1 luciferase activity as well as the expression of cFos 
(Fujioka et al. 2004). Studies by Schmidt and colleagues have also revealed that Btk deficiency 
decreases the activity of AP-1 in TLR4- and TLR9- stimulated murine macrophages (Schmidt et 
al. 2006) thus pointing to AP-1 as a likely candidate factor in Btk-mediated TLR8 signalling. 
Current findings also show that the downregulation of Btk affected the activity of AP-1, 
specifically interfering with phospho-cJun binding to the AP-1 motif (Figure 5.9). These results 
justified further investigation of the specific involvement of cJun, ATF-2 and cFos in the Btk-
dependent regulation of TNF production.  Using ChIP, it was demonstrated that the 
downregulation of Btk increased both the basal and R848-induced cJun and ATF-2, but not cFos, 
recruitment to the TNF 5‟promoter (Figure 5.10) where well documented CRE/ATF/AP-1 sites 
are located (Steer et al. 2000).  Surprisingly, cJun, ATF-2 and cFos also bound to the 3‟enhancer 
near κB site 4 although a putative AP-1 binding site has not been reported previously. However, 
detailed bioinformatics analysis with MatInspector software revealed a possible AP-1 binding 
motif in close proximity to NFκB site 4. The new AP-1 site is located in the 3‟enhancer region 
which was shown in the luciferase experiment to be independent on Btk indicating that although 
Btk regulates the recruitment of cJun and ATF-2 to the AP-1 motif in the 3‟ enhancer, the site is 
not important for Btk-mediated TNF transcription.  
The unexpected enrichment of the cJun and ATF2 at the TNF gene in unstimulated macrophages 
and their release upon R848 stimulation suggests that these AP-1 components may be negative 
regulators of TNF production. AP-1 has been previously shown to have anti-inflammatory 
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properties as JunB
-/-
 cJun
-/-
 mice develop psoriasis- like phenotype also characterised by elevated 
expression of TNF, IL-1 and IL-6 in epidermis  (Schonthaler et al. 2009). Unfortunately, as the 
attempt to downregulate cJun, ATF-2 or cFos in human primary macrophages proved to be 
unsuccessful, the possible function and the mechanism of action of these AP-1 components in 
inflammatory conditions can be only speculated. One possible explanation for this is the co-
repression hypothesis. Data from a number of laboratories have established that under basal 
conditions, the promoters of many TLR-dependent genes in macrophages are occupied by co-
repressor complexes comprising histone deacetylase 3 (HDAC3), which is associated with 
inactive chromatin and consequently with gene repression. It has been shown recently that a cJun 
homodimer can also be a part of such co-repressor complexes. Upon stimulation, cJun is 
phosphorylated, which ultimately leads to the release of HDAC3 complex followed by the 
substitution of one of the cJun homodimer components with cFos. The rearrangement of the dimer 
components results in the recruitment of a coactivator complex and subsequent transcription of the 
gene (Newell et al. 1994; Ogawa et al. 2004; Huang et al. 2009). Current data strongly agrees with 
this hypothesis as the recruitment of cJun to the TNF gene fell, whereas the recruitment of cFos 
rose upon R848 stimulation, supporting the rearrangement of a cJun homodimer into cJun/cFos 
heterodimer theory (Figure 5.10). On the other hand, the recruitment of phosphorylated cJun to 
the AP-1 consensus site increased upon R848 stimulation, once again being in agreement with the 
co-repression hypothesis (Figure 5.9).  Additional downregulation of Btk increased the 
recruitment of cJun and ATF-2 to the TNF promoter, potentially augmenting the repressor 
function of cJun homodimers resulting in decreased TNF production. Conversely, downregulation 
of Btk resulted in the decreased recruitment of phosphorylated cJun to the AP-1 motif upon R848 
stimulation, potentially impairing the activator function of cJun, once again resulting in decreased 
TNF production (Figure 5.16).  
 
Independent studies have shown that MAPK are crucial for TNF expression as they regulate both 
transcription and mRNA stability of TNF. Btk has been previously shown to employ p38 MAPK 
in the regulation of TNF production following TLR4 receptor engagement in human macrophages 
(Horwood et al. 2003). At the same time, studies performed on murine macrophages have shown 
that Btk does not affect the phosphorylation of MAPK upon LPS stimulation (Schmidt et al. 
2006). As evident from the current results, Btk overexpression did not alter R848-induced 
phosphorylation of p38, JNK or ERK indicating that the Btk-regulated AP-1 and NFκB activity is 
not mediated through MAPK (Figure 5.12). In common with the results reported here, selective 
activation of p38, JNK or ERK by transiently expressing upstream MAPK kinases induced TNF 
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Figure 5.16 Model of Btk-dependent de-repression of AP-1 target genes in R848-stimulated 
macrophages. In basal conditions, cJun homodimers are bound to the promoter of TNF. These form a 
scaffold for the co-repressor complex involving HDAC which is associates with inactive chromatin and gene 
repression. The engagement of TLR8 leads to Btk-mediated phosphorylation of cJun and subsequent 
exchange of one cJun subunits into another AP-1 component. Newly formed heterodimer attracts a co-
activator complex and HAT what leads to TNF transcription. Btk downregulation increases the repressor 
function of cJun homodimers and decreases the activator function of phosphorylated cJun ultimately 
leading to impaired TNF production. HDAC, histone deacetylase; HAT, histone acetyl transferase. 
 
transcription independently on cis acting elements such as NFκB or AP-1 motifs in the TNF 
promoter (Zhu et al. 2000). The question remains how Btk regulates AP-1 components if this is 
not through MAPK. Firstly, Btk could act on AP-1 indirectly through the NFκB pathway, which 
has been shown to be crucial for AP-1 activity as IKKε phosphorylates cJun following TLR4 
engagement leading to NCoR clearance and gene de-repression (Huang et al. 2009). Secondly, Btk 
could affect AP-1 directly as the kinase is able to shuttle to the nucleus and interact with 
transcription factors such as TFII-I or CREB (Novina et al. 1999; Mohamed et al. 2000; Yang et 
al. 2004). Lastly, Btk could employ other pathways to indirectly regulate AP-1 such as TAK1 
which has been shown to activate AP-1 (Shim et al. 2005), c-Abl or CSK involved in AP-1 
stability or degradation, respectively (Xie and Sabapathy 2010). 
One of the molecules implicated in Btk signalling could be TAK1 whose phosphorylation has 
been shown to be triggered by many stimuli including growth factors, environmental stress or 
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inflammatory cytokines (Landstrom 2010). It has been demonstrated that TAK1 activates AP-1 
under IL-1R or under TLR4 engagement (Shim et al. 2005; Yu et al. 2008) becoming an obvious 
candidate to be involved in the Btk pathway. Initial experiments demonstrated that TAK1 behaves 
similarly to Btk as AdTAK1 WT increased TNF and IL-6 production whereas AdTAK1 DN 
decreased the cytokine production under R848 stimulation (Figure 5.13). Furthermore, AdTAK1 
WT considerably increased the binding of NFκB and AP-1 to their consensus DNA motifs once 
again mimicking the Btk effect (Figure 5.14). The ultimate experiment has revealed that Btk-
dependent super-induction of TNF and IL-6 is dependent on TAK1 (Figure 5.15). TAK1 was 
originally identified as a MAPKKK (Yamaguchi et al. 1995) lying upstream of p38 MAPK in LPS 
signalling in the THP-1 cell line. This may be in disagreement with the current hypothesis that Btk 
employs TAK1 to regulate AP-1 and NFκB independently of MAPK. Experiments performed in 
human primary macrophages revealed, however, that TAK1 does not activate p38, JNK or ERK 
MAPK upon TLR4 engagement (Lynn Williams, manuscript in preparation). The activation of 
MAPK by TAK1 in TLR8 signalling has not been investigated but similarly to TLR4 pathway 
may be absent. TAK1 has been previously shown to be differentially phosphorylated by IL-1 and 
TGF-κ stimulation indicating that the TAK1 mode of action is stimuli-dependent (Sorrentino et al. 
2008; Yu et al. 2008; Yamazaki et al. 2009).    
Data presented in this chapter further strengthens the hypothesis established in Chapter 4 that Btk 
regulates the initiation of TNF transcription. Following the engagement of TLR8, Btk activates 
NFκB and AP-1 leading to the recruitment of these transcription factors to the TNF promoter and 
3‟ enhancer region. p38, JNK or ERK MAPK are not involved in Btk signalling under TLR8 
engagement in human primary macrophages. TAK1 also activates NFκB and AP-1 resulting in 
TNF and IL-6 production thus resembling the Btk effect on cytokine production. However, the 
nature of the Btk interaction with TAK1 remains to be further investigated.  
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6.1 Concluding discussion 
 
Inflammation, the defensive response of the immune system against pathogens, irritants and 
damaged cells, is a tightly regulated process. If the immune response fails to eradicate a causative 
agent or if the immune regulatory mechanisms fail to resolve the immune response, the 
inflammation persists and becomes a pathological chronic condition which poses a serious threat 
to the host. The initiation of the immune response involves the detection of antigen by pattern 
recognition receptors such as TLRs. The immune system is designed to recognise both 
endogenous and exogenous molecules but not to be activated by self antigens. Failure to do so 
results in the development of autoimmune diseases such as RA, SLE or IBD in which perpetuating 
chronic inflammation leads to severe tissue damage. Macrophages, abundant in the inflamed 
synovial membrane, appear to be involved in both the initiation and development of RA. In 
particular, they directly respond to injurious stimuli via TLRs and are the main source of the 
pivotal cytokine TNF. Expression of TLRs 2, 3, 4, 7 and 8 is elevated in the synovial tissue of RA 
patients (Radstake et al. 2004; Roelofs et al. 2005; Brentano et al. 2005a) and the blockade of 
TLRs has been considered as an attractive treatment strategy for the treatment of various 
autoimmune conditions (Clanchy and Sacre 2010). Endosomal TLRs may be of particular interest 
as their inhibition with the antidepressant mianserine or with chloroquine, an inhibitor of 
endosomal acidification, blocked spontaneous release of TNF from RA synovial membrane 
cultures (Sacre et al. 2008). TLRs on the cell membrane have been extensively investigated and it 
is now clear that non-receptor tyrosine kinases including Src, Syk, Pyk2 and Tec family kinases 
are implicated in the TLR4 pathway as they regulate the production of various cytokines and 
chemokines following LPS stimulation. Whether tyrosine kinases fulfil the same role in 
endosomal TLRs has been poorly investigated and still remains unclear.   
 
These studies focused on the role of Btk, a member of the Tec family of tyrosine kinases, in 
endosomal TLR signalling in human primary macrophages. The major finding of this work is that 
Btk is an essential component of TLR8 signalling as Btk abrogation abolished TLR8-induced TNF 
production. Btk downregulation or overexpression also modulated IL-6 production from R848-
challenged human primary macrophages. The initial results demonstrated a rapid tyrosine 
phosphorylation and auto-phosphorylation of Btk in either LPS- or R848-stimulated macrophages 
(Figure 6.1). This was in line with previous research showing activation of Btk within 5-10 min 
following LPS challenge in human and mouse macrophages (Horwood et al. 2003; Schmidt et al. 
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2006). The effect of Btk on IL-6 and TNF production was previously observed by Sochorova et al 
(2007) who found that DCs obtained from XLA patients exhibited decreased response to ssRNA 
stimulation in terms of cytokine production. The later finding was not, however, consistent with 
the work performed by Taneichi et al (2008) who did not record any changes in IL-6 production 
from XLA-derived DCs stimulated with R848.  Taneichi et al also found an impaired XLA DC 
response to LPS. In contrast, Sochorova et al did not observe any decrease in TNF production in 
LPS-stimulated XLA DCs. This discrepancy could be the result of different experimental settings 
(control, time course or type of TLR8 ligand). It is also possible that both workers obtained blood 
samples from different XLA patients and that the occurring mutations could cause different 
phenotypic changes. The number of unique mutations detected in the BTK gene of XLA patients 
currently exceeds 550 in more than 800 unrelated families. Although most of the investigated 
patients have the classical severe form of XLA, there are few exceptions (Lindvall et al. 2005). 
The effect of Btk on cytokine production would, therefore, have to be established in wild type 
DCs subjected to Btk inhibition or overexpression. Surprisingly, the deficiency of Btk in murine B 
cells led to increased responsiveness to the TLR9 ligand as the cells secreted elevated levels of 
TNF, IL-6 and IL-12p40 but less inhibitory cytokine IL-10 (Hasan et al. 2008; Lee et al. 2008). In 
human primary macrophages, Btk overexpression or downregulation did not alter IL-10 
production from R848- or LPS-challenged cells. This would suggest that Btk depletion does not 
exhibit a consistent anti-inflammatory effect among the cells of the immune system. Nevertheless, 
the cumulative effect of Btk depletion is an impaired immune response to enteroviral infections as 
observed in XLA patients, or higher susceptibility to acute mouse adenovirus type-1 as observed 
in Xid mice (Moore et al. 2004; Winkelstein et al. 2006).   
 
Another key observation of this work is that the dependence of TLR8 on Btk is greater than for 
TLR4 signalling. First of all, Btk was involved in R848-induced TNF and IL-6 production as 
opposed to only TNF in LPS-stimulated human primary macrophages. Furthermore, siRNA-
mediated Btk downregulation almost completely abrogated TNF production in TLR8 but not in 
TLR4 signalling. Previously, Jefferies et al (2003) reported using yeast two-hybrid system that 
Btk interacts with TIR domains of TLR4, 6, 8 and 9 with the strongest association with TLR8 
suggesting that Btk may be an indispensable member of Tec PTKs involved in TLR8 signalling. 
Indeed, to date no other Tec family member has been associated with the TLR8 pathway. In 
contrast, TLR4 has been found to depend on Bmx to induce TNF and IL-6 production in human 
primary macrophages and rheumatoid synovial fibroblasts (Palmer et al. 2008; Palmer et al. 2008). 
Unlike the role of Btk in TLR4 and TLR8 signalling, the kinase did not affect PolyI:C –induced 
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IP-10 production suggesting that Btk is not involved in the TLR3 pathway in human primary 
macrophages. The major difference between TLRs 4, 8 and TLR3 is that the latter does not utilise 
the adaptor molecule Myd88. Btk has been previously associated with Myd88-dependent 
signalling as it controls TNF and IL-1β production upon TLR1/2, TLR2/6 and TLR4 engagement 
(Horwood et al. 2006)(Christine Palmer, thesis). The lack of Btk effect on TLR3 signalling is not 
only restricted to human macrophages, as myeloid DCs obtained from XLA patients or treated 
with a Btk inhibitor LFM-A13 exhibited normal production of TNF and IL-6 following TLR3 
stimulation (Sochorova et al. 2007). Btk has been also found to physically interact with Myd88 as 
well as to phosphorylate the Myd88-bridging molecule, Mal, in response to LPS stimulation 
(Jefferies et al. 2003; Gray et al. 2006) further supporting the hypothesis that Btk is limited to the 
Myd88-dependent signalling. 
 
Detailed investigation of Btk-dependent signalling cascades revealed that the kinase does not 
regulate MAPK activation in R848-stimulated human primary macrophages. In particular, Btk 
overexpression did not alter p38, JNK or ERK phosphorylation levels or p38 kinase activity up to 
40 min post stimulation. These results were consistent with studies published by Olsson and 
Sundler describing no effect of LFM-A13 on p38 MAPK phosphorylation in LPS-stimulated 
murine macrophages (Olsson and Sundler 2006). Similarly, studies in Btk
-/- 
BMDM showed that 
Btk deficiency did not reduce p38 MAPK phosphorylation (Schmidt et al. 2006). In addition, 
another Tec family member, Bmx, also appears to signal independently of p38 in terms of 
regulating LPS-induced TNF and IL-6 message stability in human primary macrophages (Palmer 
et al. 2008). These observations contradict a previously published study from our laboratory where 
the phosphorylation of p38 MAPK was found to be defective in LPS-stimulated PBMCs derived 
from XLA patients (Horwood et al. 2003). One of the possible explanations for the discrepancy 
between the current and XLA-derived studies could be the use of different model systems and 
different TLR stimuli. It is likely that p38 activation is already saturated following TLR8 
engagement. Therefore, the overexpression of Btk could not increase the levels of p38 
phosphorylation any further and the effect of Btk on p38 activation could have been missed. 
Further, more detailed studies performed in cells obtained from XLA patients are necessary to 
explain some of these data.  
 
Instead of MAPK activation, Btk regulated the induction of the NFκB pathway in TLR8 signalling 
as Btk downregulation decreased the phosphorylation of p65 on Serine 536 (Figure 6.1).  This 
regulation was independent of the IκBα pathway as the level of IκBα degradation was unchanged. 
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The current data is consistent with an earlier observation made in Xid-derived BMDM which 
showed reduced levels of phosphorylated p65 at Ser536 and normal patterns of IκBα degradation 
post LPS stimulation (Doyle et al. 2005). The current findings are also comparable with the results 
obtained in B cells derived from Btk
-/-
 mice which did not display impaired IκBα degradation 
following TLR9 engagement (Lee et al. 2008). IKKα and IKKβ have been found to phosphorylate 
p65 on Ser536. This post-transcription modification of Ser536 as well as Ser311 or Ser276  has 
been shown to be required for the association of p65 with the co-activator CBP/p300 and histone 
acetylotransferases (HATs) and thus for the p65 target gene expression (Hayden and Ghosh 2008). 
Whether Btk is involved in these phosphorylation events directly or indirectly has to be examined 
further. It is, however, possible that the kinase activates p65 itself as Btk has been described to 
directly phosphorylate CREB at Serine 133 during neuronal differentiation (Yang et al. 2004). 
 
Btk ablation also impaired R848-induced NFκB binding to DNA. This observation is in line with 
studies performed in endothelial cells overexpressing Btk as well as in murine and human cell 
lines treated with LFM-A13 (Jefferies et al. 2003). In particular, Jefferies and colleagues showed 
that TLR4-HEK293 cells transfected with the K430R Btk mutant exhibited reduced NFκB 
luciferase activity following LPS stimulation. Furthermore, the treatment of human myeloid THP-
1 cells with LFM-A13 decreased the binding of NFκB to DNA post LPS treatment. Similarly, 
NFκB luciferase activity was decreased in HEK293 transfected with either CD4-TLR8 or CD4-
TLR9 and dominant negative mutants of Btk (Doyle et al. 2007). The interpretation of these data, 
has to be, however, viewed with caution as non-myeloid HEK293 cells do not express endogenous 
Btk or TLRs, whereas LFM-A13 has been found to also inhibit Jak2 and Polo-like kinase (PLK) 
activity as well to reduce viability of primary human macrophages (van den Akker et al. 2004; 
Uckun et al. 2007) (John McDaid, thesis). The link between Btk and NFκB-regulated TNF 
transcription has not been previously investigated in the literature. 
 
TNF is a pivotal cytokine that controls the production of both pro-inflammatory and anti-
inflammatory mediators (Butler et al. 1995; Feldmann 2002).  The crucial role of TNF in the 
development of autoimmune diseases has been highlighted by the fact that anti-TNF therapies 
proved to be successful in the treatment of RA, IBD and the skin disease, psoriasis. Because of its 
predominant functions, the regulation of TNF production has been extensively studied and it is 
now clear that TNF is precisely regulated at every stage of gene expression (Falvo et al. 2010). 
This study for the first time demonstrated that Btk is a central regulatory component of TNF 
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transcription in TLR8 signalling, as Btk downregulation almost completely abolished the synthesis 
of the primary TNF transcript.   Btk knockdown also significantly decreased Pol II recruitment to 
the 5‟ promoter of TNF indicating that Btk affects the initiation of TNF transcription in TLR8 
signalling. Transcription initiation involves the signal-dependent binding of transcription factors 
to target promoters, enabling the recruitment of various components of the transcription initiation 
machinery including Pol II. The human TNF 5‟ promoter and downstream 3‟ enhancer regions 
contain multiple transcription factor binding sites which have been described to be involved in 
TLR-driven induction of TNF including κB sites, CRE and AP-1-like sites (Kramer et al. 1995; 
Liu et al. 2000). 
 
Studies here have shown that Btk-mediated induction of TNF was dependent on the 3‟ enhancer 
region of TNF where the putative κB site 4 is located. Additional analysis revealed that mutation 
of all four κB sites in the 3‟ and 5‟ TNF regions abolished Btk-mediated super-induction of 
luciferase indicating that the kinase requires NFκB to regulate TNF transcription. This hypothesis 
was confirmed using the ChIP technique which showed for the first time that Btk mediates p65 
recruitment to TNF as Btk downregulation inhibited R848-induced p65 binding to the gene 
(Figure 6.1). Although inhibitory p50-p50 dimers have been found to be constitutively bound to 
DNA, the signal-dependent activation of NFκB increases the binding of activatory p50-p65 
heterodimers to the target genes (Hoberg et al. 2006). In basal conditions p50 homodimers provide 
a scaffold for a co-repressor complex comprising the silencing mediator for retinoic acid and 
thyroid hormone receptor (SMRT) and histone deacetylase 3(HDAC3) which is associated with 
gene repression. Upon stimulation, IKKα phosphorylates SMRT to initiate p50-p50-HDAC3 
displacement and p50-phospho-p65 recruitment to the κB site. Phosphorylation of p65 allows 
p300 to load and subsequently acetylate p65 at Lys310, which is required for full NFκB 
transcription activity (Chen et al. 2002b; Hoberg et al. 2006).  
 
The components of the transcription factor AP-1 such as cJun, ATF-2 and cFos were also found to 
bind to TNF, however the recruitment of cJun and ATF-2 dropped upon R848 stimulation in 
comparison to cFos and p65. One possible explanation is that cJun-cJun dimers are constitutively 
bound to AP-1 target genes just like p50-p50 dimers are bound to the κB sites. cJun homodimers 
attract a co-repressor complex comprising nuclear receptor coreceptor (NCoR) and HDAC3, an 
enzyme associated with inactive chromatin. Stimulation of macrophages leads to c-Jun 
phosphorylation on Serines 63 and 73 resulting in the release of the co-repressor complex and 
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substitution of one cJun subunit with a cFos subunit. The newly formed cJun/cFos heterodimer 
attracts a co-activator complex comprising HATs allowing gene transcription (Ogawa et al. 2004) 
(Figures 5.16 and 6.1). Btk downregulation increased cJun and ATF-2 binding to TNF at both 
basal and post-stimulation conditions but did not affect cFos activity. Therefore, Btk ablation 
increased the levels of cJun-cJun-dependent co-repressor complexes that ultimately led to 
decreased TNF transcription. Btk has been previously linked to AP-1 activation as Btk-depleted 
BMDM exhibited impaired AP-1 binding to its consensus site upon LPS and CpG DNA 
stimulation (Schmidt et al. 2006).  The current data expand on this finding by revealing the role of 
Btk in the recruitment of a particular AP-1 component to human TNF in whole genome setting 
taking into consideration the complexity of chromatin, thus reflecting the real in vivo situation. 
 
Apart from affecting the basal recruitment of cJun to TNF, Btk also regulated the recruitment of 
phospho-cJun to an AP-1 consensus site upon R848 stimulation. However, Btk overexpression did 
not affect the activation of MAPKs which are considered to be the major upstream regulators of 
AP-1. This observation is in line with studies performed on the Src family kinase, Hck, which also 
regulated AP-1 activity through a MAPK-independent pathway in LPS-stimulated human primary 
macrophages (Maria Smolinska, manuscript submitted). The mechanism by which Btk controls 
AP-1 activation in TLR8 signalling therefore remains unclear.  It could be that Btk acts on AP-1 
activation indirectly by regulating the NFκB pathway. CRE/ATF and AP-1 sites are located in 
close proximity to the κB site 3 in the core promoter of TNF and studies by (Yao et al. 1997) have 
demonstrated that NFκB and AP-1 components interact with each other and are mutually 
dependent as increasing the spacing between CRE and κB site 3 abolished LPS-driven induction 
of TNF. It has been shown that p65 recruitment to κB sites located at close proximity to the cJun-
binding sites allows cJun phosphorylation and subsequent gene de-repression (Huang et al. 2009). 
In particular, in response to TLR4 stimulation, p65-p50 heterodimers bind to the inos promoter 
and recruit IKKε which in turn phosphorylates cJun and initiates NCoR clearance. IKKε has been 
shown to be the central regulator of cJun activation in this instance as IKKε downregulation 
completely abolished cJun phosphorylation on Serines 63 and 73 and NCoR clearance. 
Interestingly, phosphorylation of Serine 536 on p65, the one dependent on Btk, creates a docking 
site for recruitment of IKKε. Furthermore, NCoR clearance has been shown to be JNK-
independent (Huang et al. 2009), once again supporting the hypothesis that Btk regulates AP-1 
activation through the NFκB but not the MAPK pathway (Figure 6.1). 
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Figure 6.1 Proposed mechanism of Btk signalling in TLR8-induced cytokine production. 
 
 
Another interesting finding of this work was that the monocytic-like cell lines do not carry 
functional TLRs 3 and 8. The present data has revealed that although THP-1, U937 and 
Monomac-6 cells express TLRs3 and 8 on the protein level they do not secrete TNF, IL-6, IL-10 
or IP-10 upon PolyI:C or R848 stimulation. Nevertheless, these cells are routinely used for 
deciphering the endosomal TLR pathways. For instance, THP-1 cells were previously used for 
determining the role of Btk in TLR8 or TLR9- activated signalling pathways but did not refer to 
the ability of TLR to induce cytokine production (Doyle et al. 2007). Similarly, U937 were 
recently used for TLR3 and TLR9 studies which did not measure cytokine levels upon 
stimulation. U937 cells did, however, respond to CpG DNA and PolyI:C in terms of NO 
production and IFN-β mRNA expression (Motoyama et al. 2009). The current results imply that, 
although the examined cell lines are wildly used as a model for the investigation of macrophage 
biology, they do not always reflect the results obtained from primary cells. Therefore, the results 
obtained from cell line models have to be viewed with caution and the use of primary cells should 
be considered instead to investigate the endosomal TLR pathways. 
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In summary, the data obtained from TLR-challenged human primary macrophages provide further 
insight into the molecular mechanisms used by Btk to control cytokine production. In particular, 
Btk proved to be the central regulator of TNF in TLR8 signalling as Btk downregulation 
dramatically reduced TNF transcription and as a consequence TNF protein production from R848-
stimulated cells. Cumulative data show that in response to R848 stimulation Btk becomes rapidly 
phosphorylated on Tyr551 and auto-phosphorylated on Tyr223. Btk signals upstream of NFκB, 
AP-1, possibly TAK1 but not MAPK to regulate the initiation of TNF transcription as well as IL-6 
expression. Activated Btk mediates p65 phosphorylation on Ser536, possibly through IKKα, 
leading to NFκB translocation to the nucleus and gene transactivation. Btk also mediates cJun 
phosphorylation that facilitates rearrangement of cJun homodimers into cJun/cFos heterodimers 
and consequently TNF transcription. IKKε may be required for cJun de-repression as the kinase is 
able to phosphorylate cJun on Ser63/73 (Figure 6.1).  
 
These findings are of particular importance as TNF is the major pro-inflammatory cytokine able to 
regulate the production of other inflammatory mediators (IL-1, IL-6, IL-12), acute phase proteins, 
ROS, NO and prostaglandins (Schottelius et al. 2004). Anti-cytokine therapies have proven highly 
efficacious in the treatment of RA, SLE and IBD (Suresh 2010).  However, not all RA patients 
respond equally well to the anti-TNF therapy indicating that therapies that simultaneously target 
several cytokines may be more beneficial in these patients. For instance, chemical inhibition of 
particular non-receptor tyrosine kinases may prove to be a more systemic and a cheaper alternative 
than existing antibody-based biological treatments.  The current findings propose a mechanism of 
TNF gene control and provide molecular targets that could be targeted in the course of 
development of more efficient anti-inflammatory therapeutics. 
 
6.2 Future work 
 
6.2.1 Positioning Btk in the TLR8 signalling network 
 
Previous published results have shown that Btk interacts with Myd88 and Mal under TLR4 
engagement and that Btk phosphorylates Mal in the THP-1 cell line (Jefferies et al. 2003; Gray et 
al. 2006). As the TLR8 pathway does not utilize Mal it becomes clear that Btk-Mal interactions 
are not important in TLR8 signalling. Therefore, Btk-Myd88 interactions may be of more 
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importance. However, the requirement for and hierarchy of Btk-MyD88 interaction has not been 
proved in TLR8 signalling.  Thus, the effect of Myd88 deletion and mutation on Btk 
phosphorylation can be pursued by means of Myd88 knockout mice and adenoviruses carrying 
murine and human mutated versions of Myd88 (both available in house). The results will clarify if 
Myd88 is functionally associated with Btk, and if so, whether it is located upstream or 
downstream of Btk in TLR8 signalling.  The outcome would then provide further evidence for the 
role of Btk in Myd88-dependent signalling, such as TLR and IL-1R, and possibly help to explain 
the effect of Btk on downstream signalling components. 
 
Current results suggest that Btk shares a signalling cascade with TAK1 as both kinases mediate 
AP-1 and NFκB activation as well as TNF production in R848-challenged human primary 
macrophages. Furthermore, Btk-dependent TNF super-induction was abrogated in the presence of 
dominant-negative TAK1. TAK1 is known to be activated by TRAF6 which in turn is activated by 
the Myd88/IRAK pathway in LPS-challenged cells (Landstrom 2010). Btk, on the other hand, has 
been shown to interact with Myd88, TLR4 and IRAK1 but not TRAF6 (Jefferies et al. 2003) 
suggesting that it could be located upstream of TAK1. To confirm this hypothesis, the effect of 
Btk downregulation on TAK1 or TRAF6 activation sould be investigated thus adding more detail 
to a potential Btk-TAK1-NFκB pathway.  
 
6.2.2 The role of Btk in transcription factor activation 
 
From this study it is clear that Btk regulates p65-mediated TNF transactivation in R848-stimulated 
human primary macrophages. One of the Btk-dependent mechanisms which facilitates p65 nuclear 
translocation and recruitment to TNF is the phosphorylation of p65 on Ser536. Further studies 
should be conducted to determine whether Btk affects other p65 activation events. The 
transactivation activity of NFκB downstream of IκB degradation has been found to be regulated 
on several levels. The phosphorylation of p65 at Ser276 by protein kinase A (PKA) or by 
mitogen- and stress-activated protein kinases MSK1 and MSK2 is one example (Zhong et al. 
1998; Vermeulen et al. 2003).  This particular phosphorylation event has been found to promote 
the interaction of p65 with the transcription co-activators p300 and CREB-binding protein (CBP) 
(Zhong et al. 1998). Similarly, the phopshorylation of p65 at Ser536 by IKKα and IKKβ has been 
found to be required for p300/CBP association (Sakurai et al. 2003; Chen et al. 2005). PKCδ can 
phosphorylate p65 at Ser311 and PKCδ deficiency blocks p65 interaction with the co-activator 
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CBP as well as Pol II recruitment to the IL-6 promoter in response to TNF (Duran et al. 2003). 
The association with the co-activator CBP/p300 and histone acetylotransferases (HATs) results in 
acetylation of p65 at Lysine 310 and promotion of target NFκB gene transcription (Chen et al. 
2002b; Hayden and Ghosh 2008). Future experiments should focus on deciphering whether Btk 
interacts with any of the kinases that have been implicated in the transcriptional activity of p65 or 
whether Btk phosphorylates p65 itself. The outcome would not only explain the role of Btk in 
NFκB signalling but also shed more light onto general control mechanisms of TNF transcription in 
TLR signalling. 
 
Studies presented in this thesis have shown a role for Btk in the regulation of AP-1 activation and 
also provided insight into the mechanism of this regulation. Although Btk has been found to 
regulate total cJun recruitment to TNF, further ChIP analysis should be performed to assess 
whether the recruitment of phospho-cJun to TNF is also affected. If so, this would provide a basis 
for further validation of the co-repression hypothesis. Firstly, the presence of NCoR at the human 
TNF gene has to be confirmed. It would be then interesting to examine if Btk regulates NCoR 
clearance from the cJun-cJun co-repressor complex in R848 signalling. This could be achieved by 
performing NCoR ChIP in the presence of Btk knockdown.  
 
p65 bound to the inos promoter has been found to recruit IKKε which phosphorylates cJun on 
Ser63 and Ser73 upon LPS stimulation (Huang et al. 2009). The interaction between p65 and 
IKKε is dependent on phosphorylation of p65 on Ser536. Studies should be conducted to establish 
whether Btk affects IKKε- mediated cJun activation as Btk regulates p65 recruitment to TNF as 
well as p65 phosphorylation. Furthermore, cJun-binding sites are located in close proximity to κB 
site 3 in the TNF promoter; this is a prerequisite for the AP-1-NFκB collaboration. This question 
could be answered by examining the effect of Btk knockdown on phospho-cJun recruitment to 
TNF in the presence of inhibited or down-regulated p65.  
 
Finally, there is a possibility that Btk itself could be found in the DNA-binding complexes. The 
kinase has been found to constantly shuttle between the nucleus and the cytoplasm (Mohamed et 
al. 2000). Moreover, the kinase interacts with the transcription factors TFII-I, STAT5A and Bright 
(Webb et al. 2000; Mahajan et al. 2001; Rajaiya et al. 2006). TFII-I is a general transcription 
factor whose binding sites in TNF can be identified using the MatInspector programme. Confocal 
microscopy could be used to establish wether Btk shuttles to the nucleus upon R848 stimulation. 
An adenovirus expressing Btk conjugated with GFP is available in house and can be used for 
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imaging of Btk cellular localisation in human macrophages. Subsequent immunoprecipitation of 
Btk-TFII-I complexes would then provide further evidence for Btk direct involvement in gene 
transcription.   
 
6.2.3 Mechanism of Btk-dependent regulation of IL-6 expression 
 
Btk has been found to regulate IL-6 production in R848-stimulated human primary macrophages. 
However, the effect of Btk downregulation on IL-6 was largely delayed as opposed to TNF 
indicating that there are differential mechanisms of Btk mediated induction of IL-6 expression as 
compared to TNF expression. The IL6 gene, in contrast to TNF, is considered as a secondary 
response gene as it is transcribed later than primary response genes due to the limited chromatin 
accessibility and the requirement for new protein synthesis (Saccani et al. 2001). Although the 
mechanisms that distinguishably regulate IL-6 expression are poorly understood, it is clear that 
factors involved in the induction of the IL6 promoter activity include NFκB, AP-1, NF-IL6, 
C/EBPβ and CREB (Keller et al. 1996; Hershko et al. 2002). Since Btk has been implicated in 
NFκB and AP-1 activation, it is possible that the kinase regulates IL6 transcription in R848 
signalling. However, as Btk depletion decreased IL-6 levels after as late as 8h post R848 
stimulation (2h for TNF) it is more likely that Btk affects other stages of IL-6 gene expression. It 
would be also interesting to see the effect of Btk downregulation on Brahma-related gene1 (Brg1) 
recruitment to the IL6 promoter. Brg1 is a subunit of switch/sucrose nonfermenting (SWI/SNF) 
complexes which are required for nucleosome remodelling and chromatin accessibility to 
transcription factors (Ramirez-Carrozzi et al. 2006). Brg1 has been shown to be recruited to 
secondary response genes such as IL6 upon LPS stimulation in human primary monocytes (Chen 
and Ivashkiv 2010). Alternatively, Btk may affect IL-6 mRNA stability following R848 
stimulation similarly to the way it is able to regulate TNF message stability in LPS-stimulated 
macrophages (Horwood et al. 2003).  
 
6.2.4 Btk as a drug target in RA 
 
Btk inhibition has been considered as an attractive treatment approach against B cell diseases and 
a small molecular inhibitor PCI-32765 is now undergoing clinical evaluation for the treatment of 
B-cell lymphoma (Honigberg et al. 2010). In the recent publication by Di Paolo and colleagues, 
Btk specific inhibition by CGI1746 blocked BCR-dependent B cell proliferation and autoantibody 
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production as well as FcγRIII-dependent TNF, IL-6 and IL-1 production in macrophages derived 
from rodent arthritis models (Di Paolo 2010). Further experiments are required to validate if Btk 
inhibition ameliorates RA in humans. For instance, the effect of Btk downregulation with siRNA 
on spontaneous release of pro-inflammatory cytokines from RA synovial cultures could be first 
investigated. The design of selective Btk inhibitors would then allow the investigation of the effect 
of anti-Btk therapy in RA and other autoimmune diseases in larger preclinical and clinical studies. 
  
6.2.5 Implication of future work 
 
In conclusion, the future objectives outlined above will add more detail into not only the role of 
tyrosine kinases in controlling cytokine production but also into understanding the molecular 
mechanisms that control TNF production under inflammatory conditions. The development of 
advanced molecular techniques such as ChIP has already accelerated the process of understanding 
gene regulatory networks including the interplay between co-repressor and co-activator complexes 
as well the factors involved in chromatin remodelling. The current project has proven that by 
investigating the role of one tyrosine kinase in cytokine production, it is possible to reveal 
unknown mechanisms that control cytokine gene expression. For instance, the current results have 
exposed a differential kinetics of AP-1 component recruitment to human TNF upon TLR8 
engagement. Future studies would therefore shed more light into the role of Btk in TNF 
transcription as well as provide novel drug targets whose inhibition could be more specific and 
cost-effective. 
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